

RADIOLOGIX INC
Form DEFM14A
October 20, 2006
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of
the Securities Exchange Act of 1934 (Amendment No.)

Filed by the Registrant x

Filed by a Party other than the Registrant o

Check the appropriate box:

- o Preliminary Proxy Statement
- o **Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))**
- x Definitive Proxy Statement
- o Definitive Additional Materials
- o Soliciting Material Pursuant to §240.14a-12

RADIOLOGIX, INC.

(Name of Registrant as Specified In Its Charter)

N/A

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):

- x No fee required.
- o Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
 - (1) Title of each class of securities to which transaction applies:
 - (2) Aggregate number of securities to which transaction applies:
 - (3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):
 - (4) Proposed maximum aggregate value of transaction:
 - (5) Total fee paid:
- o Fee paid previously with preliminary materials.
- o Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.
 - (1) Amount Previously Paid:
 - (2) Form, Schedule or Registration Statement No.:
 - (3) Filing Party:
 - (4) Date Filed:

Persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

**Filed Pursuant to 424(b)(3)
Registration No. 333-136800**

**TO THE STOCKHOLDERS OF
PRIMEDEX HEALTH SYSTEMS, INC. AND
RADIOLOGIX, INC.**

Primedex Health Systems, Inc., which is referred to as Primedex, and Radiologix, Inc., which is referred to as Radiologix, have entered into an agreement and plan of merger for the acquisition of Radiologix by Primedex through the merger of a wholly-owned subsidiary of Primedex with and into Radiologix. Upon successful completion of the merger, Radiologix stockholders will receive a combination of cash and Primedex common stock in exchange for their shares of Radiologix common stock. Pursuant to the merger, Radiologix stockholders will receive aggregate consideration of 22,621,922 shares of Primedex common stock and \$42,950,000 in cash. Based upon the closing price of \$2.69 for Primedex common stock as of October 6, 2006, the record date for the stockholder meetings, each Radiologix stockholder would receive \$1.78 in cash for each Radiologix share, plus one share of Primedex common stock for total consideration valued at \$4.47 per share. Upon completion of the merger, we estimate that, subject to adjustment as described above, Radiologix's former stockholders will own approximately 33.9% of the outstanding shares of Primedex common stock, based on the number of shares of Radiologix and Primedex common stock outstanding on the record date. Primedex's stockholders will continue to own their existing shares. In connection with the proposals set forth in this joint proxy statement/prospectus, Primedex stock may be subject to transfer restrictions which are necessary to preserve Primedex's unrestricted use of its net operating loss carry-forwards.

Shares of Primedex common stock are currently traded on the Over-The-Counter Bulletin Board under the symbol PMDX.OB. Upon completion of the merger, Radiologix common stock, which is currently traded on the American Stock Exchange under the symbol RGX, will be delisted.

The merger will be nontaxable for federal income tax purposes to Primedex and its stockholders. The merger will be taxable for federal income tax purposes to the stockholders of Radiologix.

We are each holding meetings of our stockholders in order to obtain those approvals necessary to consummate the merger and to approve other matters as described in this joint proxy statement/prospectus. At the Primedex special meeting, Primedex will ask its common stockholders to adopt the merger agreement and the transactions contemplated by the merger agreement, including the merger and the issuance of shares of Primedex common stock in connection with the merger and to approve other Primedex special meeting matters described in this joint proxy statement/prospectus. At the Radiologix special meeting, Radiologix will ask its common stockholders to adopt the merger agreement and the transactions contemplated by the merger agreement, including the merger, and to vote on the other Radiologix special meeting matters described in this joint proxy statement/prospectus. The obligations of Primedex and Radiologix to complete the merger are also subject to the satisfaction or waiver of several other conditions to the merger, including antitrust clearance. We received early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act on August 21, 2006. More information about Primedex, Radiologix and the proposed merger is contained in this joint proxy statement/prospectus. **We urge you to read this joint proxy statement/prospectus, and the documents incorporated by reference into this joint proxy statement/prospectus, carefully and in their entirety, in particular, see Risk Factors beginning on page 48.**

After careful consideration, each of our boards of directors has approved the merger agreement and has determined that the merger agreement and the merger are advisable and in the best interests of the stockholders of Primedex and Radiologix, respectively. **Accordingly, the Radiologix board of directors recommends that the Radiologix stockholders vote FOR the adoption of the merger agreement and the transactions contemplated by the merger agreement, including the merger, and FOR the other Radiologix special meeting matters. The Primedex board of directors recommends that the Primedex stockholders vote FOR the adoption of the merger agreement and the transactions contemplated by the merger agreement, including the merger and the issuance of Primedex common stock to be issued in connection with the merger, and FOR the other Primedex special meeting matters.**

We are very excited about the opportunities the proposed merger brings to both Radiologix and Primedex stockholders, and we thank you for your consideration and continued support.

Howard G. Berger, M.D.
President and Chief Executive Officer
Primedex Health Systems, Inc.

Sami S. Abbasi
President and Chief Executive Officer
Radiologix, Inc.

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this joint proxy statement/prospectus. Any representation to the contrary is a criminal offense.

Edgar Filing: RADIOLOGIX INC - Form DEFM14A

This joint proxy statement/prospectus is dated October 20, 2006,
and is first being mailed to Radiologix and Primedex stockholders on or about October 20, 2006.

REFERENCES TO ADDITIONAL INFORMATION

Except where we indicate otherwise, as used in this joint proxy statement/prospectus, Primedex refers to Primedex and its consolidated subsidiaries and Radiologix refers to Radiologix and its consolidated subsidiaries. Primedex and Radiologix file annual, quarterly and special reports with the Securities and Exchange Commission, referred to as the SEC, that have not been included in or delivered with this joint proxy statement/prospectus. These annual, quarterly and special reports are available to you without charge upon your written or oral request. You can obtain Primedex's and Radiologix's reports filed with the SEC by accessing the SEC's website maintained at www.sec.gov.

In addition, Primedex's SEC filings are available to the public on Primedex's website, www.radnetonline.com, and Radiologix's SEC filings are available to the public on Radiologix's website, www.radiologix.com. Information contained on Primedex's website, Radiologix's website or the website of any other person should not be considered by you as part of this joint proxy statement/prospectus.

Primedex will provide you with copies of this information relating to Primedex, without charge, if you request them in writing or by telephone from:

Primedex Health Systems, Inc.
1510 Cotner Avenue
Los Angeles, CA 90025
Attention: Investor Relations
(310) 478-7808

Radiologix will provide you with copies of this information relating to Radiologix, without charge, if you request them in writing or by telephone from:

Radiologix, Inc.
3600 JPMorgan Chase Tower
2200 Ross Avenue
Dallas, Texas 75201-2776
Attention: General Counsel
(214) 303-2776

If you would like to request documents, please do so by November 3, 2006, in order to receive them before the stockholder meetings.

Primedex has supplied all information contained in or incorporated by reference in this joint proxy statement/prospectus relating to Primedex, and Radiologix has supplied all information contained in or incorporated by reference in this joint proxy statement/prospectus relating to Radiologix.

RADIOLOGIX, INC.
3600 JPMorgan Chase Tower
2200 Ross Avenue
Dallas, Texas 75201-2776

**NOTICE OF SPECIAL MEETING OF STOCKHOLDERS
TO BE HELD ON NOVEMBER 15, 2006**

To the Stockholders of Radiologix, Inc.:

We will hold a special meeting of stockholders at 3900 JPMorgan Chase Tower, 2200 Ross Avenue, Dallas, Texas 75201 at 9:00 a.m., Central Time, on November 15, 2006, unless postponed or adjourned to a later date. The Radiologix special meeting will be held for the following purposes:

1. To adopt the Agreement and Plan of Merger, dated as of July 6, 2006, by and among Radiologix, Inc., Primedex Health Systems, Inc., PR Acquisition Corporation, an indirect wholly-owned subsidiary of Primedex, and RadNet Management, Inc., a wholly-owned subsidiary of Primedex and sole stockholder of PR Acquisition Corporation, and the transactions contemplated by the merger agreement, including the merger, pursuant to which Primedex will acquire Radiologix through the merger of PR Acquisition Corporation with and into Radiologix, on the terms and subject to the conditions contained in the merger agreement, and Radiologix stockholders will receive aggregate consideration of 22,621,922 shares of Primedex common stock and \$42,950,000 in cash. A copy of the merger agreement is attached as *Annex A* to this joint proxy statement/prospectus;
2. To approve adjournments or postponements of the Radiologix special meeting, if necessary, to permit further solicitation of proxies if there are not sufficient votes at the time of the Radiologix special meeting to approve the above proposal; and
3. To consider and take action upon any other business that may properly come before the Radiologix special meeting or any reconvened meeting following an adjournment or postponement of the Radiologix special meeting.

These items of business are described in this joint proxy statement/prospectus. Only stockholders of record at the close of business on October 6, 2006, are entitled to notice of the Radiologix special meeting and to vote at the Radiologix special meeting and any adjournments or postponements of the Radiologix special meeting.

Radiologix's board of directors unanimously approved the merger agreement and the transactions contemplated by the merger agreement, including the merger, on July 6, 2006, and determined that the transactions contemplated by the merger agreement are advisable and fair to, and in the best interests of, Radiologix and its stockholders. Radiologix's board of directors recommends that you vote FOR the adoption of the merger agreement and the transactions contemplated by the merger agreement, including the merger.

Radiologix's board of directors also recommends that you vote FOR the other Radiologix special meeting proposals, all of which are described in detail in this joint proxy statement/prospectus. Approval of the other Radiologix special meeting proposals is not a condition to the merger.

Under Delaware law, appraisal rights will be available to Radiologix stockholders of record who vote against adoption of the merger agreement. To exercise your appraisal rights, you must strictly follow the procedures prescribed by Delaware law. These procedures are summarized in this joint proxy statement/prospectus.

Your vote is very important. Whether or not you plan to attend the Radiologix special meeting in person, please complete, sign and date the enclosed proxy card(s) or voting instruction card(s) as soon as possible and return it in the postage-prepaid envelope provided, as described in this joint proxy

statement/prospectus. Completing a proxy now will not prevent you from being able to vote at the meeting by attending in person and casting a vote. **However, if you do not return or submit the proxy or vote in person at the meeting, the effect will be the same as a vote AGAINST the proposal to adopt the merger agreement and the transactions contemplated by the merger agreement, including the merger.**

By order of the board of directors,

Michael L. Silhol
Senior Vice President, General Counsel and Secretary

Please vote your shares promptly. You can find instructions for voting on the enclosed proxy card or voting instruction card.

If you have questions, contact:

Radiologix, Inc.
3600 JPMorgan Chase Tower
2200 Ross Avenue
Dallas, Texas 75201-2776
Attention: General Counsel
(214) 303-2776

Dallas, Texas, October 20, 2006

Your vote is important. Please complete, date, sign and return your proxy card(s) or voting instruction card(s), or vote your shares at your earliest convenience so that your shares are represented at the meeting.

PRIMEDEX HEALTH SYSTEMS, INC.
1510 Cotner Avenue
Los Angeles, CA 90025

**NOTICE OF SPECIAL MEETING OF STOCKHOLDERS IN LIEU OF ANNUAL MEETING
TO BE HELD ON NOVEMBER 15, 2006**

To the Stockholders of Primedex Health Systems, Inc.:

The special meeting of stockholders of Primedex Health Systems, Inc. (Primedex) will be held at The Olympic Collection, 11301 Olympic Boulevard, Los Angeles, California 90064 at 9:00 a.m., Pacific Time, on November 15, 2006, unless postponed or adjourned to a later date. The Primedex special meeting will be held for the following purposes:

1. To adopt the Agreement and Plan of Merger, dated as of July 6, 2006, by and among Radiologix, Inc., Primedex Health Systems, Inc., PR Acquisition Corporation, an indirect wholly-owned subsidiary of Primedex, and RadNet Management, Inc., a wholly-owned subsidiary of Primedex and sole stockholder of PR Acquisition Corporation, and the transactions contemplated by the merger agreement, including the merger and the issuance of shares of Primedex common stock in connection with the merger, pursuant to which PR Acquisition Corporation will merge with and into Radiologix, on the terms and subject to the conditions contained in the merger agreement, and Radiologix stockholders will receive aggregate consideration of 22,621,922 shares of Primedex common stock and \$42,950,000 in cash. A copy of the merger agreement is attached as *Annex A* to this joint proxy statement/prospectus;
2. To adopt an amendment to Primedex s certificate of incorporation to change Primedex s name to RadNet, Inc. ;
3. To adopt an amendment to Primedex s certificate of incorporation to (i) increase the number of authorized shares of Primedex common stock from 100,000,000 shares to 200,000,000 shares and reduce the par value of each share of common stock from \$0.01 to \$0.0001, (ii) undesignate all of Primedex s preferred stock, and (iii) increase the authorized number of shares of Primedex preferred stock from 10,000,000 shares to 30,000,000 shares and reduce the par value of each share of preferred stock from \$0.01 to \$0.0001;
4. To adopt an amendment to Primedex s certificate of incorporation to implement stock transfer restrictions to preserve Primedex s unrestricted use of its net operating loss carry-forwards;
5. To adopt Primedex s 2006 Stock Incentive Plan, substantially in the form attached hereto as *Annex E*;
6. To elect five directors to Primedex s board of directors;
7. To adopt an amendment to Primedex s certificate of incorporation to effect a one-for-two reverse stock split;
8. To ratify the appointment of Moss Adams LLP as Primedex s independent registered public accounting firm for the fiscal year ending October 31, 2006;
9. To approve adjournments or postponements of the Primedex special meeting, if necessary, to permit further solicitation of proxies if there are not sufficient votes at the time of the Primedex special meeting to approve the above proposals; and

In addition, Primedex stockholders may also consider and take action upon any other business that may properly come before the Primedex special meeting or any reconvened meeting following an adjournment or postponement of the Primedex special meeting.

These items of business are described in this joint proxy statement/prospectus. Only stockholders of record at the close of business on October 6, 2006, are entitled to notice of the Primedex special meeting and to vote at the Primedex special meeting and any adjournments or postponements of the Primedex special meeting.

Primedex's board of directors unanimously approved the merger agreement and the transactions contemplated by the merger agreement, including the merger, on July 6, 2006, and determined that the transactions contemplated by the merger agreement are advisable and fair to, and in the best interests of, Primedex and its stockholders. Primedex's board of directors recommends that you vote FOR the adoption of the merger agreement and the transactions contemplated by the merger agreement, including the merger and the issuance of Primedex common stock pursuant to the merger agreement.

Primedex's board of directors also recommends that you vote FOR all of the other Primedex special meeting proposals, all of which are described in detail in this joint proxy statement/prospectus. Approval of the other Primedex special meeting proposals is not a condition to the merger.

If a class of equity securities of Primedex is not listed on a national securities exchange at the time of the merger, under California law, any stockholder of Primedex will have the right to dissent from the merger by exercising dissenters' rights. If a Primedex stockholder elects to exercise dissenters' rights, the stockholder must precisely comply with all of the procedures set forth in Chapter 13 of the California General Corporation Law. These procedures are summarized in this joint proxy statement/prospectus.

Your vote is very important. Whether or not you plan to attend the Primedex special meeting in person, please complete, sign and date the enclosed proxy card(s) or voting instruction card(s) as soon as possible and return it in the postage-prepaid envelope provided, or vote your shares by telephone or over the Internet as described in this joint proxy statement/prospectus. Completing a proxy now will not prevent you from being able to vote at the special meeting by attending in person and casting a vote. **However, if you do not return or submit the proxy or vote in person at the meeting, the effect will be the same as a vote AGAINST the proposal to adopt and approve the merger agreement and the transactions contemplated by the merger agreement, including the merger.**

By order of the board of directors,

Norman R. Hames
Secretary and Vice President

Please vote your shares promptly. You can find instructions for voting on the enclosed proxy card or voting instruction card.

If you have questions, contact:

Primedex Health Systems, Inc.
1510 Cotner Avenue
Los Angeles, CA 90025
Attention: General Counsel
(310) 478-7808

Los Angeles, California, October 20, 2006

Your vote is important. Please complete, date, sign and return your proxy card(s) or voting instruction card(s) or, if available, vote your shares by telephone or over the Internet at your earliest convenience so that your shares are represented at the meeting.

TABLE OF CONTENTS

<u>SUMMARY</u>	1
<u>Information about Primedex</u>	1
<u>Information about Radiologix</u>	1
<u>Information about RadNet Management, Inc.</u>	1
<u>Information about PR Acquisition Corporation</u>	2
<u>The Merger</u>	2
<u>Financing of Merger</u>	3
<u>Fractional Shares</u>	3
<u>Radiologix Options and Unvested Shares</u>	4
<u>Recommendation of the Boards of Directors to Radiologix and Primedex Stockholders</u>	4
<u>Opinions of our Financial Advisors</u>	4
<u>Record Date: Outstanding Shares: Shares Entitled to Vote</u>	5
<u>Stock Ownership of Directors and Executive Officers</u>	6
<u>Ownership of Primedex After the Merger</u>	6
<u>Interests of Radiologix Directors and Executive Officers in the Merger</u>	6
<u>Primedex Board of Directors After the Merger</u>	7
<u>Listing of Primedex Common Stock and Delisting of Radiologix Common Stock</u>	7
<u>Appraisal and Dissenters' Rights</u>	7
<u>Conditions to the Closing of the Merger</u>	8
<u>Termination of the Merger Agreement</u>	11
<u>Termination Fees and Expenses</u>	12
<u>Limitation on Considering Other Acquisition Proposals</u>	15
<u>Material United States Federal Income Tax Consequences</u>	17
<u>Accounting Treatment</u>	17
<u>Risks</u>	17
<u>Comparison of Rights of Stockholders</u>	17
<u>FINANCIAL SUMMARY</u>	18
<u>Primedex Market Price Data and Dividends</u>	18
<u>Radiologix Market Price Data and Dividends</u>	19
<u>Selected Historical Financial Data of Primedex</u>	19
<u>Selected Historical Financial Data of Radiologix</u>	21
<u>SELECTED CONSOLIDATED FINANCIAL DATA (in thousands, except per share data)</u>	22
<u>PRIMEDEX HEALTH SYSTEMS, INC. UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS</u>	24
<u>PRIMEDEX HEALTH SYSTEMS, INC. UNAUDITED PRO FORMA CONDENSED COMBINED BALANCE SHEET JULY 31, 2006 (in thousands)</u>	25
<u>PRIMEDEX HEALTH SYSTEMS, INC. UNAUDITED PRO FORMA CONDENSED COMBINED STATEMENT OF OPERATIONS For the Nine Months Ended July 31, 2006 (in thousands, except per share data)</u>	26
<u>PRIMEDEX HEALTH SYSTEMS, INC. UNAUDITED PRO FORMA CONDENSED COMBINED STATEMENT OF OPERATIONS For the Twelve Months Ended October 31, 2005 (in thousands, except per share data)</u>	28
<u>NOTES TO UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS</u>	29
<u>QUESTIONS AND ANSWERS ABOUT THE STOCKHOLDER MEETINGS AND THE MERGER</u>	35
<u>The Merger</u>	35
<u>Other Primedex Special Meeting Proposals</u>	38

<u>Other Radiologix Special Meeting Proposals</u>	39
<u>Procedures</u>	40
<u>COMPARATIVE PER SHARE INFORMATION</u>	44
<u>COMPARATIVE MARKET VALUE INFORMATION</u>	46
<u>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</u>	47
<u>RISK FACTORS</u>	48
<u>Risks Relating to the Merger</u>	48
<u>Risks Relating to Primedex's Operations After the Consummation of the Merger</u>	50
<u>Risks Related to the Transfer Restrictions on Primedex Common Stock</u>	63
<u>Risks Related to Primedex's Future use of NOLs</u>	64
<u>THE RADIOLOGIX SPECIAL MEETING</u>	65
<u>General</u>	65
<u>Date, Time and Place of the Radiologix Special Meeting</u>	65
<u>Purposes of the Radiologix Special Meeting</u>	65
<u>Record Date and Outstanding Voting Securities</u>	65
<u>Voting and Revocation of Proxies</u>	66
<u>Required Stockholder Vote</u>	67
<u>Recommendation of Board of Directors</u>	68
<u>Other Business; Adjournments or Postponements</u>	68
<u>Solicitation of Proxies</u>	68
<u>Voting Agreement</u>	69
<u>Security Ownership of Principal Stockholders, Directors and Executive Officers</u>	69
<u>Assistance</u>	69
<u>Appraisal and Dissenters' Rights</u>	69
<u>Interest of Certain Persons in Matters to be Acted Upon</u>	69
<u>PROPOSAL NO. 1 ADOPTION OF THE MERGER AGREEMENT AND THE MERGER</u>	70
<u>Recommendation</u>	70
<u>PROPOSAL NO. 2 APPROVAL OF ADJOURNMENTS OR POSTPONEMENTS OF THE RADIOLOGIX SPECIAL MEETING</u>	70
<u>Recommendation</u>	70
<u>THE PRIMEDEX SPECIAL MEETING</u>	71
<u>General</u>	71
<u>Date, Time and Place of the Primedex Special Meeting</u>	71
<u>Purposes of the Primedex Special Meeting</u>	71
<u>Record Date and Outstanding Voting Securities</u>	72
<u>Voting and Revocation of Proxies</u>	72
<u>Required Stockholder Vote</u>	74
<u>Recommendation by the Board of Directors</u>	75
<u>Other Business; Adjournments or Postponements</u>	75
<u>Solicitation of Proxies</u>	76
<u>Security Ownership of Principal Stockholders, Directors and Executive Officers</u>	76
<u>Assistance</u>	76
<u>Appraisal and Dissenters' Rights</u>	76
<u>Interest of Certain Persons in Matters to be Acted Upon</u>	77
<u>Stockholder Proposals and Nominations</u>	77
<u>PROPOSAL NO. 1 ADOPTION OF THE MERGER AGREEMENT AND APPROVAL OF THE MERGER AND ISSUANCE OF PRIMEDEX COMMON STOCK PURSUANT TO THE MERGER AGREEMENT</u>	78
<u>Recommendation</u>	78
ii	

<u>PROPOSAL NO. 2 AMENDMENT TO CERTIFICATE OF INCORPORATION TO CHANGE NAME TO RADNET, INC.</u>	78
<u>Purpose of Proposed Name Change</u>	78
<u>Restated Certificate of Incorporation</u>	78
<u>Effect of Name Change on Stockholders</u>	79
<u>New Trading Symbol</u>	79
<u>Recommendation</u>	79
<u>PROPOSAL NO. 3 AMENDMENT TO CERTIFICATE OF INCORPORATION TO INCREASE AUTHORIZED NUMBER OF SHARES</u>	79
<u>Purpose and Effect of the Amendment</u>	80
<u>Existing Anti-Takeover Mechanisms</u>	81
<u>Recommendation</u>	82
<u>PROPOSAL NO. 4 AMENDMENT TO CERTIFICATE OF INCORPORATION TO IMPLEMENT TRANSFER RESTRICTIONS</u>	82
<u>Introduction</u>	82
<u>Limitations on use of NOLs</u>	82
<u>Summary of Transfer Restrictions</u>	83
<u>Expiration of Transfer Restrictions</u>	87
<u>Reasons for Transfer Restrictions</u>	87
<u>Interests of Certain Persons</u>	88
<u>Recommendation</u>	88
<u>PROPOSAL NO. 5 APPROVAL OF THE 2006 STOCK INCENTIVE PLAN</u>	88
<u>Description of the Proposal</u>	88
<u>Description of the 2006 Equity Incentive Plan</u>	88
<u>Award Types</u>	89
<u>Other Provisions of the 2006 Plan</u>	91
<u>Certain Federal Income Tax Information</u>	92
<u>Plan Benefits</u>	94
<u>Amendment and Termination</u>	94
<u>PROPOSAL NO. 6 ELECTION OF DIRECTORS</u>	94
<u>Recommendation</u>	95
<u>PROPOSAL NO. 7 AMENDMENT TO THE CERTIFICATE OF INCORPORATION FOR A REVERSE STOCK SPLIT</u>	95
<u>Reasons for Board Recommendation</u>	95
<u>Potential Disadvantages to Reverse Stock split</u>	95
<u>Effect on Fractional shares</u>	96
<u>Effect of Reverse Stock split on Options and Warrants</u>	96
<u>Implementation and Effect of the Reverse Stock split</u>	96
<u>Exchange of Stock certificates</u>	97
<u>No Appraisal Rights</u>	97
<u>Federal Income Tax consequences</u>	97
<u>Recommendation</u>	98
<u>PROPOSAL NO. 8 RATIFICATION OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</u>	98
<u>Audit Committee Pre-Approval Policy</u>	99
<u>Recommendation</u>	99
<u>PROPOSAL NO. 9 APPROVAL OF ADJOURNMENTS OR POSTPONEMENTS OF THE PRIMEDEX SPECIAL MEETING</u>	99
<u>Recommendation</u>	99
<u>THE MERGER</u>	100

<u>Background of the Merger</u>	100
<u>Radiologix's Reasons for the Merger and Recommendation of Radiologix's Board of Directors</u>	105
<u>Primedex's Reasons for the Merger and Recommendation of Primedex's Board of Directors</u>	107
<u>Opinions of Our Financial Advisors</u>	109
<u>Interests of Radiologix Directors and Executive Officers in the Merger</u>	126
<u>Primedex Board of Directors After the Merger</u>	126
<u>Employment, Change of Control and Severance Agreements</u>	127
<u>Employment Agreements</u>	127
<u>Change of Control Agreements</u>	127
<u>Settlement Payments to Executive Officers</u>	128
<u>Equity-Based Awards</u>	128
<u>Retirement Benefits; Profit Sharing Plan; Welfare Benefit Plan</u>	129
<u>Financing of the Merger</u>	129
<u>Accounting Treatment</u>	130
<u>Appraisal and Dissenters' Rights</u>	130
<u>Appraisal Rights of Radiologix Stockholders</u>	130
<u>Appraisal Rights of Primedex Stockholders</u>	134
<u>Delisting and Deregistration of Radiologix Common Stock</u>	136
<u>Federal Securities Laws Consequences; Resale Restrictions; Transfer Restrictions</u>	136
<u>MATERIAL UNITED STATES FEDERAL INCOME TAX CONSEQUENCES</u>	138
<u>U.S. Holders</u>	139
<u>Non-U.S. Holders</u>	140
<u>THE MERGER AGREEMENT</u>	141
<u>The Merger</u>	141
<u>Parties to the Merger Agreement</u>	141
<u>Completion and Effectiveness of the Merger</u>	141
<u>Conversion of Shares; Procedures for Exchange of Certificates</u>	141
<u>Financing of the Merger</u>	142
<u>Fractional Shares</u>	142
<u>Radiologix Options and Unvested Shares</u>	143
<u>Voting Agreement</u>	143
<u>Representations and Warranties</u>	143
<u>Material Adverse Effect</u>	144
<u>Conduct of Business Pending the Merger</u>	145
<u>Limitation on Considering Other Acquisition Proposals</u>	147
<u>Conditions to the Closing of the Merger</u>	149
<u>Termination of the Merger Agreement</u>	152
<u>Termination Fees and Expenses</u>	153
<u>Indemnification and Insurance for Radiologix's Directors and Officers</u>	156
<u>Extension, Waiver and Amendment of the Merger Agreement</u>	156
<u>COMPARISON OF RIGHTS OF STOCKHOLDERS</u>	157
<u>Authorized Capital Stock</u>	157
<u>Voting Rights</u>	158
<u>Cumulative Voting</u>	158
<u>Stockholders Meetings</u>	158
<u>Matters Relating to the Board of Directors</u>	160
<u>Preemptive Rights</u>	162
<u>Dividends</u>	162

<u>Limitation of Personal Liability of Directors</u>	163
<u>Indemnification of Directors and Officers</u>	163
<u>Anti-Takeover Matters</u>	164
<u>Certain Business Combination Restrictions</u>	164
<u>Vote on Certain Fundamental Issues</u>	165
<u>Amendments to Constituent Documents</u>	165
<u>INFORMATION ABOUT PRIMEDEX</u>	167
<u>Business</u>	167
<u>General</u>	167
<u>Business Strategy</u>	168
<u>Primedex's Services</u>	169
<u>Radiology Professional</u>	170
<u>Payors</u>	171
<u>Facilities</u>	172
<u>Diagnostic Imaging Equipment</u>	173
<u>Information Technology</u>	173
<u>Employees</u>	174
<u>Marketing</u>	174
<u>Suppliers</u>	175
<u>Competition</u>	175
<u>Insurance</u>	176
<u>Regulation</u>	176
<u>Environmental Matters</u>	181
<u>Properties</u>	182
<u>Legal Proceedings</u>	183
<u>Directors and Executive Officers of Primedex</u>	184
<u>Attendance at Board Meetings</u>	185
<u>Director Attendance at Special Meetings</u>	185
<u>Communications with the Board</u>	185
<u>Committees of the Board</u>	186
<u>Director Nomination Procedures</u>	186
<u>Director Compensation</u>	186
<u>Compensation Committee Interlocks and Insider Participation</u>	186
<u>Certain Relationships and Related Transaction</u>	187
<u>Compliance with Section 16(a) of the Exchange Act</u>	188
<u>Code of Ethics for Senior Financial Officers</u>	188
<u>Executive Compensation</u>	188
<u>SUMMARY COMPENSATION TABLE</u>	189
<u>AGGREGATED OPTION EXERCISES IN LAST FISCAL YEAR AND FISCAL YEAR END OPTION VALUES</u>	190
<u>STOCK INCENTIVE PLAN</u>	190
<u>Administration</u>	190
<u>Eligibility</u>	190
<u>Amount of Awards</u>	190
<u>Stock Options</u>	191
<u>Other Awards</u>	191
<u>Performance Criteria</u>	191
<u>Amendments</u>	192
<u>Employment Agreements</u>	192
<u>Report of the Audit Committee</u>	194

<u>Report on Executive Compensation</u>	195
<u>Stock Performance Graph</u>	197
<u>Stock Ownership of Directors and Executive Officers</u>	198
<u>Securities Authorized for Issuance Under Equity Compensation Plans</u>	199
<u>EQUITY COMPENSATION PLAN INFORMATION</u>	199
<u>MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS OF PRIMEDEX</u>	200
<u>Overview</u>	200
<u>Adoption of SFAS No. 123(R) and Equity-Based Compensation Expense</u>	201
<u>Primedex's Relationship With BRMG</u>	202
<u>Results of Operations</u>	203
<u>Nine Months Ended July 31, 2005 Compared To The Nine Months Ended July 31, 2006</u>	203
<u>Year Ended October 31, 2005 Compared To The Year Ended October 31, 2004</u>	208
<u>Year Ended October 31, 2004 Compared To The Year Ended October 31, 2003</u>	210
<u>STATEMENT OF OPERATIONS DATA</u>	214
<u>Financial Condition</u>	214
<u>Critical Accounting Estimates</u>	218
<u>Recent Events</u>	220
<u>Recent Accounting Pronouncements</u>	221
<u>Quantitative and Qualitative Disclosures About Market Risk</u>	223
<u>INFORMATION ABOUT RADIOLOGIX</u>	224
<u>Overview</u>	224
<u>Competitive Strengths/Business Strategy</u>	224
<u>Diagnostic Imaging Centers</u>	226
<u>Contracted Radiology Practices</u>	227
<u>Sales and Marketing</u>	228
<u>Government Regulation and Supervision</u>	228
<u>Competition</u>	234
<u>Corporate Liability and Insurance</u>	234
<u>Employees</u>	235
<u>Properties</u>	235
<u>Legal Proceedings</u>	235
<u>MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS OF RADIOLOGIX</u>	236
<u>Restatement of Financial Statements</u>	236
<u>Overview</u>	236
<u>Results of Operations</u>	239
<u>Six Months Ended June 30, 2006 Compared to Six Months Ended June 30, 2005</u>	239
<u>Year Ended December 31, 2005 Compared to Year Ended December 31, 2004</u>	241
<u>Imaging Centers - Questar</u>	242
<u>Management Services Agreements</u>	243
<u>Mid-Atlantic Management Services Agreement</u>	243
<u>Other Charges</u>	244
<u>Operating Expenses</u>	245
<u>Year Ended December 31, 2004 compared to year Ended December 31, 2003</u>	248
<u>Imaging Centers - Questar</u>	248
<u>Management Services Agreements</u>	249
<u>Mid-Atlantic Management Services Agreement</u>	249
<u>San Antonio, Texas Management Services Agreement</u>	250
<u>Other Management Services Agreement</u>	250

<u>Other Charges</u>	250
<u>Operating Expenses</u>	251
<u>SUMMARY OF OPERATIONS BY QUARTER</u>	254
<u>LIQUIDITY AND CAPITAL RESOURCES</u>	255
<u>CRITICAL ACCOUNTING POLICIES</u>	256
<u>SECURITY OWNERSHIP OF CERTAIN OWNERS AND MANAGEMENT OF RADIOLOGIX</u>	259
<u>DESCRIPTION OF PRIMEDEX CAPITAL STOCK</u>	261
<u>LEGAL MATTERS</u>	262
<u>EXPERTS</u>	262
<u>SUBMISSION OF FUTURE STOCKHOLDER PROPOSALS</u>	262
<u>WHERE YOU CAN FIND MORE INFORMATION</u>	263
<u>INDEX TO FINANCIAL STATEMENTS</u>	
<u>Primedex:</u>	
<u>Consolidated Financial Statements for the Years Ended October 31, 2003, 2004 and 2005</u>	
<u>Consolidated Balance Sheets as of October 31, 2004 and 2005</u>	F-3
<u>Consolidated Statements of Operations for the Years Ended October 31, 2003, 2004 and 2005</u>	F-4
<u>Consolidated Statements of Stockholders Deficit for the Years Ended October 31, 2003, 2004 and 2005</u>	F-5
<u>Consolidated Statements of Cash Flows for the Years Ended October 31, 2003, 2004 and 2005</u>	F-6
<u>Notes to Consolidated Financial Statements</u>	F-8
<u>Consolidated Financial Statements for the Nine Months Ended July 31, 2005 and 2006</u>	
<u>Consolidated Balance Sheets as of July 31, 2006 (Unaudited) and October 31, 2005 (Audited)</u>	F-28
<u>Consolidated Statements of Operations (Unaudited) for the nine months ended July 31, 2005 and 2006</u>	F-29
<u>Consolidated Statement of Stockholders Deficit (Unaudited) for the nine months ended July 31, 2006</u>	F-30
<u>Consolidated Statement of Cash Flows (Unaudited) for the nine months ended July 31, 2005 and 2006</u>	F-31
<u>Notes to Consolidated Financial Statements (Unaudited)</u>	F-32
<u>Radiologix:</u>	
<u>Consolidated Financial Statements for the Years Ended December 31, 2005, 2004 and 2003</u>	
<u>Consolidated Balance Sheets as of December 31, 2004 and 2005</u>	F-43
<u>Consolidated Statements of Operations for the Years Ended December 31, 2005, 2004 and 2003</u>	F-44
<u>Consolidated Statements of Stockholders Equity for the Years Ended December 31, 2005, 2004 and 2003</u>	F-45
<u>Consolidated Statements of Cash Flows for the Years Ended December 31, 2005, 2004 and 2003</u>	F-46
<u>Notes to Consolidated Financial Statements</u>	F-47
<u>Consolidated Financial Statements for the Six Months Ended June 30, 2005 and 2006 (Unaudited)</u>	
<u>Consolidated Balance Sheets as of June 30, 2006 (Unaudited) and December 31, 2005 (Audited)</u>	F-52

<u>Consolidated Statements of Operations (Unaudited) for the six months ended June 30, 2005 and 2006</u>	F-53
<u>Consolidated Statements of Cash Flows (Unaudited) for the six months ended June 30, 2005 and 2006</u>	F-54
<u>Schedule II Valuation and Qualifying Accounts</u>	F-84
<u>Notes to Consolidated Financial Statements (Unaudited)</u>	F-88
ANNEX A Agreement and Plan of Merger	A-1
ANNEX B Form of Amendment to Certificate of Incorporation	B-1
ANNEX C Opinion of Bear, Stearns & Co. Inc.	C-1
ANNEX D Opinion of Jefferies & Company, Inc.	D-1
ANNEX E 2006 Equity Incentive Plan	E-1
ANNEX F Selected Provisions of the Delaware General Corporation Law Regarding Appraisal Rights	F-1
ANNEX G Selected Provisions of the California General Corporation Law Regarding Dissenters' Rights	G-1
ANNEX H Primedex Health Systems, Inc. Audit Committee Of The Board Of Directors Charter	H-1
ANNEX I Form of Proxy Card for Radiologix Common Stockholder	I-1
ANNEX J Form of Proxy Card for Primedex Common Stockholder	J-1

SUMMARY

*This summary of the material information contained in this joint proxy statement/prospectus may not include all the information that is important to you. To fully understand the proposed merger, and for a more detailed description of the terms and conditions of the merger and other matters being considered at your stockholder meeting, you should read this entire joint proxy statement/prospectus and the documents to which we have referred you. See *Where You Can Find More Information* beginning on page 263. We have included page references parenthetically in this summary to direct you to a more detailed description of each topic presented in this summary.*

Information about Primedex (beginning on page 167)

Primedex, a New York corporation, through its subsidiaries, operates a group of regional networks comprised of 65 fixed-site, freestanding outpatient diagnostic imaging facilities in California. Primedex is headquartered in California and employs approximately 1,023 full-time, 65 part-time and 122 per-diem employees. Howard G. Berger, M.D. is Primedex's President and Chief Executive Officer, a member of Primedex's Board of Directors and owns approximately 30% of Primedex's outstanding common stock. Dr. Berger also owns, indirectly, 99% of the equity interests in Beverly Radiology Medical Group III, or BRMG. BRMG provides all of the professional medical services at 50 of Primedex's facilities under a management agreement with Primedex, and contracts with various other independent physicians and physician groups to provide the professional medical services at most of Primedex's other facilities.

Primedex Health Systems, Inc.
1510 Cotner Avenue
Los Angeles, CA 90025
Attention: General Counsel
(310) 478-7808

Information about Radiologix (beginning on page 224)

Radiologix, a Delaware corporation, through its subsidiaries, is a national provider of diagnostic imaging services through the ownership and operation of freestanding, outpatient diagnostic imaging centers. Radiologix owns, operates and maintains equipment in 69 locations, with imaging centers located in 7 states, including primary operations in the Mid-Atlantic; the Bay Area, California; the Treasure Coast area, Florida; Northeast Kansas; and the Finger Lakes (Rochester) and Hudson Valley areas of New York state.

Radiologix, Inc.
3600 JPMorgan Chase Tower
2200 Ross Avenue
Dallas, Texas 75201-2776
Attention: General Counsel
(214) 303-2776

Information about RadNet Management, Inc.

RadNet Management, Inc., a Delaware corporation, and a wholly-owned subsidiary of Primedex, is the operating subsidiary through which Primedex conducts its operations.

RadNet Management, Inc.
1510 Cotner Avenue
Los Angeles, CA 90025
Attention: General Counsel
(310) 478-7808

Information about PR Acquisition Corporation

PR Acquisition Corporation, a Delaware corporation, which is referred to as Merger Sub, is a direct wholly-owned subsidiary of RadNet Management, Inc. and an indirect wholly-owned subsidiary of Primedex. PR Acquisition Corporation has not engaged in any business activity other than activities related to the purpose of merging with Radiologix. If the merger is completed, Merger Sub will cease to exist following its merger with and into Radiologix.

PR Acquisition Corporation
1510 Cotner Avenue
Los Angeles, CA 90025
Attention: General Counsel
(310) 478-7808

The Merger (beginning on page 100)

General

On July 6, 2006, the boards of directors of Radiologix and Primedex each unanimously approved the merger of Radiologix with Merger Sub, a newly formed and wholly-owned indirect subsidiary of Primedex, upon the terms and subject to the conditions contained in the merger agreement. The surviving company of the merger will become a wholly-owned indirect subsidiary of Primedex.

We encourage you to read the merger agreement, which governs the merger and is attached as *Annex A* to this joint proxy statement/prospectus, because it sets forth the terms of the merger of Merger Sub with and into Radiologix.

Merger Consideration

If the merger is completed, holders of Radiologix common stock (other than dissenting Radiologix stockholders who properly exercise their appraisal rights) will be entitled to receive aggregate consideration of 22,621,922 shares of Primedex and \$42,950,000 in cash (cash and stock together is referred to as the merger consideration). After the merger is completed, Radiologix stockholders will have the right to receive the merger consideration but they will no longer have any rights as Radiologix stockholders. Based upon the closing price of Primedex common stock on October 6, 2006, the record date, of \$2.69, each Radiologix stockholder would receive \$1.78 in cash for each Radiologix share, plus one share of Primedex common stock for total consideration valued at \$4.47 per share. Based upon the closing price of Primedex common stock, on the record date, of \$2.69, Radiologix stockholders will collectively own approximately 33.9% of the outstanding Primedex shares, or 30.5% of the Primedex shares on a fully diluted basis. The merger agreement also provides Primedex the option to elect to reduce the share consideration by up to 3.5 million shares and to increase the cash consideration by \$2 per share, provided that Primedex advises Radiologix of its election prior to the mailing of this Proxy Statement. Primedex has advised Radiologix that it does not intend to exercise this option because Primedex believes it is in the best interests of all stockholders for Primedex to preserve the \$7 million of cash for other purposes. In connection with the proposals set forth in this proxy statement, Primedex's common stock may be subject to transfer restrictions which are necessary to preserve Primedex's unrestricted use of its net operating loss carry-forwards. Radiologix stockholders will receive the merger consideration after exchanging their Radiologix certificates in accordance with the instructions contained in the letter of transmittal to be sent to all Radiologix stockholders shortly after the closing of the merger.

The total value of the merger consideration that a Radiologix stockholder receives in the merger may vary. The value of the stock portion of the merger consideration is not fixed and will depend upon the value of Primedex common stock on the effective date of the merger. This value may be ascertained by

multiplying the trading price of Primedex common stock by the number of shares of Primedex common stock received in the merger. The value of the cash portion of the merger consideration will depend on the amount of cash delivered to Radiologix option holders. As illustrated in the table below, the cash portion of the merger consideration decreases as the value of Primedex common stock on the effective date of the merger increases. This result occurs because additional Radiologix option holders will receive cash out of the merger consideration equal to the difference between the value of the per share merger consideration and the exercise price per share of their options, as the value of Primedex common stock becomes greater than the exercise price of the option holder's option. As more Radiologix option holders hold options that are in-the-money, the total amount of cash delivered to such option holders increases and the cash available to the Radiologix stockholders decreases.

Hypothetical Trading Price of Primedex's Common Stock	Cash Consideration	Corresponding Value of Merger Consideration
\$2.00	\$ 1.83	\$3.83
\$2.05	\$ 1.83	\$3.88
\$2.10	\$ 1.83	\$3.93
\$2.15	\$ 1.82	\$3.97
\$2.20	\$ 1.82	\$4.02
\$2.25	\$ 1.82	\$4.07
\$2.30	\$ 1.81	\$4.11
\$2.35	\$ 1.81	\$4.16
\$2.40	\$ 1.80	\$4.20
\$2.45	\$ 1.80	\$4.25
\$2.50	\$ 1.80	\$4.30
\$2.55	\$ 1.79	\$4.34
\$2.60	\$ 1.79	\$4.39
\$2.65	\$ 1.79	\$4.44
\$2.70	\$ 1.78	\$4.48
\$2.75	\$ 1.78	\$4.53
\$2.80	\$ 1.77	\$4.57
\$2.85	\$ 1.77	\$4.62
\$2.90	\$1.77	\$4.67
\$2.95	\$1.76	\$4.71
\$3.00	\$1.76	\$4.76

Financing of Merger

Primedex has signed a commitment letter with GE Commercial Finance Healthcare Financial Services for a \$405 million senior secured credit facility, which is expected to close concurrently with the closing of the merger. The facility will be used to finance the merger, to refinance existing indebtedness, to pay transaction costs and expenses relating to the merger and the credit facility and to provide financing for working capital needs post-merger. Consummation of the financing is a condition to the closing of the merger.

Fractional Shares

No fractional Primedex common shares will be issued in the merger. Instead, holders who would otherwise be entitled to receive a fractional share of Primedex common stock will receive an amount in cash (without interest) determined by multiplying the fractional share interest by the average closing price for a share of Primedex common stock as reported on the Over-The-Counter Bulletin Board for the ten trading days prior to, but not including, the effective time of the merger.

Radiologix Options and Unvested Shares

Radiologix Stock Options

Holders of unvested options exercisable for Radiologix common stock will become vested in their options as a result of the merger. Holders of options exercisable for Radiologix common stock, whose exercise price per share is less than the value of the per share merger consideration, will receive for each share subject to such options an amount in cash out of the aggregate merger consideration equal to the difference between the value of the per share merger consideration and the exercise price per share of their options. Options exercisable for Radiologix common stock with an exercise price per share that is greater than the value of the per share merger consideration shall not be assumed or substituted by Primedex but shall vest upon the effective date of the merger and become fully exercisable to the holder of such option pursuant to the terms of the applicable option agreement. Any vested option that is not exercised prior to the effective time shall terminate and be void as of the effective time of the merger.

Unvested Shares of Radiologix Common Stock

Immediately prior to the effective time of the merger, Radiologix will have cancelled, repurchased, accelerated, vested or otherwise extinguished or awarded all shares of Radiologix common stock that are restricted, not fully vested or subject to any other restriction, and there will be no remaining unvested shares of Radiologix common stock at the effective time of the merger.

Recommendation of the Boards of Directors to Radiologix and Primedex Stockholders (beginning on page 105)

Radiologix Stockholders

The Radiologix board of directors believes that the merger agreement and the transactions contemplated by the merger agreement, including the merger, are advisable and fair to, and in the best interests of, Radiologix and its stockholders and has approved the merger agreement and the transactions contemplated by the merger agreement, including the merger. The Radiologix board of directors has unanimously resolved to recommend that Radiologix stockholders vote **FOR** the adoption of the merger agreement and the transactions contemplated by the merger agreement, including the merger.

Primedex Stockholders

The Primedex board of directors believes that the merger agreement and the transactions contemplated by the merger agreement, including the merger and the issuance of Primedex common stock pursuant to the merger agreement, are advisable and fair to, and in the best interests of, Primedex and its stockholders and has approved the merger agreement and the transactions contemplated by the merger agreement, including the merger and the issuance of shares of Primedex common stock pursuant to the merger agreement. The Primedex board of directors has unanimously resolved to recommend that Primedex stockholders vote **FOR** the approval and adoption of the merger agreement and the transactions contemplated by the merger agreement, including the merger and the issuance of Primedex common stock pursuant to the merger agreement.

Opinions of our Financial Advisors (beginning on page 109)

Opinion of Radiologix's Financial Advisor

In deciding to approve the merger agreement, the Radiologix board of directors considered the opinion of Radiologix's financial advisor, Bear, Stearns & Co. Inc., which is referred to as Bear Stearns. The Radiologix board of directors received a written opinion from Bear Stearns to the effect that, as of July 6, 2006, and based upon and subject to the various considerations, assumptions and limitations

described in its opinion, the merger consideration to be received by holders of shares of Radiologix common stock pursuant to the merger agreement was fair, from a financial point of view, to such holders. The full text of Bear Stearns' written opinion is attached to this joint proxy statement/prospectus as *Annex C*. Radiologix encourages you to read this opinion carefully in its entirety for a description of the procedures followed, assumptions made, matters considered and limitations on the review undertaken. Bear Stearns' opinion is addressed to the Radiologix board of directors and is one of many factors considered by the Radiologix board of directors in deciding to approve the merger. Bear Stearns' opinion does not constitute a recommendation to any stockholder as to how such stockholder should vote or whether such stockholder should take any other action relating to the transaction. For its services, Bear Stearns will be entitled to receive a transaction fee equal to 1.10% of the total aggregate value of the merger consideration paid to Radiologix stockholders, currently estimated to be \$2,200,000, the principal portion of which is payable upon the completion of the transaction.

Opinion of Primedex's Financial Advisor

Jefferies & Company, Inc., which is referred to as Jefferies, served as Primedex's financial advisor in connection with the merger. On July 6, 2006, Jefferies rendered to Primedex's board of directors its opinion as investment bankers to the effect that, as of that date and based upon and subject to the various considerations and assumptions set forth therein, the aggregate merger consideration of 22,621,922 shares of Primedex common stock and \$42.95 million in cash to be paid by Primedex pursuant to the merger was fair, from a financial point of view, to Primedex. The full text of the Jefferies opinion, which sets forth the assumptions made, matters considered and limitations on the scope of review undertaken by Jefferies in rendering its opinion, is attached to this joint proxy statement/prospectus as *Annex D*. The Jefferies opinion was provided to Primedex's board of directors in connection with its consideration of the merger. The Jefferies opinion does not constitute a recommendation as to how any Primedex stockholder should vote on the merger or any other matter. For its services, Jefferies will be entitled to a transaction fee of \$2,000,000, of which \$500,000 was paid upon delivery of its opinion and the balance of which is payable upon the completion of the transaction.

Record Date; Outstanding Shares; Shares Entitled to Vote (beginning on page 72 for Primedex and 65 for Radiologix)

Radiologix Stockholders

The record date for the special meeting of Radiologix stockholders was October 6, 2006. This means that you must have been a stockholder of record of Radiologix's common stock at the close of business on October 6, 2006, in order to vote at the special meeting. You are entitled to one vote for each share of common stock you own.

Contrarian Equity Fund, L.P., the largest single Radiologix stockholder, which owns approximately 16.9% of the outstanding shares of Radiologix common stock, is a party to a voting agreement with Primedex under which it is obligated to vote its shares in favor of adopting the merger agreement and the merger.

Primedex Stockholders

The record date for the special meeting of Primedex stockholders was October 6, 2006. This means that you must have been a stockholder of record of Primedex's common stock at the close of business on October 6, 2006, in order to vote at the special meeting. You are entitled to one vote for each share of common stock you own.

Stock Ownership of Directors and Executive Officers

Radiologix

At the close of business on the record date for the Radiologix special meeting, directors and executive officers of Radiologix and their affiliates beneficially owned and were entitled to vote approximately 400,773 shares of Radiologix common stock, collectively representing 1.8% of the shares of Radiologix common stock outstanding on that date.

Primedex

At the close of business on the record date for the Primedex special meeting, directors and executive officers of Primedex and their affiliates beneficially owned and were entitled to vote approximately 20,258,475 shares of Primedex common stock, collectively representing approximately 33% of the shares of Primedex common stock outstanding on that date, on a fully diluted basis.

Ownership of Primedex After the Merger

Based on the number of shares of Primedex and Radiologix common stock outstanding on the record date, after completion of the merger, Primedex will issue 22,621,922 shares of Primedex common stock and former Radiologix stockholders will own approximately 33.9% of the outstanding shares of Primedex common stock.

Interests of Radiologix Directors and Executive Officers in the Merger (beginning on page 126)

When considering the recommendation of its board of directors with respect to the merger agreement and the transactions contemplated by the merger agreement, including the merger, Radiologix stockholders should be aware that some directors and executive officers of Radiologix have interests in the transactions contemplated by the merger agreement that may be different from, or in addition to, their interests as stockholders and the interests of Radiologix stockholders. These interests include:

- payments under employment agreements which are triggered in the event of a merger;
- potential appointment to the Primedex board of directors following the merger;
- potentially becoming executive officers, employees or consultants of Primedex after the transaction;
- accelerated vesting and exercisability of Radiologix stock options, restricted stock and restricted stock units issued under Radiologix's equity compensation plans;
- with respect to certain Radiologix officers and employees who continue employment with Primedex immediately after the effective date of the merger, to the extent the closing of the merger occurs during the 2006 calendar year, continued benefits under Radiologix plans until December 31, 2006, and to the extent the closing of the merger occurs after the 2006 calendar year, continued benefits under Radiologix plans for six months after the closing or the end of the calendar year in which the closing of the merger occurs, whichever is earlier;
- with respect to the Radiologix officers who do not continue employment with Primedex immediately after the effective date of the merger, payment of up to \$1,000 per month to cover the medical insurance benefits described in such officer's employment agreement until the earlier of (a) two years after the effective date of the merger or (b) the date on which such individual obtains substantially equivalent benefits from another party; and
- Primedex's agreement to indemnify each present and former Radiologix officer and director against liabilities arising out of that person's services as an officer or director, and maintain directors' and

officers liability insurance for a period of six years after closing to cover Radiologix directors and officers, subject to various limitations.

The Radiologix board of directors was aware of these arrangements during its deliberations on the merits of the merger and in deciding to recommend that you vote for the adoption of the merger agreement and the transactions contemplated by the merger agreement, including the merger, at the Radiologix special meeting.

Primedex Board of Directors After the Merger

The members of the Primedex board of directors who are in office immediately prior to the merger are expected to remain as members of the Primedex board of directors following the merger if elected pursuant to Primedex's proposal No. 6. Promptly after the effective date of the merger, Primedex shall use its reasonable best efforts to cause to be elected to its board of directors up to three persons designated by Radiologix and reasonably acceptable to Primedex, two of whom shall, no later than January 1, 2007, meet the independence requirements of the SEC and any applicable exchange on which Primedex's common stock is then traded.

Listing of Primedex Common Stock and Delisting of Radiologix Common Stock

Application will be made to have the shares of Primedex common stock issued in the merger approved for listing on the Over-The-Counter Bulletin Board, where Primedex common stock currently is traded under the symbol PMDX.OB. If Primedex's proposal No. 2 is approved to change Primedex's name to Radnet, Inc., Primedex common stock will then trade on the Over-The-Counter Bulletin Board under the symbol RDNT. If the merger is completed, Radiologix common stock will no longer be listed on the American Stock Exchange and will be deregistered under the Securities Exchange Act of 1934, as amended, which is referred to as the Exchange Act, and Radiologix will no longer file periodic reports with the SEC.

Primedex intends to apply to have its shares of common stock listed on a national securities exchange or the NASDAQ Stock Market as soon as reasonably practicable after Primedex meets the listing criteria. Initial listing on a national securities exchange or the NASDAQ Stock Market requires the satisfaction by Primedex of quantitative listing standards relating to minimum trading price, market capitalization, number of public stockholders, market value of public float and other criteria. Primedex does not currently qualify for listing under these criteria. Primedex will work diligently to be listed on a national securities exchange or the NASDAQ Stock Market but can give no assurance that such listing will occur after the merger, or at all.

Appraisal and Dissenters' Rights (beginning on page 130)

Radiologix

Holders of Radiologix common stock who do not wish to accept the consideration payable pursuant to the merger may seek, under Section 262 of the Delaware General Corporation Law, or DGCL, judicial appraisal of the fair value of their shares by the Delaware Court of Chancery. This value could be more than, less than or the same as the merger consideration for the Radiologix common stock. Failure to strictly comply with all the procedures required by Section 262 of the DGCL will result in a loss of the right to appraisal.

Annex F to this joint proxy statement/prospectus contains the full text of Section 262 of the DGCL, which relates to the rights of appraisal. We encourage you to read these provisions carefully and in their entirety.

Merely voting against the merger will not preserve the right of Radiologix stockholders to appraisal under Delaware law. Also, because a submitted proxy not marked against or abstain will be voted for the proposal to adopt the merger agreement and the transactions contemplated by the merger agreement, including the merger, the submission of a proxy not marked against or abstain will result in the waiver of appraisal rights. Radiologix stockholders who hold shares in the name of a broker or other nominee must instruct their nominee to take the steps necessary to enable them to demand appraisal for their shares.

Holders of Radiologix common stock are not entitled to appraisal rights in connection with any other proposals to be voted on at the Radiologix special meeting.

Primedex

Under New York law, holders of Primedex common stock are not entitled to appraisal rights in connection with either the approval of the merger agreement and the transactions contemplated by the merger agreement, including the merger, or the issuance of Primedex common stock in the merger or in connection with any other proposal to be voted on at the Primedex special meeting.

Under California law, if a class of equity securities of Primedex is not listed on the NASDAQ Stock Market (or another applicable national securities exchange) at the time of the merger, a holder of Primedex common stock may have the right to dissent from the merger by exercising dissenters' rights. If a Primedex stockholder elects to exercise dissenters' rights, the stockholder must precisely comply with all of the procedures set forth in Chapter 13 of the California General Corporation Law. Merely voting against the merger will not preserve the right of Primedex stockholders to appraisal under California law. *Annex G* to this joint proxy statement/prospectus sets forth the full text of Chapter 13 of the California General Corporation Law, which relates to rights of appraisal. We encourage you to read these provisions carefully and in their entirety.

Conditions to the Closing of the Merger (beginning on page 149)

The merger is subject to the satisfaction or waiver of various conditions, which include the following:

Primedex and Radiologix are not obligated to effect the merger unless the following conditions are satisfied or waived:

- the merger agreement is adopted by Primedex and Radiologix stockholders at the stockholder meetings of the companies;
- the shares of Primedex common stock issuable to Radiologix stockholders pursuant to the merger agreement are authorized for listing on the Over-The-Counter Bulletin Board;
- no governmental entity has obtained, enacted, issued, promulgated or enforced any statute, rule, regulation, executive order, decree, judgment, injunction, arbitration award, finding or other order (whether temporary, preliminary or permanent), in any case that is in effect and prevents or prohibits consummation of the merger;
- any applicable waiting periods, together with any extensions thereof, under the HSR Act (as defined herein) and other applicable antitrust laws required to consummate the merger shall have expired or been terminated;
- this joint proxy statement/prospectus has become effective under the Securities Act of 1933, as amended and there are no stop orders or proceedings initiated or threatened to suspend this joint proxy statement/prospectus; and

- there is no pending or threatened action, suit, proceeding, claim, arbitration or investigation in which any governmental entity is a party wherein an unfavorable injunction, judgment, order, decree, charge or ruling would:
- prevent, restrain or otherwise interfere with the consummation of the merger;
- adversely affect the right or powers of Primedex to own, operate or control Radiologix or any portion of the business or assets of Radiologix or Primedex; and
- no such injunction, judgment or ruling is in effect.

Primedex and Merger Sub are not obligated to effect the merger unless the following additional conditions are satisfied or waived:

- the representations and warranties made by Radiologix in the merger agreement related to Radiologix's organization, capitalization, authority to enter into the merger agreement and complete the merger, and its receipt of necessary consents and governmental approvals are true and correct in all material respects as of the date of the merger agreement and as of the effective time of the merger (except that those representations and warranties that address matters only as of a particular date need only be true and correct as of such date);
- Radiologix's remaining representations and warranties in the merger agreement and in any certificate or other writing delivered by Radiologix pursuant to the merger agreement, in each case disregarding all qualifications and exceptions contained therein relating to materiality or material adverse effect, are true and correct as of the date of the merger agreement and as of the effective time of the merger (except that those representations and warranties that address matters only as of a particular date need only be true and correct as of such date), except where the failure of such representations and warranties to be so true and correct has not had and would not have a material adverse effect on Radiologix;
- Radiologix has performed or complied in all material respects with all agreements and covenants required by the merger agreement to be performed or complied with by Radiologix on or prior to the effective time of the merger;
- there has not occurred any material adverse effect with respect to Radiologix;
- Radiologix has obtained the consent or approval of each person or entity whose consent or approval is required under any contract to which Radiologix or any of its subsidiaries is a party, except where the failure to obtain any consent or approval would not have a material adverse effect on Radiologix;
- Radiologix has obtained and delivered to Primedex all consents, waivers and approvals required under all material real property and equipment leases to which Radiologix or any of its subsidiaries is a party, except where the failure to obtain any consent or approval would not have a material adverse effect on Radiologix;
- Radiologix has obtained all permits, authorizations, consents, and approvals required on its part to perform its obligations under and consummate the merger agreement, except where the failure to obtain such permits, authorizations, consents and approval would not have a material adverse effect on Radiologix;
- Radiologix has delivered to Primedex a certificate, signed by Radiologix's chief executive officer and dated as of the closing date, to the effect that the conditions set forth in the merger agreement have been satisfied;

- Primedex has consummated the financing described in the commitment letter from GE Commercial Finance Healthcare Financial Services dated June 27, 2006 with respect to a financing in the amount of \$405 million;
- holders of no more than 10% of outstanding Radiologix common shares entitled to appraisal of their shares have properly demanded appraisal of their shares in accordance with applicable law;
- holders of no more than 10% of outstanding Primedex common shares have exercised or retain the unexpired right to exercise dissenters' rights (or similar rights of dissent) in respect of the merger available under applicable law;
- Primedex has received all permits and approvals necessary under state securities laws to consummate the merger;
- Radiologix has cash (not including restricted cash) on its balance sheet of at least \$32.6 million as of the closing date; and
- Primedex has received an affiliates letter from each of Radiologix's directors and officers identified as an affiliate of Radiologix within the meaning of Rule 145 promulgated under the Securities Act of 1933.

Radiologix is not obligated to effect the merger unless the following additional conditions are satisfied or waived:

- Primedex's and Merger Sub's representations and warranties in the merger agreement related to Primedex's and Merger Sub's organization, capitalization, authority to enter into the merger agreement, necessary consents and governmental approvals are true and correct in all material respects as of the date of the merger agreement and as of the effective time of the merger (except that those representations and warranties that address matters only as of a particular date need only be true and correct as of such date);
- Primedex's and Merger Sub's remaining representations and warranties in the merger agreement and in any certificate or other writing delivered by Primedex or Merger Sub pursuant to the merger agreement, in each case disregarding all qualifications and exceptions contained therein relating to materiality or material adverse effect on Primedex, are true and correct as of the date of the merger agreement and as of the effective time of the merger (except that those representations and warranties that address matters only as of a particular date need only be true and correct as of such date), except where the failure of such representations and warranties to be so true and correct has not had and would not have a material adverse effect on Primedex;
- Primedex has performed or complied with all agreements and covenants required by the merger agreement to be performed or complied with by Primedex on or prior to the effective time of the merger, except where the failure to perform or comply with agreements and covenants required by the merger agreement has not had and would not have a material adverse effect on Primedex;
- there has not occurred any material adverse effect with respect to Primedex; and
- Primedex has delivered to Radiologix a certificate, signed by an authorized officer of Primedex and dated as of the closing date, to the effect that the conditions set forth in the merger agreement have been satisfied.

Antitrust Clearance

The completion of the merger is subject to compliance with the Hart Scott Rodino Antitrust Improvements Act, which we refer to as the HSR Act. The notifications required under the HSR Act to

the U.S. Federal Trade Commission, or the FTC, and the Antitrust Division of the U.S. Department of Justice, or the Antitrust Division, were filed on July 21, 2006, and early termination of the waiting period was granted August 21, 2006.

Primedex and Radiologix have agreed to use their reasonable best efforts to take, or cause to be taken, all actions necessary proper or advisable under applicable law and regulations, including the HSR Act, to complete the merger as promptly as practicable, but in no event later than April 30, 2007, which date may be extended to May 31, 2007, in circumstances described below, in Summary Termination of the Merger Agreement beginning on page 11 and in The Merger Agreement Termination of the Merger Agreement beginning on page 152.

Termination of the Merger Agreement (beginning on page 152)

Primedex and Radiologix can terminate the merger agreement before the effective date of the merger under enumerated circumstances, including:

- by mutual written consent of Primedex and Radiologix;
- by either Primedex or Radiologix, if the merger has not been completed before April 30, 2007, provided that such date may be extended by Primedex or Radiologix up to and including May 31, 2007 if all conditions to effect the merger other than one or more regulatory conditions have been or are capable of being satisfied at the time of such extension, and the regulatory conditions have been or are reasonably capable of being satisfied on or prior to May 31, 2007;
- by either Primedex or Radiologix, if any governmental entity has issued any statute, rule, regulation, executive order, decree, judgment, injunction, arbitration award, finding or other order (whether temporary, preliminary or permanent), that is in effect and that prevents or prohibits consummation of the merger;
- by either Primedex or Radiologix, if Radiologix stockholders do not adopt the merger agreement at the special meeting and, in the case of a termination by Radiologix, the failure to obtain stockholder approval is not the result of Radiologix's violation of the merger agreement. If, at the time of such termination, Primedex was entitled to terminate pursuant to the following bullet, termination by Radiologix as a result of Radiologix stockholders' non-adoption of the merger agreement is effective only if Radiologix fulfills any obligations Radiologix may have to pay a termination fee of \$3 million to Primedex and to reimburse Primedex for up to \$1 million for its fees and expenses incurred in connection with the transactions contemplated by the merger agreement;
- by Primedex, if prior to the receipt of Radiologix stockholder approval:
- Radiologix's board of directors withdraws, withholds, amends or modifies in a manner adverse to Primedex its recommendation to Radiologix's stockholders in favor of adoption of the merger agreement;
- Radiologix fails to include such recommendation in this proxy statement;
- Radiologix's board of directors approves or publicly recommends to its stockholders any other acquisition proposal;
- Radiologix enters into any letter of intent or other contract for any other acquisition proposal;
- Radiologix breaches any of its covenants relating to its obligation to hold the stockholder meeting, its board of directors' obligation to recommend the adoption of the merger agreement or its obligation not to solicit other acquisition proposals; or

- Radiologix's board of directors fails to make a statement recommending the rejection of a tender or exchange offer not made by Primedex or any of its affiliates for Radiologix common stock within 10 business days after such tender or exchange offer is first published or given.
- by either Primedex or Radiologix, if Primedex stockholders do not adopt the merger agreement at the special meeting and, in the case of a termination by Primedex, the failure to obtain stockholder approval is not the result of Primedex's violation of the merger agreement.
- by Primedex, if there is a material adverse effect with respect to Radiologix or if any of Radiologix's covenants, agreements, representations or warranties are breached and not cured within 20 business days and, as a result of Radiologix's breach or misrepresentation, the conditions to closing would not be satisfied;
- by Radiologix, if there is a material adverse effect with respect to Primedex, RadNet or Merger Sub or if any of the covenants, agreements, representations or warranties of Primedex or Merger Sub is breached and not cured within 20 business days and, as a result, the conditions to closing would not be satisfied; and
- by Radiologix, if prior to the receipt of Radiologix stockholder approval:
- Radiologix has not violated any of the covenants with respect to considering other acquisition proposals,
- a superior offer is made to Radiologix and is not withdrawn,
- Radiologix has promptly provided written notice to Primedex advising Primedex that Radiologix has received a superior offer and intends to change the recommendation of its board of directors with respect to the merger or to terminate the merger agreement and the manner and timing in which Radiologix intends to do so,
- Primedex has not, within five days after receipt of the notice of superior offer, made an offer that Radiologix's board of directors determines in its good faith judgment (after consultation with a financial advisor) to be at least as favorable to Radiologix stockholders as such superior offer, and
- Radiologix's board of directors concludes in good faith, after consultation with its outside legal counsel, that, in light of such superior offer and any offer made by Primedex within five days after receipt of the notice of superior offer, the Radiologix board is required to withdraw or modify its recommendation to Radiologix stockholders to vote in favor of the merger, or to terminate the merger agreement and pay to Primedex a termination fee of \$3 million plus up to \$1 million for fees and expenses incurred by Primedex in connection with the transactions contemplated by the merger agreement, to comply with its fiduciary obligations to Radiologix stockholders under applicable law.

Termination Fees and Expenses (beginning on page 153)

Primedex

The merger agreement provides that Primedex will pay to Radiologix the sum of the fees and expenses Radiologix incurred in connection with the transactions contemplated by the merger agreement, in an amount up to \$1 million, if the merger agreement is terminated by Radiologix under either of the following circumstances:

- any of Primedex's, RadNet's or Merger Sub's representations or warranties set forth in the merger agreement have become untrue or incorrect, Primedex, RadNet or Merger Sub has not cured the misrepresentation within 20 business days after written notice of the misrepresentation, and the misrepresentation would cause conditions to the closing of the merger not to be satisfied; or

- Primedex, RadNet or Merger Sub has breached any of its covenants or agreements set forth in the merger agreement, has not cured the breach within 20 business days after written notice of the breach and the breach would cause conditions to the closing of the merger not to be satisfied.

Radiologix

The merger agreement provides that Radiologix will pay to Primedex the sum of the fees and expenses Primedex incurred in connection with the transactions contemplated by the merger agreement, in an amount up to \$1 million, if the merger agreement is terminated under the following circumstances:

- by either Primedex or Radiologix, if Radiologix stockholders do not adopt the merger agreement at the special meeting of Radiologix stockholders and an alternative acquisition proposal is publicly announced at any time after the date of the merger agreement and before the vote on the merger agreement at the special meeting;
- by Primedex, if prior to the receipt of Radiologix stockholder approval:
 - the Radiologix board of directors withdraws, withholds, amends or modifies in a manner adverse to Primedex its recommendation to Radiologix stockholders in favor of adoption of the merger agreement;
 - Radiologix fails to include such recommendation in this proxy statement;
 - the Radiologix board of directors approves or recommends to Radiologix stockholders any other acquisition proposal;
 - Radiologix enters into any letter of intent or other contract for any other acquisition proposal;
 - Radiologix breaches any of its covenants with respect to its obligation to hold the stockholder meeting, its board of director's obligation to recommend to Radiologix stockholders the adoption of the merger agreement, or Radiologix's obligation not to solicit other acquisition proposals; or
 - Radiologix's board of directors fails to make a statement recommending the rejection of a tender or exchange offer not made by Primedex or any of its affiliates for Radiologix common stock within 10 business days after such tender or exchange offer is first published or given;
- by Primedex, if:
 - any of Radiologix's representations or warranties set forth in the merger agreement have become untrue or incorrect, Radiologix has not cured the misrepresentation within 20 business days after written notice of the misrepresentation, and the misrepresentation would cause conditions to the closing of the merger not to be satisfied; or
 - Radiologix has breached any of its covenants or agreements set forth in the merger agreement, has not cured the breach within 20 business days after written notice of the breach and the breach would cause conditions to the closing of the merger not to be satisfied;
- by Radiologix, if prior to the receipt of Radiologix stockholder approval:
 - Radiologix has not violated any of the covenants with respect to considering other acquisition proposals,
 - a superior offer is made to Radiologix and is not withdrawn,

- Radiologix has promptly provided written notice to Primedex advising Primedex that Radiologix has received a superior offer and intends to change the recommendation of its board of directors with respect to the merger or to terminate the merger agreement and the manner and timing in which it intends to do so;

13

- Primedex has not, within five days after receipt of the notice of superior offer, made an offer that Radiologix's board of directors determines in its good faith judgment (after consultation with a financial advisor) to be at least as favorable to Radiologix stockholders as such superior offer, and
- Radiologix's board of directors concludes in good faith, after consultation with its outside legal counsel, that, in light of such superior offer and any offer made by Primedex within five days after receipt of the notice of superior offer, the Radiologix board is required to withdraw or modify its recommendation to Radiologix stockholders to vote in favor of the merger, or to terminate the merger agreement and pay to Primedex a termination fee of \$3 million, to comply with its fiduciary obligations to Radiologix's stockholders under applicable law.

In addition to payment of Primedex's expenses, Radiologix must pay Primedex a termination fee of \$3 million if the merger agreement is terminated:

- by Primedex, if prior to the receipt of Radiologix stockholder approval:
- the Radiologix board of directors withdraws, withholds, amends or modifies in a manner adverse to Primedex its recommendation to Radiologix stockholders in favor of adoption of the merger agreement;
- Radiologix fails to include such recommendation in this proxy statement;
- the Radiologix board of directors approves or recommends to Radiologix stockholders any other acquisition proposal;
- Radiologix enters into any letter of intent or other contract for any other acquisition proposal;
- Radiologix breaches any of its covenants with respect to its obligation to hold the stockholder meeting, its board of director's obligation to recommend to Radiologix stockholders the adoption of the merger agreement, or Radiologix's obligation not to solicit other acquisition proposals; or
- Radiologix's board of directors fails to make a statement recommending the rejection of a tender or exchange offer not made by Primedex or any of its affiliates for Radiologix common stock within 10 business days after such tender or exchange offer is first published or given;
- by Radiologix, if its stockholders do not adopt the merger agreement at the special meeting, and if at such time Primedex was entitled to terminate pursuant to any of the circumstances described in the immediately preceding bullet points;
- by Radiologix or Primedex, if Radiologix stockholders do not adopt the merger as a result of Radiologix's breach of the merger agreement, and an alternative acquisition proposal has been publicly announced at any time after the date of the merger agreement and before the vote on the merger agreement at the special meeting, and Radiologix enters into an alternative acquisition transaction involving at least 50% of its stock or assets within twelve months after the termination of the merger agreement; or
- by Radiologix, if prior to the receipt of Radiologix stockholder approval:
- Radiologix has not violated any of the covenants with respect to considering other acquisition proposals;
- a superior offer is made to Radiologix and is not withdrawn;

- Radiologix has promptly provided written notice to Primedex advising Primedex that Radiologix has received a superior offer and intends to change the recommendation of its board of directors with respect to the merger or to terminate the merger agreement and the manner and timing in which it intends to do so;

14

- Primedex has not, within five days after receipt of the notice of superior offer, made an offer that Radiologix's board of directors determines in its good faith judgment (after consultation with a financial advisor) to be at least as favorable to Radiologix stockholders as such superior offer; and
- Radiologix's board of directors concludes in good faith, after consultation with its outside legal counsel, that, in light of such superior offer and any offer made by Primedex within five days after receipt of the notice of superior offer, the Radiologix board is required to withdraw or modify its recommendation to Radiologix stockholders to vote in favor of the merger, or to terminate the merger agreement and pay to Primedex a termination fee of \$3 million, to comply with its fiduciary obligations to Radiologix's stockholders under applicable law.

Limitation on Considering Other Acquisition Proposals (beginning on page 147)

Radiologix has agreed that it will not, and will not permit any of its subsidiaries to, and will use all reasonable efforts to ensure that Radiologix or its representatives do not, directly or indirectly:

- solicit, initiate, seek, entertain, encourage, facilitate, support or induce any acquisition proposal or the making of any inquiry or proposal that could reasonably be expected to lead to an acquisition proposal;
- enter into, participate in, maintain or continue any communications or negotiations regarding, or furnish to any person any non-public information in response to or in connection with, any acquisition proposal;
- agree to, accept, approve, endorse or recommend any acquisition proposal;
- enter into any letter of intent or any other contract relating to any acquisition proposal;
- submit any acquisition proposal to the vote of Radiologix stockholders;
- withhold, withdraw or modify, in a manner adverse to Primedex, the approval of the Radiologix board of directors of the merger agreement; or
- take any action or position that is inconsistent with, or withdraw or modify, in a manner adverse to Primedex, the unanimous recommendation of the board that Radiologix stockholders vote in favor of the adoption of the merger agreement.

An acquisition proposal means any agreement, offer, proposal or indication of interest (other than from Primedex) relating to, or involving: the acquisition by any person or group of more than a 10% interest in Radiologix's total outstanding voting securities or more than a 5% interest in the total outstanding voting securities of any material company subsidiary or any tender or exchange offer that would result in any person beneficially owning 10% or more of Radiologix's total outstanding voting securities or more than a 5% interest in the total outstanding voting securities of any material company subsidiary; any merger or other business combination involving Radiologix or its subsidiaries; or any sale, lease, mortgage, exchange, license, acquisition, transfer, pledge or disposition of 10% or more of Radiologix's consolidated assets.

At any time prior to obtaining stockholder approval, subject to various restrictions, the Radiologix board of directors may nevertheless in response to an acquisition proposal that the Radiologix board of directors concludes in good faith (after consultation with outside legal and financial advisors) is, or is reasonably likely to become, a superior offer:

- enter into discussions with the person making the acquisition proposal; and
- furnish to the person making the acquisition proposal information with respect to Radiologix and its subsidiaries pursuant to a confidentiality agreement which contains terms that are at least as restrictive as the terms of the confidentiality agreement that Radiologix and Primedex have

executed in connection with the merger and provided that Radiologix furnishes Primedex with the same information it has furnished to the person making the acquisition proposal prior to or at the same time as the information is furnished to the person making the acquisition proposal.

However, in each case:

- neither Radiologix, its subsidiaries, nor any of Radiologix's or its subsidiaries' directors, officers, employees, affiliates, accountants, consultants, legal counsel, advisors, investment bankers, brokers, agents and other representatives will have violated the restrictions on considering other acquisition proposals set forth in the merger agreement and summarized in the preceding bullet points;
- the Radiologix board of directors must first conclude in good faith, after consultation with outside legal counsel, that such action is reasonably required for the Radiologix board to comply with its fiduciary obligations to Radiologix stockholders; and
- Radiologix must first notify Primedex in writing of the identity of the person making such acquisition proposal and the material terms and conditions of such acquisition proposal, and Radiologix's intention to take actions in response to such acquisition proposal.

A superior offer means an unsolicited, bona fide written offer made by a third party for the acquisition by any person or group of more than a 50% interest in total outstanding Radiologix voting securities or any tender or exchange offer that would result in any person beneficially owning 50% or more of Radiologix's total outstanding voting securities; any merger or other business combination involving Radiologix or its subsidiaries; or any sale, lease, transfer, pledge or disposition of 50% or more of its consolidated assets, on terms that the Radiologix board of directors has in good faith concluded (after consultation with outside legal counsel and financial advisor) to be more favorable, from a financial point of view, to Radiologix stockholders than the terms of the merger agreement and is reasonably capable of being consummated.

Radiologix has agreed to advise Primedex within twenty-four hours of the receipt of any acquisition proposal, of any inquiry or offer that contemplates an acquisition proposal, any other notice that any person is considering making an acquisition proposal, or any request for non-public information that could reasonably be expected to lead to an acquisition proposal:

- of the material terms and conditions of such acquisition proposal, inquiry or request, and
- the identity of the person making any such acquisition proposal, inquiry or request.

Nothing in the merger agreement prevents the Radiologix board of directors from withholding or modifying its unanimous recommendation to Radiologix stockholders in favor of adoption of the merger agreement, or terminating the merger agreement simultaneously with the payment of a termination fee to Primedex in the amount of \$3 million plus up to \$1 million for incurrence by Primedex of expenses in connection with the transactions contemplated by the merger agreement, if: Radiologix stockholders' approval of the merger has not yet been obtained; Radiologix has not violated any of the restrictions on considering other acquisition proposals set forth in the merger agreement and summarized in the preceding paragraphs; a superior offer is made to Radiologix and is not withdrawn; Radiologix has promptly provided written notice to Primedex of the superior offer and the Radiologix board of directors' intent to change its recommendation or to terminate the merger agreement; Primedex has not, within 5 business days after receipt of the written notice of a superior offer, made an offer to Radiologix that the Radiologix board of directors concludes in its good faith judgment after consultation with a financial advisor of national standing to be at least as favorable to Radiologix stockholders as such superior offer; and the Radiologix board of directors has concluded in good faith, after consultation with legal counsel, that, in light of such superior offer and any offer made by Primedex, it is required to withhold or modify such recommendation, or to terminate the merger agreement and pay to Primedex a termination fee in the amount of \$3 million plus up to \$1 million for incurrence by Primedex of expenses in connection with the

transactions contemplated by the merger agreement, to comply with its fiduciary obligations to Radiologix stockholders under applicable legal requirements.

Material United States Federal Income Tax Consequences (beginning on page 138)

The merger will be taxable for U.S. federal income tax purposes to Radiologix stockholders. As a result, Radiologix stockholders will recognize gain or loss in respect of the merger equal to the difference between (i) the sum of the amount of cash received and the fair market value of the shares of Primedex common stock received as of the effective time of the merger and (ii) the stockholder's adjusted tax basis in his or its shares of Radiologix common stock. Such gain or loss will be capital gain or loss if the stockholder held his or its shares of Radiologix common stock exchanged in the merger for more than one year.

Tax matters are complicated, and the tax consequences of the merger to each Radiologix stockholder will depend on the facts of each stockholder's situation. Radiologix stockholders are urged to read carefully the discussion in the section entitled "Material United States Federal Income Tax Consequences" beginning on page 138 and to consult their own tax advisors for a full understanding of the tax consequences of their participation in the merger.

Accounting Treatment

The merger will be accounted for as a business combination using the purchase method of accounting. Primedex will be the acquirer for financial accounting purposes.

Risks (beginning on page 48)

In evaluating the merger you should carefully read this joint proxy statement/prospectus and especially consider the factors discussed in the section entitled "Risk Factors" beginning on page 48.

Comparison of Rights of Stockholders (beginning on page 157)

As a result of the merger, the holders of Radiologix common stock will become holders of Primedex common stock. Following the merger, Radiologix stockholders will have different rights as stockholders of Primedex than as stockholders of Radiologix due to differences among New York, California and Delaware law, and the difference between the certificates of incorporation and by-laws of Primedex and Radiologix.

For a summary of the material differences between the rights of Radiologix stockholders and Primedex stockholders, see "Comparison of Rights of Stockholders" beginning on page 157.

FINANCIAL SUMMARY**Primedex Market Price Data and Dividends**

Primedex common stock trades on the Over-The-Counter Bulletin Board under the symbol PMDX.OB. The following table shows for the periods indicated the high and low sales prices for Primedex common stock as reported on the Over-The-Counter Bulletin Board.

Fiscal Year Ended	Price Range of Common Stock	
	High	Low
October 31, 2004:		
First Quarter	\$.75	\$.38
Second Quarter	.72	.38
Third Quarter	.47	.27
Fourth Quarter	.70	.30
October 31, 2005:		
First Quarter	\$.60	\$.41
Second Quarter	.49	.24
Third Quarter	.43	.26
Fourth Quarter	.43	.26
October 31, 2006:		
First Quarter	\$.59	\$.25
Second Quarter	1.40	.35
Third Quarter	2.10	1.20
Fourth Quarter (through October 13, 2006)	2.90	1.50

The last reported sales prices of Primedex common stock on the Over-The-Counter Bulletin Board on July 6, 2006, and October 13, 2006, were \$1.75 and \$2.64, respectively. July 6, 2006, was the last full trading day prior to the public announcement of the merger. October 13, 2006, was the most recent practicable date prior to the mailing of this joint proxy statement/prospectus to Primedex's and Radiologix's stockholders.

As of October 6, 2006, the record date, there were approximately 3,935 holders of record of Primedex common stock.

The Primedex board of directors has the power to determine the amount and frequency of the payment of dividends. Decisions regarding whether or not to pay dividends and the amount of any dividends are based on compliance with the New York Business Corporations Law, California General Corporation Law, compliance with agreements governing Primedex's indebtedness, earnings, cash requirements, results of operations, cash flows, financial condition and other factors that the board of directors considers important.

Radiologix Market Price Data and Dividends

Radiologix common stock is traded on the American Stock Exchange under the symbol RGX. The following table shows for the periods indicated the high and low sales prices for Radiologix common stock on the American Stock Exchange.

Fiscal Year Ended	Price Range of Common Stock	
	High	Low
December 31, 2004:		
First Quarter	\$ 4.25	\$ 3.25
Second Quarter	4.65	3.31
Third Quarter	4.68	3.30
Fourth Quarter	4.53	2.99
December 31, 2005:		
First Quarter	\$ 4.98	\$ 4.08
Second Quarter	4.27	3.10
Third Quarter	4.55	3.15
Fourth Quarter	3.84	2.75
December 31, 2006:		
First Quarter	\$ 3.03	\$ 1.47
Second Quarter	2.40	1.60
Third Quarter	4.10	2.15
Fourth Quarter (through October 13, 2006)	4.13	3.83

The last reported sales prices of Radiologix common stock on the American Stock Exchange on July 6, 2006, and October 13, 2006, were \$2.25 and \$4.05, respectively. July 6, 2006, was the last full trading day prior to the public announcement of the merger. October 13, 2006, was the most recent practicable date prior to the mailing of this joint proxy statement/prospectus to Primedex's and Radiologix's stockholders.

As of October 6, 2006, the record date, there were approximately 68 holders of record of Radiologix common stock.

The Radiologix board of directors has the power to determine the amount and frequency of the payment of dividends. Decisions regarding whether or not to pay dividends and the amount of any dividends are based on compliance with the DGCL, compliance with agreements governing Radiologix's indebtedness, earnings, cash requirements, results of operations, cash flows, financial condition and other factors that the board of directors considers important.

Selected Historical Financial Data of Primedex

The following table shows selected historical financial data for Primedex. The data has been derived from Primedex's audited consolidated financial statements for each of the five years ended October 31, 2005, and unaudited consolidated financial statements for the nine months ended July 31, 2005 and 2006.

This information is only a summary. Detailed historical financial information is included in the audited consolidated balance sheets as of October 31, 2005, and October 31, 2004, and the related consolidated statements of operations, stockholders' equity and cash flows for each of the years in the three-year period ended October 31, 2005 included in Primedex's Annual Report on Form 10-K for the fiscal year ended October 31, 2005, filed with the SEC on February 14, 2006, as amended on October 2, 2006. You should read the following selected financial data together with Primedex's historical consolidated financial statements, including the related notes, the section titled "Management's Discussion and Analysis of Financial Condition and Results of Operations of Primedex" and the other information

Edgar Filing: RADIOLOGIX INC - Form DEFM14A

contained or incorporated by reference in this joint proxy statement/prospectus. See [Where You Can Find More Information](#) beginning on page 263.

	Years Ended October 31,					Nine Months Ended	
	2005	2004	2003	2002	2001	July 31, 2006 (Unaudited)	2005
(Amounts in thousands, except per share data)							
Net Revenue	\$ 145,573	\$ 137,277	\$ 140,259	\$ 134,078	\$ 107,567	\$ 118,462	\$ 105,478
Operating Expenses							
Operating expenses	109,012	105,828	106,078	102,286	75,457	88,701	79,792
Depreciation and amortization	17,101	17,762	16,874	15,010	10,315	12,175	12,905
Provision for bad debts	4,929	3,911	4,944	6,892	3,851	4,739	2,789
Loss on disposal of equipment, net	696					210	698
Total operating expenses	131,738	127,501	127,896	124,188	89,623	105,825	96,184
Income from Operations	13,835	9,776	12,363	9,890	17,944	12,637	9,294
Other Expense (Income)							
Interest expense	17,493	17,285	17,948	16,627	13,521	14,386	12,788
Loss (Gain) on debt extinguishment, net						2,097	(515)
Other income	(872)	(176)	(556)	(765)	(4,817)		(173)
Other expense	349	1,657	334	552	563	788	25
Total other expense	16,970	18,766	17,726	16,414	9,267	17,271	12,125
Income (Loss) Before Income Taxes, Minority Interest and Discontinued Operation	(3,135)	(8,990)	(5,363)	(6,524)	8,677	(4,634)	(2,831)
Income Tax Provision (Benefit)		5,235			(5,110)		
Income (Loss) Before Minority Interest and Discontinued Operation	(3,135)	(14,225)	(5,363)	(6,524)	13,787	(4,634)	(2,831)
Equity in Income of investee						61	
Minority Interest in Earnings (Loss) of Subsidiaries		351	101	(89)	(26)		
Income (Loss) from Continuing Operations	(3,135)	(14,576)	(5,464)	(6,435)	13,813	(4,573)	(2,831)
Discontinued Operation:							
Income from operation of Westchester Imaging Group			255	884	688		
Gain on sale of discontinued operation			2,942				
Income from Discontinued Operation			3,197	884	688		
Net Income (Loss)	\$ (3,135)	\$ (14,576)	\$ (2,267)	\$ (5,551)	\$ 14,501	\$ (4,573)	\$ (2,831)
Basic Earnings Per Share							
Income (loss) from continuing operations	\$ (0.08)	\$ (0.35)	\$ (0.13)	\$ (0.16)	\$ 0.34	\$ (0.11)	\$ (0.07)
Income from discontinued operation			0.08	0.02	0.02		
Basic Net Income (Loss) Per Share	\$ (0.08)	\$ (0.35)	\$ (0.05)	\$ (0.14)	\$ 0.36	\$ (0.11)	\$ (0.07)
Diluted Earnings Per Share							
Income (loss) from continuing operations	\$ (0.08)	\$ (0.35)	\$ (0.13)	\$ (0.16)	\$ 0.31	\$ (0.11)	\$ (0.07)
Income from discontinued operation			0.08	0.02	0.02		
Diluted Net Income (Loss) Per Share	\$ (0.08)	\$ (0.35)	\$ (0.05)	\$ (0.14)	\$ 0.33	\$ (0.11)	\$ (0.07)
Weighted Average Shares Outstanding							
Basic	41,208	41,107	41,091	40,876	39,961	41,664	41,137
Diluted	41,208	41,107	41,091	40,876	44,171	41,664	41,137

	As of October 31,					As of July 31,	
	2005	2004	2003	2002	2001	2006 (Unaudited)	2005
Balance Sheet Data:							
Working capital	\$ (143,430)	\$ (32,172)	\$ (44,615)	\$ (44,668)	\$ (26,987)	\$ (357)	
Total assets	121,233	127,451	142,035	151,639	128,429	126,600	
Line of Credit, Notes Payable and Capital							
Lease Obligations	149,794	153,142	149,534	158,587	131,190	158,290	
Subordinated Bond Debentures	16,147	16,147	16,215	16,291	16,303	16,147	
Stockholders' Equity	(70,633)	(67,555)	(53,087)	(50,921)	(45,642)	(74,569)	

Selected Historical Financial Data of Radiologix

The following table shows selected historical financial data for Radiologix. The data as of and for each of the five years ended December 31, 2005, were derived from Radiologix's audited consolidated financial statements and the data for the six months ended June 30, 2005 and 2006 were derived from Radiologix's unaudited consolidated financial statements.

This information is only a summary. Detailed historical financial information is included in the audited consolidated balance sheets as of December 31, 2005, and December 31, 2004, and the related consolidated statements of operations, stockholders' equity and cash flows for each of the years in the three-year period ended December 31, 2005, included in Radiologix's Annual Report on Form 10-K for the fiscal year ended December 31, 2005, filed with the SEC on March 31, 2006, as amended. You should read the following selected financial data together with Radiologix's historical consolidated financial statements, including the related notes, the section titled "Management's Discussion and Analysis of Financial Condition and Results of Operations of Radiologix" and the other information contained or incorporated by reference in this joint proxy statement/prospectus. See "Where You Can Find More Information" beginning on page 262.

SELECTED CONSOLIDATED FINANCIAL DATA

(in thousands, except per share data)

	YEAR ENDED DECEMBER 31,					For the Six Months Ended June 30,	
	2005	2004(a)(b) (As restated)	2003(c)	2002	2001(d)	2006(e) (unaudited)	2005 (As restated)
SERVICE FEE REVENUE	\$ 251,440	\$ 251,291	\$ 242,038	\$ 256,344	\$ 256,334	\$ 130,246	\$ 127,062
COSTS OF OPERATIONS:							
Cost of services	160,898	158,613	149,034	145,049	138,715	81,248	80,449
Equipment lease	13,035	17,660	17,230	15,653	18,357	7,642	6,037
Provision for doubtful accounts	19,033	22,337	20,228	21,540	22,877	10,887	9,126
Depreciation and amortization	23,430	22,999	23,926	24,568	22,037	12,024	11,502
Gross profit	35,044	29,682	31,620	49,534	54,348	18,445	19,948
Severance and Other Related Costs	670	405	1,568	978			
Lease Termination Expense		13,948					
Corporate General and Administrative	16,872	18,919	15,335	15,172	14,336	9,164	9,333
Impairment of Goodwill, Intangible and Long-lived Assets	2,241	14,558	523	794			
Merger Related Costs					1,000		
Supplemental Incentive Compensation					615		
Loss on Early Extinguishment of Debt					4,730		
Interest Expense, Net	18,295	18,596	19,281	18,388	14,911	8,803	9,241
Gain on Sale of Operations		(4,669)					
Income (loss) before Equity in Earnings of Unconsolidated Affiliates, Non-Operating Income, Minority Interest in Consolidated Subsidiaries, Income Taxes and Discontinued Operations	(3,034)	(32,075)	(5,087)	14,202	18,756	478	1,374
Equity in Earnings of Unconsolidated Affiliates	3,928	2,865	4,082	4,568	5,017	2,070	1,661
Non-Operating Income					1,300		
Minority Interests In Income of Consolidated Subsidiaries	(632)	(791)	(748)	(1,185)	(1,092)	(378)	(303)
INCOME (LOSS) BEFORE INCOME TAXES AND DISCONTINUED OPERATIONS	262	(30,001)	(1,753)	17,585	23,981	2,170	2,732
Income Tax Expense (Benefit)	662	(5,848)	(701)	7,034	9,592	170	169
INCOME (LOSS) FROM CONTINUING OPERATIONS	(400)	(24,153)	(1,052)	10,551	14,389	2,000	2,563
Discontinued Operations:							
Income (loss) from discontinued operations before income taxes	(1,131)	(13,128)	(11,519)	342	(931)	277	(404)
Income tax expense (benefit)		(5,426)	(4,608)	137	(372)		
Income (loss) from discontinued operations	(1,131)	(7,702)	(6,911)	205	(559)	277	(404)
NET INCOME (LOSS)	\$ (1,531)	\$ (31,855)	\$ (7,963)	\$ 10,756	\$ 13,830	\$ 2,277	\$ 2,159
EARNINGS (LOSS) PER COMMON SHARE:							
Income (loss) from continuing operations basic	\$ (0.02)	\$ (1.11)	\$ (0.05)	\$ 0.50	\$ 0.74	0.09	0.12
Income (loss) from discontinued operations basic	(0.05)	(0.35)	(0.32)	0.01	(0.03)	0.01	(0.02)
Net income (loss) basic	\$ (0.07)	\$ (1.46)	\$ (0.37)	\$ 0.51	\$ 0.71	\$ 0.10	\$ 0.10
Income (loss) from continuing operations diluted	\$ (0.02)	\$ (1.11)	\$ (0.05)	\$ 0.47	\$ 0.68	\$ 0.09	\$ 0.11
Income (loss) from discontinued operations diluted	(0.05)	(0.35)	(0.32)	0.01	(0.02)	0.01	(0.01)
Net income (loss) diluted	\$ (0.07)	\$ (1.46)	\$ (0.37)	\$ 0.48	\$ 0.66	\$ 0.10	\$ 0.10
WEIGHTED AVERAGE SHARES OUTSTANDING:							
Basic	22,067,445	21,789,517	21,724,165	20,957,026	19,559,185	22,242,417	22,128,425
Diluted	22,067,445	21,789,517	21,724,165	23,967,427	22,652,372	22,316,713	22,625,931

(a) Service fee revenue and equity in earnings of unconsolidated affiliates were reduced by \$9.1 million and \$286,000, respectively, due to a change in estimating contractual adjustments, in the fourth quarter of 2004.

Edgar Filing: RADIOLOGIX INC - Form DEFM14A

(b) Cost of services for the year ended December 31, 2004 includes: (i) \$315,000 for lease termination costs related to diagnostic equipment no longer in use; (ii) \$200,000 to write-off software costs associated with canceling a software contract and (iii) \$295,000 for a litigation settlement.

(c) Cost of services for the year ended December 31, 2003 includes: (i) \$546,000 to meet HIPAA compliance requirements, (ii) \$775,000 associated with self reporting certain lease agreements terms to the U.S. Department of Health & Human Services Office of the Inspector General (OIG), (iii) \$300,000 for a legal settlement, and (iv) \$363,000 for financing costs related to an amendment of the credit facility.

(d) Non-operating income in 2001 represents \$1.3 million for partial consideration for an early termination of management services provided at certain imaging centers not owned or operated by Radiologix.

(e) Cost of services for the six months-ended June 30, 2006, includes \$245,000 for litigation expenses.

	As of December 31,					As of June 30,
	2005	2004	2003	2002	2001	2006
		(As restated)				(unaudited)
Balance Sheet Data:						
Working capital	\$ 70,509	\$ 72,644	\$ 74,050	\$ 60,450	\$ 55,214	\$ 76,049
Total assets	234,528	238,889	279,514	296,091	284,725	237,154
Long-term debt and capital lease obligations	158,364	158,519	162,075	166,249	172,947	158,348
Convertible debt	11,980	11,980	11,980	11,980	24,205	11,980
Stockholders equity	28,971	29,097	60,684	68,367	44,476	31,995

PRIMEDEX HEALTH SYSTEMS, INC.
UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS

The unaudited pro forma condensed combined financial statements are based on the historical consolidated statements of Primedex after giving effect to the merger with Radiologix, borrowings used to finance the merger and the assumptions and adjustments described in the attached to the unaudited pro forma condensed combined financial statements.

The unaudited pro forma condensed combined statement of operations is prepared using the historical consolidated statements of operations of Primedex for the year ended October 31, 2005 and the nine months ended July 31, 2006 and the historical consolidated statements of operations of Radiologix for the year ended December 31, 2005 and the nine months ended June 30, 2006 as if the merger and borrowings to finance the merger occurred on November 1, 2004. The unaudited pro forma condensed combined balance sheet is presented as if the merger and borrowings used to finance the merger occurred on July 31, 2006 and combines the unaudited condensed balance sheets of Primedex as of July 31, 2006 and Radiologix as of June 30, 2006.

The preliminary allocation of purchase price used in the unaudited pro forma condensed combined financial statements is based upon preliminary estimates. The estimates and assumptions are subject to change upon the effective date of the merger and finalization of the valuation of Radiologix's assets and liabilities. The unaudited pro forma condensed combined financial statements do not include the effects of any anticipated operating efficiencies or cost savings upon the merger. The unaudited pro forma condensed combined financial statements are for illustrative purposes only, and are not necessarily indicative of the consolidated results of operations or financial position of Primedex that would have been reported had the merger and borrowings been completed as of the dates presented, and should not be taken as representative of the future consolidated results of operations or financial position of Primedex. The pro forma adjustments are based on preliminary information available at the time of the preparation of this document. Estimated valuation of stock-based compensation included in the unaudited pro forma condensed combined financial statement for the year ended October 31, 2005 for Primedex and the year ended December 31, 2005 for Radiologix do not include the impact of SFAS No. 123 (revised 2004) Share-Based Payment (SFAS No. 123R).

GE Healthcare Financial Services has provided a commitment for a \$405.0 million of senior debt financing, which includes a \$45.0 million revolving credit facility for working capital and general corporate purposes that will be substantially undrawn and available to Primedex at the close of the transaction. The remaining \$360.0 million will fund the cash purchase price of Radiologix and refinance substantially all of the existing debt of Primedex and Radiologix.

The unaudited pro forma condensed combined financial statements and the accompanying notes are based upon the respective historical consolidated financial statements of Primedex and Radiologix and should be read in conjunction with the historical consolidated financial statements and accompanying notes of Primedex and Radiologix included in this filing.

PRIMEDEX HEALTH SYSTEMS, INC.

UNAUDITED PRO FORMA CONDENSED COMBINED BALANCE SHEET

July 31, 2006

(in thousands)

	Primedex July 31, 2006	Radiologix June 30, 2006	Pro Forma Adjustments		Pro Forma Combined
Assets					
Current assets:					
Cash and cash equivalents	\$ 2	\$ 43,671	\$ (43,180)	A	\$ 493
Restricted cash		5,750			5,750
Accounts receivable, net of allowances	24,299	41,237			65,536
Unbilled receivables and other receivables	1,035				1,035
Due from affiliates		704			704
Federal and state income tax receivables		6,101			6,101
Other current assets	3,533	4,643			8,176
Total current assets	28,869	102,106	(43,180)		87,795
Long-term assets:					
Property and equipment, net	62,836	68,610	14,020	B	145,466
Accounts receivable, net of allowances	1,379				1,379
Investments in joint ventures		9,113			9,113
Goodwill	23,099		41,396	C	64,495
Other intangible assets, net		52,384	7,725	D	60,109
Deferred financing costs, net	5,198	4,117	(132)	E	9,183
Other assets	5,219	824	(1,075)	F	4,968
Total long-term assets	97,731	135,048	61,934		294,713
Total assets	\$ 126,600	\$ 237,154	\$ 18,754		\$ 382,508
Liabilities and Stockholders Equity					
Current liabilities:					
Cash disbursements in transit	\$ 5,748	\$	\$		\$ 5,748
Accounts payable and other accrued expenses	20,962	8,777	(3,760)	G	25,979
Accrued physician retention		8,115			8,115
Accrued salaries and benefits		7,767	3,403	H	11,170
Accrued interest		683	357	I	1,040
Accrued restructuring charges			332	J	332
Current maturities of term loan B			2,250	K	2,250
Current maturities of notes payable	867		(860)	K	7
Current maturities of capital lease obligations	1,849	33			1,882
Other current liabilities		682			682
Total current liabilities	29,426	26,057	1,722		57,205
Long-term liabilities:					
Subordinated bond debentures	16,147		(16,147)	K	
Line of credit	6,868		(2,868)	K	4,000
Term loan B-long term			222,750	K	222,750
Second lien credit facility-long term			135,000	K	135,000
Long-term debt, net of current portion	145,154	158,270	(303,356)	K	68
Convertible debt		11,980	(11,980)	K	
Capital lease obligations, net of current portion	3,552	45			3,597
Deferred revenue		6,290	(6,290)	L	
Other liabilities	22	1,372			1,394
Total long-term liabilities	171,743	177,957	17,109		366,809
Commitments and contingencies					
Minority interests in consolidated subsidiaries		1,145			1,145
Stockholders equity	(74,569)	31,995	(77)	M	(42,651)
Total liabilities and stockholders equity	\$126,000	\$237,154	\$18,754		\$382,508

PRIMEDEX HEALTH SYSTEMS, INC.
UNAUDITED PRO FORMA CONDENSED COMBINED STATEMENT OF OPERATIONS
For the Nine Months Ended July 31, 2006
(in thousands, except per share data)

	For the Nine Months Ended July 31, 2006 Primedex	For the Nine Months Ended June 30, 2006 Radiologix(1)	Pro Forma Adjustments		Pro Forma Combined
Service fee revenue	\$ 118,462	\$ 192,366	\$ (307)	N	\$ 310,521
Cost of operations:					
Cost of services	88,701	121,308	12,667	O	222,676
Equipment leases		11,095	174	P	11,269
Provision for doubtful accounts	4,739	16,273			21,012
Depreciation and amortization	12,175	18,021	1,374	Q	31,570
Loss (gain) on disposal of equipment, net	210				210
Gross profit	12,637	25,669	(14,522)		23,784
Severance and other related costs		670			670
Corporate general and administrative		12,841	(12,841)	S	
Impairment of goodwill, intangible and long-lived assets		2,241			2,241
Interest expense, net, including amortization of deferred financing costs	14,386	13,296	2,154	T	29,836
Loss (gain) on debt extinguishment	2,097				2,097
Other expense (income), net	788				788
Income (loss) before equity in earnings of unconsolidated affiliates, minority interests in consolidated subsidiaries, income taxes and discontinued operations	(4,634)	(3,379)	(3,835)		(11,848)
Equity in earnings of unconsolidated affiliates	61	3,110			3,171
Minority interests in income of consolidated subsidiaries		(523)			(523)
LOSS BEFORE INCOME TAXES FROM CONTINUING OPERATIONS	(4,573)	(792)	(3,835)		(9,200)
Income tax expense		388			388
LOSS FROM CONTINUING OPERATIONS	\$ (4,573)	\$ (1,180)	\$ (3,835)		\$ (9,588)
LOSS PER COMMON SHARE:					
Loss from continuing operations basic	\$ (0.11)	\$ (0.05)			\$ (0.15)
Loss from continuing operations diluted	\$ (0.11)	\$ (0.05)			\$ (0.15)
WEIGHTED AVERAGE SHARES OUTSTANDING:					
Basic	41,663,841	22,242,417	379,505	M	64,285,763
Diluted	41,663,841	22,242,417	379,505	M	64,285,763

(1) The financial statements of Radiologix, Inc. for the interim period were derived by adding the three months ended December 31, 2005, to Radiologix's six months ended June 30, 2006. The nine months

ended June 30, 2006, includes the three-month period ended December 31, 2005, which also was included in the pro forma income statement for the year ended December 31, 2005. Summarized operating information about the duplicated quarter is as follows:

Service fee revenue	\$	62,120	
Cost of operations:			
Cost of services		40,060	
Equipment leases		3,453	
Provision for doubtful accounts		5,386	
Depreciation and amortization		5,997	
Gross profit		7,224	
Severance and other related costs		670	
Corporate general and administrative		3,677	
Impairment of goodwill, intangible and long-lived assets		2,241	
Interest expense, net, including amortization of deferred financing costs		4,493	
Loss before equity in earnings of unconsolidated affiliates, minority interests in consolidated subsidiaries, income taxes and discontinued operations		(3,857))
Equity in earnings of unconsolidated affiliates		1,040)
Minority interests in income of consolidated subsidiaries		(145))
LOSS BEFORE INCOME TAXES FROM CONTINUING OPERATIONS		(2,962))
Income tax expense		218	
LOSS FROM CONTINUING OPERATIONS	\$	(3,180))
LOSS PER COMMON SHARE:			
Loss from continuing operations basic		(0.14))
Loss from continuing operations diluted		(0.14))
WEIGHTED AVERAGE SHARES OUTSTANDING:			
Basic		22,242,417	
Diluted		22,242,417	

PRIMEDEX HEALTH SYSTEMS, INC.
UNAUDITED PRO FORMA CONDENSED COMBINED STATEMENT OF OPERATIONS
For the Twelve Months Ended October 31, 2005
(in thousands, except per share data)

	For the Twelve Months Ended October 31, 2005 Primedex	For the Twelve Months Ended December 31, 2005 Radiologix	Pro Forma Adjustments		Pro Forma Combined
Service fee revenue	\$ 145,573	\$ 251,440	\$ (409)	N	\$ 396,604
Cost of operations:					
Cost of services	109,012	160,898	16,687	O	286,597
Equipment leases		13,035	166	P	13,201
Provision for doubtful accounts	4,929	19,033			23,962
Depreciation and amortization	17,101	23,430	1,834	Q	42,365
Gain on disposal of equipment, net	696		19	R	715
Gross profit	13,835	35,044	(19,115)		29,764
Corporate general and administrative		16,872	(16,872)	S	
Impairment of goodwill, intangible and long-lived assets		2,241			2,241
Interest expense, net, including amortization of deferred financing costs	17,493	18,295	3,999	T	39,787
Other expense (income), net	(523)	670			147
Loss before equity in earnings of unconsolidated affiliates, minority interests in consolidated subsidiaries, income taxes and discontinued operations	(3,135)	(3,034)	(6,242)		(12,411)
Equity in earnings of unconsolidated affiliates		3,928			3,928
Minority interests in income of consolidated subsidiaries		(632)			(632)
INCOME (LOSS) BEFORE INCOME TAXES FROM CONTINUING OPERATIONS	(3,135)	262	(6,242)		(9,115)
Income tax expense		662			662
LOSS FROM CONTINUING OPERATIONS	\$ (3,135)	\$ (400)	\$ (6,242)		\$ (9,777)
LOSS PER COMMON SHARE:					
Loss from continuing operations basic	\$ (0.08)	\$ (0.02)			\$ (0.15)
Loss from continuing operations diluted	\$ (0.08)	\$ (0.02)			\$ (0.15)
WEIGHTED AVERAGE SHARES OUTSTANDING:					
Basic	41,207,909	22,067,445	554,477	M	63,829,831
Diluted	41,207,909	22,067,445	554,477	M	63,829,831

**NOTES TO UNAUDITED PRO FORMA
CONDENSED COMBINED FINANCIAL STATEMENTS**

1. Basis of Pro Forma Presentation

On July 6, 2006, Primedex Health Systems, Inc. and Radiologix, Inc. entered into a definitive agreement under which Primedex would merge with and into Radiologix in a business combination to be accounted for using the purchase method. The combined unaudited pro forma historical financial statements assume the issuance of 22,621,922 shares of Primedex common stock and \$42,950,000 in cash. The average market price per share of Primedex common stock of approximately \$1.74 is based on the average closing price for June 28, 2006 through July 13, 2006.

The estimated purchase price and the allocation of the estimated purchase price discussed below are preliminary based on management's best estimate because the proposed merger has not yet been completed and the final valuation has not been completed. The final allocation of the purchase price will be based on Radiologix's assets and liabilities on the closing date.

The following notes to the unaudited pro forma condensed consolidated financial statements give effect to the Radiologix merger as if it had occurred, for balance sheet purposes, on July 31, 2006 and, for statement of operations purposes, on November 1, 2004. The preliminary estimated total purchase price of the merger is as follows:

	(in thousands)
Value of stock given by Primedex to Radiologix	\$ 39,400 *
Cash	42,950
Estimated transaction fees and expenses	13,552 **
Total Purchase Price	\$ 95,902

(*) Calculated as 22,621,922 shares multiplied by \$1.74 (average closing price for June 28, 2006 to July 13, 2006).

(**) Includes \$6,940,000 in assumed liabilities of Radiologix, including \$2,200,000 in merger and acquisition fees and \$4,740,000 in bond prepayment penalties.

Under the purchase method of accounting, the total estimated purchase price as shown above is allocated to Radiologix's net tangible and intangible assets based on their estimated fair values as of the date of the completion of the merger. The preliminary allocation of the pro forma purchase price is as follows:

	(in thousands)
Current assets	\$ 102,106
Property and equipment, net	82,630
Identifiable intangible assets	59,034
Goodwill	41,396
Investments in joint ventures	9,113
Other assets	824
Current liabilities	(26,057)
Accrued restructuring charges	(332)
Long-term liabilities	(171,667)
Minority interests in consolidated subsidiaries	(1,145)
Total purchase price	\$ 95,902

We have estimated the fair value of tangible assets acquired and liabilities assumed. Some of these estimates are subject to change, particularly those estimates relating to the valuation of property and equipment and identifiable intangible assets. The allocation of the purchase price is preliminary and based upon management's best estimate because the proposed merger has not yet been completed and the final valuation has not been completed. The final allocation of the purchase price will be based upon Radiologix's assets and liabilities on the closing date and the allocation of the purchase price will be reviewed by an external valuation expert.

Cash, marketable securities, investments and other assets: Primedex values cash, marketable securities, investments and other assets at their respective carrying amounts as Primedex believes that these amounts approximate their current fair values or the fair values.

Identifiable intangible assets. Primedex expects identifiable intangible assets acquired to include management service agreements. Management service agreements represent the underlying relationships and agreements with certain professional radiology groups.

Identifiable intangible assets consist of:

	Estimated Fair Value (in thousands)	Amortization Period	Estimated Annual Amortization
Management service agreements	\$ 59,034	25 years	\$ 2,361

Primedex has determined the preliminary fair value of intangible assets with limited discussions with Radiologix management and a review of certain transaction-related documents prepared by Radiologix management.

Estimated useful lives for the intangible assets were based on the average contract terms, which are greater than the amortization period that will be used for management contracts. Intangible assets are being amortized using the straight-line method, considering the pattern in which the economic benefits of the intangible assets are consumed.

Goodwill. Approximately \$41,396,000 has been allocated to goodwill. Goodwill represents the excess of the purchase price over the fair value of the underlying net tangible and intangible assets. In accordance with SFAS No. 142, *Goodwill and Other Intangible Assets*, goodwill will not be amortized but instead will be tested for impairment at least annually. In the event that the management of the combined company determines that the value of goodwill has become impaired, the combined company will incur an accounting charge for the amount of impairment during the fiscal quarter in which the determination is made.

2. Pro Forma Adjustments

The following is a brief description of the preliminary adjustments which may change as additional information is obtained. These adjustments are based on management's best estimate. In addition, these adjustments include reclassifications to conform the financial statement presentation of Radiologix with Primedex.

	(In thousands)
(A) To record the cash portion of the purchase price:	
Cash	\$ 42,950
Estimated transaction fees and expenses	13,552
	56,502
Less: Increase in cash from borrowings (see Note K)	13,322
	\$ 43,180

(B)	Adjustments to property and equipment, net:	
	To record the estimated fair market value adjustment to net property and equipment	\$ 14,020
(C)	Adjustments to goodwill:	
	To record the preliminary purchase price allocation to goodwill as though the acquisition had occurred on July 31, 2006:	
	Total purchase price	\$ 95,902
	Net assets of Radiologix:	
	Book equity of Radiologix	\$ 31,995
	Fair market value adjustment to property and equipment	14,020
	Increase in other intangible assets	6,650
	Elimination of deferred financing costs	(4,117)
	Accrued restructuring charges	(332)
	Elimination of deferred revenue	6,290
	Adjusted net assets	\$ 54,506
	Goodwill	\$ 41,396
(D)	Adjustments to other intangible assets:	
	To reclass Primedex intangible asset trade name from other assets	\$ 1,075
	To eliminate Radiologix historical intangible assets	(52,384)
	To record the preliminary purchase price allocation to other intangible assets as though the acquisition had occurred on July 31, 2006	59,034
		\$ 7,725
(E)	Adjustments to deferred financing costs:	
	To eliminate Radiologix historical net deferred financing costs due to refinancing of this debt	\$ (4,117)
	To write-off Primedex historical deferred financing charges and loan fees	(5,198)
	To record the estimated deferred financing costs	9,183
		\$ (132)
(F)	Adjustments to other assets:	
	To reclass Primedex other asset trade name to intangible assets	\$ (1,075)
(G)	Adjustments to accounts payable and other accrued expenses:	
	To reclass Primedex accrued salaries and benefits	\$ (3,403)
	To reclass Primedex accrued interest	(357)
		\$ (3,760)
(H)	To reclass Primedex accrued salaries and benefits	\$ 3,403
(I)	To reclass Primedex accrued interest	\$ 357
(J)	To record restructuring charges related to severance for certain employees of Radiologix.	\$ 332

31

(K)	To record the payments to be made from the proceeds of the new indebtedness:	
	<i>Sources:</i>	
	Term loan B current	\$ 2,250
	Line of Credit	4,000
	Term loan B long-term	222,750
	Second lien credit facility	135,000
	Total sources	\$ 364,000
	<i>Uses:</i>	
	Current maturities of notes payable Primedex	\$ 860
	Subordinated bond debentures Primedex	16,147
	Line of credit Primedex	6,868
	Long-term debt Primedex	145,086
	Long-term debt Radiologix	158,270
	Convertible debt Radiologix	11,980
	Deferred financing fees (see Note E)	9,183
	Primedex fees and expenses (see Note M)	2,284
	Total uses	\$ 350,678
	Increase in cash (see Note A)	\$ 13,322
(L)	To eliminate Radiologix deferred revenue	\$ (6,290)
(M)	Adjustments to stockholders' equity:	
	To eliminate Radiologix historical stockholders' equity and weighted shares outstanding as part of the purchase transaction	\$ (31,995)
	To record the issuance of 22,621,922 shares of Primedex stock at an average market price of \$1.74 per share to acquire Radiologix	39,400
	To write-off Primedex historical deferred financing charges and loan fees	(5,198)
	To record Primedex fees and expenses	(2,284)
		\$ (77)

	Nine Months Ended July 31, 2006 (In thousands)	Year Ended October 31, 2005
(N)	To eliminate Radiologix deferred revenue amortization	\$ (307) \$ (409)

	Nine Months Ended July 31, 2006 (In thousands)	Year Ended October 31, 2005
(O)	To reclass Radiologix corporate overhead as cost of services	\$ 12,841 \$ 16,872
	To reclass Primedex equipment rental from cost of services	(174) (166)
	To reclass Radiologix losses from sale or disposal of assets from cost of services	(19)
		\$ 12,667 \$ 16,687

	Nine Months Ended July 31, 2006 (In thousands)	Year Ended October 31, 2005
(P)	To reclass Primedex equipment rental from cost of services	\$ 174 \$ 166

	Nine Months Ended July 31, 2006 (In thousands)	Year Ended October 31, 2005
(Q) To record additional depreciation on property and equipment revaluation as a result of the purchase price allocation	\$ 2,103	\$ 2,804
To eliminate Radiologix amortization expense on historical intangible assets related to management service agreements	(2,500)	(3,331)
To add amortization of identifiable intangible assets recorded as a result of purchase price allocation	1,771	2,361
	\$ 1,374	\$ 1,834

	Nine Months Ended July 31, 2006 (In thousands)	Year Ended October 31, 2005
(R) To reclass Radiologix losses from sale or disposal of assets from cost of services	\$	\$ 19

	Nine Months Ended July 31, 2006 (In thousands)	Year Ended October 31, 2005
(S) To reclass Radiologix corporate overhead as cost of services	\$ (12,841)	\$ (16,872)

	Nine Months Ended July 31, 2006 (In thousands)	Year Ended October 31, 2005
(T) To eliminate Radiologix interest income with use of cash as part of the purchase transaction	\$ 1,117	\$ 956
To reverse interest expense related to historical notes, leases, bonds and lines of credit with new financing related to the purchase transaction:		
For Radiologix	(13,432)	(17,908)
For Primedex	(13,292)	(15,871)
To add interest expense related to new financing related to the purchase transaction(1)	28,620	38,160
To reverse interest expense related to historical deferred financing charges and loan fees with new financing related to the purchase transaction:		
For Radiologix	(1,237)	(1,650)
For Primedex	(710)	(1,137)
To add interest expense related to new financing transaction fees(2)	1,088	1,449
	\$ 2,154	\$ 3,999

(1) Assume a first lien six-year, 1% principal payment per year, note payable of \$225 million at LIBOR + 3.5%, or an estimated 9.0%, and a second lien seven-year, interest-only note payable of \$135 million at LIBOR + 7.5%, or an estimated 13.0% and an estimated line of credit draw of \$4.0 million.

The interest expense calculation presented above uses the actual LIBOR rates for the periods presented to determine the interest rate applied to the borrowings under the Term Loan B and the Second Lien Credit Facility. If the LIBOR rate increases or decreases, the effect on interest expense would be as follows:

LIBOR rate Increase/Decrease	Effect on Interest Expense	
	Nine Months Ended July 31, 2006 (in thousands)	Year Ended October 31, 2005
0.25%	\$ 683	\$ 910
0.50%	1,365	1,820
0.75%	2,048	2,730
1.00%	2,730	3,640

(2) Estimated financing fees of \$9.2 million for the Primedex acquisition of Radiologix amortized over the weighted-average financing period of approximately 76 months, or approximately \$121,000 per month.

The pro forma statements of income contain no adjustment of the Primedex net deferred financing costs of \$5,198,000 as of July 31, 2006, and debt prepayment penalties of \$2,284,000 that will be expensed upon refinancing the existing debt of Primedex. In addition, the pro forma financial statements contain no adjustment for any proposed reverse stock split.

QUESTIONS AND ANSWERS ABOUT THE STOCKHOLDER MEETINGS AND THE MERGER

The following questions and answers briefly address some commonly asked questions about the stockholder meetings and the merger. They may not include all the information that is important to you. Primedex and Radiologix urge you to carefully read this entire joint proxy statement/prospectus, including the annexes and the other documents to which we have referred you. We have included page references in parts of this summary to direct you to a more detailed description of each topic presented elsewhere in this joint proxy statement/prospectus.

The Merger

Q: Why am I receiving this joint proxy statement/prospectus?

A: Radiologix and Primedex have agreed to the acquisition of Radiologix by Primedex under the terms of a merger agreement that is described in this joint proxy statement/prospectus. A copy of the merger agreement is attached to this joint proxy statement/prospectus as *Annex A*.

In order to complete the merger, Primedex stockholders and Radiologix stockholders must adopt the merger agreement and the transactions contemplated by the merger agreement, including the merger. Radiologix and Primedex will hold separate meetings of their respective stockholders to obtain these approvals, as well as for Primedex to consider various other proposals unrelated to the transaction.

This joint proxy statement/prospectus contains important information about the merger, the merger agreement and the meetings of the respective stockholders of Radiologix and Primedex, which you should read carefully. The enclosed voting materials allow you to vote your shares without attending your respective company's meeting.

Your vote is very important. We encourage you to vote as soon as possible.

Q: What is the proposed transaction for which I am being asked to vote?

A: Radiologix stockholders are being asked to adopt the merger agreement and the transactions contemplated by the merger agreement, including the merger. The approval of this proposal by Radiologix stockholders is a condition to the effectiveness of the merger.

Primedex stockholders are being asked to adopt the merger agreement and the transactions contemplated by the merger agreement, including the merger and the issuance of Primedex common stock pursuant to the terms of the merger agreement. The approval of this proposal by the Primedex stockholders is a condition to the effectiveness of the merger. See *The Merger Agreement Conditions to Completion of the Merger* beginning on page 149 and *Summary Conditions to Completion of the Merger* beginning on page 8.

Q: What are the positions of the Radiologix and Primedex boards of directors regarding the merger?

A: Both boards of directors have unanimously approved the merger agreement and the transactions contemplated by the merger agreement, including the merger, and determined that the transactions contemplated by the merger agreement are advisable and fair to, and in the best interests of, their respective company and stockholders. The Radiologix board of directors recommends that the Radiologix stockholders vote **FOR** the proposal to adopt the merger agreement and the transactions contemplated by the merger agreement, including the merger, at the Radiologix special meeting. The Primedex board of directors recommends that the Primedex stockholders vote **FOR** the proposal to adopt the merger agreement and the transactions contemplated by the merger agreement, including the merger and the issuance of Primedex common stock pursuant to the terms of the merger agreement, at the Primedex special meeting. See *The Merger Primedex's Reasons for the Merger and Recommendation of Primedex's Board of Directors* beginning on page 107,

The Merger Radiologix's Reasons for the Merger and Recommendation of Radiologix's Board of Directors beginning on page 105, Summary Recommendation of the Boards of Directors to Radiologix and Primedex Stockholders beginning on page 4.

Q: What vote is needed by Radiologix stockholders to adopt the merger agreement and the transactions contemplated by the merger agreement, including the merger, at the Radiologix special meeting?

A: The adoption of the merger agreement and the transactions contemplated by the merger agreement, including the merger, requires the affirmative vote of a majority of the outstanding shares of Radiologix common stock. If a Radiologix stockholder does not vote, it will have the same effect as a vote **AGAINST** the adoption of the merger agreement and the transactions contemplated by the merger agreement, including the merger. See The Radiologix Special Meeting Required Stockholder Vote beginning on page 67.

Q: What vote is needed by Primedex stockholders to adopt the merger agreement and the transactions contemplated by the merger agreement, including the merger and the issuance of Primedex common stock pursuant to the terms of the merger agreement at the Primedex special meeting?

A: The adoption of the merger agreement and the transactions contemplated by the merger agreement, including the merger and the issuance of Primedex common stock pursuant to the terms of the merger agreement, requires the affirmative vote a majority of the outstanding shares of Primedex common stock. If a Primedex stockholder does not vote, it will have the same effect as a vote **AGAINST** the adoption of the merger agreement and the transactions contemplated by the merger agreement, including the merger and the issuance of Primedex common stock. See The Primedex Special Meeting Required Stockholder Vote beginning on page 74.

Q: Are there any Radiologix officers, directors or stockholders already committed to voting in favor of the merger?

A: Yes. Contrarian Equity Fund, L.P., a Radiologix stockholder, which owns approximately 16.9% of the outstanding shares of Radiologix common stock, is a party to a voting agreement with Primedex under which it is obligated to vote its shares in favor of adopting the merger agreement and the merger.

Q: Do Radiologix stockholders have appraisal rights?

A: Yes. Radiologix stockholders who do not vote in favor of adopting the merger agreement and the transactions contemplated by the merger agreement, including the merger, and who otherwise comply with the requirements of Delaware law will be entitled to appraisal rights to receive the statutorily determined fair value of their shares of Radiologix common stock as determined by the Delaware Chancery Court, rather than the merger consideration. Radiologix stockholders will not have appraisal rights in connection with any of the other meeting proposals. For a description of the appraisal rights available to Radiologix stockholders, see Summary Appraisal and Dissenters Rights beginning on page 6 and The Merger Appraisal and Dissenters Rights beginning on page 130.

Q: Do Primedex stockholders have appraisal rights?

A: Yes. If you are a Primedex stockholder and a class of equity securities of Primedex is not listed on the NASDAQ Stock Market (or another applicable national securities exchange) at the time of the merger, under California law you will have the right to dissent from the merger by exercising dissenters' rights. If a Primedex stockholder elects to exercise dissenters' rights, the stockholder must precisely comply with all of the procedures set forth in Chapter 13 of the California General Corporation Law. Chapter 13 of the California General Corporation Law is reprinted in its entirety

and attached to this joint proxy statement/prospectus as *Annex G*. For a description of the dissenters' rights available to Primedex stockholders, see *Summary Appraisal and Dissenters' Rights* beginning on page 7. Primedex stockholders are not entitled to dissenters' rights under New York law, see *The Merger Appraisal and Dissenters' Rights* beginning on page 130.

Q: Why do California corporate laws apply to Primedex, a corporation organized under the laws of New York?

A: Until shares of Primedex common stock are listed on a national securities exchange or designated for trading on the NASDAQ Stock Market, pursuant to California law, Primedex is currently subject to Section 2115 of the California General Corporation Law, which mandates that certain California's corporate laws apply to non-California corporations, because (1) a majority of the holders of record of Primedex's common stock were residents of California on the record date for the latest meeting of stockholders held during its latest full income year and (2) Primedex met certain tests regarding property, payroll and sales in California during its latest full income year.

Q: When do you expect to complete the merger?

A: If the merger agreement and the transactions contemplated by the merger agreement, including the merger, are adopted at the Radiologix special meeting and the merger agreement and the transactions contemplated by the merger agreement, including the merger and the issuance of Primedex common stock are adopted at the Primedex special meeting, we expect to complete the merger as soon as possible after the satisfaction of the other conditions to the merger. We currently anticipate that the merger will be completed by the end of the 2006 calendar year. See *The Merger Agreement Completion and Effectiveness of the Merger* on page 141.

Q: What are the material U.S. federal income tax consequences of the merger to stockholders?

A: The merger will be taxable for federal income tax purposes to Radiologix stockholders. As a result, each Radiologix stockholder will recognize gain or loss in respect of the merger equal to the difference between (i) the sum of the amount of cash received and the fair market value of the shares of Primedex common stock received as of the effective time of the merger and (ii) the stockholder's adjusted tax basis in the stockholder's shares of Radiologix common stock. Such gain or loss will be a capital gain or loss if the stockholder held the stockholder's shares of Radiologix common stock exchanged in the merger for more than one year.

We anticipate that the merger will have no material U.S. federal income tax consequences to Primedex stockholders.

Tax matters are very complicated. You should be aware that the tax consequences to you of the merger may depend upon your own situation. In addition, you may be subject to state, local or foreign tax laws that are not discussed in this joint proxy statement/prospectus. You should therefore consult with your own tax advisor for a full understanding of the tax consequences to you of the merger. For more information regarding the tax consequences of the merger, please see *Material United States Federal Income Tax Consequences* beginning on page 138.

Q: Should I send in my stock certificates now?

A: No. If the merger is completed, Primedex will send Radiologix stockholders written instructions for sending in their stock certificates. See *The Radiologix Special Meeting Solicitations of Proxies* beginning on page 68 and *The Merger Agreement Conversion of Shares; Procedures for Exchange of Certificates* on page 141. Primedex stockholders will not need to send in their stock certificates.

Q: Who can answer my questions about the merger?

A: If you have any questions about the merger or your stockholder meeting, need assistance in voting your shares, or need additional copies of this joint proxy statement/prospectus or the enclosed proxy card(s) or voting instructions, you should contact:

Primedex Health Systems, Inc.
1510 Cotner Avenue
Los Angeles, CA 90025
Attention: Investor Relations
Telephone: (310) 478-7808

or

Radiologix, Inc.
3600 JPMorgan Chase Tower
2200 Ross Avenue
Dallas, Texas 75201-2776
Attention: General Counsel
Telephone: (214) 303-2776

Other Primedex Special Meeting Proposals

Q: On what other proposals am I being asked to vote at the Primedex special meeting?

A: At Primedex's special meeting, in addition to voting on the approval and the adoption of the merger agreement, Primedex stockholders will be asked:

- To adopt an amendment to Primedex's certificate of incorporation to change Primedex's name to RadNet, Inc. ;
- To adopt an amendment to Primedex's certificate of incorporation to (i) increase the number of authorized shares of Primedex common stock from 100,000,000 shares to 200,000,000 shares and reduce the par value of each share of common stock from \$0.01 to \$0.0001, (ii) undesignate all of Primedex's preferred stock, and (iii) increase the authorized number of shares of Primedex preferred stock from 10,000,000 shares to 30,000,000 shares and reduce the par value of each share of preferred stock from \$0.01 to \$0.0001;
- To adopt an amendment to Primedex's certificate of incorporation to implement stock transfer restrictions to preserve Primedex's unrestricted use of its net operating loss carry-forwards;
- To elect five directors to Primedex's board of directors;
- To approve Primedex's 2006 Stock Incentive Plan, substantially in the form attached hereto as *Annex E*;
- To adopt an amendment to Primedex's certificate of incorporation to effect a one-for-two reverse stock split;
- To ratify the appointment of Moss Adams LLP as Primedex's independent registered public accounting firm for the fiscal year ending October 31, 2006;
- To approve adjournments or postponements of the Primedex special meeting, if necessary, to permit further solicitation of proxies if there are not sufficient votes at the time of the Primedex special meeting to approve the above proposals; and

- To consider and take action upon any other business that may properly come before the Primedex special meeting (or any reconvened meeting) following an adjournment or postponement of the Primedex special meeting.

See The Primedex Special Meeting Purposes of the Primedex Special Meeting beginning on page 71.

Q: What vote is necessary to approve the other proposals at the Primedex special meeting?

A: The proposal to amend Primedex's certificate of incorporation to change Primedex's name to RadNet, Inc. requires the affirmative vote of a majority of the outstanding shares of Primedex common stock.

The proposal to adopt an amendment to Primedex's certificate of incorporation to (i) increase the number of authorized shares of Primedex common stock from 100,000,000 shares to 200,000,000 shares and reduce the par value of each share of common stock from \$0.01 to \$0.0001, (ii) undesignate all of Primedex's preferred stock, (iii) increase the authorized number of shares of Primedex preferred stock from 10,000,000 shares to 30,000,000 shares and reduce the par value of each share of preferred stock from \$0.01 to \$0.0001, and (iv) effect a reverse stock split requires the vote of a majority of the outstanding shares of Primedex common stock.

The election of five directors to Primedex's board of directors will be decided by either plurality voting or cumulative voting, should a stockholder give proper notice of intent to cumulate votes at the special meeting. In either case, the five directors with the most affirmative votes will be elected.

The proposal to approve Primedex's 2006 Stock Incentive Plan requires the affirmative vote of a majority of Primedex's common stock present in person or represented by proxy entitled to vote and actually voted at the Primedex special meeting.

Ratification of the appointment of Moss Adams LLP as Primedex's independent registered public accounting firm requires the affirmative vote of a majority of Primedex's common stock present in person or represented by proxy entitled to vote and actually voted at the Primedex special meeting.

A proposal to approve adjournments or postponements of the Primedex special meeting, if necessary, to permit further solicitation of proxies if there are not sufficient votes at the time of the Primedex special meeting to approve the above proposals requires the affirmative vote of a majority of Primedex's common stock present in person or represented by proxy entitled to vote and actually voted at the Primedex special meeting.

Other Radiologix Special Meeting Proposals

Q: On what other proposals am I being asked to vote at the Radiologix special meeting?

A: At Radiologix's special meeting, in addition to voting upon the adoption of the merger agreement and the transactions contemplated by the merger agreement, including the merger, Radiologix stockholders will be asked:

- To approve adjournments or postponements of the Radiologix special meeting if necessary, to permit further solicitation of proxies if there are not sufficient votes at the time of the Radiologix special meeting to approve the above proposals; and
- To consider and take action upon any other business that may properly come before the Radiologix special meeting (or any reconvened meeting) following an adjournment or postponement of the Radiologix special meeting.

See The Radiologix Special Meeting Purposes of the Radiologix Special Meeting beginning on page 65.

Q: What vote is necessary to approve the other proposals at the Radiologix special meeting?

A: A proposal to approve adjournments or postponements of the Radiologix special meeting, if necessary, to permit further solicitation of proxies if there are not sufficient votes at the time of the Radiologix special meeting requires the affirmative vote of a majority of the shares of Radiologix common stock, present in person or represented by proxy and entitled to vote at the Radiologix special meeting.

Procedures

Q: When and where are the meetings?

A: The Radiologix special meeting will be held at 3900 JPMorgan Chase Tower, 2200 Ross Avenue, Dallas, Texas 75201 at 9:00 a.m., Central Time, on November 15, 2006, unless postponed or adjourned to a later date.

The Primedex special meeting will be held at The Olympic Collection, 11301 Olympic Boulevard, Los Angeles, California 90064, at 9:00 a.m., Pacific Time, on November 15, 2006, unless postponed or adjourned to a later date.

Q: Who is eligible to vote at Radiologix's special meeting and Primedex's special meeting?

A: Owners of Radiologix common stock are eligible to vote at the Radiologix special meeting if they were stockholders of record at the close of business on October 6, 2006. See The Radiologix Special Meeting Record Date and Outstanding Voting Securities beginning on page 65.

Owners of Primedex common stock are eligible to vote at the Primedex special meeting if they were stockholders of record at the close of business on October 6, 2006. See The Primedex Special Meeting Record Date and Outstanding Voting Securities beginning on page 72.

Q: What should I do now?

A: You should read this joint proxy statement/prospectus carefully, including the annexes, and return your completed, signed and dated proxy card(s) or voting instruction card(s) by mail in the enclosed postage-paid envelope, or if available, by submitting your proxy by telephone or over the Internet as soon as possible so that your shares will be represented and voted at your stockholder meeting. You may vote your shares by signing, dating and mailing the enclosed proxy card(s) or voting instruction card(s). A number of banks and brokerage firms participate in a program that also permits stockholders whose shares are held in street name to direct their vote by the Internet or telephone. This option, if available, will be reflected in the voting instructions from the bank or brokerage firm that accompany this joint proxy statement/prospectus. If your shares are held in an account at a bank or brokerage firm that participates in such a program, you may direct the vote of these shares by the Internet or telephone by following the voting instructions enclosed with the proxy form from the bank or brokerage firm. See The Radiologix Special Meeting Voting and Revocation of Proxies on page 66, The Primedex Special Meeting Voting and Revocation of Proxies on page 66.

Q: If I am going to attend my stockholder meeting, should I return my proxy card(s) or voting instruction card(s)?

A: Yes. Returning your signed and dated proxy card(s) or voting instruction card(s) or voting by telephone or over the Internet, if available, ensures that your shares will be represented and voted at

your stockholder meeting. See *The Radiologix Special Meeting Voting and Revocation of Proxies* beginning on page 66 and *The Primedex Special Meeting Voting and Revocation of Proxies* beginning on page 72.

Q: How will my proxy be voted?

A: If you complete, sign and date your proxy card(s) or voting instruction card(s), or, if available, vote by telephone or the Internet your proxy will be voted in accordance with your instructions. If you sign and date your proxy card(s) or voting instruction card(s) but do not indicate how you want to vote at your stockholder meeting:

- For Radiologix stockholders, your shares will be voted **FOR** the adoption of the merger agreement. If you vote **FOR** the adoption of the merger agreement at the Radiologix special meeting, you will lose the appraisal rights to which you would otherwise be entitled. See *Summary Appraisal and Dissenters Rights* beginning on page 7, *The Merger Appraisal Rights of Radiologix Stockholders* beginning on page 130 and *The Radiologix Special Meeting Voting and Revocation of Proxies* beginning on page 66.
- For Primedex stockholders, your shares will be voted **FOR** the adoption of the merger agreement and the merger and the issuance of Primedex common stock, **FOR** the four separate amendments to the certificate of incorporation, **FOR** the re-election of the five existing members of Primedex's board of directors, **FOR** the adoption of the 2006 Stock Incentive Plan and **FOR** the ratification of the independent registered public accounting firm. See *The Primedex Special Meeting Voting and Revocation of Proxies* beginning on page 72.

Q: Can I change my vote after I mail my proxy card(s) or voting instruction card(s), or, if available, vote by telephone or the Internet?

A: Yes. If you are a record holder of Radiologix common stock or Primedex common stock, you can change your vote by:

- sending a written notice to the corporate secretary of the company in which you hold shares that is received prior to your stockholder meeting and states that you revoke your proxy;
- signing and delivering a new proxy card(s) or voting instruction card(s) bearing a later date;
- if available, voting again by telephone or over the Internet and submitting your proxy so that it is received prior to your stockholder meeting; or
- attending your stockholder meeting and voting in person although your attendance alone will not revoke your proxy.

If your shares are held in a street name account, you must contact your broker, bank or other nominee to change your vote.

Q: What if my shares are held in street name by my broker?

A: If a broker holds your common stock for your benefit but not in your own name, your shares are in street name. In that case, your broker will send you a voting instruction form to use in voting your shares. The availability of Internet and telephone voting depends on your broker's voting procedures. Please follow the instructions on the voting instruction form your broker sends you. If your shares are held in your broker's name and you wish to vote in person at your stockholder meeting, you must contact your broker and request a document called a legal proxy. You must bring this legal proxy to your respective stockholder meeting in order to vote in person.

Q: What if I don't provide my broker with instructions on how to vote?

A: Generally, a broker may only vote the common stock that it holds for you in accordance with your instructions. However, if your broker has not received your instructions, your broker has the discretion to vote on matters that are considered routine. A broker non-vote occurs if your broker cannot vote on a particular matter because your broker has not received instructions from you and because the proposal is not routine.

Radiologix Stockholders

If you wish to vote on the proposal to adopt the merger, you must provide instructions to your broker because this proposal is not routine. If you do not provide your broker with instructions, your broker will not be authorized to vote with respect to adopting the merger, and a broker non-vote will occur. This will have the same effect as a vote AGAINST the adoption of the merger agreement and the transactions contemplated by the merger agreement, including the merger.

If you wish to vote on any proposal to approve adjournments or postponements of the Radiologix special meeting, you should provide instructions to your broker. If you do not provide instructions to your broker, your broker generally will have the authority to vote on proposals such as the adjournment or postponement of meetings. However, your broker will not be authorized to vote on any proposal to adjourn or postpone the meeting solely relating to the solicitation of proxies to adopt the merger agreement and the transactions contemplated by the merger agreement, including the merger. See *The Radiologix Special Meeting Voting and Revocation of Proxies* on page 66 and *The Radiologix Special Meeting Required Stockholder Vote* beginning on page 67.

Primedex Stockholders

If you wish to vote on the proposal to adopt the merger agreement and the transactions contemplated by the merger agreement, including the merger and the issuance of Primedex common stock, you must provide instructions to your broker because this proposal is not routine. If you do not provide your broker with instructions, your broker will not be authorized to vote with respect to adopting the merger, and a broker non-vote will occur. This will have the same effect as a vote AGAINST the adoption of the merger agreement and the transactions contemplated by the merger agreement, including the merger.

If you wish to vote on any of the four proposals to amend Primedex's certificate of incorporation, you must provide instructions to your broker because none of these proposals are routine. If you do not provide your broker with instructions for any of these four proposals to amend the certificate of incorporation, your broker will not be authorized to vote with respect to that proposal, and a broker non-vote will occur. This will have the same effect as a vote AGAINST that amendment of the certificate of incorporation.

If you wish to vote on the proposal to approve the 2006 Stock Incentive Plan, you must provide instructions to your broker because this proposal is not routine. If you do not provide your broker with instructions, your broker will not be authorized to vote with respect to approving the 2006 Stock Incentive Plan, and a broker non-vote will occur. This will have the same effect as a vote against the approval of the 2006 Stock Incentive Plan.

If you wish to vote on the proposals to elect the five members of the board of directors, to ratify the appointment of Primedex's independent registered public accounting firm or to act upon any other routine business that may properly come before the Primedex special meeting, you should provide instructions to your broker. If you do not provide your broker with instructions, your brokers generally will have the authority to vote on the election of directors, the ratification of the appointment of the

independent registered public accounting firm and other routine matters that may properly come before the special meeting.

If you wish to vote on any proposal to approve adjournments or postponements of the Primedex special meeting, you should provide instructions to your broker. If you do not provide instructions to your broker, your broker generally will have the authority to vote on proposals such as the adjournment or postponement of meetings. However, your broker will not be authorized to vote on any proposal to adjourn or postpone the meeting solely relating to the solicitation of proxies to approve the proposal to adopt the merger agreement. See *The Primedex Special Meeting Voting and Revocation of Proxies* on page 72 and *The Primedex Special Meeting Required Stockholder Vote* beginning on page 74.

Q: What if I abstain from voting?

A: Your abstention from voting will have the following effect.

If you are a Radiologix stockholder:

- Abstentions will have the same effect as a vote **AGAINST** the adoption of the merger agreement and the transactions contemplated by the merger agreement, including the merger.
- An abstention has the effect of voting **AGAINST** the approval of adjournments or postponements of the Radiologix special meeting. See *The Radiologix Special Meeting Voting and Revocation of Proxies* on page 65.

If you are a Primedex stockholder:

- Abstentions will have the same effect as a vote **AGAINST** each of the following proposals:
- the adoption of the merger agreement;
- the approval and adoption of the amendment to Primedex's certificate of incorporation to change Primedex's name to RadNet, Inc. ;
- the approval and adoption of the amendment to Primedex's certificate of incorporation to increase the number of shares authorized for issuance;
- the approval and adoption of the amendment to Primedex's certificate of incorporation to implement stock transfer restrictions to preserve Primedex's unrestricted use of its net operating loss carry-forwards; and
- the approval and adoption of the amendment to Primedex's certificate of incorporation to effect a one-for-two reverse stock split.
- Abstentions will have no effect on the election of the five members of Primedex's board of directors.
- An abstention will not be counted either FOR or AGAINST, and will not affect the approval of the 2006 Stock Incentive Plan, the ratification of the appointment of the independent registered public accounting firm, or the approval of adjournments or postponements of the Primedex special meeting. See *The Primedex Special Meeting Voting and Revocation of Proxies* on page 72.

Q: What does it mean if I receive multiple proxy cards?

A: Your shares may be registered in more than one account, such as brokerage accounts and 401(k) accounts. It is important that you complete, sign, date and return each proxy card or voting instruction card you receive, or, with respect to Primedex, if available, vote using the telephone or the Internet as described in the instructions included with

your proxy card(s) or voting instruction card(s).

43

COMPARATIVE PER SHARE INFORMATION

The following table presents income from continuing operations, cash dividends declared and book value per common share data separately for Primedex and Radiologix on a historical basis, on an unaudited pro forma combined basis per Primedex common share and on an unaudited pro forma combined basis per Radiologix equivalent common share. The following unaudited pro forma data give effect to the merger as if the merger had been completed as of November 1, 2004, with respect to the pro forma income from continuing operations per common share data, and as of July 31, 2006, with respect to the pro forma book value per common share data. The following selected unaudited pro forma financial data should be read in conjunction with the historical consolidated financial statements and notes thereto of Primedex and Radiologix, which are contained elsewhere in this joint proxy statement/prospectus, and the other information contained or incorporated by reference in this joint proxy statement/prospectus. See "Where You Can Find More Information" beginning on page 263.

The unaudited pro forma combined data per Primedex common share are based upon the historical weighted average number of Primedex common shares outstanding, adjusted to include the estimated number of Primedex common shares to be issued in the merger. See "Unaudited Pro Forma Condensed Combined Financial Statements" beginning on page 24.

The following unaudited pro forma data reflect adjustments, which are based upon preliminary estimates, to allocate the purchase price to Radiologix's net assets. The purchase price allocation reflected herein is preliminary, and final allocation of the purchase price will be based upon the actual purchase price and the actual assets and liabilities of Radiologix as of the date of the completion of the merger. Accordingly, the actual purchase accounting adjustments may differ from the pro forma adjustments reflected herein.

The following unaudited pro forma data are presented for illustrative purposes only and are not necessarily indicative of what Primedex's actual financial position or results of operations would have been had the merger been completed on the dates indicated above. The following unaudited pro forma data do not give effect to (1) Primedex's or Radiologix's results of operations or other transactions or developments since October 31, 2005 and December 31, 2005, respectively, (2) the synergies, cost savings and one-time charges expected to result from the merger, or (3) the effects of transactions or developments which may occur subsequent to the merger. The foregoing matters could cause both Primedex's pro forma historical financial position and results of operations, and Primedex's actual future financial position and results of operations, to differ materially from those presented in the following selected unaudited pro forma financial data. See "Risk Factors" The unaudited pro forma financial data included in this joint proxy statement/prospectus are preliminary and Primedex's actual financial position and results of operations may differ materially from the unaudited pro forma financial data included in this joint proxy statement/prospectus on page 49.

	Primedex Historical Per Share Data	Radiologix Historical Per Share Data	Pro Forma Combined Data Per Primedex Common Share	Pro Forma Combined Data Per Radiologix Equivalent Common Share
At or for the Fiscal Year Ended October 31, 2005 and December 31, 2005:				
Loss from continuing operations per common share:				
Basic	\$ (0.08)	\$ (0.02)	\$ (0.15)	\$(0.25)
Diluted	(0.08)	(0.02)	(0.15)	(0.25)
At or for the nine months ended July 31, 2006, with respect to Primedex, and June 30, 2006, with respect to Radiologix:				
Loss from continuing operations per common share:				
Basic	(0.11)	(0.05)	(0.15)	(0.25)
Diluted	(0.11)	(0.05)	(0.15)	(0.25)
Book value per share as of:				
June 30, 2006	n/a	\$ 1.44	n/a	n/a
Cash dividends declared per common share				
	n/a	n/a	n/a	n/a

COMPARATIVE MARKET VALUE INFORMATION

The following table presents:

- the closing prices per share and aggregate market value of Primedex common stock and Radiologix common stock, in each case based on closing prices for those shares on the Over-The-Counter Bulletin Board and the American Stock Exchange, respectively, on July 6, 2006, the last trading day prior to the public announcement of the proposed merger, and October 13, 2006, the last trading day for which this information could be calculated prior to the date of this joint proxy statement/prospectus; and
- the equivalent price per share and equivalent market value of shares of Radiologix common stock, based on closing price for Primedex common stock on the Over-The-Counter Bulletin Board on October 13, 2006.

	Primedex Historical	Radiologix Historical	Radiologix Equivalent(1)
July 6, 2006			
Closing price per common share	\$ 1.75	\$ 2.25	\$ 3.59
Market value of common shares (in thousands)(2)	\$ 73,813	\$ 50,495	
October 13, 2006			
Closing price per common share	\$ 2.64	\$ 4.05	\$ 4.43
Market value of common shares (in thousands)(3)	\$ 116,422	\$ 90,892	

(1) The Radiologix equivalent price per share reflects the fluctuating value of Primedex common stock that Radiologix stockholders would receive for each share of Radiologix common stock if the merger was completed on either July 6, 2006 or October 13, 2006. The Radiologix equivalent price per share is equal to, for July 6, 2006, the sum of (i) \$1.84 and (ii) the closing price of Primedex common stock on such date of \$1.75, and for October 13, 2006, the sum of (x) \$1.79 and (y) the closing price of Primedex common stock on such date of \$2.64.

(2) Based on 42,178,761 shares of Primedex common stock and 22,442,417 shares of Radiologix common stock outstanding as of July 6, 2006.

(3) Based on 44,039,105 shares of Primedex common stock and 22,442,417 shares of Radiologix common stock outstanding as of October 6, 2006.

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

This joint proxy statement/prospectus, including information and other documents incorporated by reference into this joint proxy statement/prospectus, contains or may contain forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995 that relate to the businesses of Primedex and Radiologix. These forward-looking statements are found at various places throughout this joint proxy statement/prospectus and the other documents incorporated by reference in this joint proxy statement/prospectus. These forward-looking statements include, without limitation, those relating to projected financial and operating results, earnings and cash flows, future actions, new projects, strategies and the outcome of contingencies such as legal proceedings, in each case relating to Primedex or Radiologix, respectively. Those forward looking statements, wherever they occur in this joint proxy statement/prospectus or the other documents incorporated by reference in this joint proxy statement/prospectus, are necessarily estimates or projections reflecting the judgment of the respective management of Primedex and Radiologix and are subject to known and unknown risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by those forward-looking statements.

You should understand that the risks, uncertainties, factors and assumptions listed and discussed in this joint proxy statement/prospectus, including those set forth under the heading Risk Factors beginning on page 48; the risks discussed in Radiologix's Annual Report on Form 10-K for the fiscal year ended December 31, 2005, in Item 7A Qualitative and Quantitative Disclosures about Market Risk; the risks discussed in Primedex's Annual Report on Form 10-K for the fiscal year ended October 31, 2005, as amended, in Item 7A Qualitative and Quantitative Disclosures about Market Risk; and the following important factors and assumptions, could affect the future results of Primedex following the merger, or the future results of Primedex and Radiologix if the merger does not occur, and could cause actual results to differ materially from those expressed in any forward-looking statements:

- the ability of Primedex to integrate the Radiologix business with Primedex's business and achieve the expected synergies from the merger;
- the adoption of the merger agreement and the transactions contemplated by the merger agreement, including the merger, at the Radiologix special meeting;
- the approval of the issuance of Primedex common stock in connection with the merger at the Primedex special meeting;
- the actual financial position and results of operations of Primedex following the merger, which may differ significantly from the pro forma financial data contained in this joint proxy statement/prospectus;
- the impact of competitive products and pricing;
- general market conditions in the diagnostic imaging services industry;
- the level of capital resources required for future acquisitions and operations; and
- changes in laws and regulations.

You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of the joint proxy statement/prospectus or, in the case of documents incorporated by reference, as of the date of those documents. Neither Primedex nor Radiologix undertakes any obligation to publicly update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this joint proxy statement/prospectus or to reflect the occurrence of unanticipated events, except as required by law.

RISK FACTORS

*The merger involves a high degree of risk. By voting in favor of the merger, Radiologix stockholders will be choosing to invest in Primedex common stock. In deciding whether to vote for approval and adoption of the merger agreement and the transactions contemplated by the merger agreement, including the merger, in the case of Radiologix stockholders, or for approval and adoption of the merger agreement and the transactions contemplated by the merger agreement, including the merger and the issuance of Primedex common stock, in the case of Primedex stockholders, we urge you to carefully consider all of the information we have included and incorporated by reference in this joint proxy statement/prospectus. See *Where You Can Find More Information* beginning on page 263. You should also read and consider the risks associated with each of the businesses of Primedex and Radiologix because these risks will also affect the combined company. These risks can be found in the Primedex and Radiologix Annual Reports on Form 10-K for the years ended October 31, 2005 and December 31, 2005, as amended, respectively, which are filed with the SEC and incorporated by reference into this joint proxy statement/prospectus. In addition, we urge you to carefully consider the following material risks relating to the merger and the business of the combined company.*

Risks Relating to the Merger

Primedex's failure to integrate Radiologix successfully and on a timely basis into Primedex's operations could reduce Primedex's profitability.

Primedex expects that the acquisition of Radiologix will result in some synergies, business opportunities and growth prospects. Primedex, however, may never realize these expected synergies, business opportunities and growth prospects. Primedex may experience increased competition that limits its ability to expand its business, Primedex may not be able to capitalize on expected business opportunities, assumptions underlying estimates of expected cost savings may be inaccurate, or general industry and business conditions may deteriorate. In addition, integrating operations will require significant efforts and expenses on the part of both Primedex and Radiologix. Personnel may leave or be terminated because of the merger. Primedex's management may have its attention diverted while trying to integrate Radiologix. If these factors limit Primedex's ability to integrate the operations of Radiologix successfully or on a timely basis, Primedex's expectations of future results of operations, including certain cost savings and synergies expected to result from the merger, may not be met. In addition, Primedex's growth and operating strategies for Radiologix's business may be different from the strategies that Radiologix currently is pursuing. If Primedex's strategies are not the proper strategies for Radiologix, it could have a material adverse effect on the business, financial condition and results of operations of the combined company.

The merger is subject to closing conditions that, if not satisfied or waived, will result in the merger not being completed, which may cause the market price of Primedex common stock or Radiologix common stock to decline.

The merger is subject to customary conditions to closing, including the receipt of required approvals of the stockholders of Radiologix and Primedex. If any condition to the merger is not satisfied or, if permissible, waived, the merger will not be completed. In addition, Primedex and Radiologix may terminate the merger agreement in certain circumstances. If Primedex and Radiologix do not complete the merger, the market price of Primedex common stock or Radiologix common stock may fluctuate to the extent that the current market prices of those shares reflect a market assumption that the merger will be completed. Primedex and Radiologix will also be obligated to pay investment banking, financing, legal and accounting fees and related expenses in connection with the merger, whether or not the merger is completed. In addition, Primedex and Radiologix have each diverted significant management resources in an effort to complete the merger and are each subject to restrictions contained in the merger agreement on the conduct of its business. If the merger is not completed, Primedex and Radiologix will have incurred

significant costs, including the diversion of management resources, for which they will have received little or no benefit. Further, in specified circumstances, Radiologix or Primedex may be required to pay the other party's expenses up to \$1 million and Radiologix may be required to pay Primedex a termination fee of up to \$3 million if the merger agreement is terminated. For a detailed description of the circumstances in which such expenses and termination fee will be paid, see *The Merger Agreement Termination Fees and Expenses* on page 153.

Whether or not the merger is completed, the announcement and pendency of the merger could cause disruptions in the businesses of Primedex and Radiologix, which could have an adverse effect on their business and financial results.

Whether or not the merger is completed, the announcement and pendency of the merger could cause disruptions in the businesses of Primedex and Radiologix. Specifically:

- current and prospective employees may experience uncertainty about their future roles with the combined company, which might adversely affect Primedex and Radiologix's ability to retain key managers and other employees; and
- the attention of management of each of Primedex and Radiologix may be directed toward the completion of the merger.

Some of the directors and executive officers of Radiologix have interests and arrangements that may be different from, or in addition to, Radiologix stockholders.

When considering the recommendation of the Radiologix board of directors with respect to the merger, Radiologix stockholders should be aware that some directors and executive officers of Radiologix have interests in the merger that may be different from, or in addition to, their interests as stockholders and the interests of stockholders. These interests include payments under employment agreements and severance agreements, acceleration of vesting and exercisability of options, restricted stock and restricted stock units as a result of the merger and the right to continued indemnification and insurance coverage by Primedex for acts or omissions occurring prior to the merger.

As a result of these interests, these directors and executive officers may be more likely to support and to vote to adopt the merger agreement than if they did not have these interests. Stockholders should consider whether these interests may have influenced those directors and officers to support or recommend adoption of the merger agreement. As of the close of business on the record date for the Radiologix special meeting, Radiologix directors and executive officers were entitled to vote 1.8% of the then-outstanding shares of Radiologix common stock. See *The Merger Interests of Radiologix Directors and Executive Officers in the Merger* on page 126.

The unaudited pro forma financial data included in this joint proxy statement/prospectus are preliminary and Primedex's actual financial position and results of operations may differ materially from the unaudited pro forma financial data included in this joint proxy statement/prospectus.

The unaudited pro forma financial data in this joint proxy statement/prospectus reflect adjustments, which are based upon preliminary estimates, to allocate the purchase price to Radiologix's net assets. The purchase price allocation reflected in this joint proxy statement/prospectus is preliminary, and final allocation of the purchase price will be based upon the actual purchase price and the actual assets and liabilities of Radiologix as of the date of the completion of the merger. Primedex may need to revise materially its current estimates of those assets and liabilities as the valuation process and accounting policy review are finalized. Accordingly, the actual purchase accounting adjustments may differ materially from the pro forma adjustments reflected in this joint proxy statement/prospectus.

The unaudited pro forma financial data in this joint proxy statement/prospectus are presented for illustrative purposes only and are not necessarily indicative of what Primedex's actual financial position or results of operations would have been had the merger been completed on the dates indicated. The unaudited pro forma financial data in this joint proxy statement/prospectus do not give effect to (1) Primedex or Radiologix's results of operations or other transactions or developments since October 31, 2005 and December 31, 2005, respectively, (2) the synergies, cost savings and one-time charges expected to result from the merger or (3) the effects of transactions or developments, including sales of assets, which may occur after the merger.

The value of the Primedex common stock that Radiologix stockholders receive in the merger may be less than the value of such Primedex common stock when the merger was publicly announced. Further, at the time of the Radiologix special meeting, Radiologix stockholders will not know the exact value of Primedex common stock that will be issued in the merger.

The price of Primedex common stock will fluctuate until the Radiologix stockholders receive their shares of Primedex stock. Primedex and Radiologix are working to complete the merger as quickly as possible. However, the time period between the stockholder votes taken at the meetings and the completion of the merger will depend upon the satisfaction or waiver of the other conditions described in this joint proxy statement/prospectus, and there is currently no way to predict how long it will take to obtain these approvals. Because the date when the merger is completed may be later than the date of the stockholder meetings, Primedex and Radiologix stockholders will not know the exact value of the Primedex common stock that will be issued in the merger at the time they vote on the merger proposals. As a result, if the market price of Primedex common stock at the completion of the merger is higher or lower than the market price on the date of the Radiologix special meeting, the value of the Primedex common stock received by Radiologix stockholders in the merger will be higher or lower, respectively, than the value of such Primedex common stock on the date of the Radiologix special meeting.

Risks Relating to Primedex's Operations After the Consummation of the Merger

The market price for shares of Primedex common stock may be affected by factors different from, or in addition to, those affecting shares of Radiologix common stock, and the market value of Primedex common stock may decrease after the closing date of the merger.

Upon completion of the merger, the holders of Radiologix common stock will become holders of Primedex common stock. Primedex is involved in different geographic areas than Radiologix and the results of Primedex's operations after the merger may be affected by factors different from or in addition to those currently affecting the results of Radiologix's operations. The market value of the shares of Primedex common stock that Radiologix stockholders receive in the merger could decrease following the closing date of the merger. For a discussion of the businesses of Primedex and Radiologix and factors to consider in connection with those businesses, please see the documents incorporated by reference into this joint proxy statement/prospectus and listed under the section captioned "Where You Can Find More Information," beginning on page 263.

The price of Primedex common stock has been volatile and may continue to fluctuate significantly, which may cause you to lose a significant portion of your investment.

Edgar Filing: RADIOLOGIX INC - Form DEFM14A

The market price of Primedex common stock has been and may continue to be volatile. From June 30, 2003, to October 13, 2006, the sale price of Primedex common stock ranged from a low of \$0.11 per share to a high of \$2.90 per share. Primedex common stock may continue to be subject to fluctuations as a result of a variety of factors, including factors beyond its control. These include:

- economic, competitive, demographic, business and other conditions;
- decline in patient referrals;

50

- changes in the rates or methods of third-party reimbursement for diagnostic imaging services;
- the enforceability or termination of Primedex's contracts with radiology practices;
- the availability of additional capital to fund capital expenditure requirements;
- burdensome lawsuits against contracted radiology practices;
- reduced operating margins due to managed care contracts and capitated fee arrangements;
- any failure to comply with state and federal anti-kickback and anti-self-referral laws or any other applicable healthcare regulations;
- the ability to meet debt service requirements and liquidity constraints in light of Primedex's substantial indebtedness;
- the recruitment and retention of technologists by Primedex or radiologists by Primedex's contracted radiology groups; and
- general economic conditions and normal business uncertainty.

Primedex may fail to meet the expectations of its stockholders or of analysts at some time in the future, and its stock price could decline as a result. In addition, sales of a substantial number of shares of Primedex common stock in the public market or the appearance that these shares are available for sale could adversely affect the market price for Primedex common stock.

Anti-takeover provisions could delay, deter or prevent a change in control of Primedex even if the change in control would be beneficial to Primedex stockholders.

Primedex is a New York corporation subject to New York state law. Some provisions of New York law could interfere with or restrict takeover bids or other change in control events affecting Primedex. One statutory provision prohibits, except under specified circumstances, Primedex from engaging in any business combination with any stockholder who owns 15% or more of Primedex's common stock. Also, provisions in Primedex's certificate of incorporation, by-laws and other agreements to which Primedex is a party could delay, deter or prevent a change in control of Primedex, even if a change in control would be beneficial to stockholders.

Primedex may not be able to generate sufficient cash flow to meet Primedex's debt service obligations.

Primedex's ability to generate sufficient cash flow from operations to make payments on Primedex's debt and other contractual obligations will depend on Primedex's future financial performance. A range of economic, competitive, regulatory, legislative and business factors, many of which are outside of Primedex's control, will affect Primedex's financial performance. Primedex's inability to generate sufficient cash flow to satisfy Primedex's debt and other contractual obligations would adversely impact Primedex's business, financial condition and results of operations.

Primedex's ability to generate revenue depends in large part on referrals from physicians.

A significant reduction in referrals would have a negative impact on Primedex's business. Primedex derives substantially all of its net revenue, directly or indirectly, from fees charged for the diagnostic imaging services performed at its facilities. Primedex depends on referrals of patients from unaffiliated physicians and other third parties who have no contractual obligations to refer patients to Primedex for a substantial portion of the services performed. If a sufficiently large number of these physicians and other third parties were to discontinue referring patients to Primedex, Primedex's scan volume could decrease, which would reduce Primedex's net revenues and operating margins. Further, commercial third-party payors have implemented programs that could limit the ability of physicians to refer patients to Primedex.

For example, prepaid healthcare plans, such as health maintenance organizations, sometimes contract directly with providers and require their enrollees to obtain these services exclusively from those providers. Some insurance companies and self-insured employers also limit these services to contracted providers. These closed panel systems are now common in the managed care environment, including California. Other systems create an economic disincentive for referrals to providers outside the system's designated panel of providers. If Primedex is unable to compete successfully for these managed care contracts, Primedex's results and prospects for growth could be adversely affected.

Changes in third-party reimbursement rates or methods for diagnostic imaging services could result in a decline in Primedex's net revenue and negatively impact Primedex's business.

The fees charged for the diagnostic imaging services performed at Primedex's facilities are paid by insurance companies, Medicare and Medi-Cal, workers compensation, private and other payors. Any change in the rates or conditions for reimbursement from these sources of payment could substantially reduce the amounts reimbursed to Primedex or to Primedex's contracted radiology practices for services provided, which could have an adverse effect on Primedex's net revenue. For example, recent legislative changes in California's workers compensation rules had a negative impact on reimbursement rates for diagnostic imaging services and federal Medicare legislation intended to take effect January 1, 2007 is expected to have a negative impact on the rates paid for MRI services.

Pressure to control healthcare costs could have a negative impact on Primedex's results.

One of the principal objectives of health maintenance organizations and preferred provider organizations is to control the cost of healthcare services. Managed care contracting has become very competitive, and reimbursement schedules are at or below Medicare reimbursement levels. The development and expansion of health maintenance organizations, preferred provider organizations and other managed care organizations within the geographic areas covered by Primedex's network could have a negative impact on the utilization and pricing of Primedex's services, because these organizations will exert greater control over patients' access to diagnostic imaging services, the selections of the provider of such services and reimbursement rates for those services.

If BRMG or any of Primedex's other contracted radiology practices terminate their agreements with Primedex, Primedex's business could substantially diminish.

Primedex's relationship with BRMG is an integral part of its business. Through Primedex's management agreement, BRMG provides all of the professional medical services at 46 of Primedex's 61 facilities, contracts with various other independent physicians and physician groups to provide all of the professional medical services at most of Primedex's other facilities, and must use its best efforts to provide the professional medical services at any new facilities that Primedex opens or acquires. In addition, BRMG's strong relationships with referring physicians are largely responsible for the revenue generated at the facilities it services. Although Primedex's management agreement with BRMG runs until 2014, BRMG has the right to terminate the agreement if Primedex defaults on Primedex's obligations and fails to cure the default. Also, BRMG's ability to continue performing under the management agreement may be curtailed or eliminated due to BRMG's financial difficulties, loss of physicians or other circumstances. If BRMG cannot perform its obligation to Primedex, Primedex would need to contract with one or more other radiology groups to provide the professional medical services at the facilities serviced by BRMG. Primedex may not be able to locate radiology groups willing to provide those services on terms acceptable to Primedex, if at all. Even if Primedex were able to do so, any replacement radiology group's relationships with referring physicians may not be as extensive as those of BRMG. In any such event, Primedex's business could be seriously harmed. In addition, BRMG is party to substantially all of the managed care

contracts from which Primedex derives revenue. If Primedex were unable to readily replace these contracts, Primedex's revenue would be negatively affected.

Except for Primedex's management agreement with BRMG, most of the agreements Primedex, or BRMG, have with contracted radiology practices typically have terms of one year, which automatically renew unless either party delivers a non-renewal notice to the other within a prescribed period. Most of these agreements may be terminated by either party under some conditions, including, with respect to some of those agreements, the right of either party to terminate the agreement without cause upon 30 to 120 days notice.

If Primedex's contracted radiology practices, including BRMG, lose a significant number of their radiologists, Primedex's financial results could be adversely affected.

Recently, there has been a shortage of qualified radiologists in some of the regional markets Primedex serves. In addition, competition in recruiting radiologists may make it difficult for Primedex's contracted radiology practices to maintain adequate levels of radiologists. If a significant number of radiologists terminate their relationships with Primedex's contracted radiology practices and those radiology practices cannot recruit sufficient qualified radiologists to fulfill their obligations under Primedex's agreements with them, Primedex's ability to maximize the use of its diagnostic imaging facilities and Primedex's financial results could be adversely affected. For example, in fiscal 2002, due to a shortage of qualified radiologists in the marketplace, BRMG experienced difficulty in hiring and retaining physicians and thus engaged independent contractors and part-time fill-in physicians. Their cost was double the salary of a regular BRMG full-time physician. Increased expenses to BRMG will impact Primedex's financial results because the management fee Primedex receives from BRMG, which is based on a percentage of BRMG's collections, is adjusted annually to take into account the expenses of BRMG. Neither Primedex, nor Primedex's contracted radiology practices, maintain insurance on the lives of any affiliated physicians.

Primedex may not be able to successfully grow its business.

As part of Primedex's business strategy, Primedex intends to continue to increase its presence in California through selectively acquiring facilities, developing new facilities, adding equipment at existing facilities, and directly or indirectly through BRMG entering into contractual relationships with high-quality radiology practices.

However, Primedex's ability to successfully expand depends upon many factors, including Primedex's ability to:

- identify attractive and willing candidates for acquisitions;
- identify locations in existing or new markets for development of new facilities;
- comply with legal requirements affecting Primedex's arrangements with contracted radiology practices, including California prohibitions on fee-splitting, corporate practice of medicine and self-referrals;
- obtain regulatory approvals where necessary and comply with licensing and certification requirements applicable to Primedex's diagnostic imaging facilities, the contracted radiology practices and the physicians associated with the contracted radiology practices;
- recruit a sufficient number of qualified radiology technologists and other non-medical personnel;
- expand Primedex's infrastructure and management; and
- compete effectively for the acquisition of diagnostic imaging facilities.

Primedex may become subject to professional malpractice liability.

Providing medical services subjects Primedex to the risk of professional malpractice and other similar claims. The physicians that Primedex's contracted radiology practices employ are from time to time subject to malpractice claims. Primedex structures its relationships with the practices under its management agreements in a manner that Primedex believes does not constitute the practice of medicine by Primedex or subject Primedex to professional malpractice claims for acts or omissions of physicians employed by the contracted radiology practices. Nevertheless, claims, suits or complaints relating to services provided by the contracted radiology practices have been asserted against Primedex in the past and may be asserted against Primedex in the future. In addition, Primedex may be subject to professional liability claims, including, without limitation, for improper use or malfunction of Primedex's diagnostic imaging equipment. Primedex may not be able to maintain adequate liability insurance to protect Primedex against those claims at acceptable costs or at all.

Any claim made against Primedex that is not fully covered by insurance could be costly to defend, result in a substantial damage award against Primedex and divert the attention of Primedex's management from Primedex's operations, all of which could have an adverse effect on Primedex's financial performance. In addition, successful claims against Primedex may adversely affect Primedex's business or reputation. Although California places a \$250,000 limit on non-economic damages for medical malpractice cases, no limit applies to economic damages.

Some of Primedex's imaging modalities use radioactive materials, which generate regulated waste and could subject Primedex to liabilities for injuries or violations of environmental and health and safety laws.

Some of Primedex's imaging procedures use radioactive materials, which generate medical and other regulated wastes. For example, patients are injected with a radioactive substance before undergoing a PET scan. Storage, use and disposal of these materials and waste products present the risk of accidental environmental contamination and physical injury. Primedex is subject to federal, California and local regulations governing storage, handling and disposal of these materials. Primedex could incur significant costs and the diversion of management's attention in order to comply with current or future environmental and health and safety laws and regulations. Also, Primedex cannot completely eliminate the risk of accidental contamination or injury from these hazardous materials. In the event of an accident, Primedex could be held liable for any resulting damages, and any liability could exceed the limits of or fall outside the coverage of Primedex's insurance.

Primedex experiences competition from other diagnostic imaging companies and hospitals. This competition could adversely affect Primedex's revenue and business.

The market for diagnostic imaging services in California is highly competitive. Primedex competes principally on the basis of its reputation, Primedex's ability to provide multiple modalities at many of its facilities, the location of Primedex's facilities and the quality of Primedex's diagnostic imaging services. Primedex competes locally with groups of radiologists, established hospitals, clinics and other independent organizations that own and operate imaging equipment. Primedex's major national competitors include Alliance Imaging, Inc., HealthSouth Corporation and Insight Health Services. Some of Primedex's competitors may now or in the future have access to greater financial resources than Primedex and may have access to newer, more advanced equipment.

State and federal anti-kickback and anti-self-referral laws may adversely affect income.

Various federal and state laws govern financial arrangements among healthcare providers. The federal anti-kickback law prohibits the knowing and willful offer, payment, solicitation or receipt of any form of remuneration in return for, or to induce, the referral of Medicare, Medicaid, or other federal

healthcare program patients, or in return for, or to induce, the purchase, lease or order of items or services that are covered by Medicare, Medicaid, or other federal healthcare programs. Similarly, many state laws prohibit the solicitation, payment or receipt of remuneration in return for, or to induce the referral of patients in private as well as government programs. Violation of these anti-kickback laws may result in substantial civil or criminal penalties for individuals or entities and/or exclusion from federal or state healthcare programs. Radiologix and Primedex believe that they are operating in compliance with applicable law and believe that their arrangements with providers would not be found to violate the anti-kickback laws. However, these laws could be interpreted in a manner inconsistent with their operations.

Federal law prohibiting physician self-referrals (the Stark Law) prohibits a physician from referring Medicare or Medicaid patients to an entity for certain designated health services if the physician has a prohibited financial relationship with that entity, unless an exception applies. Certain radiology services are considered designated health services under the Stark Law. Although Primedex and Radiologix believe that their operations do not violate the Stark Law, their activities may be challenged. If a challenge to their activities is successful, it could have an adverse effect on their operations. In addition, legislation may be enacted in the future that further addresses Medicare and Medicaid fraud and abuse or that imposes additional requirements or burdens on them.

All of the states in which Radiologix's and Primedex's diagnostic imaging centers are located have adopted a form of anti-kickback law and almost all of those states have also adopted a form of Stark Law. The scope of these laws and the interpretations of them vary from state to state and are enforced by state courts and regulatory authorities, each with broad discretion. A determination of liability under the laws described in this risk factor could result in fines and penalties and restrictions on Radiologix's and Primedex's ability to operate in these jurisdictions.

Technological changes in Primedex's industry could reduce the demand for Primedex's services and require Primedex to incur significant costs to upgrade equipment.

The development of new technologies or refinements of existing modalities may require Primedex to upgrade and enhance Primedex's existing equipment before Primedex may otherwise intend. Many companies currently manufacture diagnostic imaging equipment. Competition among manufacturers for a greater share of the diagnostic imaging equipment market may result in technological advances in the speed and imaging capacity of new equipment. This may accelerate the obsolescence of Primedex's equipment, and Primedex may not have the financial ability to acquire the new or improved equipment. In that event, Primedex may be unable to deliver Primedex's services in the efficient and effective manner that payors, physicians and patients expect and thus Primedex's revenue could substantially decrease. During fiscal 2005, Primedex traded in and upgraded Primedex's existing MRI at one of its facilities in Tarzana, California to increase throughput and patient volume and compete in the marketplace. Primedex incurred a loss on disposal of equipment of approximately \$696,000 for the upgrade.

Primedex has experienced operating losses and Primedex has a substantial accumulated deficit. If Primedex is unable to improve its financial performance, Primedex may be unable to pay its obligations.

Primedex has incurred net losses of \$14.6 million and \$3.1 million during the years ended October 31, 2004 and 2005, respectively, and at October 31, 2005 Primedex had an accumulated stockholders' deficit of \$70.6 million. Also, in recent periods, Primedex has suffered liquidity shortfalls which have led Primedex to, among other things, undertake and complete a pre-packaged Chapter 11 plan of reorganization in 2003 and modify the terms of various of Primedex's financial obligations. While Primedex believes that by taking these and other actions, in the future it will be able to address these issues and solidify its financial condition, Primedex cannot give assurances that it will be able to generate sufficient cash flow from operations to satisfy its debt obligations.

A failure to meet Primedex's capital expenditure requirements could adversely affect Primedex's business.

Primedex operates in a capital intensive, high fixed-cost industry that requires significant amounts of capital to fund operations, particularly the initial start-up and development expenses of new diagnostic imaging facilities and the acquisition of additional facilities and new diagnostic imaging equipment. Primedex incurs capital expenditures to, among other things, upgrade and replace existing equipment for existing facilities and expand within Primedex's existing markets and enter new markets. To the extent Primedex is unable to generate sufficient cash from its operations, funds are not available from its lenders or it is unable to structure or obtain financing through operating leases, long-term installment notes or capital leases, Primedex may be unable to meet its capital expenditure requirements.

Because Primedex has high fixed costs, lower scan volumes per system could adversely affect Primedex's business.

The principal components of Primedex's expenses, excluding depreciation, consist of compensation paid to technologists, salaries, real estate lease expenses and equipment maintenance costs. Because a majority of these expenses are fixed, a relatively small change in Primedex's revenue could have a disproportionate effect on Primedex's operating and financial results depending on the source of Primedex's revenue. Thus, decreased revenue as a result of lower scan volumes per system could result in lower margins, which would adversely affect Primedex's business.

Primedex's success depends in part on Primedex's key personnel and Primedex may not be able to retain sufficient qualified personnel. In addition, former employees could use the experience and relationships developed while employed with Primedex to compete with Primedex.

Primedex's success depends in part on Primedex's ability to attract and retain qualified senior and executive management, managerial and technical personnel. Competition in recruiting these personnel may make it difficult for Primedex to continue Primedex's growth and success. The loss of their services or Primedex's inability in the future to attract and retain management and other key personnel could hinder the implementation of Primedex's business strategy. The loss of the services of Dr. Howard G. Berger, Primedex's President and Chief Executive Officer, or Norman R. Hames, Primedex's Chief Operating Officer, could have a significant negative impact on Primedex's operations. Primedex believes that those executives could not easily be replaced with executives of equal experience and capabilities. Primedex does not maintain key person insurance on the life of any of Primedex's executive officers with the exception of a \$5.0 million policy on the life of Dr. Berger. Also, if Primedex loses the services of Dr. Berger, Primedex's relationship with BRMG could deteriorate, which would adversely affect Primedex's business.

Unlike many other states, California does not enforce agreements that prohibit a former employee from competing with the former employer. As a result, any of Primedex's employees whose employment is terminated is free to compete with Primedex, subject to prohibitions on the use of confidential information and, depending on the terms of the employee's employment agreement, on solicitation of existing employees and customers. A former executive, manager or other key employee who joins one of Primedex's competitors could use the relationships he or she established with third party payors, radiologists or referring physicians while Primedex's employee and the industry knowledge he or she acquired during that tenure to enhance the new employer's ability to compete with Primedex.

Capitation fee arrangements could reduce Primedex's operating margins.

For fiscal 2005, Primedex derived approximately 26% of Primedex's net revenue from capitation arrangements, and Primedex intends to increase the revenue it derives from capitation arrangements in the future. Under capitation arrangements, the payor pays a pre-determined amount per-patient per-month in exchange for Primedex providing all necessary covered services to the patients covered under the arrangement. These contracts pass much of the financial risk of providing diagnostic imaging services,

including the risk of over-use, from the payor to the provider. Primedex's success depends in part on its ability to negotiate effectively, on behalf of the contracted radiology practices and Primedex's diagnostic imaging facilities, contracts with health maintenance organizations, employer groups and other third-party payors for services to be provided on a capitated basis and to efficiently manage the utilization of those services. If Primedex is not successful in managing the utilization of services under these capitation arrangements or if patients or enrollees covered by these contracts require more frequent or extensive care than anticipated, Primedex would incur unanticipated costs not offset by additional revenue, which would reduce operating margins.

Primedex may be unable to effectively maintain its equipment or generate revenue when its equipment is not operational.

Timely, effective service is essential to maintaining Primedex's reputation and high use rates on Primedex's imaging equipment. Although Primedex has an agreement with GE Healthcare pursuant to which it maintains and repairs the majority of Primedex's imaging equipment, this agreement does not compensate Primedex for loss of revenue when Primedex's systems are not fully operational and Primedex's business interruption insurance may not provide sufficient coverage for the loss of revenue. Also, GE Healthcare may not be able to perform repairs or supply needed parts in a timely manner. Therefore, if Primedex experiences more equipment malfunctions than anticipated or if Primedex is unable to promptly obtain the service necessary to keep its equipment functioning effectively, Primedex's ability to provide services would be adversely affected and its revenue could decline.

Disruption or malfunction in Primedex's information systems could adversely affect Primedex's business.

Primedex's information technology system is vulnerable to damage or interruption from:

- earthquakes, fires, floods and other natural disasters;
- power losses, computer systems failures, internet and telecommunications or data network failures, operator negligence, improper operation by or supervision of employees, physical and electronic losses of data and similar events; and
- computer viruses, penetration by hackers seeking to disrupt operations or misappropriate information and other breaches of security.

Primedex relies on its information technology to perform functions critical to its ability to operate, including patient scheduling, billing, collections, image storage and image transmission. Accordingly, an extended interruption in the system's function could significantly curtail, directly and indirectly, Primedex's ability to conduct its business and generate revenue.

Primedex's actual financial results may vary significantly from the projections Primedex filed with the bankruptcy court.

In connection with Primedex's pre-packaged Chapter 11 plan of reorganization that was confirmed by the Bankruptcy Court on October 20, 2003, Primedex was required to prepare projected financial information to demonstrate to the Bankruptcy Court the feasibility of the plan of reorganization and Primedex's ability to continue operations upon its emergence from bankruptcy. The projected financial information and various estimates of value discussed in the disclosure statement contained in the plan of reorganization should not be regarded as representations or warranties by Primedex or any other person as to the accuracy of that information or that those projections or valuations will be realized. Primedex, and Primedex's advisors, prepared the information in the disclosure statement, including the projected financial information and estimates of value. This information was not audited or reviewed by Primedex's

independent accountants. The significant assumptions used in preparation of the information and estimates of value were included as an exhibit to the disclosure statement.

Those projections are not included in this joint proxy statement/prospectus, and you should not rely upon them in any way or manner. Primedex has not updated, nor will Primedex update, those projections. At the time Primedex prepared the projections, they reflected numerous assumptions concerning Primedex's anticipated future performance with respect to prevailing and anticipated market and economic conditions which were and remain beyond Primedex's control and which may not materialize. Projections are inherently subject to significant and numerous uncertainties and to a wide variety of significant business, economic and competitive risks and the assumptions underlying the projections may be wrong in many material respects. Primedex's actual results may vary significantly from those contemplated by the projections. As a result, Primedex cautions you not to rely upon those projections.

Primedex is vulnerable to earthquakes and other natural disasters.

Primedex's headquarters and all of Primedex's facilities are located in California, an area prone to earthquakes and other natural disasters. An earthquake or other natural disaster could seriously impair Primedex's operations, and Primedex's insurance may not be sufficient to cover Primedex for the resulting losses.

Complying with federal and state regulations is an expensive and time-consuming process, and any failure to comply could result in substantial penalties.

Primedex is directly or indirectly through the radiology practices with which Primedex contracts subject to extensive regulation by both the federal government and the State of California, including:

- the federal False Claims Act;
- the federal Medicare and Medicaid anti-kickback laws, and California anti-kickback prohibitions;
- Federal and California billing and claims submission laws and regulations;
- the federal Health Insurance Portability and Accountability Act of 1996;
- the federal physician self-referral prohibition commonly known as the Stark Law and the California equivalent of the Stark Law;
- California laws that prohibit the practice of medicine by non-physicians and prohibit fee-splitting arrangements involving physicians;
- Federal and California laws governing the diagnostic imaging and therapeutic equipment Primedex uses in its business concerning patient safety, equipment operating specifications and radiation exposure levels; and
- California laws governing reimbursement for diagnostic services related to services compensable under workers compensation rules.

If Primedex's operations are found to be in violation of any of the laws and regulations to which Primedex or the radiology practices with which Primedex contracts are subject, Primedex may be subject to the applicable penalty associated with the violation, including civil and criminal penalties, damages, fines and the curtailment of Primedex's operations. Any penalties, damages, fines or curtailment of Primedex's operations, individually or in the aggregate, could adversely affect Primedex's ability to operate its business. The risk of Primedex being found in violation of these laws and regulations is increased by the fact that many of them have not been fully interpreted by the regulatory authorities or the courts, and their provisions are open to a variety of interpretations. Any action brought against Primedex for violation of

these laws or regulations, even if Primedex successfully defends against it, could cause Primedex to incur significant legal expenses and divert management's attention from the operation of Primedex's business.

If Primedex fails to comply with various licensure, certification and accreditation standards, Primedex may be subject to loss of licensure, certification or accreditation, which would adversely affect Primedex's operations.

Ownership, construction, operation, expansion and acquisition of Primedex's diagnostic imaging facilities is subject to various federal and California laws, regulations and approvals concerning licensing of personnel, other required certificates for certain types of healthcare facilities and medical equipment. In addition, freestanding diagnostic imaging facilities that provide services independent of a physician's office must be enrolled by Medicare as an independent diagnostic testing facility to bill the Medicare program. Medicare carriers have discretion in applying the independent diagnostic testing facility requirements and therefore the application of these requirements may vary from jurisdiction to jurisdiction. Primedex may not be able to receive the required regulatory approvals for any future acquisitions, expansions or replacements, and the failure to obtain these approvals could limit the opportunity to expand Primedex's services.

Primedex's facilities are subject to periodic inspection by governmental and other authorities to assure continued compliance with the various standards necessary for licensure and certification. If any facility loses its certification under the Medicare program, then the facility will be ineligible to receive reimbursement from the Medicare and Medi-Cal programs. For the year ended October 31, 2005, approximately 18% of Primedex's net revenue came from the Medicare and Medi-Cal programs. A change in the applicable certification status of one of Primedex's facilities could adversely affect Primedex's other facilities and in turn Primedex as a whole.

Primedex's agreements with the contracted radiology practices must be structured to avoid the corporate practice of medicine and fee-splitting.

California law prohibits Primedex from exercising control over the medical judgments or decisions of physicians and from engaging in some financial arrangements, such as splitting professional fees with physicians. These laws are enforced by state courts and regulatory authorities, each with broad discretion. A component of Primedex's business has been to enter into management agreements with radiology practices. Primedex provides management, administrative, technical and other non-medical services to the radiology practices in exchange for a service fee typically based on a percentage of the practice's revenue. Primedex structures its relationships with the radiology practices, including the purchase of diagnostic imaging facilities, in a manner that Primedex believes keeps it from engaging in the practice of medicine or exercising control over the medical judgments or decisions of the radiology practices or their physicians or violating the prohibitions against fee-splitting. However, because challenges to these types of arrangements are not required to be reported, Primedex cannot substantiate this belief. There can be no assurance that Primedex's present arrangements with BRMG or the physicians providing medical services and medical supervision at Primedex's imaging facilities will not be challenged, and, if challenged, that they will not be found to violate the corporate practice prohibition, thus subjecting Primedex to potential damages, injunction and/or civil and criminal penalties or require Primedex to restructure its arrangements in a way that would affect the control or quality of Primedex's services and/or change the amounts Primedex receives under its management agreements. Any of these results could jeopardize Primedex's business.

Future federal legislation could limit the prices Primedex can charge for its services, which would reduce its revenue and adversely affect its operating results.

In addition to extensive existing government healthcare regulation, there are numerous initiatives affecting the coverage of and payment for healthcare services, including proposals that would significantly limit reimbursement under the Medicare and Medi-Cal programs as well as recently enacted federal legislation slated to become effective January 1, 2007 which will reduce Medicare reimbursement for MRI procedures by on average 30% to 35% and CT procedures by on average 15% to 20%. Limitations on reimbursement amounts and other cost containment pressures have in the past resulted in a decrease in the revenue Primedex receives for each scan Primedex performs. Limitations on reimbursement amounts and other cost containment pressures have in the past resulted in a decrease in the revenue Primedex receives for each scan Primedex performs.

The regulatory framework in which Primedex operates is uncertain and evolving.

Healthcare laws and regulations may change significantly in the future. Primedex continuously monitors these developments and modifies Primedex's operations from time to time as the regulatory environment changes. Primedex cannot assure you, however, that it will be able to adapt its operations to address new regulations or that new regulations will not adversely affect its business. In addition, although Primedex believes that it is operating in compliance with applicable federal and California laws, neither Primedex's current or anticipated business operations nor the operations of the contracted radiology practices have been the subject of judicial or regulatory interpretation. Primedex cannot assure you that a review of Primedex's business by courts or regulatory authorities will not result in a determination that could adversely affect Primedex's operations or that the healthcare regulatory environment will not change in a way that restricts Primedex's operations.

Some states have enacted statutes or adopted regulations affecting risk assumption in the healthcare industry, including statutes and regulations that subject any physician or physician network engaged in risk-based managed care contracting to applicable insurance laws and regulations. These laws and regulations, if adopted in California, may require physicians and physician networks to meet minimum capital requirements and other safety and soundness requirements. Implementing additional regulations or compliance requirements could result in substantial costs to Primedex and the contracted radiology practices and limit Primedex's ability to enter into capitation or other risk sharing managed care arrangements.

Primedex's substantial debt could adversely affect its financial condition and prevent Primedex from fulfilling its obligations.

In connection with the merger, Primedex intends to refinance all of its and Radiologix's current outstanding indebtedness with a \$405 million credit facility. This indebtedness and any future indebtedness that Primedex incurs could have important consequences by adversely affecting its financial condition, which could make it more difficult for Primedex to satisfy its obligations to creditors. Primedex's substantial indebtedness could also:

- require Primedex to dedicate a substantial portion of its cash flow from operations to payments on Primedex's debt, reducing the availability of Primedex's cash flow to fund working capital, capital expenditures and other general corporate purposes;
- increase Primedex's vulnerability to adverse general economic and industry conditions;
- limit Primedex's flexibility in planning for, or reacting to, changes in Primedex's business and the industry in which Primedex operates;

- place Primedex at a competitive disadvantage compared to Primedex's competitors that have less debt; and
- limit Primedex's ability to borrow additional funds on terms that are satisfactory to Primedex or at all.

Primedex has identified ineffective disclosure controls and procedures that if unsuccessfully remediated could adversely affect its ability to report its financial results on a timely and accurate basis.

Primedex determined that its disclosure controls and procedures were ineffective for the fiscal year ended October 31, 2005 and for the subsequent quarters ended January 31, 2006, April 30, 2006 and July 31, 2006. With respect to Primedex's ineffective disclosure controls and procedures, Primedex determined that it had insufficient personnel resources and technical accounting expertise within the accounting function to resolve the following non-routine accounting matters: the recording of non-typical cost-based investments and unusual debt-related transactions and the appropriate analysis of the amortization lives of leasehold improvements in accordance with GAAP.

Primedex believes that it has adequately remediated the material weakness by entering into a consulting agreement on August 1, 2006 with MorganFranklin Corporation to advise it with respect to non-routine accounting matters. However, if Primedex has not effectively remediated the material weakness, such material weakness could result in non-timely filing of periodic reports or accounting deficiencies in its financial reporting.

Primedex may identify additional material weaknesses or other deficiencies in its internal controls in the future. Any material weaknesses or other deficiencies in Primedex's control systems may affect its ability to comply with SEC reporting requirements and listing standards or cause Primedex's financial statements to contain material misstatements which could negatively affect market price and trading liquidity of its common stock. In addition, there are inherent limitations in all control systems, and misstatements due to error or fraud may occur and not be detected.

Agreements with Radiologix's contracted radiology practices must be structured to avoid the corporate practice of medicine and fee-splitting.

The laws of many states, including many of the states in which Radiologix's contracted radiology practices are located, prohibit Radiologix from exercising control over the medical judgments or decisions of physicians and from engaging in some financial arrangements, such as splitting professional fees with physicians. These laws and their interpretations vary from state to state and are enforced by state courts and regulatory authorities, each with broad discretion. A component of Radiologix's business has been to enter into service agreements with radiology practices. Radiologix provides management, administrative, technical and other non-medical services to the radiology practices in exchange for a service fee. Radiologix structures its relationships with the radiology practices, including the purchase of diagnostic imaging centers, in a manner that it believes keeps it from engaging in the practice of medicine or exercising control over the medical judgments or decisions of the radiology practices or their physicians or violating the prohibitions against fee-splitting. State regulatory authorities or other parties may assert that Radiologix is engaged in the corporate practice of medicine or that the payment of service fees to Radiologix by the radiology practices constitutes fee-splitting. If such a claim were successfully asserted, Radiologix could be subject to civil and criminal penalties and could be required to restructure or terminate the applicable contractual arrangements. This result, or Radiologix's inability to successfully restructure its relationships to comply with these statutes, could jeopardize Radiologix's business.

Deficit Reduction Act of 2005.

On February 8, 2006, the President signed into law the Deficit Reduction Act of 2005, referred to as the DRA. The DRA provides that reimbursement for the technical component for imaging services (excluding diagnostic and screening mammography) in non-hospital based freestanding facilities will be capped at the lesser of reimbursement under the Medicare Part B physician fee schedule or the Hospital Outpatient Prospective Payment System (HOPPS) schedule.

Currently, the technical component of Radiologix's and Primedex's imaging services is reimbursed under the Part B physician fee schedule, which, in most cases, allows for higher reimbursement than under the HOPPS. Under the DRA, Radiologix and Primedex will be reimbursed at the lower of the two schedules, beginning January 1, 2007.

The DRA also codifies the reduction in reimbursement for multiple images on contiguous body parts previously announced by the Centers for Medicare and Medicaid Services (CMS). In November 2005, CMS announced that it will pay 100% of the technical component of the higher priced imaging procedure and 50% for the technical component of each additional imaging procedure for imaging procedures involving contiguous body parts within a family of codes when performed in the same session. Under current methodology, Medicare pays 100% of the technical component of each procedure. CMS had indicated that it would phase in this rate reduction over two years, so that the reduction will be 25% for each additional imaging procedure in 2006 and another 25% in 2007. On August 8, 2006, CMS issued a proposed rule that would eliminate the 25% reduction in 2007.

For the fiscal year ended December 31, 2005, Medicare revenue from Radiologix's imaging centers represented approximately 26% of Radiologix's total revenue from its imaging centers. If both reimbursement reductions contained in the DRA had been in effect during fiscal year 2005, Radiologix estimates that its Medicare revenue would have been reduced by approximately \$13.3 million and equity in earnings of unconsolidated affiliates would have been reduced by \$1.6 million. The estimated future reduction in revenue and pre-tax earnings from the reimbursement changes contained in the DRA is as follows:

Estimated Reduction in Revenue and Pre-Tax Earnings from DRA

	2006	2007
	(In thousands of dollars)	
Consolidated Operations:		
Contiguous Body Parts	\$ 1,900	\$ 2,900
Fee Schedule Change		10,400
Total	\$ 1,900	\$ 13,300
Unconsolidated Operations:		
Contiguous Body Parts	\$ 200	\$ 200
Fee Schedule Change		1,400
Total	\$ 200	\$ 1,600

For the fiscal year ended October 31, 2005, Medicare revenue from Primedex's imaging centers represented approximately 14.7% of Primedex's total revenue from its imaging centers. If both reimbursement reductions contained in the DRA had been in effect during fiscal year 2005, Primedex estimates that its Medicare revenue would have been reduced by approximately \$4.5 million. The estimated future reduction in revenue and pre-tax earnings from the reimbursement changes contained in the DRA is as follows:

Estimated Reduction in Revenue and Pre-Tax Earnings from DRA

	2006	2007
	(In thousands of dollars)	
Consolidated Operations:		
Contiguous Body Parts	\$ 400	\$ 1,000
Fee Schedule Change		3,500
Total	\$ 400	\$ 4,500

Risks Related to the Transfer Restrictions on Primedex Common Stock

The imposition of transfer restrictions may cause the market price of Primedex's stock to decline.

If the amendment to the certificate of incorporation imposing transfer restrictions is approved, the transfer restrictions will be applicable to Primedex's common stock. These transfer restrictions currently do not apply to Primedex's common stock. It is possible that the transfer restrictions will have an adverse effect on the market price of Primedex common stock. If the transfer restrictions are approved, they will remain in effect until such time as the board of directors of Primedex determines that they are no longer necessary, which should be the earlier of full usage of the NOLs, as defined on page 82, or their expiration. The latest date of expiration of Primedex's NOLs is estimated to be 2025.

The transfer restrictions may impede or discourage efforts by a third party to acquire Primedex, even if doing so would benefit Primedex's stockholders.

Although the transfer restrictions are designed as a protective measure to preserve Primedex's \$161 million of NOLs, the transfer restrictions may have the effect of impeding or discouraging a merger, tender offer or proxy contest, even if such a transaction may be favorable to the interests of some or all of the stockholders of Primedex. This effect might prevent stockholders from realizing an opportunity to sell all or a portion of their shares of common stock of Primedex at a premium above market prices. In addition, the transfer restrictions may delay the assumption of control by a holder of a large block of Primedex's stock and the removal of incumbent directors and management, even if such removal may be beneficial to some or all of the stockholders of Primedex.

The transfer restrictions may not be enforceable, and an ownership change may occur with the result that the ability to use the NOLs could be severely limited.

The transfer restrictions could be challenged, and a court could refuse to enforce them. It also is possible that the tax authorities (including the IRS) could take the position that the transfer restrictions were not effective and did not protect Primedex from an ownership change for tax purposes. Furthermore, transactions permitted under the transfer restrictions, such as transfers by pre-existing 5% stockholders, could trigger an ownership change for purposes of Section 382 and result in limitations on Primedex's ability to use the NOLs in the future.

Risks Related to Primedex's Future use of NOLs

Future legislation may result in Primedex being unable to realize the tax benefits of the NOLs.

It is possible that legislation or regulations will be adopted that would limit Primedex's ability to use the tax benefits associated with the NOLs. However, we are not aware of any proposed changes in the tax laws or regulations that would materially impact the ability of Primedex to use the NOLs.

Primedex may not be able to make use of the existing tax benefits of the NOLs because Primedex may not generate taxable income.

The use of the NOLs is subject to uncertainty because it is dependent upon the amount of taxable income and capital gains generated by Primedex. Primedex has not generated taxable income on an annual basis since October 31, 2001, and there can be no assurance that Primedex will have sufficient taxable income or capital gains in future years to use the NOLs before they expire.

This is especially true for the capital loss carryforwards because they expire over a shorter period of time than the net operating loss carryforwards.

The IRS could challenge the amount of the NOLs or claim Primedex experienced an ownership change, which could reduce the amount of NOLs that Primedex can use.

The amount of the NOLs has not been audited or otherwise validated by the IRS. The IRS could challenge the amount of the NOLs, which could result in an increase in the liability of Primedex in the future for income taxes. In addition, calculating whether an ownership change has occurred is subject to uncertainty, both because of the complexity and ambiguity of Section 382 and because of limitations on a publicly traded company's knowledge as to the ownership of, and transactions in, its securities. Therefore, Primedex cannot assure you that a governmental authority will not claim that Primedex experienced an ownership change and attempt to reduce or eliminate the benefit of the NOLs even though the stock of Primedex is subject to the transfer restrictions.

Primedex's business could be adversely affected if the amendment to its certificate of incorporation is not approved.

Primedex currently does not have restrictions in place that limit transfers of its common stock. If the amendment to its certificate of incorporation imposing transfer restrictions is not approved, Primedex will not have the ability to prohibit any transfers. As a result, an ownership change could occur. An ownership change could severely limit Primedex's ability to use the NOLs. Primedex's ability to use the NOLs to reduce its future liability to pay federal income tax is an important aspect of its business strategy. Primedex's business could be adversely affected if it is unable to make use of the NOLs.

THE RADIOLOGIX SPECIAL MEETING

General

Radiologix is furnishing this joint proxy statement/prospectus to you in order to provide you with important information regarding the matters to be considered at the special meeting of Radiologix stockholders and at any adjournment or postponement of the special meeting. Radiologix first mailed this joint proxy statement/prospectus and the accompanying form of proxy to its stockholders on or about October 20, 2006.

Date, Time and Place of the Radiologix Special Meeting

Radiologix will hold its special meeting of stockholders at 3900 JPMorgan Chase Tower, 2200 Ross Avenue, Dallas, Texas 75201 at 9:00 a.m. Central Time on November 15, 2006, unless postponed or adjourned to a later date.

Purposes of the Radiologix Special Meeting

At the Radiologix special meeting, Radiologix stockholders will be asked to consider and vote on the following proposals:

1. To adopt the Agreement and Plan of Merger, dated as of July 6, 2006, by and among Radiologix, Inc., Primedex Health Systems, Inc., PR Acquisition Corporation, an indirect wholly-owned subsidiary of Primedex, and RadNet Management, Inc., a wholly-owned subsidiary of Primedex and sole stockholder of PR Acquisition Corporation, and the transactions contemplated by the merger agreement, including the merger, pursuant to which PR Acquisition Corporation will merge with and into Radiologix, on the terms and subject to the conditions contained in the merger agreement, and Radiologix stockholders will receive aggregate consideration of 22,621,922 shares of Primedex common stock and \$42,950,000 in cash. A copy of the merger agreement is attached as *Annex A* to this joint proxy statement/prospectus;
2. To approve adjournments or postponements of the Radiologix special meeting, if necessary, to permit further solicitation of proxies if there are not sufficient votes at the time of the Radiologix special meeting to approve the above proposals; and
3. To consider and take action upon any other business that may properly come before the Radiologix special meeting or any reconvened meeting following an adjournment or postponement of the Radiologix special meeting.

Record Date and Outstanding Voting Securities

Radiologix's board of directors has established October 6, 2006, as the record date for determining the Radiologix stockholders entitled to receive notice of and to vote at the special meeting. On the record date, there were issued and outstanding 22,442,417 shares of Radiologix common stock, which are entitled to one vote per share upon the proposals presented at the special meeting. On the record date, there were no shares of Radiologix preferred stock issued and outstanding.

As of the record date, the directors and officers of Radiologix and their affiliates held shares of common stock representing approximately 1.8% of the outstanding shares of Radiologix common stock.

A list of stockholders eligible to vote at the special meeting will be available for your review during Radiologix's regular business hours at its headquarters in Dallas, Texas for at least ten days prior to the special meeting for any purpose related to the special meeting.

Voting and Revocation of Proxies

The proxy regarding the Radiologix special meeting accompanying this joint proxy statement/prospectus is solicited on behalf of the board of directors of Radiologix for use at the special meeting.

General

Shares represented by a properly signed and dated proxy will be voted at the special meeting in accordance with the instructions indicated on the proxy. Proxies that are properly signed and dated but that do not contain voting instructions will be voted FOR each of the proposals described in this joint proxy statement/prospectus.

Abstentions

Radiologix will count a properly executed proxy marked *abstain* with respect to a particular proposal as present for purposes of determining whether a quorum is present, but the shares represented by that proxy will not be voted at the special meeting with respect to such proposal. Because approval of Proposal No. 1 will require the affirmative vote of a majority of the outstanding shares of Radiologix common stock and approval of Proposal No. 2 will require the affirmative vote of a majority of the shares of Radiologix common stock, present in person or represented by proxy and entitled to vote at the Radiologix special meeting, abstentions on these proposals will have the same effect as a vote AGAINST those proposals.

Broker Non-Votes

If your shares are held by your broker or other nominee, your broker or other nominee will vote your shares for you if you provide instructions to your broker or other nominee on how to vote. You should follow the directions provided by your broker or other nominee regarding how to instruct your broker or other nominee to vote your shares. *Broker non-votes* are shares held by a broker or other nominee that are represented at the special meeting, but with respect to which the broker or other nominee is not instructed by the beneficial owner of the shares to vote on the particular proposal and the broker or other nominee does not have discretionary voting power on the proposal. *Broker non-votes* will be counted for purposes of determining the presence or absence of a quorum but will not be counted for purposes of determining the number of shares represented and voting with respect to a proposal. Failure to instruct your broker or other nominee on how to vote your shares on Proposal No. 1 will have the effect of voting AGAINST the proposal. If you do not provide instructions to your broker on how to vote your shares on Proposal No. 2, your broker generally will have the authority to vote on proposals to adjourn or postpone the meeting. However, your broker will not be authorized to vote on any proposal to adjourn or postpone the meeting solely relating to the solicitation of proxies to adopt the merger agreement and the transactions contemplated by the merger agreement, including the merger.

Voting Shares in Person that are Held Through Brokers or Other Nominees

If your Radiologix shares are held in *street name* (that is, through a broker or other nominee) and you would like to attend the special meeting and vote in person, you will need to bring an account statement or other acceptable evidence of ownership of Radiologix common stock as of the close of business on October 6, 2006, the record date for voting. Alternatively, in order to vote, you may contact the person in whose name your shares are registered, obtain a properly executed legal proxy from that person, identifying you as a Radiologix stockholder, authorizing you to act on behalf of the nominee at the Radiologix special meeting and identifying the number of shares with respect to which the authorization is granted, and bring that proxy to the special meeting.

Revocation of Proxies

If you submit a proxy, you may revoke it at any time before it is voted by:

- delivering to the corporate secretary of Radiologix a written notice, dated later than the proxy you wish to revoke, stating that the proxy is revoked;
- submitting to the corporate secretary of Radiologix a new, signed proxy card with a later date than the proxy you wish to revoke;
- if available, voting again by telephone or over the Internet and submitting your proxy so that it is received prior to your stockholder meeting; or
- attending the special meeting and voting in person (attendance by itself will not revoke your proxy).

Attendance and Procedures at the Special Meeting

Attendance at the special meeting will be limited to stockholders of record, beneficial owners of common stock entitled to vote at the meeting having evidence of ownership, the authorized representative (one only) of an absent stockholder, and invited guests of management. If you plan to attend the special meeting and you hold your shares directly in your name, please vote your proxy and bring valid picture identification with you to the meeting. Stockholders who hold their shares through a broker or other nominee will need to bring a copy of a brokerage or other statement reflecting their stock ownership as of the record date. All stockholders will be asked to present valid picture identification. Any person claiming to be an authorized representative of a stockholder must, upon request, produce written evidence of the authorization.

Notices to the corporate secretary of Radiologix should be sent to 3600 JPMorgan Chase Tower, 2200 Ross Avenue, Dallas, Texas 75201-2776.

If you have instructed your broker or other nominee to vote your shares, you must follow directions received from your broker or other nominee to change those instructions.

Required Stockholder Vote

In order to conduct business at the Radiologix special meeting, a quorum must be present. The holders of a majority of the common stock issued and outstanding and entitled to vote at the special meeting, present in person or represented by proxy, will constitute a quorum at the special meeting for the transaction of business under Radiologix's certificate of incorporation and bylaws. All shares of Radiologix common stock represented at the special meeting, including broker non-votes and shares voted abstain or withheld, will be treated as shares that are present and entitled to vote for purposes of determining the presence of a quorum. Radiologix will treat shares of Radiologix common stock represented by a properly signed and returned proxy, including abstentions and broker non-votes, as present at the Radiologix special meeting for the purposes of determining the existence of a quorum. If a quorum is not present, it is expected that the special meeting will be adjourned to solicit additional proxies.

For Proposal No. 1, the vote of a majority of the outstanding shares of Radiologix common stock for the proposal will be the act of the stockholders. For Proposal No. 2, the vote of a majority of the shares of Radiologix common stock, present in person or represented by proxy and entitled to vote at the Radiologix special meeting. Therefore, shares voted abstain and broker non-votes on those proposals will have the same effect as votes against those proposals.

The votes required to approve the respective proposals at the Radiologix special meeting are:

Proposal No. 1 Adoption of the merger agreement and the merger requires the affirmative vote of a majority of the outstanding shares of Radiologix common stock. Abstentions and broker non-votes will have the same effect as voting AGAINST Proposal No. 1.

Proposal No. 2 To approve adjournments or postponements of the Radiologix special meeting, if necessary, to permit further solicitation of proxies if there are not sufficient votes at the time of the Radiologix special meeting to approve Proposal No. 1 requires the affirmative vote of a majority of the shares of Radiologix common stock, present in person or represented by proxy and entitled to vote at the Radiologix special meeting. Abstentions and broker non-votes will have the same effect as voting AGAINST Proposal No. 2.

The inspector of elections for the Radiologix special meeting will tabulate the votes.

Recommendation of Board of Directors

After careful consideration, the board of directors of Radiologix has unanimously determined that each proposal is advisable and in the best interests of Radiologix and its stockholders and recommends that Radiologix stockholders vote FOR each of the proposals.

Other Business; Adjournments or Postponements

We are not aware of any other business to be acted upon at the special meeting. If, however, other matters are properly brought before the special meeting, your proxies will have discretion to vote or act on those matters according to their best judgment.

Any adjournment may be made from time to time by approval of the stockholders holding a majority of the voting power present in person or by proxy at the special meeting, whether or not a quorum exists, without further notice other than by an announcement made at the special meeting. In addition, if the adjournment of the special meeting is for more than 30 days or if after the adjournment a new record date is fixed for an adjourned meeting, notice of the adjourned meeting must be given to each stockholder of record entitled to vote at such special meeting. If a quorum is not present at the special meeting, stockholders may be asked to vote on a proposal to adjourn or postpone the special meeting to solicit additional proxies. If a quorum is not present at the special meeting, the holders of a majority of the shares entitled to vote who are present in person or by proxy may adjourn or postpone the special meeting. If a quorum is present at the special meeting but there are not sufficient votes at the time of the special meeting to approve the other proposal(s), holders of common stock may also be asked to vote on a proposal to approve the adjournment or postponement of the special meeting to permit further solicitation of proxies.

Solicitation of Proxies

This solicitation of proxies for the Radiologix special meeting is being made by management of Radiologix on behalf of the Radiologix board of directors and will be made by mail, telephone, the Internet, facsimile and electronic transmission or overnight delivery. Radiologix will bear the entire cost of soliciting proxies from Radiologix stockholders. In addition to this mailing, Radiologix's directors, officers and employees (who will not receive any additional compensation for their services) may solicit proxies personally, by mail, telephone, the Internet, facsimile and electronic transmission or overnight delivery. Radiologix has also engaged D. F. King for a fee of approximately \$10,000 plus a per call fee and reimbursement of expenses to assist in the solicitation of proxies. Radiologix and its proxy solicitors will also request that banks, brokerage houses and other custodians, nominees and fiduciaries send proxy materials to the beneficial owners of Radiologix common stock and will, if requested, reimburse the record

holders for their reasonable out-of-pocket expenses in doing so. The extent to which these proxy-soliciting efforts will be necessary depends upon how promptly proxies are submitted. You should promptly vote by submitting your completed proxy card without delay by mail.

Voting Agreement

Contrarian Equity Fund, L.P., a Radiologix stockholder, which owns approximately 16.9% of the outstanding shares of Radiologix common stock, is a party to a voting agreement with Primedex under which it is obligated to vote its shares in favor of adopting the merger agreement and the merger.

Security Ownership of Principal Stockholders, Directors and Executive Officers

For information regarding the security ownership of Radiologix common stock by principal stockholders, directors and executive officers of Radiologix, see the disclosure below under the caption "Information About Radiologix Beneficial Ownership of Radiologix Common Stock" beginning on page 259.

Assistance

If you need assistance in completing your proxy card or have questions regarding Radiologix's special meeting, please contact Radiologix's General Counsel at 214-303-2776 or write to Radiologix, Inc., 3600 JPMorgan Chase Tower, 2200 Ross Avenue, Dallas, Texas 75201-2776, Attention: General Counsel.

Appraisal and Dissenters' Rights

Holders of Radiologix common stock have dissenters' rights under Delaware law with respect to the merger transaction. For information regarding such dissenters' rights, see "The Merger Appraisal and Dissenters' Rights" beginning on page 130.

Interest of Certain Persons in Matters to be Acted Upon

Under the merger agreement, Sami S. Abbasi will be paid \$2,392,000 in full and final settlement of Radiologix's obligations to him as a result of a Change of Control (as defined in his employment agreement), and his employment agreement shall automatically terminate and be cancelled effective as of the closing date of the merger, except for non-competition covenants and Radiologix's obligation to pay some of the taxes Mr. Abbasi may owe as a result of this payment to him. The \$2,392,000 is in addition to the \$175,000 payable to him as a 2005 bonus, the amount to be received by him as a result of the exercise of stock options, and the merger consideration to be received by Mr. Abbasi with respect to his Radiologix common stock. As a result of the merger, Mr. Abbasi will become vested in 200,000 shares of Radiologix common stock that were restricted and options to purchase 637,922 shares of Radiologix common stock.

The matters to be considered at the special meeting are of great importance to the stockholders of Radiologix. You are accordingly urged to read and carefully consider the information presented in this joint proxy statement/prospectus, and to submit your proxy by mail in the enclosed postage-paid envelope.

PROPOSAL NO. 1

**ADOPTION OF THE MERGER AGREEMENT
AND THE MERGER**

As discussed elsewhere in this joint proxy statement/prospectus, Radiologix stockholders are considering and voting on a proposal to adopt the merger agreement and the merger. Radiologix stockholders should read carefully this joint proxy statement/prospectus in its entirety for more detailed information concerning the merger agreement and the merger, including the sections of this joint proxy statement/prospectus titled *The Merger*, which begins on page 100, and *The Merger Agreement*, which begins on page 141. In addition, Radiologix stockholders should read the merger agreement, which is attached as *Annex A* to this joint proxy statement/prospectus, in its entirety.

Recommendation

The Radiologix board of directors unanimously recommends a vote **FOR** adopting the merger agreement and the merger, and your proxy will be so voted unless you specify otherwise.

PROPOSAL NO. 2

**APPROVAL OF ADJOURNMENTS OR POSTPONEMENTS
OF THE RADIOLOGIX SPECIAL MEETING**

As discussed elsewhere in this joint proxy statement/prospectus, Radiologix stockholders are considering and voting on a proposal to approve adjournments or postponements of the Radiologix special meeting, if necessary, to permit further solicitation of proxies if there are not sufficient votes at the time of the Radiologix special meeting to approve the Proposal No. 1. Radiologix stockholders should read carefully this joint proxy statement/prospectus in its entirety for more detailed information concerning the merger agreement and the merger, including the sections of this joint proxy statement/prospectus titled *The Merger*, which begins on page 100, and *The Merger Agreement*, which begins on page 141. In addition, Radiologix stockholders should read the merger agreement, which is attached as *Annex A* to this joint proxy statement/prospectus, in its entirety.

Recommendation

The Radiologix board of directors unanimously recommends a vote **FOR** the proposal to approve adjournments or postponements of the Radiologix special meeting, if necessary, to permit further solicitation of proxies if there are not sufficient votes at the time of the Radiologix special meeting to approve Proposal No. 1, and your proxy will be so voted unless you specify otherwise.

THE PRIMEDEX SPECIAL MEETING

General

Primedex is furnishing this joint proxy statement/prospectus to you in order to provide you with important information regarding the matters to be considered at the 2006 special meeting of Primedex stockholders and at any adjournment or postponement of the special meeting. Primedex first mailed this joint proxy statement/prospectus and the accompanying form of proxy to its stockholders on or about October 20, 2006.

Date, Time and Place of the Primedex Special Meeting

Primedex will hold its 2006 special meeting of stockholders at The Olympic Collection, 11301 Olympic Boulevard, Los Angeles, California 90064 at 9:00 a.m., Pacific Time, on November 15, 2006.

Purposes of the Primedex Special Meeting

At the Primedex special meeting, Primedex stockholders will be asked to consider and vote on the following proposals:

- **Proposal No. 1** To adopt the Agreement and Plan of Merger, dated as of July 6, 2006, by and among Radiologix, Inc., Primedex Health Systems, Inc., PR Acquisition Corporation, an indirect wholly-owned subsidiary of Primedex, and RadNet Management, Inc., a wholly-owned subsidiary of Primedex and sole stockholder of PR Acquisition Corporation, and the transactions contemplated by the merger agreement, including the merger and the issuance of Primedex common stock in connection with the merger, pursuant to which PR Acquisition Corporation will merge with and into Radiologix, on the terms and subject to the conditions contained in the merger agreement, and Radiologix stockholders will receive aggregate consideration of 22,621,922 shares of Primedex common stock and \$42,950,000 in cash. A copy of the merger agreement is attached as *Annex A* to this joint proxy statement/prospectus.
- **Proposal No. 2** To adopt an amendment to Primedex's certificate of incorporation to change Primedex's name to RadNet, Inc.
- **Proposal No. 3** To adopt an amendment to Primedex's certificate of incorporation to (i) increase the number of authorized shares of Primedex common stock from 100,000,000 shares to 200,000,000 shares and reduce the par value of each share of common stock from \$0.01 to \$0.0001, (ii) undesignate all of Primedex's preferred stock, and (iii) increase the authorized number of shares of Primedex preferred stock from 10,000,000 shares to 30,000,000 shares and reduce the par value of each share of preferred stock from \$0.01 to \$0.0001.
- **Proposal No. 4** To adopt an amendment to Primedex's certificate of incorporation to implement stock transfer restrictions to preserve Primedex's unrestricted use of its net operating loss carry-forwards.
- **Proposal No. 5** To adopt Primedex's 2006 Stock Incentive Plan.
- **Proposal No. 6** To elect five directors to Primedex's board of directors.
- **Proposal No. 7** To adopt an amendment to Primedex's certificate of incorporation to effect a one-for-two reverse stock split.
- **Proposal No. 8** To ratify the appointment of Moss Adams LLP as Primedex's independent registered public accounting firm for its fiscal year ending October 31, 2006.

- **Proposal No. 9** To approve adjournments or postponements of the Primedex special meeting, if necessary, to permit further solicitation of proxies if there are not sufficient votes at the time of the Primedex special meeting to approve the above proposals.

In addition, Primedex stockholders may also consider and take action upon any other business that may properly come before the Primedex special meeting or any reconvened meeting following an adjournment or postponement of the Primedex special meeting.

Record Date and Outstanding Voting Securities

Primedex's board of directors has established October 6, 2006, as the record date for determining the Primedex stockholders entitled to receive notice of and to vote at the special meeting. On the record date, there were issued and outstanding 44,039,105 shares of Primedex common stock, which are entitled to one vote per share upon the proposals presented at the special meeting, except for the election of directors in the event that a stockholder gives notice of his intent to cumulate votes. Cumulative voting is explained below under Required Stockholder Vote. On the record date, there were no shares of Primedex preferred stock issued and outstanding.

As of the record date, the directors and officers of Primedex and their affiliates held shares of common stock representing approximately 33% of the outstanding shares of Primedex common stock, on a fully diluted basis.

A list of stockholders eligible to vote at the special meeting will be available for your review during Primedex's regular business hours at its headquarters in Los Angeles, California for at least ten days prior to the special meeting for any purpose related to the special meeting.

Voting and Revocation of Proxies

The proxy accompanying this joint proxy statement/prospectus is solicited on behalf of the board of directors of Primedex for use at the special meeting.

General

Shares represented by a properly signed and dated proxy will be voted at the special meeting in accordance with the instructions indicated on the proxy. Proxies that are properly signed and dated but that do not contain voting instructions will be voted FOR each of the proposals described in this joint proxy statement/prospectus.

Abstentions

Primedex will count a properly executed proxy marked abstain with respect to a particular proposal as present for purposes of determining whether a quorum is present, but the shares represented by that proxy will not be voted at the special meeting with respect to such proposal. Because approval of Proposals No. 1, No. 2, No. 3, No. 4, and No. 7 will require the affirmative vote of a majority of the voting power of the Primedex shares outstanding, abstentions on these proposals will have the same effect as a vote AGAINST those proposals. However, because approvals of Proposals No. 5 and 8 will require the affirmative vote of a majority of the shares present in person or represented by proxy and voted at the special meeting, and abstentions are not counted as votes cast, abstentions will have no effect on the outcome of those proposals, so long as a quorum is present at the special meeting. In addition, abstentions will have no direct effect on the outcome of Proposal No. 6, assuming that a quorum is present at the special meeting, because the election of directors will be decided by either plurality or cumulative voting.

Broker Non-Votes

If your shares are held by your broker or other nominee, your broker or other nominee will vote your shares for you if you provide instructions to them on how to vote. You should follow the directions provided by your broker or other nominee regarding how to instruct them to vote your shares. Broker non-votes are shares held by a broker or other nominee that are represented at the special meeting, but with respect to which the broker or other nominee is not instructed by the beneficial owner of the shares to vote on the particular proposal and the broker or other nominee does not have discretionary voting power on the proposal because it is not deemed to be a routine matter. Broker non-votes will be counted for purposes of determining the presence or absence of a quorum but will not be counted for purposes of determining the number of shares represented and voting with respect to a proposal. Failure to instruct your broker or other nominee on how to vote your shares on Proposal No. 1, Proposal No. 2, Proposal No. 3, Proposal No. 4, Proposal No. 5, and Proposal No. 7 will have the effect of voting AGAINST those proposals. We believe that Proposal No. 6 and Proposal No. 8 will be deemed routine, and brokers will therefore vote in accordance with management's recommendation in the absence of specific instructions from you.

Voting Shares in Person that are Held Through Brokers or Other Nominees

If your Primedex shares are held in street name (that is, through a broker or other nominee) and you would like to attend the special meeting and vote in person, you will need to bring an account statement or other acceptable evidence of ownership of Primedex common stock as of the close of business on October 6, 2006, the record date for voting. Alternatively, in order to vote, you may contact the person in whose name your shares are registered, obtain a properly executed legal proxy from that person, identifying you as a Primedex stockholder, authorizing you to act on behalf of the nominee at the Primedex special meeting and identifying the number of shares with respect to which the authorization is granted, and bring that proxy to the special meeting.

Revocation of Proxies

If you submit a proxy, you may revoke it at any time before it is voted by:

- delivering to the corporate secretary of Primedex a written notice, dated later than the proxy you wish to revoke, stating that the proxy is revoked;
- submitting to the corporate secretary of Primedex a new, signed proxy card with a later date than the proxy you wish to revoke;
- if available, voting again by telephone or over the Internet and submitting your proxy so that it is received prior to your stockholder meeting; or
- attending the special meeting and voting in person (attendance by itself will not revoke your proxy).

Attendance and Procedures at the Special Meeting

Attendance at the special meeting will be limited to stockholders of record, beneficial owners of common stock entitled to vote at the meeting having evidence of ownership, the authorized representative (one only) of an absent stockholder, and invited guests of management. If you plan to attend the special meeting and you hold your shares directly in your name, please vote your proxy but keep the admission ticket attached to your proxy card and bring it with you to the meeting. Stockholders who hold their shares through a broker or other nominee, will need to bring a copy of a brokerage or other statement reflecting their stock ownership as of the record date. All stockholders will be asked to present valid picture identification. Any person claiming to be an authorized representative of a stockholder must, upon request, produce written evidence of the authorization.

Notices to the corporate secretary of Primedex should be sent to 1510 Cotner Avenue, Los Angeles, California 90025.

If you have instructed your broker or other nominee to vote your shares, you must follow directions received from your broker or other nominee to change those instructions.

Required Stockholder Vote

In order to conduct business at the Primedex special meeting, a quorum must be present. The holders of a majority of the common stock issued and outstanding and entitled to vote at the special meeting, present in person or represented by proxy, will constitute a quorum at the special meeting for the transaction of business under Primedex's certificate of incorporation and bylaws. All shares of Primedex common stock represented at the special meeting, including broker non-votes and shares voted abstain or withheld, will be treated as shares that are present and entitled to vote for purposes of determining the presence of a quorum. Primedex will treat shares of Primedex common stock represented by a properly signed and returned proxy, including abstentions and broker non-votes, as present at the Primedex special meeting for the purposes of determining the existence of a quorum. If a quorum is not present, it is expected that the special meeting will be adjourned to solicit additional proxies.

For Proposals No. 1, No. 2, No. 3, No 4, and No. 7 the vote of a majority of the outstanding shares of Primedex common stock for the proposal will be the act of the stockholders. Therefore, shares voted abstain and broker non-votes on those proposals will have the same effect as votes against those proposals. For Proposals No. 5 and No. 8, the vote of a majority of the shares present in person or represented by proxy at the special meeting, entitled to vote and voting for the proposal, will be the act of the stockholders.

For the election of directors in Proposal No. 6, each stockholder is entitled to cumulative voting rights, which means that the total number of votes which the stockholder may cast for the election of directors equals the number of directors to be elected multiplied by the number of shares held, and the stockholder may cast all of such votes for one candidate for director or may distribute the total votes among all or several candidates, as the stockholder sees fit. A stockholder may not cumulate votes for a candidate unless the candidate's name has been placed in nomination prior to the voting and unless the stockholder gives notice at the special meeting, prior to the voting, of an intention to cumulate votes. If any stockholder present at the special meeting gives such notice, all stockholders may cumulate their votes. In such event, the persons designated in the accompanying proxy card will allocate votes among the candidates nominated as directed by the board of directors. If cumulative voting is not invoked, the candidates receiving the highest number of votes of the shares entitled to vote for them, up to the number of directors to be elected, shall be elected. The proxy card provided with this proxy statement indicates the number of shares of Primedex common stock that you own and are entitled to vote.

The votes required to approve the respective proposals at the Primedex special meeting are:

Proposal No. 1 Adoption and approval of the merger agreement and approval of the transactions contemplated thereby, including the merger and the issuance of shares of Primedex common stock in connection with the merger agreement, requires the affirmative vote of a majority of the outstanding shares of Primedex common stock. Abstentions and broker non-votes will have the same effect as voting AGAINST Proposal No. 1.

Proposal No. 2 Adoption and approval of an amendment to Primedex's certificate of incorporation to change Primedex's name to RadNet, Inc. requires the affirmative vote of a majority of the outstanding shares of Primedex common stock. Abstentions and broker non-votes will have the same effect as voting AGAINST Proposal No. 2.

Proposal No. 3 Adoption and approval of an amendment to Primedex's certificate of incorporation to (i) increase the number of authorized shares of Primedex common stock from 100,000,000 shares to 200,000,000 shares and reduce the par value of each share of common stock from \$0.01 to \$0.0001, (ii) undesignate all of Primedex's preferred stock, and (iii) increase the authorized number of shares of Primedex preferred stock from 10,000,000 shares to 30,000,000 shares and reduce the par value of each share of preferred stock from \$0.01 to \$0.0001 requires the affirmative vote of a majority of the outstanding shares of Primedex common stock. Abstentions and broker non-votes will have the same effect as voting AGAINST Proposal No. 3.

Proposal No. 4 Adoption and approval of an amendment to Primedex's certificate of incorporation to implement certain stock transfer restrictions to preserve Primedex's unrestricted use of its net operating loss carry-forwards requires the affirmative vote of a majority of the outstanding shares of Primedex common stock. Abstentions and broker non-votes will have the same effect as voting AGAINST Proposal No. 4.

Proposal No. 5 Adoption and approval of the 2006 Stock Incentive Plan requires the affirmative vote of a majority of the votes cast at the special meeting. Neither broker non-votes nor abstentions will have any effect on Proposal No. 5.

Proposal No. 6 Election of the five existing members of Primedex's board of directors will be decided by plurality voting unless a stockholder gives proper notice of intent to cumulate votes at the special meeting, in which case it will be decided by cumulative voting. In either event, the five directors who receive the most for votes will be elected, and broker non-votes, abstentions and votes against or withheld will have no effect on the election.

Proposal No. 7 Adoption and approval of an amendment to Primedex's certificate of incorporation to effect a one-for-two reverse stock split requires the affirmative vote of a majority of the outstanding shares of Primedex common stock. Abstentions and broker non-votes will have the same effect as voting AGAINST Proposal No. 7.

Proposal No. 8 Ratification of the appointment of Moss Adams LLP as Primedex's independent registered public accounting firm for the new fiscal year ending December 31, 2006 requires the affirmative vote of a majority of the votes cast at the special meeting. Neither broker non-votes nor abstentions will any effect on Proposal No. 8.

Proposal No. 9 To approve adjournments or postponements of the Primedex special meeting, if necessary, to permit further solicitation of proxies if there are not sufficient votes at the time of the Primedex special meeting to approve the above proposals. Abstentions and broker non-votes will have the same effect as voting AGAINST Proposal No. 9.

The inspector of elections for the Primedex special meeting will tabulate the votes.

Recommendation by the Board of Directors

After careful consideration, the board of directors of Primedex has determined that each proposal is advisable and in the best interests of Primedex and its stockholders and recommends that Primedex stockholders vote FOR each of the proposals.

Other Business; Adjournments or Postponements

We are not aware of any other business to be acted upon at the special meeting. If, however, other matters are properly brought before the special meeting, your proxies will have discretion to vote or act on those matters according to their best judgment.

Any adjournment may be made from time to time by approval of the stockholders holding a majority of the voting power present in person or by proxy at the special meeting, whether or not a quorum exists, without further notice other than by an announcement made at the special meeting. In addition, if the adjournment of the special meeting is for more than 30 days or if after the adjournment a new record date is fixed for an adjourned meeting, notice of the adjourned meeting must be given to each stockholder of record entitled to vote at such special meeting. If a quorum is not present at the special meeting, stockholders may be asked to vote on a proposal to adjourn or postpone the special meeting to solicit additional proxies. If a quorum is not present at the special meeting, the holders of a majority of the shares entitled to vote who are present in person or by proxy may adjourn or postpone the special meeting. If a quorum is present at the special meeting but there are not sufficient votes at the time of the special meeting to approve the other proposal(s), holders of common stock may also be asked to vote on a proposal to approve the adjournment or postponement of the special meeting to permit further solicitation of proxies.

Solicitation of Proxies

This solicitation of proxies for the Primedex special meeting is being made by management of Primedex on behalf of the Primedex board of directors and will be made by mail, telephone, the Internet, facsimile and electronic transmission or overnight delivery. Primedex will bear the entire cost of soliciting proxies from Primedex stockholders, except that Primedex and Radiologix will share equally the expenses incurred in connection with the filing with the SEC of the registration statement of which this joint proxy statement/prospectus forms a part and the printing and mailing of this joint proxy statement/prospectus. In addition to this mailing, Primedex's directors, officers and employees (who will not receive any additional compensation for their services) may solicit proxies personally, by mail, telephone, the Internet, facsimile and electronic transmission or overnight delivery. Primedex and its proxy solicitors will also request that banks, brokerage houses and other custodians, nominees and fiduciaries send proxy materials to the beneficial owners of Primedex common stock and will, if requested, reimburse the record holders for their reasonable out-of-pocket expenses in doing so. The extent to which these proxy-soliciting efforts will be necessary depends upon how promptly proxies are submitted. You should promptly vote by submitting your completed proxy card without delay by mail.

Security Ownership of Principal Stockholders, Directors and Executive Officers

For information regarding the security ownership of Primedex common stock by principal stockholders, directors and executive officers of Primedex, see the disclosure below under the caption "Information About Primedex Stock Ownership of Directors and Executive Officers" beginning on page 198.

Assistance

If you need assistance in completing your proxy card or have questions regarding Primedex's special meeting, please contact Primedex's Investor Relations at (310) 478-7808 or write to Primedex Health Systems, Inc., 1510 Cotner Avenue, Los Angeles, California, 90025, Attention: Investor Relations.

Appraisal and Dissenters' Rights

Holders of Primedex common stock have dissenters' rights under California law with respect to the merger transaction. For information regarding such dissenters' rights, see "The Merger Appraisal and Dissenters' Rights" beginning on page 130.

Interest of Certain Persons in Matters to be Acted Upon

The officers and directors of Primedex do not have interests in the merger that are materially different from those of Primedex stockholders with respect to any of the proposals. Dr. Howard Berger, Primedex's President and Chief Executive Officer, owns more than 5% of Primedex's outstanding shares of common stock. If Proposal No. 4 is approved, the new transfer restrictions included in Primedex's certificate of incorporation will treat pre-existing 5% stockholders differently from persons who become 5% stockholders after August 21, 2006. See Proposal No. 4 Amendment to Certificate of Incorporation to Implement Transfer Restrictions Treatment of Pre-existing 5% Stockholders.

Stockholder Proposals and Nominations

Requirements for Stockholder Proposals to be Brought Before an Annual Meeting

For stockholder nominations to the board of directors or other proposals to be considered at an annual meeting, the stockholder must have given timely notice of the proposal or nomination in writing to Primedex's Secretary pursuant to Rule 14a-4 under the Securities Exchange Act of 1934, as amended. To be timely for the 2007 annual meeting, a stockholder's notice must be delivered to or mailed and received by Primedex's Secretary at Primedex's principal executive offices not later than June 21, 2007. If the date of the 2007 annual meeting is advanced or delayed more than 30 days from the date of this 2006 special meeting held in lieu of the annual meeting, stockholder proposals intended to be included in the Proxy Statement for the 2007 annual meeting must be received by us within a reasonable time before Primedex begins to print and mail the proxy statement for the 2007 annual meeting. Upon any determination that the date of the 2007 annual meeting will be advanced or delayed by more than 30 days from the date of this 2006 meeting, the Company will disclose the change in the earliest practicable Quarterly Report on Form 10-Q.

Requirements for Stockholder Proposals to be Considered for Inclusion in Primedex's Proxy Materials

Stockholder proposals submitted pursuant to Rule 14a-8 under the Securities Exchange Act of 1934, as amended, and intended to be presented at Primedex's 2007 annual meeting must be received by Primedex not later than June 21, 2007 to be considered for inclusion in Primedex's proxy materials for that meeting.

The matters to be considered at this special meeting are of great importance to the stockholders of Primedex. You are accordingly urged to read and carefully consider the information presented in this joint proxy statement/prospectus, and to submit your proxy by mail in the enclosed postage-paid envelope.

PROPOSAL NO. 1

**ADOPTION OF THE MERGER AGREEMENT
AND APPROVAL OF THE MERGER AND
ISSUANCE OF PRIMEDEX COMMON STOCK
PURSUANT TO THE MERGER AGREEMENT**

As discussed elsewhere in this joint proxy statement/prospectus, Primedex stockholders are considering and voting on a proposal to adopt the merger agreement and approve the merger and the issuance of Primedex common stock pursuant to the terms of the merger agreement. Primedex stockholders should read carefully this joint proxy statement/prospectus in its entirety for more detailed information concerning the merger agreement and the merger, including the sections of this joint proxy statement/prospectus titled "The Merger," which begin on page 100, and "The Merger Agreement," which begin on page 141. In addition, Primedex stockholders should read the merger agreement, which is attached as *Annex A* to this joint proxy statement/prospectus, in its entirety.

Recommendation

The Primedex board of directors unanimously recommends a vote **FOR** adopting the merger agreement and approving the merger and issuance of Primedex common stock pursuant to the terms of the merger agreement, and your proxy will be so voted unless you specify otherwise.

PROPOSAL NO. 2

**AMENDMENT TO CERTIFICATE OF INCORPORATION TO
CHANGE NAME TO RADNET, INC.**

Edgar Filing: RADIOLOGIX INC - Form DEFM14A

On October 11, 2006, Primedex's board of directors unanimously approved an amendment to Primedex's certificate of incorporation to, among other things, change Primedex's name from Primedex Health Systems, Inc. to RadNet, Inc., and unanimously recommended that Primedex's stockholders adopt the amendment. The form of certificate of amendment approved by Primedex's board of directors to effect that amendment is attached to this joint proxy statement/prospectus as *Annex B*.

Purpose of Proposed Name Change.

Edgar Filing: RADIOLOGIX INC - Form DEFM14A

As a consequence of the merger, Primedex intends to change its corporate name to RadNet, Inc., which borrows its name from the operating entity in which Primedex currently conducts its operations. Accordingly, the Primedex board of directors believes that, as Primedex continues to execute its business plan and reach new patients, the new RadNet, Inc. name is more likely to have a greater intangible value, and a greater name recognition value in the future than its current name.

Restated Certificate of Incorporation.

Edgar Filing: RADIOLOGIX INC - Form DEFM14A

If approved, the FIRST paragraph of Primedex's certificate of incorporation would be restated in its entirety as follows:

FIRST: The name of the Corporation shall be RADNET, INC.

The form of the certificate of amendment to the certificate of incorporation is included as *Annex B* to this joint proxy statement/prospectus. If adopted, the certificate of amendment will become effective upon its filing with the Department of State of the State of New York, and will be filed as soon as practicable.

78

Effect of Name Change on Stockholders.

Primedex stockholders will not be required to submit their stock certificates for exchange. Stock certificates bearing the Primedex Health Services, Inc. name will continue to be valid certificates and will evidence ownership of the same number of shares of Primedex's capital stock after the name change as stated in Primedex's amended certificate of incorporation. Following the effective date of the amended certificate of incorporation, all new stock certificates issued by Primedex will be printed using the new name.

New Trading Symbol.

Edgar Filing: RADIOLOGIX INC - Form DEFM14A

If Primedex's name change is approved at the special meeting, Primedex will promptly thereafter apply to change its Over-The-Counter Bulletin Board trading symbol to a new trading symbol more readily identifiable with its new corporate name. Primedex's new Over-The-Counter Bulletin Board trading symbol is expected to be RDNT.

Recommendation

The Primedex board of directors unanimously recommends a vote **FOR** amending the certificate of incorporation to change Primedex's name to RadNet, Inc., and your proxy will be so voted unless you specify otherwise.

PROPOSAL NO. 3 AMENDMENT TO CERTIFICATE OF INCORPORATION TO INCREASE AUTHORIZED NUMBER OF SHARES

On October 11, 2006, Primedex's board of directors unanimously approved an amendment to Primedex's certificate of incorporation to, among other things, (i) increase the authorized number of shares of Primedex common stock from 100,000,000 shares to 200,000,000 shares and reduce the par value of each share of common stock from \$0.01 to \$0.0001, (ii) undesignate all of Primedex's preferred stock, none of which is currently outstanding, so that it returns to the status of authorized but undesignated and unissued, and (iii) increase the authorized number of shares of Primedex preferred stock from 10,000,000 shares to 30,000,000 shares and reduce the par value of each share of Preferred Stock from \$0.01 to \$0.0001, and unanimously recommended that Primedex's stockholders adopt the amendment. The form of certificate of amendment approved by Primedex's board of directors to effect that amendment is attached to this joint proxy statement/prospectus as *Annex B*.

The additional shares of Primedex common stock to be authorized by adoption of the amendment would have rights identical to the currently outstanding shares of common stock. See the section of this joint proxy statement/prospectus titled "Description of Primedex Capital Stock - Common Stock" on page 210 for more information on Primedex's common stock. Adoption of the amendment would not affect the rights of the holders of currently outstanding common stock, except to the extent additional shares are actually issued, which may have various effects, including dilution of the earnings per share and voting rights of current holders of common stock.

Primedex has "blank check" preferred stock authorized under its certificate of incorporation, which may be issued by the Primedex board of directors in one or more designated series. Currently, the only designated series is Series A 5% convertible preference stock, of which there are currently 5,600,000 shares designated. There are no shares of Series A 5% convertible preference stock currently outstanding. See the section of this joint proxy statement/prospectus titled "Description of Primedex Capital Stock - Preferred Stock" on page 261 for more information on Primedex's preferred stock. The amendment, if adopted by Primedex's stockholders, would undesignate the Series A 5% convertible preference stock as a series of preferred stock authorized for issuance by Primedex, such that all 10,000,000 authorized shares of Primedex preferred stock would be undesignated and available for subsequent designation and issuance by

the Primedex board of directors in accordance with its certificate of incorporation, bylaws and applicable law. As no Primedex preferred stock is currently outstanding, adoption of the amendment would not affect the rights of any Primedex stockholders, except to the extent one or more series of preferred stock are actually designated and additional shares of preferred stock are actually issued, which may have various effects, including subordination of liquidation preference, dividend rights and voting rights and dilution of the earnings per share and voting rights of current holders of common stock.

If adopted, the certificate of amendment will become effective upon its filing with the Department of State of the State of New York, and will be filed as soon as practicable. On the record date, 44,039,105 shares of common stock were outstanding, and 15,756,334 were reserved for options, warrants, employee equity plans and convertible debentures (not including shares issuable in the merger described in Proposal No. 1), and no shares of preferred stock were outstanding. Upon the approval of this Proposal No. 3, there would be approximately 111,066,239 authorized and unreserved shares of common stock available for issuance, and 30,000,000 authorized and undesignated shares of preferred stock available for designation into one or more series and for issuance.

Purpose and Effect of the Amendment

The principal purpose of this amendment is to provide Primedex with the flexibility to issue shares of common stock and to designate for issuance and issue one or more series of preferred stock for proper corporate purposes, which may be identified in the future, such as to raise equity capital, make additional acquisitions through the use of stock or reserve additional shares for issuance under equity incentive plans. Primedex intends to use a portion of the newly authorized shares of common stock to perform its obligations under the merger agreement described in Proposal No. 1. Except as discussed above, Primedex has at this time no plans, proposals or arrangements, written or otherwise, to issue any of the additional authorized shares of common stock or to designate or issue any of the authorized shares of preferred stock.

The increased reserve of shares available for issuance may be used to facilitate public or private financings. If required operating funds cannot be generated by operations, Primedex may need to, among other things, issue and sell unregistered common stock or preferred stock, or securities convertible into common stock or preferred stock, in private transactions. Such transactions might not be available on terms favorable to Primedex, or at all. Primedex may sell common stock or preferred stock at prices less than the public trading price of the common stock at the time, and may grant additional contractual rights to purchase not available to other holders of common stock, such as warrants to purchase additional shares of common stock or anti-dilution protections.

The increased reserve of shares available for issuance also may be used in connection with potential acquisitions. The ability to use its stock as consideration provides Primedex with negotiation benefits and increases its ability to execute its growth strategy which may include the acquisition of other businesses or technologies.

In addition, the increased reserve of shares available for issuance may be used for Primedex's future equity incentive plans for grants to its employees, consultants and directors. Such equity incentive plans could also be used to attract and retain employees of acquired companies in connection with potential acquisitions.

The flexibility of the board of directors to issue additional shares of common stock and to designate and issue all authorized shares of preferred stock could also enhance the ability of Primedex's board of directors to negotiate on behalf of the stockholders in a takeover situation. The authorized, but unissued shares of common stock and the authorized, but undesignated and unissued shares of preferred stock could be used by the board of directors to discourage, delay or make more difficult a change in the control of Primedex. For example, such shares could be privately placed with purchasers who might align themselves with the board of directors in opposing a hostile takeover bid. The issuance of additional shares

could dilute the stock ownership of persons seeking to obtain control and increase the cost of acquiring a given percentage of the outstanding stock. Stockholders should therefore be aware that approval of the amendment could facilitate future efforts by Primedex to deter or prevent changes in control of Primedex, including transactions in which the stockholders might otherwise receive a premium for their shares over then current market prices.

The availability of additional shares of common stock is particularly important in the event that the board of directors needs to undertake any of the foregoing actions on an expedited basis and therefore needs to avoid the time (and expense) of seeking stockholder approval in connection with the contemplated action. If the amendment is approved by the stockholders, the board of directors does not intend to solicit further stockholder approval prior to the issuance of any additional shares of common stock or prior to the designation for issuance or issuance of any shares of preferred stock, except as may be required by applicable law or rules. For example, if Primedex common stock trades on the American Stock Exchange, under the rules and policies of such exchange, stockholder approval is required for any issuance of 20% or more of Primedex outstanding shares in connection with acquisitions or discounted private placements. Additionally, under California law, to the extent it may apply to Primedex under Section 2115 of the California General Corporation Law, stockholder approval is required for the adoption and approval of the merger agreement and approval of the merger and the issuance of Primedex common stock pursuant to the terms of the merger agreement, where Primedex stockholders, immediately before such merger and stock issuance, do not continue to hold at least five-sixths of Primedex's combined voting power after such merger and stock issuance. Primedex reserves the right to seek a further increase in the authorized number of shares from time to time as considered appropriate by the board of directors.

Existing Anti-Takeover Mechanisms

Primedex's certificate of incorporation and bylaws contain provisions that may make it less likely that Primedex management would be changed, or someone would acquire voting control of Primedex, without the consent of Primedex's board of directors. These provisions include:

- shares of Primedex authorized but unissued blank check preferred stock (as well as shares of Primedex authorized but unissued common stock) could be issued in an effort to dilute the stock ownership and voting power of persons seeking to obtain control of Primedex, or could be issued to purchasers who would support Primedex's board of directors in opposing an unsolicited takeover proposal;
- Primedex stockholders are only allowed to take actions by unanimous written consent, other than actions taken at a duly noticed meeting of stockholders; and
- Primedex's board of directors may increase the number of directors and may fill the vacancies created by such action.

Other than as described above, there are currently no anti-takeover mechanisms present in Primedex's governing documents or otherwise. If Primedex's stockholders approve Proposal No. 4 to amend Primedex's certificate of incorporation to include transfer restrictions, those transfer restrictions, which are described in greater detail in **PROPOSAL NO. 4 AMENDMENT OF CERTIFICATE OF INCORPORATION TO IMPLEMENT TRANSFER RESTRICTIONS** below, may have material anti-takeover consequences. Other than those transfer restrictions, Primedex has no present plans or proposals to adopt other provisions or enter into other arrangements that may have material anti-takeover consequences.

Recommendation

The Primedex board of directors unanimously recommends a vote **FOR** amending the certificate of incorporation to increase the authorized number of shares of common stock, and your proxy will be so voted unless you specify otherwise.

PROPOSAL NO. 4 AMENDMENT TO CERTIFICATE OF INCORPORATION TO IMPLEMENT TRANSFER RESTRICTIONS

Introduction

As of October 31, 2005, Primedex had accumulated federal and state net operating losses totaling approximately \$161,319,000 and \$41,224,000, respectively, that Primedex can carry forward as potential tax deductions until they expire at various intervals from the years 2006 to 2025. In this joint proxy statement/prospectus, we refer to these net operating losses and capital losses together as NOLs.

NOLs can benefit Primedex by offsetting federal taxable income dollar-for-dollar by the amount of the NOLs, thereby reducing or eliminating Primedex's U.S. federal corporate tax (other than alternative minimum tax) on such income. Assuming Primedex can fully use its NOLs to reduce its U.S. federal corporate tax, Primedex expects to be subject to the alternative minimum tax, which would result in 10% of Primedex's alternative minimum taxable income being subject to the 20% alternative minimum tax. The maximum federal corporate tax rate is currently 35%.

The benefit of the NOLs to Primedex can be reduced or eliminated under Section 382 of the Internal Revenue Code (or Code), if Primedex experiences an ownership change, as defined in Section 382 of the Code and described in more detail below. An ownership change can occur through one or more acquisitions of Primedex stock, whether occurring contemporaneously or pursuant to a single plan, by which stockholders or groups of stockholders, each of whom owns or is deemed to own directly or indirectly at least 5% of Primedex's stock, increase their ownership of Primedex stock by more than 50 percentage points within a three-year period. Primedex currently does not have the ability to restrict transactions that could result in an ownership change.

The Primedex board of directors believes the best interests of Primedex and its stockholders will be served by adopting provisions that are designed to restrict direct and indirect transfers of Primedex stock if such transfers will affect the percentage of stock that is treated as owned by a 5% stockholder. In this joint proxy statement/prospectus, we refer to these provisions as the transfer restrictions.

As of October 6, 2006, Primedex does not believe that it has experienced an ownership change, but calculating whether an ownership change has occurred is subject to inherent uncertainty. This uncertainty results from the complexity and ambiguity of the Section 382 provisions, as well as limitations on the knowledge that any publicly traded company can have about the ownership of and transactions in its securities.

If you approve this proposal, Primedex's certificate of incorporation will be amended to add the transfer restrictions within Article FOURTH to the certificate of incorporation. **Stockholders are urged to read carefully the accompanying Annex B, which sets forth the complete text of the certificate of amendment of certificate of incorporation of Primedex that will be filed if this proposal is approved.**

Limitations on use of NOLs

The benefit of the NOLs to Primedex can be reduced or eliminated under Section 382 of the Code if Primedex experiences an ownership change, as defined in Section 382. Generally, an ownership change can occur through one or more acquisitions, by which one or more stockholders, each of whom owns or is deemed to own directly or indirectly 5% or more in value of a corporation's stock, increase their aggregate

percentage ownership by more than 50 percentage points over the lowest percentage of stock owned by such stockholders (with the lowest percentage measured separately for each stockholder) at any time during the preceding three-year period. The amount of the increase in the percentage of stock ownership of each 5% stockholder is computed separately, and each such increase is then added together with any other such increase to determine whether an ownership change has occurred. For this purpose, all holders who own less than 5% of a corporation's stock are generally treated together as one 5% stockholder (although in some circumstances these smaller holders may be counted as two or more separate stockholders, with each being a public group and a separate 5% stockholder, for purposes of Section 382 of the Code). Transactions in the public markets among stockholders owning less than 5% of the equity securities generally do not affect the calculation of an ownership change (but can if a corporation has more than one public group). In addition, constructive ownership rules, which generally attribute ownership of stock owned by estates, trusts, corporations, partnerships or other entities to the ultimate indirect individual owner thereof, or to related individuals, are applied in determining the level of stock ownership of a particular stockholder. Special rules, described below, can result in the treatment of options (including warrants) or other similar interests as having been exercised if such treatment would result in an ownership change. All percentage determinations are based on the fair market value of a corporation's stock.

For example, if a single investor acquired 50.1% of Primedex's stock in a three-year period, a change of ownership would occur. Similarly, if ten persons, none of whom owned Primedex stock, each acquired slightly over 5% of Primedex's stock within a three-year period (so that such persons owned, in the aggregate more than 50%), an ownership change would occur.

If Primedex were to experience an ownership change, then the amount of taxable income in any year (or portion of a year) subsequent to the ownership change that could be offset by NOLs from periods prior to such ownership change could not exceed the product obtained by multiplying (i) the aggregate value of Primedex stock immediately prior to the ownership change (with adjustments) by (ii) the then applicable federal long-term tax exempt rate (this resulting product is referred to as the Section 382 limitation). If Primedex experiences an ownership change for tax purposes, the Section 382 limitation would be reduced to zero in the event Primedex was deemed to fail to continue the business enterprise that we engaged in before the ownership change for the two-year period following the ownership change. Any portion of the annual Section 382 limitation amount not utilized in any year may be carried forward and increase the available Section 382 limitation amount for the succeeding tax year. Thus, an ownership change could significantly reduce or eliminate the annual utilization of Primedex's NOLs and cause a substantial portion or all of such NOLs to expire prior to their use.

Summary of Transfer Restrictions

The following is a summary of the proposed transfer restrictions. This summary is qualified in its entirety by reference to the full text of the proposed transfer restrictions, which if approved by Primedex's stockholders will be contained in Article FOURTH in the certificate of amendment of certificate of incorporation of Primedex and as set forth in the accompanying *Annex B*. **Stockholders are urged to read in their entirety the transfer restrictions set forth in the accompanying *Annex B*.**

Prohibited Transfers

The transfer restrictions generally will restrict any direct or indirect transfer (such as transfers of stock of Primedex that result from the transfer of interests in other entities that own stock of Primedex) if the effect would be to:

1. increase the direct or indirect ownership of Primedex stock by any person from less than 5% to 5% or more of the stock of Primedex;

2. increase the percentage of Primedex stock owned directly or indirectly by a person (or public group) owning or deemed to own 5% or more of the stock of Primedex; or
3. create a new public group.

Transfers included under the transfer restrictions include sales to persons whose resulting percentage ownership (direct or indirect) of stock would exceed the 5% thresholds discussed above, or to persons whose direct or indirect ownership of stock would by attribution cause another person to exceed such threshold. Complicated rules of constructive ownership, aggregation, segregation, combination and other stock ownership rules prescribed by the Code (and related regulations) will apply in determining whether a person or group of persons constitute a 5% stockholder under Section 382 and whether less than 5% stockholders will be treated as one or more public groups, each of which is a 5% stockholder under Section 382.

However, the transfer restrictions will not apply to issuance of stock by Primedex, nor will they apply to the creation or grant of an option by Primedex. As a result, the transfer restrictions do not prevent the exercise of either currently outstanding options to purchase Primedex stock or options that may be granted in the future by Primedex to purchase its stock. These have been excluded from the operation of the transfer restriction because the Primedex board of directors has determined that the issuance of Primedex shares under these circumstances would not adversely affect NOLs. In addition, since Primedex's board of directors will be able to consider the effect on NOLs of future issuances of Primedex shares at the time of the issuance, whether as a result of transactions with third parties, or the issuance of Primedex shares in a private placement or public offering, or as compensation to Primedex's employees, officers or directors, or otherwise, future issuances of Primedex shares, as well as grants of options or warrants, by Primedex also have been excluded from the transfer restrictions. Consequently, persons or entities who are able to acquire Primedex shares directly from us, including our employees, officers and directors, may do so without application of the transfer restrictions, irrespective of the number of Primedex shares they are acquiring. As a result, those persons or entities dealing directly with Primedex may be seen to receive an advantage over persons or entities who are not able to acquire Primedex shares directly from us and, therefore, are restricted by the terms of the transfer restrictions. It should be noted, however, that any direct acquisitions of Primedex shares from us first requires approval of Primedex's board of directors, and in granting such approval, the Primedex board of directors will review the implications of any such issuance for the NOLs.

For purposes of determining the existence and identity of, and the amount of stock owned by, any stockholder, Primedex will be entitled to rely conclusively on (a) the existence or absence of filings with the SEC of Schedules 13D and 13G (or any similar SEC filings) as of any date and (b) Primedex's actual knowledge of the ownership of Primedex stock. The transfer restrictions will include the right to require a proposed transferee, as a condition to registration of a transfer of stock, to provide all information reasonably requested regarding such person's direct and indirect ownership of Primedex stock. The transfer restrictions may result in the delay or refusal of certain requested transfers of Primedex's common stock.

As a result of these rules, the transfer restrictions could result in prohibiting ownership (thus requiring dispositions) of stock of Primedex as a result of a change in the relationship between two or more persons or entities, or of a transfer of an interest in an entity other than Primedex, such as an interest in an entity that, directly or indirectly, owns stock of Primedex. The transfer restrictions will also apply to proscribe the creation or transfer of certain options (which are broadly defined by Section 382) in respect of Primedex stock to the extent that, in various circumstances, creation, transfer or exercise of the option would result in a proscribed level of ownership.

Absent a court determination, there can be no assurance that the transfer restrictions will be enforceable against all of our stockholders, and the transfer restrictions may be subject to challenge on

equitable grounds. It is possible that the transfer restrictions may not be enforceable against current Primedex stockholders who vote against or abstain from voting on the amendment. Nonetheless, Primedex believes that the transfer restrictions are in the best interest of Primedex and its stockholders and are reasonable, and if they are approved by the stockholders, Primedex will act vigorously to enforce the transfer restrictions against all current and future holders of Primedex stock regardless of how they vote on the amendment. Primedex believes that each of its stockholders who vote in favor of the amendment will in effect have consented to the implementation of the transfer restriction and therefore will be bound by the transfer restrictions. If a Primedex stockholder votes for the transfer restrictions, Primedex intends to assert that such stockholder would be estopped from challenging the implementation of the transfer restrictions. All Primedex shareholders should carefully consider this point in deciding whether to vote in favor of the amendment to implement the transfer restrictions.

Treatment of Pre-existing 5% Stockholders

The transfer restrictions will contain exceptions permitting otherwise prohibited transfers by pre-existing 5% stockholders. Pre-existing 5% stockholders are:

- any person or entity who (1) has filed a Schedule 13D or 13G on or before August 21, 2006 or (2) establishes, within 30 days of August 21, 2006, to the satisfaction of the board of directors of Primedex, that such person or entity was a direct or indirect owner of 5% of common stock of Primedex on August 21, 2006 and
- persons and entities with specified ownership interests in the foregoing persons or entities.

Pre-existing 5% stockholders will receive the following different treatment under the transfer restrictions.

- In contrast to the treatment of persons who become 5-percent stockholders (as defined in Section 382) after August 21, 2006, who will be prohibited from disposing of any shares of Primedex common stock without the express consent of Primedex's board of directors, a direct or indirect transfer of shares of common stock of Primedex by (but not to) a pre-existing 5% stockholder will be permitted so long as such a transfer would not:
 - increase the ownership of stock by any person (other than a public group) to 5% or more of the stock of Primedex or
 - increase the percentage of stock owned by a person owning 5% or more of the stock of Primedex.
- These permitted transfers by pre-existing 5% stockholders include transfers to a public group even though the public group becomes a new public group as a result of such transfer and is treated as a 5% stockholder under Section 382.
- In addition, the transferred shares must have been received in exchange for shares of Primedex common stock already owned by such pre-existing 5% stockholder on August 21, 2006.

These provisions will not permit pre-existing 5% stockholders to increase their ownership of common stock of Primedex without specific approval of the board of directors of Primedex, except for transfers by pre-existing 5% stockholders as described above, but they will permit pre-existing 5% stockholders to dispose of shares of Primedex already owned by them prior to Primedex's first public announcement of Primedex's intention to seek to implement the transfer restrictions, subject to the conditions above.

Consequences of Prohibited Transfers

Upon adoption of the transfer restrictions, any direct or indirect transfer attempted in violation of the restrictions would be void as of the date of the purported transfer as to the purported transferee (or, in the case of an indirect transfer, the ownership of the direct owner of Primedex stock would terminate simultaneously with the transfer), and the purported transferee (or in the case of any indirect transfer, the direct owner) would not be recognized as the owner of the shares owned in violation of the restrictions for any purpose, including for purposes of voting and receiving dividends or other distributions in respect of such stock, or in the case of options, receiving stock in respect of their exercise. In this joint proxy statement/prospectus, we refer to stock acquired in violation of the transfer restrictions as excess stock.

In addition to the purported transfer being void as of the date of the purported transfer, upon demand, the purported transferee must transfer the excess stock to Primedex's agent along with any dividends or other distributions paid with respect to such excess stock. Primedex's agent is required to sell such excess stock in an arms-length transaction (or series of transactions) that would not constitute a violation under the transfer restrictions. The net proceeds of the sale, together with any other distributions with respect to such excess stock received by Primedex's agent, after deduction of all costs incurred by the agent, will be distributed first to the purported transferee in an amount, if any, equal to the cost (or in the case of gift, inheritance or similar transfer, the fair market value of the excess stock on the date of the violative transfer) incurred by the purported transferee to acquire such excess stock, and the balance of the proceeds, if any, will be distributed to a charitable beneficiary. If the excess stock is sold by the purported transferee, such person will be treated as having sold the excess stock on behalf of the agent, and will be required to remit all proceeds to Primedex's agent (except to the extent Primedex grants written permission to the purported transferee to retain an amount not to exceed the amount such person otherwise would have been entitled to retain had Primedex's agent sold such shares).

Any stockholder who knowingly violates the transfer restrictions will be liable for any and all damages suffered by Primedex as a result of such violation, including damages resulting from a reduction in or elimination of the ability to utilize the NOLs and any professional fees incurred in connection with addressing such violation.

With respect to any transfer of stock which does not involve a transfer of securities of Primedex within the meaning of the New York Business Corporation Law but which would cause any 5% stockholder to violate the transfer restrictions, the following procedure will apply in lieu of those described above. In such case, no such 5% stockholder shall be required to dispose of any interest that is not a security of Primedex, but such 5% stockholder and/or any person whose ownership of securities of Primedex is attributed to such 5% stockholder will be deemed to have disposed of (and will be required to dispose of) sufficient securities, simultaneously with the transfer, to cause such 5% stockholder not to be in violation of the transfer restrictions, and such securities will be treated as excess stock to be disposed of through the agent under the provisions summarized above, with the maximum amount payable to such 5% stockholder or such other person that was the direct holder of such excess stock from the proceeds of sale by the agent being the fair market value of such excess stock at the time of the prohibited transfer.

Common Stock Legend and Exchange of Share Certificates

Section 4 of Paragraph (c) of Article FOURTH provides that all certificates representing shares of Primedex common stock will bear a legend indicating that the shares are subject to the transfer restrictions contained in Primedex's certificate of incorporation. Each share of Primedex common stock issued subsequent to the approval of this Proposal No. 4, including shares of Primedex common stock received by Radiologix stockholders in connection with the merger, will bear such legend, however, existing Primedex stockholders will not be required to surrender or exchange their existing shares of Primedex common stock.

Modification and Waiver of Transfer Restrictions

The board of directors of Primedex will have the discretion to approve a transfer of stock that would otherwise violate the transfer restrictions. If the board of directors of Primedex decides to permit a transfer that would otherwise violate the transfer restrictions, that transfer or later transfers may result in an ownership change that could limit Primedex's use of the NOLs. As a condition to granting an exemption from the transfer restrictions, the board of directors may require an opinion of counsel (the cost of which will be borne by the transferor and/or the transferee) that the transfer will not result in a limitation on the use of the NOLs under Section 382.

In addition, in the event of a change in law, the board of directors of Primedex will be authorized to eliminate the transfer restrictions, modify the applicable allowable percentage ownership interest (now 5%) or modify any of the terms and conditions of the transfer restrictions, provided that the board of directors concludes in writing that such change is reasonably necessary or advisable to preserve the NOLs or that the continuation of the affected terms and conditions of the transfer restrictions is no longer reasonably necessary for such purpose. The board's determination in such circumstances must be based upon a written opinion of tax counsel. Written notice of any such determination will be provided to stockholders.

The Primedex board of directors may establish, modify, amend or rescind by-laws, regulations and procedures for purposes of determining whether any transfer of stock of Primedex would jeopardize Primedex's ability to preserve and use the NOLs. Assuming the amendment is approved, Primedex's board of directors will amend Primedex's bylaws to further implement the transfer restrictions and to provide for the legend of all certificates evidencing shares of Primedex stock.

Expiration of Transfer Restrictions

The transfer restrictions will remain in effect until the board of directors of Primedex determines that the NOLs are no longer available to reduce Primedex's future income tax liability, which should be the earlier of full usage of the NOLs or their expiration. We estimate that the latest date of expiration of the NOLs is 2025. The board of directors of Primedex is permitted to accelerate or extend the expiration date of the transfer restrictions in the event of a change in the law or otherwise.

Reasons for Transfer Restrictions

The purpose of the transfer restrictions is solely to help preserve the long-term value to Primedex and its stockholders of Primedex's accumulated NOL and capital loss carryforwards. The proposed transfer restrictions are designed to prohibit certain transfers of Primedex's stock in excess of amounts that, because of provisions of the Code, could inhibit Primedex's ability to use its NOLs to reduce future income tax liability.

The transfer restrictions may have anti-takeover effects because they will restrict the ability of a person or group from accumulating aggregate of 5% or more of stock of Primedex and the ability of persons or groups now owning 5% or more of stock of Primedex from acquiring additional stock. The transfer restrictions are not in response to any effort to accumulate Primedex common stock or to obtain control of Primedex. Primedex's board of directors considers the transfer restrictions to be reasonable and in the best interests of Primedex and its stockholders because the transfer restrictions reduce certain of the risks related to Primedex's future use of the NOLs. In the opinion of Primedex's board of directors, the fundamental importance to Primedex's stockholders of maintaining the availability of the NOLs is a more significant consideration than the indirect anti-takeover effect the transfer restrictions may have.

Interests of Certain Persons

The officers and directors of Primedex do not have interests in the merger that are materially different from those of Primedex stockholders with respect to any of the proposals. However, Dr. Howard Berger, Primedex's President and Chief Executive Officer, owns more than 5% of Primedex's outstanding shares of Common Stock. If Proposal No. 4 is approved, the new transfer restrictions included in Primedex's certificate of incorporation will treat pre-existing 5% stockholders differently from persons who become 5% stockholders after .

Recommendation

The Primedex board of directors unanimously recommends a vote **FOR** amending the certificate of incorporation to include the transfer restrictions, and your proxy will be so voted unless you specify otherwise.

PROPOSAL NO. 5 APPROVAL OF THE 2006 STOCK INCENTIVE PLAN

The stockholders are being asked to approve the adoption of the 2006 Equity Incentive Plan, or the 2006 Plan. The 2006 Plan is intended to replace the 2000 Long-Term Incentive Plan, or the 2000 Plan. Primedex's board of directors adopted the 2006 Plan on October 11, 2006, subject to the approval of the stockholders at the special meeting. Stockholder approval of the 2006 Plan is being sought to qualify certain compensation under the 2006 Plan as performance-based compensation not subject to the tax deduction limitation under Section 162(m) of the Code, and to qualify certain stock options that may be granted under the 2006 Plan as incentive stock options under Section 422 of the Code.

Description of the Proposal

The board of directors approved the 2006 Plan because it believes that the best means for aligning the interests of employees and stockholders is through equity incentives. As of the record date for Primedex's special meeting, Primedex had 1,232,500 shares available for future issuance under its 2000 Plan. Additionally, the 2006 Plan includes provisions that are not part of the 2000 Plan and which are necessary for Primedex to offer a competitive equity incentive program. Recent changes in the accounting treatment for stock options should make the use of these alternative types of awards more attractive in the future.

Description of the 2006 Equity Incentive Plan

A copy of the 2006 Plan is attached to this proxy statement as *Annex E*. The following description of the 2006 Plan is a summary and is qualified by reference to the complete text of the 2006 Plan.

Background and Purpose

The primary purpose of the 2006 Plan is to encourage ownership in our company by key personnel whose long-term service we consider essential to our continued progress, thereby linking these employees directly to stockholder interests through increased stock ownership. We currently have one stock option plan from which awards can be made, which we refer to as the 2000 Plan. The 2000 Plan authorizes up to 2,000,000 shares for issuance pursuant to stock options. The 2006 Plan will provide for added flexibility over the 2000 Plan in light of recent changes in the rules affecting such plans.

As of the record date, options with respect to 767,500 shares were outstanding under the 2000 Plan at exercise prices ranging from \$0.38 to \$1.67 and 1,232,500 shares remained available for future grants. The Board has determined that the 2000 Plan will no longer be available for further option grants upon the effective date of the approval of our stockholders of the 2006 Plan.

Eligible Participants

Awards may be granted under the 2006 Plan to any of our employees, officers, directors, or consultants or those of our affiliates. As of the record date, there were approximately 997 full-time employees and three non-employee directors who would be eligible to participate. An incentive stock option may be granted under the 2006 Plan only to a person who, at the time of the grant, is an employee of Primedex or a related corporation.

Number of Shares of Common Stock Available

If approved by the stockholders, a total of 5,000,000 new shares of our common stock will be reserved for issuance under the 2006 Plan. The maximum aggregate number of shares that may be issued under the 2006 Plan through the exercise of incentive stock options is 5,000,000. If an award is cancelled, terminates, expires, or lapses for any reason without having been fully exercised or vested, or is settled for less than the full number of shares of common stock represented by such award actually being issued, the unvested, cancelled, or unissued shares of common stock generally will be returned to the available pool of shares reserved for issuance under the 2006 Plan. In addition, if we experience a stock dividend, reorganization, or other change in our capital structure, the administrator may, in its discretion, adjust the number of shares available for issuance under the 2006 Plan and any outstanding awards as appropriate to reflect the stock dividend or other change. The share number limitations included in the 2006 Plan will also adjust appropriately upon such event.

Administration of the 2006 Plan

The 2006 Plan will be administered by the board of directors or one or more committees of the board of directors, which we refer to as the Committee. The Primedex board has appointed the Compensation Committee as the Committee referred to in the 2006 Plan. In the case of awards intended to qualify as performance-based-compensation excludable from the deduction limitation under Section 162(m) of the Code, the Committee will consist of two or more outside directors within the meaning of Section 162(m).

The administrator has the authority to, among other things, select the individuals to whom awards will be granted and to determine the type of award to grant; determine the terms of the awards, including the exercise price, the number of shares subject to each award, the exercisability of the awards, and the form of consideration payable upon exercise; to provide for a right to dividends or dividend equivalents; and to interpret the 2006 Plan and adopt rules and procedures relating to administration of the 2006 Plan. Except to the extent prohibited by any applicable law, the administrator may delegate to one or more individuals the day-to-day administration of the 2006 Plan.

Award Types

Options

A stock option is the right to purchase shares of Primedex's common stock at a fixed exercise price for a fixed period. An option under the 2006 Plan may be an incentive stock option or a nonstatutory stock option. The exercise price of an option granted under the 2006 Plan must be at least equal to the fair market value of Primedex's common stock on the date of grant. In addition, the exercise price for any incentive stock option granted to any employee owning more than ten percent of our common stock may not be less than 110 percent of the fair market value of Primedex's common stock on the date of grant.

Unless the administrator determines to use another method, the fair market value of our common stock on the date of grant will be determined as the closing sales price for our common stock on the date the option is granted (or if no sales are reported that day, the closing price on the last preceding day on which a sale occurred), using a reporting source selected by the administrator. As of the record date, the average quoted sales price on the Over the Counter Bulletin Board for our common stock was \$2.69 per

share. The administrator determines the acceptable form of consideration for exercising an option, including the method of payment, either through the terms of the option agreement or at the time of exercise of an option, provided that consideration must have a value of not less than the par value of the shares to be issued and must be actually received before issuing any shares. The 2006 Plan permits payment in the form of cash, check or wire transfer, other shares of common stock of Primedex, cashless exercises, any other form of consideration and method of payment permitted by applicable laws, or any combination thereof.

An option granted under the 2006 Plan cannot be exercised until it becomes vested. The administrator establishes the vesting schedule of each option at the time of grant and the option will expire at the time established by the administrator. After termination of the optionee's service, he or she may exercise his or her option for the period stated in the option agreement, to the extent the option is vested on the date of termination. If termination is due to death or disability, the option usually will remain exercisable for twelve months following such termination. In all other cases, the option generally will remain exercisable for three months. Nevertheless, an option may never be exercised later than the expiration of its term. The term of any stock option may not exceed ten years, except that with respect to any participant who owns ten percent or more of the voting power of all classes of Primedex's outstanding capital stock, the term for incentive stock options must not exceed five years.

Stock Awards

Stock awards are awards or issuances of shares of our common stock that vest in accordance with terms and conditions established by the administrator. Stock awards include stock units, which are bookkeeping entries representing an amount equivalent to the fair market value of a share of common stock, payable in cash, property, or other shares of stock. The administrator may determine the number of shares to be granted, and impose whatever conditions to vesting it determines to be appropriate, including performance criteria and level of achievement versus the criteria that the administrator determines. The criteria may be based on financial performance, personal performance evaluations, and completion of service by the participant. Unless the administrator determines otherwise, shares that do not vest typically will be subject to forfeiture or to a right of repurchase of the unvested portion of such shares at the original price paid by the participant, which Primedex may exercise upon the voluntary or involuntary termination of the awardee's service with Primedex for any reason, including death or disability.

For stock awards intended to qualify as performance-based compensation within the meaning of Section 162(m) of the Code, the measures established by the administrator must be qualifying performance criteria. Qualifying performance criteria under the 2006 Plan include any of the following performance criteria, individually or in combination:

- cash flow
- earnings (including gross margin, earnings before interest and taxes, earnings before taxes, and net earnings)
- earnings per share
- growth in earnings or earnings per share
- stock price
- return on equity or average stockholders' equity
- total stockholder return
- return on capital
- return on assets or net assets
- return on investment
- revenue
- income or net income
- operating income or net operating income
- operating profit or net operating profit

- operating margin
- market share
- overhead or other expense reduction
- credit rating
- improvement in workforce diversity
- any other similar criteria
- return on operating revenue
- contract awards or backlog
- growth in stockholder value relative to the moving average of the S&P 500 Index or a peer group index
- strategic plan development and implementation
- EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization)

Qualifying performance criteria may be applied either to Primedex as a whole or to a business unit, affiliate, or business segment, individually or in any combination. Qualifying performance criteria may be measured either annually or cumulatively over a period of years, and may be measured on an absolute basis or relative to a pre-established target, to previous years' results, or to a designated comparison group, in each case as specified by the administrator in writing in the award.

Stock Appreciation Rights

A stock appreciation right is the right to receive the appreciation in the fair market value of our common stock in an amount equal to the difference between (a) the fair market value of a share of our common stock on the date of exercise, and (b) the exercise price. This amount will be paid, as determined by the administrator, in shares of our common stock with equivalent value, cash, or a combination of both. The exercise price must be at least equal to the fair market value of our common stock on the date of grant. Subject to these limitations, the administrator determines the exercise price, term, vesting schedule, and other terms and conditions of stock appreciation rights, except that stock appreciation rights terminate under the same rules that apply to stock options.

Cash Awards

Cash awards confer upon the participant the opportunity to earn future cash payments tied to the level of achievement with respect to one or more performance criteria established by the administrator for a performance period. The administrator will establish the performance criteria and level of achievement versus these criteria, which will determine the target and the minimum and maximum amount payable under a cash award. The criteria may be based on financial performance or personal performance evaluations, or both. For cash awards intended to qualify as performance-based compensation within the meaning of Section 162(m) of the Code, the measures established by the administrator must be specified in writing.

Other Provisions of the 2006 Plan

Transferability of Award

Unless the administrator determines otherwise, the 2006 Plan does not permit the transfer of awards other than by beneficiary designation, will, or by the laws of descent or distribution, and only the participant may exercise an award during his or her lifetime.

Preemptive Rights

The 2006 Plan provides that no shares will be issued in violation of any preemptive rights held by any stockholder of Primedex.

Adjustments upon Merger or Change in Control

The 2006 Plan provides that in the event of a merger with or into another corporation in which Primedex is not the surviving entity or Primedex's change in control, including the sale of all or substantially all of Primedex's assets, and various other events, Primedex's Board or the Committee may, in its discretion, provide for the assumption or substitution of, or adjustment to, each outstanding award; accelerate the vesting of options and stock appreciation rights, and terminate any restrictions on stock awards or cash awards; provide for the cancellation of awards in exchange for a cash payment to the participant; or provide for the cancellation of awards that have not been exercised or redeemed as of the relevant event.

Certain Federal Income Tax Information

The following is a summary as of this date of the federal income tax consequences to Primedex and to U.S. participants for awards granted under the 2006 Plan. The federal tax laws may change and the federal, state, and local tax consequences for any participant will depend upon his or her individual circumstances. Tax consequences for any particular individual may be different.

Tax Effects for Participants

Incentive Stock Options. For federal income tax purposes, an optionee does not recognize taxable income when an incentive stock option is granted or upon its exercise. When an incentive stock option is exercised, however, the difference between the option exercise price and the fair market value of the shares on the exercise date is an adjustment in computing the holder's alternative minimum taxable income and may be subject to an alternative minimum tax, which is paid if such tax exceeds the optionee's regular tax for the year.

An optionee who disposes of shares acquired by exercise of an incentive stock option more than two years after the option is granted and one year after its exercise recognizes a long-term capital gain or loss equal to the difference between the sale price and the exercise price. If the holding periods are not met and the sale price *exceeds* the exercise price, the optionee generally will recognize ordinary income as of the exercise date equal to the difference between the exercise price and the lower of the sale price of the shares or their fair market value on the exercise date. Any gain or loss recognized on such premature sale of the shares in excess of the amount of ordinary income is characterized as capital gain or loss. If the holding periods are not met and the sale price is *less than* the exercise price, the option will recognize a capital loss equal to the difference between the exercise price and the sale price.

Nonstatutory Stock Options. A participant who receives a nonstatutory stock option with an exercise price equal to or greater than the fair market value of the stock on the grant date generally will not realize taxable income on the grant of such option, but will realize ordinary income when he or she exercises the option, equal to the excess of the fair market value of the shares on the date of exercise over the option exercise price. Any additional gain or loss recognized upon any later disposition of shares would be capital gain or loss. Any taxable income recognized in connection with an option exercise by an employee or former employee of Primedex is subject to tax withholding by Primedex.

Stock Awards. A participant who receives a stock award that is not subject to a substantial risk of forfeiture will recognize ordinary income at the time of grant equal to the difference between the fair market value of the stock on the date of grant less the amount paid for the stock, if any. A restricted stock award is subject to a substantial risk of forfeiture within the meaning of Section 83 of the Code to the extent the award will be forfeited if the participant ceases to provide services to Primedex. A participant who receives a stock award that is subject to a substantial risk of forfeiture will not recognize ordinary income at the time of grant, but will recognize ordinary income on the date or dates when the stock is no longer subject to a substantial risk of forfeiture, or when the stock becomes transferable, if earlier. The

participant's ordinary income is measured as the difference between the fair market value of the stock on the date the stock is no longer subject to a substantial risk of forfeiture less the amount paid for the stock, if any.

The participant may accelerate his or her recognition of ordinary income, if any, and begin his or her capital gains holding period by timely filing (i.e., within thirty days of the award) an election pursuant to Section 83(b) of the Code. In such event, the ordinary income recognized, if any, is measured as the difference between the fair market value of the stock on the date of award less the amount paid for the stock, if any, and the capital gain holding period commences on such date. The ordinary income recognized by an employee or former employee will be subject to tax withholding by Primedex. If the stock award consists of stock units, no taxable income is reportable when stock units are granted to a participant or upon vesting. Upon settlement, the participant will recognize ordinary income in an amount equal to the value of the payment received pursuant to the stock units.

Stock Appreciation Rights. No taxable income is reportable when a stock appreciation right with an exercise price equal to or greater than the fair market value of the stock on the date of grant is granted to a participant or upon vesting. Upon exercise, the participant will recognize ordinary income in an amount equal to the fair market value of any shares or cash received. If the participant receives shares upon exercise, any additional gain or loss recognized upon any later disposition of the shares would be capital gain or loss.

Cash Awards. Upon receipt of cash, the recipient will have taxable ordinary income, in the year of receipt, equal to the cash received. Any cash received by an employee or former employee will be subject to tax withholding by Primedex.

Tax Effect for Primedex. Unless limited by Section 162(m) or Section 280G of the Code, Primedex generally will be entitled to a tax deduction in connection with an award under the 2006 Plan in an amount equal to the ordinary income realized by a participant at the time the participant recognizes such income (for example, upon the exercise of a nonstatutory stock option).

Section 162(m) Limits. Section 162(m) of the Code places a limit of \$1 million on the amount of compensation that we may deduct in any one year with respect to the chief executive officer and each of the four other most highly paid executive officers. Certain performance-based compensation approved by stockholders is not subject to the deduction limit. The 2006 Plan is qualified such that awards under the Plan may constitute performance-based compensation not subject to Section 162(m) of the Code. One of the requirements for equity compensation plans is that there must be a limit to the number of shares granted to any one individual under the plan. Accordingly, the 2006 Plan provides that the maximum number of shares for which awards may be made to any employee, in any calendar year, is 200,000, except that in connection with his or her initial service, an awardee may be granted awards covering up to an additional 350,000 shares. The maximum amount payable pursuant to that portion of a cash award granted under the 2006 Plan for any fiscal year to any employee that is intended to satisfy the requirements for performance-based compensation under Section 162(m) of the Code may not exceed \$1,000,000.

Section 409A. Section 409A of the Code makes compensation that is deferred under a nonqualified deferred compensation arrangement taxable generally on the date of grant (or when vested, if later) and subject to additional taxes and interest, unless various requirements are met. These requirements may apply to some types of awards available under the 2006 Plan. In addition, certain actions may subject an award to which these requirements do not otherwise apply to Code Section 409A. The 2006 Plan provides that it and awards granted thereunder are intended to comply with the requirements of Section 409A of the Code, and are to be interpreted in a manner consistent with that intention.

Section 280G Limits. Section 280G of the Code limits the amount of compensation payable upon a change in control of Primedex, so-called parachute payments. If stock options or other awards vest upon a change in control, or if other payments contingent upon such a change in control are made, the vesting or

payment may in whole or in part result in a nondeductible parachute payment. In addition, the recipient of the parachute payment would be subject to a twenty percent excise tax that we would be required to withhold in addition to federal income tax. The 2006 Plan provides discretion to the board of directors to provide for the vesting of awards upon a change in control.

Plan Benefits

Primedex has no current plans, proposals or arrangements to grant any awards under the 2006 Plan.

Amendment and Termination

The administrator may amend the 2006 Plan at any time or from time to time or may terminate it, but any such amendment shall be subject to the approval of the stockholders in the manner and to the extent required by applicable law, rules, or regulations. Nevertheless, no action by the administrator or the stockholders may alter or impair any option or other type of award under the 2006 Plan, unless mutually agreed otherwise between the holder of the award and the administrator. The 2006 Plan will continue in effect for a term of ten years, unless terminated earlier in accordance with the provisions of the 2006 Plan.

Primedex's board of directors unanimously recommends a vote FOR Proposal No. 5 to approve the 2006 Equity Incentive Plan.

PROPOSAL NO. 6 ELECTION OF DIRECTORS

The following individuals are the nominees of Primedex's board of directors for election to the board of directors:

- Howard G. Berger, M.D.
- John V. Crues, III, M.D.
- Norman R. Hames
- Lawrence L. Levitt
- David L. Swartz

Each director will be elected to serve for a one-year term, unless he or she resigns or is removed before his or her term expires, or until his or her replacement is elected and qualified. All five of the nominees are currently members of the board of directors and have consented to serve as directors if elected. More detailed information about each of the nominees is available in the section of this joint proxy statement/prospectus titled "Information About Primedex Directors of Primedex," which begins on page 184.

If any of the nominees cannot serve for any reason (which is not anticipated), the board of directors may designate a substitute nominee or nominees. If a substitute is nominated, Primedex will vote all valid proxies for the election of the substitute nominee or nominees. Alternatively, the board of directors may also decide to leave the board seat or seats open until a suitable candidate or candidates are located, or it may decide to reduce the size of the board.

Section 6.19 of the merger agreement provides that promptly after the closing date of the merger, Primedex will use its reasonable best efforts to cause to be elected to its board of directors up to three persons designated by Radiologix and reasonably acceptable to Primedex, and that two of those nominees must meet the independence requirements of the SEC by January 1, 2007. Radiologix has not yet designated any persons as nominees to the Primedex board of directors.

Recommendation

The Primedex board of directors unanimously recommends a vote **FOR** each of the nominees to the board of directors, and your proxy will be so voted unless you specify otherwise.

PROPOSAL NO. 7 AMENDMENT TO THE CERTIFICATE OF INCORPORATION TO EFFECT A REVERSE STOCK SPLIT

On October 11, 2006, Primedex's board of directors unanimously adopted a resolution approving, declaring advisable and recommending to the stockholders for their approval an amendment to Primedex's certificate of incorporation to effect a reverse stock split of the outstanding shares of common stock at a ratio of one-to-two.

The reverse stock split will be effected by filing an amendment to Primedex's certificate of incorporation with the Department of State of the State of New York. The certificate of amendment will effect a reverse stock split of the shares by reducing the number of issued and outstanding shares of common stock by the ratio determined by the board of directors to be in the best interests of the Company and its stockholders, but will not change the number of authorized shares of common stock or preferred stock or the par value of the common stock or preferred stock. A copy of the proposed amendment to the certificate of incorporation effecting the 1-for-2 reverse stock split is attached at the back of this joint proxy statement/prospectus as **Annex B**.

Reasons for Board Recommendation

Primedex's board of directors approved this resolution because it feels that an increased per share stock price may have the effect of making Primedex's common stock more attractive to individuals as well as institutional investors in the future and this would also ultimately aid Primedex if it sought listing on a national securities exchange or the NASDAQ Stock Market by increasing the per share price of its stock to meet the minimum listing price.

Primedex's board of directors feels that having its common stock listed on a national securities exchange or the NASDAQ Stock Market is in the best interests of the long-term success of Primedex. As part of this resolution, the Board will have the authority to effect the reverse split.

Potential Disadvantages to the Reverse Stock Split

Reduced Market Capitalization.

As noted above, the principal purpose of the reverse stock split would be to help maintain the price of Primedex's common stock at a higher level. Primedex cannot assure you that the reverse stock split will accomplish this objective. While Primedex expects that the reduction in its outstanding shares of common stock will increase the market price of its common stock, Primedex cannot assure you that the reverse stock split will increase the market price of its common stock by a multiple equal to the number of pre-split shares in the reverse split ratio determined by the board of directors or result in any permanent increase in the market price, which can be dependent upon many factors, including Primedex business and financial performance and prospects. Should the market price decline after the reverse stock split, the percentage decline may be greater, due to the smaller number of shares outstanding, than it would have been prior to the reverse stock split. In some cases the stock price of companies that have effected reverse stock splits has subsequently declined back to pre-reverse split levels. Accordingly, Primedex cannot assure you that the market price of our common stock immediately after the effective date of the proposed reverse stock split will be maintained for any period of time or that the ratio of post and pre-split shares will remain the same after the reverse stock split is effected, or that the reverse stock split will not have an adverse effect on our stock price due to the reduced number of shares outstanding after the reverse stock split. A reverse stock split is often viewed negatively by the market and, consequently, can lead to a decrease in our overall

market capitalization. If the per share price does not increase proportionately as a result of the reverse stock split, then Primedex's overall market capitalization will be reduced.

Increased Transaction Costs.

The number of shares held by each individual stockholder will be reduced if the reverse stock split is implemented. This will increase the number of stockholders who hold less than a round lot, or 100 shares. Typically, the transaction costs to stockholders selling odd lots are higher on a per share basis. Consequently, the reverse stock split could increase the transaction costs to existing stockholders in the event they wish to sell all or a portion of their position.

Liquidity.

Although Primedex's board of directors believes that the decrease in the number of shares of its common stock outstanding as a consequence of the reverse stock split and the anticipated increase in the price of our common stock could encourage interest in our common stock and possibly promote greater liquidity for Primedex stockholders, such liquidity could also be adversely affected by the reduced number of shares outstanding after the reverse stock split.

Effect on Fractional Shares

Primedex will not issue fractional shares of its common stock in connection with the proposed reverse stock split. Instead, in the event Primedex effects the reverse stock split, any fractional share that results from the proposed reverse stock split will be paid an amount in cash (without interest) determined by multiplying the fractional share interest by the average closing price for a share of Primedex common stock as reported on the Over-The-Counter Bulletin Board for the ten trading days prior to, but not including, the effective time of the reverse split.

Effect of Reverse Stock Split on Options and Warrants

The number of shares subject to outstanding options and Warrants to purchase shares of Primedex's common stock also would automatically be reduced in the same ratio as the reduction in the outstanding shares. Correspondingly, the per share exercise price of those options will be increased in direct proportion to the reverse stock split ratio, so that the aggregate dollar amount payable for the purchase of the shares subject to the options will remain unchanged.

Implementation and Effect of the Reverse Stock Split

If the reverse stock split is approved by Primedex's stockholders at the special meeting, the board of directors will effect the reverse stock split by directing management to file the certificate of amendment of its certificate of incorporation with the New York Department of State. The reverse stock split will become effective at the time specified in the certificate of amendment after the filing of the amendment with the New York Department of State, which we refer to as the effective time.

Primedex estimates that, following the reverse stock split, it would have approximately the same number of stockholders and the completion of the reverse stock split would not affect any stockholder's proportionate equity interest in Primedex. By way of example, a stockholder who owns a number of shares that prior to the reverse stock split represented one-half of a percent of the outstanding shares of Primedex would continue to own one-half of a percent of the outstanding shares after the reverse stock split. The reverse stock split also will not affect the number of shares of common stock that Primedex's board of directors is authorized to issue under its certificate of incorporation. However, it will have the effect of increasing the number of shares available for future issuance because the reduction in the number of shares that will be outstanding after giving effect to the reverse stock split.

Exchange of Stock Certificates

Exchange of Stock Certificates.

Assuming approval of the reverse stock split, promptly after the effective time, you will be notified that the reverse stock split has been effected. Primedex's stock transfer agent, American Stock Transfer Corporation, referred to as the exchange agent, would implement the exchange of stock certificates representing outstanding shares of common stock. You will be asked to surrender to the exchange agent certificates for your pre-split shares in exchange for certificates representing your post-split shares in accordance with the procedures to be set forth in a letter of transmittal which Primedex would send to you. You would not receive a new stock certificate representing your post-split shares until you surrender your outstanding certificate(s) representing your pre-split shares, together with the properly completed and executed letter of transmittal to the exchange agent.

IF THIS REVERSE SPLIT WERE TO BE EFFECTED, PLEASE DO NOT DESTROY ANY STOCK CERTIFICATE OR SUBMIT ANY OF YOUR CERTIFICATES UNTIL YOU ARE REQUESTED TO DO SO.

Effect of Failure to Exchange Stock Certificates.

Upon the filing of the amendment to our certificate of incorporation with the New York Department of State, each certificate representing shares of Primedex common stock outstanding prior to that time would, until surrendered and exchanged as described above, be deemed, for all corporate purposes, to evidence ownership of the whole number of shares of Primedex common stock. However, a holder of such unexchanged certificates would not be entitled to receive any dividends or other distributions payable by Primedex after the effective date, until the old certificates have been surrendered. Such dividends and distributions, if any, would be accumulated, and at the time of surrender of the old certificates, all such unpaid dividends or distributions will be paid without interest.

No Appraisal Rights

Under the NYBCL, the CGCL, and Primedex's certificate of incorporation and bylaws, you are not entitled to appraisal rights with respect to the reverse stock split.

Federal Income Tax Consequences of the Reverse Stock Split

The following is a summary of the material U.S. federal income tax consequences of the proposed reverse stock split. This discussion is based on the Internal Revenue Code, the Treasury Regulations promulgated thereunder, published statements by the Internal Revenue Service and other applicable authorities on the date of this proxy statement, all of which are subject to change, possibly with retroactive effect. This discussion does not address the tax consequences to stockholders that are subject to special tax rules, such as banks, insurance companies, regulated investment companies, personal holding companies, foreign entities, nonresident alien individuals, broker-dealers and tax-exempt entities. Further, it does not address any state, local or foreign income or other tax consequences. This summary also assumes that the shares of common stock held immediately prior to the effective time of the reverse stock split were, and the new shares received will be, held as a capital asset, as defined in the Internal Revenue Code (generally, property held for investment). Subject to the discussion below concerning the treatment of the receipt of cash payments instead of fractional shares, we believe that the material U.S. federal income tax consequences of the reverse stock split are as follows:

- Primedex will not recognize any gain or loss as a result of the reverse stock split.
- Stockholders of Primedex will not recognize any gain or loss as a result of the reverse stock split, except with respect to cash received instead of fractional shares.

- The aggregate adjusted basis of the shares of Primedex common stock held by each stockholder following the reverse stock split will be equal to the aggregate adjusted basis immediately prior to the reverse stock split, reduced by any tax basis attributable to a fractional share.
- The holding period for the Primedex common stock held by each Primedex stockholder after the reverse stock split will include the holding period for the common stock held immediately prior to the reverse stock split.

In general, a stockholder who receives cash instead of a fractional share of Primedex common stock will recognize capital gain or loss based on the difference between the amount of cash received and the stockholder's adjusted basis in the fractional share. The capital gain or loss will constitute long-term capital gain or loss if the holding period for the common stock is greater than one year as of the date of the reverse stock split. The deductibility of capital losses is subject to limitations.

Primedex's view regarding the tax consequences of the reverse stock split is not binding on the Internal Revenue Service or the courts. Accordingly, please consult with a tax advisor with respect to all of the potential tax consequences of the reverse stock split.

Recommendation

The Primedex board of directors unanimously recommends a vote **FOR** amending the certificate of incorporation to effect the reverse stock split, and your proxy will be so voted unless you specify otherwise.

PROPOSAL NO. 8 RATIFICATION OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

Primedex's board of directors, upon the recommendation of the audit committee and subject to the ratification by Primedex's stockholders, has appointed Moss Adams LLP, a national accounting firm of independent certified public accountants, to act as the independent registered public accounting firm for Primedex and its consolidated subsidiaries for its 2006 fiscal year. The board believes that Moss Adams LLP's experience with and knowledge of Primedex are important, and would like to continue this relationship. Moss Adams has served as Primedex's Independent Registered Public Accounting Firm since October 1999. Moss Adams LLP has advised Primedex that the firm does not have any direct or indirect financial interest in Primedex or any of its subsidiaries, nor has Moss Adams LLP had any such interest since Primedex's inception in 1985, other than as a provider of auditing and accounting services.

In making the recommendation for Moss Adams LLP to continue as Primedex's independent accountants for the fiscal year ending October 31, 2006, the audit committee reviewed past audit results and the non-audit services performed during 2005 and proposed to be performed during 2006. In selecting Moss Adams LLP, the audit committee and the board of directors carefully considered Moss Adams LLP's independence. The audit committee has determined that the performance of the non-audit services performed by Moss Adams LLP did not impair Moss Adams LLP's independence.

Moss Adams LLP has confirmed to Primedex that it is in compliance with all rules, standards and policies of the Public Company Accounting Oversight Board and the SEC governing auditor independence.

A representative of Moss Adams LLP is expected to attend the special meeting. The Moss Adams LLP representative will have the opportunity to make a statement if he or she desires to do so and will be available to respond to appropriate questions from stockholders.

Although ratification by stockholders is not required by law, Primedex's board of directors has determined that it is desirable to request approval of this section by Primedex's stockholders. Notwithstanding its selection, the Primedex board of directors, in its discretion, may appoint a new independent registered public accounting firm at any time during the year if the board of directors believes

that such a change would be in the best interests of Primedex and its stockholders. If the stockholders do not ratify the appointment of Moss Adams LLP, the Primedex board of directors may reconsider its selection.

The Company paid the following fees to Moss Adams LLP during fiscal years ended October 31, 2005 and 2004, respectively:

	2005	2004
Audit Fees	\$ 227,000	\$ 221,000
Audit-Related Fees	\$ 13,000	\$ 239,000
Tax- Fees	\$ 92,000	\$ 104,000
Total	\$ 332,000	\$ 564,000

The Audit Fees for the years ended October 31, 2005 and October 31, 2004, respectively, were for professional services rendered for the audits of the consolidated financial statements of Primedex, consents and assistance with review of documents filed with the SEC. The Audit-Related Fees were for the audit of Primedex's 401(k) benefit plan and offering memorandum. The Tax Fees were for services provided to prepare federal, state, and local income and franchise tax returns for 2004, and related tax services and estimated tax payments for 2005.

Audit Committee Pre-Approval Policy

The Audit Committee's policy is to pre-approve all audit and non-audit services provided by the independent auditors. These services may include audit services, audit-related services, tax services, and other services. Pre-approval is generally provided for up to 12 months from the date of pre-approval and any pre-approval is detailed as to the particular service or category of services. The Audit Committee may delegate pre-approval authority to one or more of its members when expedited services are necessary. The Audit Committee has determined that the provision of non-audit services by Moss Adams LLP is compatible with maintaining Moss Adams' independence.

Recommendation

The Primedex board of directors unanimously recommends a vote **FOR** ratification of the appointment of Moss Adams LLP, and your proxy will be so voted unless you specify otherwise.

PROPOSAL NO. 9 APPROVAL OF ADJOURNMENTS OR POSTPONEMENTS OF THE PRIMEDEX SPECIAL MEETING

As discussed elsewhere in this joint proxy statement/prospectus, Primedex stockholders are considering and voting on a proposal to approve adjournments or postponements of the Primedex special meeting, if necessary, to permit further solicitation of proxies if there are not sufficient votes at the time of the Primedex special meeting to approve Proposals No. 1-8. Primedex stockholders should read carefully this joint proxy statement/prospectus in its entirety for more detailed information concerning the merger agreement and the merger, including the sections of this joint proxy statement/prospectus titled *The Merger*, which begins on page 100, and *The Merger Agreement*, which begins on page 141. In addition, Primedex stockholders should read the merger agreement, which is attached as *Annex A* to this joint proxy statement/prospectus, in its entirety.

Recommendation

The Primedex board of directors unanimously recommends a vote **FOR** the proposal to approve adjournments or postponements of the Primedex special meeting, if necessary, to permit further solicitation of proxies if there are not sufficient votes at the time of the Primedex special meeting to approve Proposals No. 1-8., and your proxy will be so voted unless you specify otherwise.

THE MERGER

Background of the Merger

The management and boards of directors of both Radiologix and Primedex continually review their companies' respective market positions in light of the changing competitive environment of the diagnostic imaging industry with the objective of determining which strategic alternatives are available to enhance shareholder value. From time to time, the management of each of Radiologix and Primedex have had conversations with other companies to explore opportunities to improve their companies' respective market positions, including through potential acquisitions or dispositions of assets, joint ventures and other strategic transactions.

On October 12, 2005, Sami S. Abbasi, Radiologix's President and Chief Executive Officer, Howard Berger, MD, Primedex's Chief Executive Officer, Mark Stolper, Primedex's Chief Financial Officer, and a representative of Bear Stearns, which had not been engaged by Radiologix at that time, met at the Admirals Club at the Los Angeles International Airport in Los Angeles, California. At the meeting, the parties discussed general industry issues, and no discussions took place regarding a possible strategic transaction between Radiologix and Primedex.

During a regular meeting of Radiologix's board on October 26, 2005, Mr. Abbasi informed the board of the October 12, 2005 meeting with Primedex and told the board that he thought Primedex might be a potential acquisition target for Radiologix. The board also discussed the possibility of taking Radiologix private. The board authorized Mr. Abbasi to initiate discussions with Primedex regarding a possible strategic transaction, to pursue other possible strategic alternatives, including a going private transaction, and to work with Bear Stearns in connection with these pursuits.

After the October 26, 2005 board meeting, Bear Stearns contacted six private equity firms to inquire of their interest in Radiologix. Four of these firms, which we will refer to as Firm A, Firm B, Firm C and Firm D, expressed interest in learning more about Radiologix.

On November 9, 2005, Mr. Abbasi and Michael N. Murdock, Radiologix's Chief Financial Officer, met with Firm A regarding a possible transaction with Radiologix.

On November 10, 2005, Mr. Abbasi, Mr. Murdock and Stephen M. Forthuber, Radiologix's then-Chief Development Officer, met with Dr. Berger and Mr. Stolper at Primedex's offices in Los Angeles, California. During this meeting, the parties discussed the operations and history of Primedex, its organizational structure and systems, industry issues and development opportunities. That evening, Mr. Abbasi and Dr. Berger began talking about a possible strategic transaction involving Radiologix and Primedex. Mr. Abbasi and Dr. Berger agreed to continue their discussions at a later date.

On November 18, 2005, Messrs. Abbasi and Murdock met with Firm B and on December 9, 2005 with Firm C regarding a possible transaction with Radiologix. Firm B notified Mr. Abbasi in late November 2005 that Firm B was not interested in pursuing a transaction with Radiologix, and Firm A notified Mr. Abbasi in early December 2005 that Firm A was not interested in pursuing a transaction with Radiologix.

During a regular meeting of Radiologix's board on December 12, 2005, the board again discussed the possibility of a strategic transaction with Primedex. The board determined not to pursue a transaction with Primedex at that time and discussions with Primedex were suspended.

On February 1, 2006, Firm C terminated discussions with Radiologix.

Diagnostic imaging reimbursement reductions were included in the Deficit Reduction Act of 2005 (DRA), which was signed into law on February 8, 2006.

Radiologix's common stock price dropped almost 50% in February 2006.

As a result of the DRA and the decrease in Radiologix's stock price, Radiologix began preserving cash and reducing capital expenditures and other costs.

During the week of February 13, 2006, another potential acquirer, which we will refer to as Company A, contacted Mr. Abbasi to discuss the possibility of acquiring Radiologix. Also in February, 2006, Mr. Abbasi met with Company A's Chief Executive Officer to discuss the possibility of a transaction between Company A and Radiologix. Company A and Radiologix executed a confidentiality agreement on February 27, 2006, but negotiations between the two companies ended after two weeks due to an internal conflict at Company A.

On March 29, 2006, Messrs. Abbasi and Murdock met with Firm D regarding a possible transaction with Radiologix. While Firm D found that Radiologix presented some opportunities, the uncertainty of regulation regarding reimbursement for diagnostic imaging surrounding the DRA caused Firm D to not pursue any transaction with Radiologix.

On April 3, 2006, Dr. Berger called Mr. Abbasi to discuss the DRA and Primedex's recent recapitalization. Dr. Berger also informed Mr. Abbasi that Primedex remained interested in a potential transaction with Radiologix.

On April 17, 2006, Dr. Berger and Mr. Abbasi had another telephone conversation during which Dr. Berger asked for an in-person meeting with Mr. Abbasi. They agreed to meet in Dallas, Texas on April 28, 2006.

At the regular meeting of the board of Radiologix on April 24 and 25, 2006, Mr. Abbasi discussed with the board his calls with Dr. Berger. At the meeting, a financial advisor gave a presentation regarding financial alternatives available to Radiologix. The Radiologix board established a special committee to oversee management's exploring financial and strategic alternatives and developing recommendations relating to Radiologix's capital structure. Marvin S. Cadwell, Chairman of the Board, and Paul D. Farrell, Chairman of the Audit Committee, were appointed to the special committee.

On April 28, 2006, Mr. Abbasi and Dr. Berger met at Radiologix's offices in Dallas, Texas. At this meeting, Dr. Berger proposed that Primedex acquire Radiologix. Mr. Abbasi informed Dr. Berger that he would need to discuss this proposal with other members of Radiologix's senior management and the special committee of the Radiologix board. At the meeting, the parties discussed the possibility of a merger in general and that the consideration for the merger would include both cash and stock, although no discussions took place regarding a possible price or valuation of Radiologix.

On May 1, 2006, Mr. Abbasi spoke to Mr. Cadwell and Mr. Farrell, who authorized Mr. Abbasi to continue discussions with Dr. Berger. On May 3, 2006, Mr. Abbasi called Dr. Berger to set up a meeting on May 16 and 17, 2006, to further discuss Dr. Berger's proposal. Subsequent to the call, Dr. Berger updated the Primedex board members regarding his discussions with Mr. Abbasi and conferred with Jefferies concerning a proposed Radiologix acquisition. They each advised Dr. Berger that they believed it was worth pursuing and the members of the Board authorized Dr. Berger to continue discussions, enter a confidentiality agreement and/or retain a financial advisor.

On May 5, 2006, Radiologix and Primedex signed a confidentiality agreement.

On May 9, 2006, Primedex retained Jefferies & Company, Inc. as its financial advisor in connection with a possible transaction with Radiologix.

On May 10, 2006, after Mr. Abbasi again consulted with the special committee, Radiologix retained Bear Stearns to act as its financial advisor in connection with a possible transaction with Primedex.

On May 16, 2006, Dr. Berger and Mr. Abbasi met at Bear Stearns' offices in New York City, New York. Dr. Berger said that Primedex was interested in acquiring Radiologix for stock and cash,

however Dr. Berger did not make any suggestions as to a price that would be offered to Radiologix. Dr. Berger also informed Mr. Abbasi that to preserve Primedex's net operating loss carryforwards, there might be restrictions imposed on the number of shares of Primedex common stock that could be issued in the transaction.

On May 17, 2006, Messrs. Berger, Stolper and Abbasi along with representatives of Bear Stearns and Jefferies met to continue the negotiations. The parties discussed a timetable for the proposed acquisition. Dr. Berger proposed that Primedex acquire Radiologix for \$30 million in cash and 18 million shares of Primedex common stock. At the completion of the meeting, Mr. Abbasi and Dr. Berger agreed to meet again in Dallas, Texas on May 23 and 24, 2006, at which time each of the parties would begin a due-diligence review.

On May 23 and 24, 2006 at Bear Stearns' offices in Dallas, Texas, Messrs. Abbasi and Murdock gave Dr. Berger and Mr. Stolper a business and financial review of Radiologix.

On May 25, 2006, the Primedex board met to further discuss the transaction.

On May 25, 2006, Dr. Berger telephoned a representative of Bear Stearns and repeated his offer to acquire Radiologix for \$30 million in cash and 18 million shares of Primedex common stock. The Bear Stearns representative relayed this information to Mr. Abbasi.

On May 26, 2006, Messrs. Abbasi and Murdock met with the special committee of the Radiologix board. The committee members authorized them to propose to Primedex a purchase price of \$45 million in cash and more than 20 million shares of Primedex common stock. Mr. Abbasi telephoned Dr. Berger to convey this counteroffer. Dr. Berger conferred with certain members of the Primedex board and then responded that, subject to obtaining approval of Primedex's board, he would be willing to offer \$44 million in cash and 18 million shares of Primedex common stock. In a telephonic meeting on May 26, 2006, Mr. Abbasi conveyed this new offer to the special committee. The special committee was receptive to this offer and requested that Bear Stearns do an in-depth analysis of the proposed transaction to be presented to the special committee and then to the Radiologix board.

On May 30, 2006, after consulting with certain members of the Primedex board, Dr. Berger telephoned a representative at Bear Stearns and modified Primedex's offer to \$42.95 million in cash and 18.75 million shares of Primedex common stock.

In the morning of May 31, 2006, the Primedex board held a special meeting at which the status of the negotiations, as well as the financial impact of the proposed merger and a proposed letter of intent to be provided to Radiologix were discussed. Following the meeting, Dr. Berger proposed the offer, \$42.95 million in cash and 18.75 million shares of Primedex common stock, in a letter to Mr. Abbasi. Mr. Abbasi conveyed this offer to the special committee, which met on June 5, 2006 with Bear Stearns, who presented a preliminary analysis of the proposed transaction. The special committee decided to recommend to the full board that Radiologix proceed with negotiations with Primedex concerning a possible acquisition.

At a special meeting of Radiologix's board on June 6, 2006, Mr. Abbasi and the special committee updated the board regarding the May 31, 2006 proposal letter and discussions with Primedex and Bear Stearns' preliminary analysis of the proposal. In-house and outside counsel for Radiologix attended this special meeting. The Radiologix board authorized management to proceed with discussions with Primedex on the basis outlined in Primedex's May 31, 2006 letter. Later that day, Mr. Abbasi phoned Dr. Berger to inform him of the outcome of the Radiologix board meeting. Mr. Abbasi and Dr. Berger agreed that legal counsel should begin preparing a merger agreement.

From June 7 through 9, 2006, representatives of Primedex conducted legal due diligence at Radiologix's offices in Dallas, Texas.

Edgar Filing: RADIOLOGIX INC - Form DEFM14A

On June 13, 2006, Dr. Berger provided Mr. Abbasi with an initial draft of the merger agreement, prepared by Sheppard Mullin Richter & Hampton LLP, Primedex's outside legal counsel.

On June 14, 2006, Mr. Abbasi met with Mr. Farrell to update him regarding the status of the merger negotiations.

On June 14, 2006, representatives of GE Healthcare Financial Services informed Mr. Abbasi and Dr. Berger that they had approval to commit \$405 million of total financing to refinance the existing indebtedness of the combined companies, the cash portion of the purchase price and fees and expenses of the transaction.

On June 15, 2006, Mr. Abbasi, Dr. Berger and Mr. Stolper, and representatives of GE Healthcare Financial Services met with rating agencies in New York City to make a presentation regarding the proposed combination of Primedex and Radiologix.

On June 16, 2006, Dr. Berger met with Mr. Abbasi and Dr. Michael L. Sherman, a radiologist and member of Radiologix's board of directors, to discuss Primedex's structure and organization from a medical and operational perspective.

On June 17, 2006, Michael L. Silhol, Radiologix's General Counsel, and Mr. Abbasi attended a conference call with Dr. Berger, Jeffrey Linden, Primedex's General Counsel, and the parties' legal advisors to discuss the initial draft of the merger agreement.

On June 19 and 20, 2006, Messrs. Abbasi and Murdock, Jeff Kent, Radiologix's Vice President, Legal, and representatives from Bear Stearns conducted business, legal and financial due diligence at Primedex's Los Angeles offices.

At a special meeting of Radiologix's board on June 22, 2006, the board met with Radiologix's legal and financial advisors to discuss the proposed merger agreement and the results of the due-diligence investigation that had been conducted with respect to Primedex. Radiologix's outside legal counsel advised the board of directors of its fiduciary duties. The board recommended that Radiologix and its legal counsel continue negotiating the terms of the merger agreement.

On June 23, 2006, Mr. Abbasi telephoned Dr. Berger to update him regarding the board meeting and recommended that the parties attempt to sign the merger agreement by July 6, 2006. Dr. Berger agreed to the timing.

Between June 23 and July 6, Radiologix and its legal counsel and Primedex and its legal counsel continued to negotiate the terms of a definitive merger agreement.

On June 26, 2006, Mr. Abbasi telephoned a representative of Contrarian Capital Management, LLC, Radiologix's largest shareholder, to explain the proposed transaction, the merger consideration and proposed timing. The telephone call and all subsequent, related communications between Radiologix and Contrarian were governed by a confidentiality agreement that was signed by Contrarian on November 30, 2005. On June 27, 2006, the Contrarian representative telephoned Mr. Abbasi and indicated he was generally supportive of the proposed transaction but believed that Radiologix should ask Primedex to increase its offer price.

On June 27, 2006, the Primedex board held a special meeting. At the meeting, representatives of Jefferies reviewed with the Primedex board the financial terms of the proposed transaction. Outside legal counsel discussed the current draft of the merger agreement that had been delivered to the board members prior to the meeting.

On June 28, 2006, Messrs. Abbasi and Murdock, representatives from Bear Stearns, and Contrarian's representative had a telephonic meeting to discuss the proposed merger. During the meeting, the Contrarian representative again stated his view that Radiologix should receive more consideration in the

merger. Messrs. Abbasi and Murdock then telephoned the special committee to convey Contrarian's views. The special committee recommended that Mr. Abbasi and a representative from Bear Stearns call Dr. Berger to discuss Contrarian's views regarding the proposed valuation of Radiologix.

On June 28, 2006, Mr. Abbasi and a representative from Bear Stearns telephoned Dr. Berger to update Dr. Berger on Mr. Abbasi's discussions with Contrarian regarding the proposed merger. Mr. Abbasi also expressed concerns about moving forward without Contrarian's support. Dr. Berger telephoned Mr. Abbasi later that day and informed him that he would discuss a possible revision to the offer with Primedex's board and financial advisors.

At a special meeting of the Radiologix board on June 30, 2006, the board discussed the status of merger negotiations. The board also discussed the possibility that, pursuant to the draft merger agreement delivered by Primedex, Contrarian enter into a voting agreement. Mr. Abbasi telephoned Contrarian's representative later that day to discuss the possibility of Contrarian entering into a voting agreement.

On June 30, 2006, the Primedex board held a special meeting to discuss the status of the merger and the position of Contrarian. The Primedex board approved an increase in the purchase price for the acquisition of Radiologix. Representatives of Jefferies provided the board with a presentation based upon the increased consideration to Radiologix. Outside legal counsel to Primedex discussed revisions in the merger agreement and the conditions to closing.

On July 3, 2006, Mr. Abbasi telephoned the Contrarian representative that Primedex had revised its offer to \$42.95 million and 22,621,922 shares of Primedex's common stock. Contrarian agreed to execute a voting agreement in support of the merger.

On July 6, 2006, the board of directors of Primedex met and approved the terms of the merger agreement. During the meeting, Dr. Berger updated the Primedex board of directors on developments since that last meeting. Jefferies rendered to Primedex's board of directors its opinion as investment bankers to the effect that, as of that date and based upon and subject to the various considerations and assumptions set forth therein, the aggregate merger consideration of 22,621,922 shares of Primedex common stock and \$42.95 million in cash to be paid by Primedex pursuant to the merger was fair, from a financial point of view, to Primedex. Primedex's legal counsel then reviewed the terms and conditions of the most recent draft of the merger agreement, a copy of which had been provided to the board of directors. After discussion, Primedex's board of directors unanimously approved the merger agreement and the terms and conditions of the merger.

On July 6, 2006, the Radiologix board also met to consider the proposed acquisition upon the terms set forth in the definitive merger agreement. During this meeting, Mr. Abbasi updated the Radiologix board of directors on developments since the June 30 meeting. Radiologix's outside legal counsel advised the board of directors of its fiduciary duties and discussed other legal and regulatory matters with the board of directors. The Radiologix board of directors was apprised of the interests of certain members of management in the transaction. Bear Stearns reviewed its financial analysis of the proposed transaction with Primedex and delivered its oral opinion, later confirmed in writing, to the effect that, as of that date and based upon and subject to the factors, assumptions and limitations set forth in the opinion, the merger consideration was fair, from a financial point of view, to the holders of Radiologix common stock. Radiologix's legal counsel then reviewed the terms and conditions of the most recent draft of the merger agreement, a copy of which had been provided to the board of directors.

After extensive discussion and deliberation relating to the proposed transaction, Radiologix's board of directors unanimously approved and declared advisable the merger agreement and the terms and conditions of the merger and determined that the merger agreement and the terms and conditions of the merger are fair to, advisable and in the best interests of Radiologix and its stockholders.

Thereafter, Radiologix and Primedex and their advisors finalized the documentation for the transaction for execution and the parties signed the merger agreement.

Radiologix and Primedex publicly announced the transaction through the issuance of a press release on July 7, 2006.

Radiologix's Reasons for the Merger and Recommendation of Radiologix's Board of Directors

At a special meeting of Radiologix's board of directors on July 6, 2006, after careful consideration, including consultation with financial and legal advisors, Radiologix's board of directors unanimously determined that the merger agreement and the terms and conditions of the merger are fair to, advisable and in the best interests of Radiologix and its stockholders. Radiologix's board of directors unanimously approved and declared advisable the merger agreement and the terms and conditions of the merger and recommends that Radiologix's stockholders vote FOR the adoption of the merger agreement.

In reaching its decision to approve the merger agreement and to recommend that Radiologix stockholders vote to adopt the merger agreement, Radiologix's board of directors consulted Messrs. Abbasi, Murdock and Silhol, members of Radiologix's senior management, Radiologix's financial advisors and legal counsel, reviewed a significant amount of information and considered a number of factors, including, among others, the following:

- the business, competitive position, strategy and prospects of Radiologix, which Radiologix's board believed had been severely impacted by the Deficit Reduction Act of 2005 (the "DRA") signed into law on February 8, 2006, the position of current and likely competitors of Radiologix, including the possibility that Primedex or other diagnostic imaging service company might acquire a competitor or otherwise enter the market; and current industry, economic and market conditions, which Radiologix's board considered to be favorable but subject to the risk of deterioration;
- the total consideration per share of \$1.84 cash and one share of Primedex stock, valued together at a total per share consideration of \$3.59, to be paid as merger consideration in relation to the then-current market price of Radiologix shares and the fact that the \$3.59 total value per share of merger consideration represents a significant premium to historical trading prices of Radiologix common stock, including a premium of 59.5% over the \$2.25 closing price of Radiologix common stock on July 6, 2006;
- the financial analysis presented by representatives of Bear Stearns, as well as the opinion of Bear Stearns to the effect that, as of July 6, 2006, and based upon and subject to the factors, assumptions and limitations set forth in the opinion, the merger consideration was fair, from a financial point of view, to the holders of Radiologix common stock;
- the value of the consideration to be received by Radiologix stockholders and the fact that a portion of the consideration would be paid in cash, which provides certainty and immediate value to Radiologix's stockholders;
- the operational benefits that may result from the transaction, including the creation of a strong national competitor in the imaging industry, which will allow entry into new geographic markets, and the diversification of payors;
- the financial benefits, including the significant cost synergies that may be realized without closing any imaging centers and the increased exposure to analysts and the broader investment community that comes with an increased size;
- that given its size and concentration in markets, the combined company will be more attractive to payors as a provider of imaging services;

- that the transaction will increase the combined company's attractiveness to potential employees and improve employee retention;
- the fact that the transaction will result in a combination of the industry's premier and most experienced management teams;
- the opportunity to explore capitated contracts in new geographic areas;
- the possible alternatives to the merger (including the possibility of continuing to operate Radiologix as an independent entity, the possibility of seeking a superior offer from a potential buyer other than Primedex, and the desirability and perceived risks of those alternatives), the range of potential benefits to Radiologix's stockholders of the possible alternatives and the timing and the likelihood of accomplishing the goals of such alternatives, the risk, which was perceived to be significant, of losing Primedex's offer if Radiologix sought another offer, and Radiologix's board of directors' assessment that none of such alternatives were reasonably likely to present superior opportunities for Radiologix or to create greater value for its stockholders, taking into account risks of execution as well as business, competitive, industry and market risks, than the merger;
- that under the terms of the merger agreement, Radiologix can furnish information to, and negotiate with, a third party in response to an unsolicited bona fide acquisition proposal that Radiologix's board of directors concludes in good faith is, or is reasonably likely to become, a superior offer and accept a superior offer should one be made and not matched by Primedex, upon payment to Primedex of a termination fee of \$3.0 million and reimbursement of expenses up to \$1.0 million; and
- the likelihood that the proposed acquisition would be completed in light of the conditions to closing in the merger agreement, and financial capabilities and reputation of Primedex.

In the course of its deliberations, Radiologix's board of directors also considered a variety of risks and other potentially negative factors, including the following:

- Radiologix will no longer exist as an independent public company and Radiologix stockholders will forgo any future increase in Radiologix's value that might result from its possible growth;
- the risks and contingencies related to the announcement and pendency of the merger, including the impact of the merger on Radiologix's employees, customers and its relationships with third parties;
- the assessment of management that further discussion was unlikely to cause Primedex to increase its valuation for Radiologix;
- the assessment of management and its legal counsel that, based on negotiations with Primedex, it was unlikely that additional discussions with Primedex would yield significantly more favorable contractual terms in the near term;
- the conditions to Primedex's obligation to complete the merger and the right of Primedex to terminate the merger agreement in certain circumstances described under "The Merger Agreement - Termination of the Merger Agreement" on page 152;
- that under the terms of the merger agreement, Radiologix cannot solicit other acquisition proposals and must pay to Primedex a termination fee of \$3.0 million plus up to \$1.0 million of expenses if the merger agreement is terminated under certain circumstances;

- that the income realized by stockholders as a result of the merger will be taxable to Radiologix's stockholders;

106

- the interests that certain directors and executive officers of Radiologix may have in the merger, in addition to their interests as stockholders of Radiologix generally, as described in *The Merger Interests of Radiologix's Executive Officers and Directors in the Merger* beginning on page 126; and
- that, pursuant to the merger agreement, Radiologix must generally conduct its business in the ordinary course and Radiologix is subject to a variety of other restrictions on the conduct of its business prior to closing of the merger or termination of the merger agreement, which may delay or prevent Radiologix from pursuing business opportunities that may arise or preclude actions that would be advisable if Radiologix were to remain an independent company.

Radiologix's board of directors did not assign any particular weight or rank to any of the positive or potentially negative factors or risks discussed in this section, and Radiologix's board of directors carefully considered all of these factors as a whole in reaching its determination and recommendation.

Primedex's Reasons for the Merger and Recommendation of Primedex's Board of Directors

Primedex's board of directors has approved the merger agreement and determined that the transactions contemplated by the merger agreement are advisable and in the best interests of Primedex and its stockholders. Primedex's board of directors recommends that Primedex stockholders vote FOR adopting the merger agreement and approving the merger and issuance of Primedex common stock pursuant to the terms of the merger agreement at the Primedex special meeting.

In reaching its conclusion to approve the merger and the related transactions and to recommend that Primedex stockholders adopt the merger agreement and approve the merger and issuance of Primedex common stock pursuant to the terms of the merger agreement, the Primedex board consulted Primedex's senior management, its financial advisors and legal counsel, reviewed a significant amount of information and considered the following factors as supporting its decision to enter into the merger agreement.

Strategic Considerations

Primedex's board believes that the merger with Radiologix will provide a number of significant strategic opportunities and benefits, including the following, all of which it viewed as supporting its decision to approve the merger with Radiologix:

- The merger is expected to create the largest owner and operator of fixed site diagnostic imaging centers in the United States, with 134 locations, including 83 centers in California, 31 centers in Maryland, 12 centers in New York and 8 centers in other states, including Florida, Kansas, Colorado and Minnesota.
- The merger will provide Primedex with 18 additional imaging locations in California. These additional centers are in markets, except for San Francisco, where Primedex currently has no presence, thereby expanding the markets and customer base it serves.
- The merger will provide Primedex with a platform for expansion in the future. By creating a national platform, Primedex will also have greater recognition in the debt and equity capital markets, making it potentially easier to access capital in the future.
- Primedex's board of directors also considered management's view that the combined companies should produce cost synergies of approximately \$11 million on an annual basis, resulting from elimination of duplicative corporate overhead. While these synergies reflect management's estimates, the Primedex board of directors recognized that there could be no assurance that they would be achieved. In addition, the potential to realize greater synergies represents an additional factor considered by Primedex's board.

- The merger will allow Primedex to expand its presence in California, and will give Primedex a concentrated platform outside of California that it plans to optimize and grow.
- The merger will allow Primedex to further its strategies of geographic clustering, exclusive capitation contracting and multi-modality product offerings on a national scale.
- Primedex's board considered that Primedex will be able to augment its talent pool with the most capable managers from Radiologix.

Other Factors Considered by the Primedex Board

In addition to considering the strategic factors outlined above, the Primedex board considered the following additional factors, all of which it viewed as supporting its decision to approve the merger with Radiologix:

- comparisons of historical information concerning Radiologix's and Primedex's respective businesses, financial performance and condition, operations, management, competitive positions and stock performance, which the members of the board used to inform themselves of the relative values of Primedex, Radiologix and the combined companies;
- the results of the due diligence review of Radiologix's businesses and operations;
- management's assessment that the proposed merger was likely to meet the criteria they deemed necessary for a successful merger: strategic fit, acceptable execution risk, and financial benefits to Primedex and Primedex's stockholders;
- the current and prospective competitive environment in which companies such as Primedex operate;
- the terms and conditions of the merger agreement, including:
- the limited number and nature of the conditions to Radiologix's obligation to consummate the merger and the limited risk of non-satisfaction of such conditions; and
- that Primedex may be entitled to receive a \$3 million termination fee from Radiologix if the merger is not consummated for certain reasons;
- the likelihood that the merger will be completed on a timely basis, including the likelihood that the merger will receive all necessary antitrust and other regulatory approvals without unacceptable conditions on a timely basis.
- the financial analysis presented by representatives of Jefferies, as well as the opinion of Jefferies to the effect that, as of July 6, 2006, and based upon and subject to the factors, assumptions and limitations set forth in the opinion, the aggregate merger consideration was fair, from a financial point of view, to Primedex;

Potential Risks Considered by the Primedex Board

Primedex's board of directors also considered the potential risks of the merger and potential conflicts of interest, including the following:

- the challenges of combining the operations of two diagnostic imaging services businesses and effecting cultural changes;

- the possible disruptions from anticipated workforce reductions to be implemented as part of the merger integration plan;

108

- the risk that anticipated operating profit synergies and cost savings will not be achieved (or the risk that cost savings will adversely affect operating profits);
- the challenge of offsetting the impact of DRA with savings to be achieved through the economics of the reorganization;
- the one-time costs of the acquisition, including transaction costs of \$13.5 million and financing costs of \$9.2 million spread over a six to seven-year period;
- the costs of the acquisition and integration related to severance of terminated employees and retention of certain employees, which management estimated at approximately \$2.6 million;
- the risk that Primedex will have to reimburse Radiologix its expenses up to \$1 million if the merger agreement is terminated under certain circumstances;
- the potential dilution to Primedex's stockholders; and
- the risk of diverting management's attention from other strategic priorities to implement merger integration efforts.

The foregoing discussion of the information and factors considered by Primedex's board of directors is not meant to be exhaustive but is believed to include all material factors considered by it in connection with its determination that the terms of the merger agreement, including the issuance of Primedex common stock in the merger, are advisable and in the best interests of Primedex and its stockholders. In view of the wide variety of factors considered in connection with its evaluation of the merger and the complexity of these matters, the Primedex board did not find it useful, and did not attempt, to quantify, rank or otherwise assign relative weights to these factors. In considering the factors described above, individual members of the Primedex board may have given different weight to different factors. The Primedex board conducted an overall analysis of the factors described above, including thorough discussions with, and questioning of, Primedex's management and Primedex's legal and financial advisors, and considered the factors overall to be favorable to, and to support, its determination.

Opinions of Our Financial Advisors

Bear Stearns

Pursuant to an engagement letter dated May 16, 2006, Radiologix retained Bear Stearns to act as its financial advisor with respect to a possible merger with Primedex. In selecting Bear Stearns, Radiologix's board of directors considered, among other things, the fact that Bear Stearns is an internationally recognized investment banking firm with substantial experience advising companies in the healthcare industry as well as substantial experience providing strategic advisory services. Bear Stearns, as part of its investment banking business, is continuously engaged in the evaluation of businesses and their debt and equity securities in connection with mergers and acquisitions, underwritings, private placements and other securities offerings, senior credit financings, valuations, and general corporate advisory services.

At the July 6, 2006 meeting of Radiologix's board of directors, Bear Stearns delivered its oral opinion, which was subsequently confirmed in writing, that, as of July 6, 2006, and based upon and subject to the assumptions, qualifications and limitations set forth in the written opinion, the merger consideration to be received was fair, from a financial point of view, to the stockholders of Radiologix.

Edgar Filing: RADIOLOGIX INC - Form DEFM14A

The full text of Bear Stearns' written opinion is attached as *Annex C* to this proxy statement and you should read the opinion carefully and in its entirety. The opinion sets forth the assumptions made, some of the matters considered and qualifications to and limitations of the review undertaken by Bear Stearns. The Bear Stearns opinion is subject to the assumptions and conditions contained therein and is necessarily based on economic, market and other conditions and the information made available to Bear Stearns as of the date of the Bear Stearns opinion.

In reading the discussion of the fairness opinion set forth below, you should be aware that Bear Stearns' opinion:

- was provided to Radiologix's board of directors for its benefit and use;
- did not constitute a recommendation to the board of directors of Radiologix or any shareholder of Radiologix as to how to vote in connection with the merger or otherwise; and
- did not address Radiologix's underlying business decision to pursue the merger, the relative merits of the merger as compared to any alternative business strategies that might exist for Radiologix, the financing of the merger or the effects of any other transaction in which Radiologix might engage.

Radiologix did not provide specific instructions to, or place any limitations on, Bear Stearns with respect to the procedures to be followed or factors to be considered by it in performing its analyses or providing its opinion.

In connection with rendering its opinion, Bear Stearns:

- reviewed the merger agreement in substantially final form;
- reviewed Radiologix's Annual Reports to Stockholders and Annual Reports on Form 10-K for the years ended December 31, 2003, 2004 and 2005, its Quarterly Report on Form 10-Q for the period ended March 31, 2006 and its Current Reports on Form 8-K filed since December 31, 2005;
- reviewed Primedex's Annual Reports to Stockholders and Annual Reports on Form 10-K for the years ended October 31, 2003, 2004 and 2005, its Quarterly Reports on Form 10-Q for the periods ended January 31, 2006 and April 30, 2006 and its Current Reports on Form 8-K filed since October 31, 2005;
- reviewed operating and financial information relating to Radiologix's businesses and prospects, including projections for the five years ending December 31, 2010, all as prepared and provided to Bear Stearns by Radiologix's management;
- reviewed operating and financial information relating to Primedex's businesses and prospects, including projections for the five years ended December 31, 2010, all as prepared and provided to Bear Stearns by Primedex's management and as reviewed by Radiologix's management;
- reviewed estimates of cost savings expected to result from the merger, including costs to obtain the cost savings (collectively, the potential synergies), all as prepared and provided to Bear Stearns by Radiologix's and Primedex's management;
- met with members of Radiologix's senior management to discuss Radiologix's businesses, operations, historical and estimated financial results and future prospects;
- met with members of Primedex's senior management to discuss Primedex's businesses, operations, historical and estimated financial results and future prospects;
- reviewed the historical prices, trading multiples and trading volumes of the common shares of Radiologix and Primedex;

- reviewed publicly available financial data, stock market performance data and trading multiples of companies which Bear Stearns deemed generally comparable to Radiologix and Primedex;
- reviewed the terms of recent mergers and acquisitions involving companies that Bear Stearns deemed generally comparable to Radiologix;
- performed discounted cash flow analyses based on the Radiologix projections, Primedex projections and potential synergies;
- reviewed the pro forma financial results, financial condition and capitalization of Primedex giving effect to the merger; and
- conducted such other studies, analyses, inquiries and investigations as Bear Stearns deemed appropriate.

Bear Stearns relied upon and assumed, without independent verification, the accuracy and completeness of the financial and other information provided to or discussed with it by Radiologix and Primedex or obtained by it from public sources, including, without limitation, the projections and potential synergies referred to above. With respect to the projections and potential synergies, Bear Stearns relied on representations that they were reasonably prepared on bases reflecting the best then available estimates and judgments of the senior management of each of Radiologix and Primedex, respectively, as to the expected future performance of Radiologix and Primedex. Bear Stearns did not assume any responsibility for the independent verification of any such information, including, without limitation, the projections and potential synergies, and Bear Stearns further relied upon the assurances of the senior management of each of Radiologix and Primedex that they are unaware of any facts that would make the information, projections and potential synergies incomplete or misleading.

In arriving at its opinion, Bear Stearns did not perform or obtain any independent appraisal of the assets or liabilities (contingent or otherwise) of Radiologix and Primedex, nor was Bear Stearns furnished with any such appraisals. Bear Stearns assumed that the transactions contemplated by the merger agreement will be consummated in a timely manner and in accordance with the terms of the merger agreement without any limitations, restrictions, conditions, amendments or modifications, regulatory or otherwise, that collectively would have a material effect on Radiologix or Primedex.

Bear Stearns did not express any opinion as to the price or range of prices at which the shares of common stock of Radiologix or Primedex may trade subsequent to the announcement or consummation of the merger.

The following is a brief summary of the material financial analyses performed by Bear Stearns and presented to Radiologix's board of directors in connection with rendering its fairness opinion.

Some of the financial analyses summarized below include summary data and information presented in tabular format. In order to understand fully the financial analyses, the summary data and tables must be read together with the full text of the analyses. Considering the summary data and tables alone could create a misleading or incomplete view of Bear Stearns' financial analyses.

Discounted Cash Flow Analysis. Based on cash flow projections for Radiologix, Primedex and potential synergies, Bear Stearns performed a discounted cash flow analysis to assist the Radiologix board of directors in valuing Radiologix, Primedex and the pro forma combined company.

Bear Stearns performed a discounted cash flow analysis assuming:

- for Radiologix, a range of illustrative discount rates of 12% to 15% and a range of terminal EBITDA multiples (based on estimated 2010 EBITDA) of 5.5x to 6.5x;

- for Primedex, a range of illustrative discount rates of 12% to 15% and a range of terminal EBITDA multiples (based on estimated 2010 EBITDA) of 6.0x to 7.0x; and
- for potential synergies, a range of illustrative discount rates of 12% to 15% and a range of terminal EBITDA multiples (based on estimated 2010 EBITDA) of 5.5x to 6.5x.

Discounted cash flow valuations were calculated for Radiologix on a stand-alone basis using the projections provided to Bear Stearns by Radiologix management along with the assumptions noted above. Bear Stearns derived a range of implied equity values and share prices for Radiologix as follows:

	Range	
	Low	High
Radiologix Stand-Alone		
Implied Equity Value (\$M)	\$ 38.9	\$ 82.1
Implied Share Price	\$ 1.75	\$ 3.66

Discounted cash flow valuations were calculated for Primedex on a stand-alone basis using the projections provided to Bear Stearns by Primedex management along with the assumptions noted above. Bear Stearns derived a range of implied equity values and share prices for Primedex as follows:

	Range	
	Low	High
Primedex Stand-Alone		
Implied Equity Value (\$M)	\$ 76.9	\$ 134.6
Implied Share Price	\$ 1.56	\$ 2.63

Discounted cash flow valuations were calculated for the pro forma combined company, both including and excluding potential synergies, using the individual company projections and potential synergies, all provided to Bear Stearns by Radiologix and Primedex management, along with the assumptions noted above. Bear Stearns derived a range of implied share prices for the pro forma combined company as follows:

	Range	
	Low	High
Pro Forma Combined Company		
Implied Share Price, excluding potential synergies	\$ 0.67	\$ 2.06
Implied Share Price, including potential synergies	1.38	2.94

The implied value of the merger consideration to be received by stockholders were calculated based on the discounted cash flow valuations for the pro forma combined company, both including and excluding potential synergies, as shown in the table above. Bear Stearns derived a range of implied values of the merger consideration per Radiologix share as follows:

	Range	
	Low	High
Implied Value Per Radiologix Share		
Excluding potential synergies	\$ 2.51	\$ 3.90
Including potential synergies	3.22	4.78

Comparable Public Companies Analysis. Bear Stearns performed a comparable public companies analysis to assist the Radiologix board of directors in valuing Radiologix based on various financial multiples of selected comparable public companies in the diagnostic imaging industry. In performing this analysis, Bear Stearns reviewed financial information relating to Radiologix and compared this

information to the corresponding financial information of publicly-traded diagnostic imaging companies, which Bear Stearns deemed to be generally comparable to Radiologix.

Bear Stearns compared the projected financial performance and the resulting multiples of Radiologix as of June 30, 2006, at the transaction price based on Primedex closing stock price as of June 30, 2006, and at the transaction price based on Primedex one month average closing stock price as of June 30, 2006, to two publicly-traded companies, which are providers of diagnostic imaging services and were deemed by Bear Stearns to be generally comparable to Radiologix. These publicly-traded comparable companies consisted of:

- Alliance Imaging, Inc.
- Primedex Health Systems, Inc.

Using publicly available information and market data as of June 30, 2006, and in the case of Radiologix and Primedex, information based on Radiologix and Primedex management estimates and using Wall Street research projections for revenue, EBITDA, EBIT and EBITDA CapEx for Alliance Imaging, Bear Stearns calculated the following harmonic mean multiples for the above publicly-traded comparable companies:

	LTM	2006E	2007E
Primary Comparable Companies			
Harmonic Mean Multiples:			
Enterprise Value/Revenue	1.8 x	1.8 x	1.7 x
Enterprise Value/EBITDA	6.4	6.5	5.9
Enterprise Value/EBIT	13.5	15.0	12.5
Enterprise Value/EBITDA CapEx	10.6	11.8	8.5
Radiologix at Market Multiples:			
Enterprise Value/Revenue	0.7 x	0.7 x	0.7 x
Enterprise Value/EBITDA	4.0	3.9	5.1
Enterprise Value/EBIT	8.5	7.8	12.6
Enterprise Value/EBITDA CapEx	12.7	5.9	8.7
Radiologix at Deal Multiples:			
(Primedex at Current Price)			
Enterprise Value/Revenue	0.8 x	0.8 x	0.8 x
Enterprise Value/EBITDA	4.7	4.5	5.9
Enterprise Value/EBIT	9.9	9.1	14.6
Enterprise Value/EBITDA CapEx	14.8	6.9	10.1
Radiologix at Deal Multiples:			
(Primedex at One Month Average)			
Enterprise Value/Revenue	0.8 x	0.8 x	0.8 x
Enterprise Value/EBITDA	4.7	4.5	5.8
Enterprise Value/EBIT	9.8	9.0	14.5
Enterprise Value/EBITDA CapEx	14.7	6.8	10.0

Bear Stearns noted that the Deficit Reduction Act of 2005 (the "DRA") signed into law on February 8, 2006 is expected to result in reimbursement reductions for certain imaging services provided by Radiologix and to have a significant negative effect on Radiologix's business and earnings in 2007 and beyond. Due to the negative impact of the DRA on Radiologix, Bear Stearns took into specific consideration the 2007 multiples and focused more on 2007 multiples than on LTM or 2006 multiples.

In addition to the primary set of comparable companies, Bear Stearns reviewed valuation multiples of a secondary set of publicly-traded comparable companies, which are health care service companies that operate via facilities and deliver health care services at multiple sites. These publicly-traded comparable companies consisted of:

- Allion Healthcare, Inc.
- HealthTronics, Inc.
- Rehabcare Group, Inc.
- US Physical Therapy, Inc.

Using publicly available information and market data as of June 30, 2006, and using Wall Street research projections for revenue, EBITDA, EBIT and EBITDA / CapEx, Bear Stearns calculated the following harmonic mean multiples for the above publicly-traded comparable companies:

	LTM	2006E	2007E
Secondary Comparable Companies			
Harmonic Mean Multiples:			
Enterprise Value/Revenue	0.9 x	0.7 x	0.5 x
Enterprise Value/EBITDA	9.8	5.9	4.5
Enterprise Value/EBIT	9.7	9.0	6.6
Enterprise Value/EBITDA / CapEx	17.1	9.1	7.1

The multiples of the secondary comparable companies should be compared to the Radiologix multiples included in the primary comparable companies table above.

Harmonic mean is calculated by taking the inverse of the average reciprocals of the multiples and gives equal weight to equal dollar investments in securities whose ratios are being averaged. Bear Stearns utilizes the harmonic mean in averaging ratios in which value is the numerator.

Enterprise Value is calculated as the sum of the value of the common equity on a fully diluted basis and the value of the net debt, minority interest and preferred stock. EBITDA is a company's earnings before interest, taxes, depreciation and amortization. EBIT is a company's earnings before interest and taxes. CapEx is a company's expenditures on property, plant and equipment. Radiologix at Market is defined as Radiologix's enterprise value and share price based on the closing share price of the Radiologix common stock as of June 30, 2006. Radiologix at Deal is defined as Radiologix enterprise value and share price based on the merger consideration plus the value of Radiologix's net debt and minority interest. Primedex at Current Price is defined as the closing share price of the Primedex common stock as of June 30, 2006. Primedex at One Month Average is defined as the one month average closing share price of the Primedex common stock as of June 30, 2006. LTM refers to the latest twelve months of publicly reported activity.

Precedent M&A Transaction Analysis. Bear Stearns performed a precedent transactions analysis to assist the Radiologix board of directors in valuing Radiologix based on various financial multiples of selected comparable precedent transactions in the diagnostic imaging industry. In performing this analysis, Bear Stearns reviewed financial information relating to Radiologix and compared this information to the corresponding financial information of precedent transactions involving diagnostic imaging companies which Bear Stearns deemed to be generally comparable to Radiologix. These comparable precedent transactions consisted of:

Date Announced	Target	Acquiror
04/05/05	Diagnostic Imaging Group LLC	Evercore Partners
08/15/02	MedQuest Associates, Inc.	JPMorgan Partners
06/30/01	Insight Health Services Corp.	J.W. Chiles Associates; Halifax Group
09/14/99	Alliance Imaging Inc.	Kohlberg Kravis Roberts & Co.
10/14/97	Insight Health Services Corp.	The Carlyle Group

Using publicly available information, and in the case of Radiologix, information based on Radiologix management estimates, for revenue, EBITDA and EBITDA CapEx, Bear Stearns calculated the following harmonic mean multiples for the above comparable precedent transactions:

	LTM	CY	CY+1
<i>Precedent Transactions Harmonic Mean Multiples:</i>			
Enterprise Value/Revenue	2.0 x	2.1 x	2.0 x
Enterprise Value/EBITDA	6.9	6.1	5.9
Enterprise Value/EBITDA CapEx	11.9	9.2	10.6
<i>Radiologix at Market Multiples:</i>			
Enterprise Value/Revenue	0.7 x	0.7 x	0.7 x
Enterprise Value/EBITDA	4.0	3.9	5.1
Enterprise Value/EBITDA CapEx	12.7	5.9	8.7
<i>Radiologix at Deal Multiples: (Primedex at Current Price)</i>			
Enterprise Value/Revenue	0.8 x	0.8 x	0.8 x
Enterprise Value/EBITDA	4.7	4.5	5.9
Enterprise Value/EBITDA CapEx	14.8	6.9	10.1
<i>Radiologix at Deal Multiples: (Primedex at One Month Average)</i>			
Enterprise Value/Revenue	0.8 x	0.8 x	0.8 x
Enterprise Value/EBITDA	4.7	4.5	5.8
Enterprise Value/EBITDA CapEx	14.7	6.8	10.0

CY refers to the fiscal year in which the transaction was consummated. CY+1 refers to the fiscal year ending after the fiscal year in which the transaction was consummated.

Due to the negative effects of the DRA on Radiologix, Bear Stearns took into specific consideration, and focused more on the CY+1 multiples than on the LTM or CY multiples

Contribution Analysis. Bear Stearns performed a contribution analysis to assist the Radiologix board of directors in valuing Radiologix based on the relative contribution by each company to the combined pro forma entity. In performing the analysis, Bear Stearns used the financial projections and potential synergies provided to Bear Stearns by Radiologix and Primedex management. Bear Stearns calculated the

relative contribution by both Radiologix and Primedex to the combined entity with respect to the enterprise value and equity value based on the value of the merger consideration and Primedex's closing stock price as of June 30, 2006 and projected financial data including revenue, EBITDA, EBITDA - CapEx, EBIT and net income with and without giving effect to the potential synergies. Bear Stearns noted that this analysis assumes a hypothetical 100% stock transaction in lieu of the actual merger consideration.

The following tables illustrate the relative contribution to revenue, EBITDA, EBITDA - CapEx, EBIT and net income by both Radiologix and Primedex, without the potential synergies, to the combined company:

	% of Contribution	
	Primedex	Radiologix
Enterprise Value	54.4 %	45.6 %
Revenue		
2007E	40.7	59.3
2008E	41.1	58.9
2009E	41.6	58.4
EBITDA		
2007E	52.6	47.4
2008E	53.3	46.7
2009E	53.9	46.1
EBITDA - CapEx		
2007E	58.8	41.2
2008E	58.8	41.2
2009E	58.9	41.1
EBIT		
2007E	62.3	37.7
2008E	60.4	39.6
2009E	61.6	38.4
Equity Value	51.3 %	48.7 %
Net Income		
2007E	100.0	NM
2008E	100.0	NM
2009E	83.7	16.3

The following table illustrates the relative contribution to revenue, EBITDA, EBITDA CapEx, EBIT and net income by both Radiologix and Primedex, with the potential synergies, to the combined company:

	% of Contribution		Potential Synergies
	Primedex	Radiologix	
Enterprise Value	54.4 %	45.6 %	NA
Revenue			
2007E	40.7	59.3	NA
2008E	41.1	58.9	NA
2009E	41.6	58.4	NA
EBITDA			
2007E	51.8	46.6	1.6 %
2008E	46.9	41.1	12.0
2009E	47.7	40.9	11.4
EBITDA CapEx			
2007E	57.5	40.3	2.3
2008E	49.1	34.3	16.6
2009E	49.7	34.7	15.6
EBIT			
2007E	60.4	36.5	3.0
2008E	48.5	31.8	19.7
2009E	50.3	31.4	18.3
Equity Value	51.3 %	48.7 %	NA
Net Income			
2007E	89.0	0.0	11.0 %
2008E	59.1	0.0	40.9
2009E	59.8	11.6	28.6

Pro Forma Transaction Analysis. Bear Stearns performed a pro forma transaction analysis to assist the Radiologix board of directors in analyzing the financial impact of the transaction to the holders of Radiologix common stock based on the following, among other items:

- Primedex finances the merger consideration with \$42.95 million in cash and 22.6 million shares of newly issued Primedex stock;
- Primedex refinances substantially all of Radiologix's and Primedex's existing debt with a \$405 million credit facility underwritten by GE Healthcare Financial Services; and
- the financial projections and potential synergies provided to Bear Stearns by Primedex and Radiologix management.

The following table shows the projected per share accretion / (dilution) to Primedex pro forma earnings including the potential synergies:

	2007E	2008E	2009E
Accretion / (Dilution) to Primedex Earnings Per Share	\$ (0.12)	\$ 0.05	\$ 0.05

Miscellaneous. The preparation of a fairness opinion is a complex process and involves various judgments and determinations as to the most appropriate and relevant assumptions and financial analyses and the application of those methods to the particular circumstances involved. Such an opinion is therefore not readily susceptible to partial analysis or summary description, and taking portions of the analyses set out above, without considering the analysis as a whole, would in the view of Bear Stearns, create an incomplete and misleading picture of the processes underlying the analyses considered in rendering the Bear Stearns opinion. Bear Stearns based its analysis on assumptions that it deemed reasonable, including assumptions concerning general business and economic conditions and industry-specific factors. Bear Stearns did not form an opinion as to whether any individual analysis or factor, whether positive or negative, considered in isolation, supported or failed to support the Bear Stearns opinion. In arriving at its opinion, Bear Stearns considered the results of all its analyses and did not attribute any particular weight to any one analysis or factor. Bear Stearns arrived at its ultimate opinion based on the results of all analyses undertaken by it and assessed as a whole and believes that the totality of the factors considered and analyses performed by Bear Stearns in connection with its opinion operated collectively to support its determination as to the fairness of the merger consideration to be received by the stockholders of Radiologix. The analyses performed by Bear Stearns, particularly those based on estimates and projections, are not necessarily indicative of actual values or actual future results, which may be significantly more or less favorable than suggested by such analyses. None of the public companies used in the comparable companies analysis described above are identical to Radiologix, and none of the precedent transactions used in the precedent transactions analysis described above are identical to the merger. Accordingly, an analysis of publicly traded comparable companies and comparable precedent transactions is not mathematical; rather it involves complex considerations and judgments concerning the differences in financial and operating characteristics of the companies and precedent transactions and other factors that could affect the value of Radiologix and the public trading values of the companies and precedent transactions to which they were compared. The analyses do not purport to be appraisals or to reflect the prices at which any securities may trade at the present time or at any time in the future.

The Bear Stearns opinion was just one of the many factors taken into consideration by Radiologix's board of directors. Consequently, Bear Stearns' analysis should not be viewed as determinative of the decision of Radiologix's board of directors with respect to the fairness of the aggregate consideration to be received, from a financial point of view, by the stockholders of Radiologix.

Pursuant to the terms of Bear Stearns' engagement letter, Radiologix has agreed to pay Bear Stearns a transaction fee of 1.10% of the total aggregate value of the consideration paid to Radiologix stockholders in connection with the transaction contemplated by the merger agreement (or approximately \$2,200,000), a substantial portion of which is payable upon consummation of the transaction contemplated by the merger agreement. In addition, Radiologix has agreed to reimburse Bear Stearns for reasonable out-of-pocket expenses incurred by Bear Stearns in connection with its engagement and the transactions contemplated by the merger agreement, including reasonable fees and disbursements of its legal counsel. Radiologix has agreed to indemnify Bear Stearns against certain liabilities arising out of or in connection with Bear Stearns' engagement.

The inclusion of the Bear Stearns opinion in this proxy statement as *Annex C* to this proxy statement and the related disclosure in this section of the proxy statement titled "The Merger - Opinions of our Financial Advisors" are permitted under the engagement letter between Radiologix and Bear Stearns.

Bear Stearns may seek to provide Primedex, or its affiliates, investment banking and other services in the future, for which Bear Stearns would expect to receive customary fees. In the ordinary course of business, Bear Stearns and its affiliates may actively trade the equity and debt securities and/or bank debt of Radiologix and/or Primedex and their respective affiliates for its own account and for the accounts of its customers and, accordingly, may at any time hold a long or short position in such securities or bank debt.

Jefferies & Company, Inc.

Primedex engaged Jefferies & Company, Inc. to serve as Primedex's financial advisor in connection with the merger and to render an opinion to Primedex's board of directors as to the fairness, from a financial point of view, to Primedex of the aggregate merger consideration to be paid by Primedex pursuant to the merger. Jefferies is an internationally recognized investment banking and advisory firm. Jefferies, as part of its investment banking services, is regularly engaged in the valuation of businesses and their securities in connection with mergers and acquisitions, negotiated underwritings, competitive biddings, secondary distributions of listed and unlisted securities, private placements, financial restructurings and other financial services.

On July 6, 2006, Jefferies rendered to Primedex's board of directors its opinion as investment bankers to the effect that, as of that date and based upon and subject to the various considerations and assumptions set forth therein, the aggregate merger consideration of 22,621,922 shares of Primedex common stock and \$42.95 million in cash to be paid by Primedex pursuant to the merger was fair, from a financial point of view, to Primedex.

The full text of the Jefferies opinion, which sets forth the assumptions made, matters considered and limitations on the scope of review undertaken by Jefferies in rendering its opinion, is attached to this joint proxy statement/prospectus as *Annex D*. Primedex and its board of directors encourage Primedex shareholders to read the Jefferies opinion carefully and in its entirety. The summary of the Jefferies opinion in the joint proxy statement/prospectus is qualified in its entirety by reference to the full text of the Jefferies opinion. **The Jefferies opinion was provided to Primedex's board of directors in connection with its consideration of the merger and addresses only the fairness, from a financial point of view, to Primedex, as of the date of the Jefferies opinion, of the aggregate merger consideration of 22,621,922 shares of Primedex common stock and \$42.95 million in cash to be paid by Primedex, and does not address any other aspect of the merger. The Jefferies opinion does not constitute a recommendation as to how any Primedex stockholder should vote on the merger or any other matter.**

In connection with its opinion, Jefferies, among other things:

- reviewed a draft of the merger agreement dated as of July 5, 2006, which for purposes of its opinion, Jefferies assumed to be identical in all material respects to the definitive merger agreement;
- reviewed Primedex's and Radiologix's respective operations and prospects;
- reviewed certain financial and other information about Primedex and Radiologix that was publicly available;
- reviewed information concerning Primedex furnished by Primedex, including certain internal financial forecasts, financial analyses, budgets, reports and other information, as well as the amount and timing of the cost savings and related expenses and synergies expected to result from the merger (which are referred to as the expected synergies);
- reviewed information concerning Radiologix furnished by Radiologix, including certain internal financial forecasts, financial analyses, budgets, reports and other information, as well as financial forecasts of Radiologix that were prepared by the management of Primedex;
- held discussions with senior management of Primedex and Radiologix concerning historical and current operations, financial conditions and prospects, including recent financial performance, and the expected synergies;
- reviewed the share trading price histories of the Primedex common stock and the Radiologix common stock and certain publicly traded securities of such other companies which were deemed to be generally relevant for a period that Jefferies deemed appropriate;

- reviewed the valuation of Radiologix implied by the merger consideration;
- prepared discounted cash flow analyses of Radiologix on a standalone basis and of the expected synergies;
- compared the historical and projected financial performance of Primedex and Radiologix with those of certain publicly traded companies which Jefferies deemed to be generally relevant in evaluating Primedex and Radiologix;
- reviewed, to the extent publicly available, the financial terms of certain public transactions which Jefferies deemed to be generally relevant in evaluating the merger; and
- reviewed the premiums paid in selected acquisition transactions.

In addition, Jefferies conducted such other quantitative reviews, analyses and inquiries relating to Primedex and Radiologix as Jefferies considered appropriate in rendering its opinion.

In its review and analysis and in rendering its opinion, Jefferies assumed and relied upon, but did not assume any responsibility to independently investigate or verify, the accuracy, completeness and fair presentation of all financial and other information that was provided to Jefferies by Primedex or Radiologix or that was publicly available (including, without limitation, the information described above), or that was otherwise reviewed by Jefferies. The Jefferies opinion was expressly conditioned upon that information, whether written or oral, being complete, accurate and fair in all respects material to Jefferies' analysis.

With respect to the financial forecasts and the expected synergies provided to and examined by Jefferies, Jefferies noted that projecting future results of any company is inherently subject to uncertainty. Primedex informed Jefferies, however, and Jefferies assumed, that those financial forecasts and the expected synergies were reasonably prepared on bases reflecting the best currently available estimates and good faith judgments of the management of Primedex as to the future performance of Primedex and Radiologix, respectively, and the expected synergies. Jefferies expressed no opinion as to any financial forecasts, the expected synergies or the assumptions on which they were made.

Accordingly, Jefferies' analyses must be considered as a whole. Considering any portion of such analyses or the factors considered, without considering all analyses and factors, could create a misleading or incomplete view of the process underlying the conclusions expressed herein. Jefferies expressly disclaimed any undertaking or obligation to advise any person of any change in any fact or matter affecting its opinion of which Jefferies became aware after the date of its opinion.

In its review, Jefferies did not obtain any independent evaluation or appraisal of the assets or liabilities of, nor did it conduct a comprehensive physical inspection of any of the assets of, Primedex or Radiologix, nor did Jefferies assume any responsibility to obtain any such evaluations, appraisals or inspections. The Jefferies opinion was based on economic, monetary, regulatory, market and other conditions existing and which could be evaluated as of the date of its opinion. Jefferies made no independent investigation of any legal or accounting matters affecting Primedex or Radiologix, and Jefferies assumed the correctness in all respects material to its analysis of all legal and accounting advice given to Primedex and its board of directors, including, without limitation, advice as to the legal, accounting and tax consequences of the terms of, and transactions contemplated by, the merger agreement to Primedex and its stockholders. In addition, in preparing its opinion Jefferies did not take into account any tax consequences of the transaction to Primedex or Radiologix or any of their respective stockholders.

In rendering its opinion, Jefferies also assumed that:

- the transactions contemplated by the merger agreement will be consummated on the terms described in the merger agreement without any waiver of any material terms or conditions;

- there was not, and there will not as a result of the consummation of the transactions contemplated by the merger agreement be, any default, or event of default, under any indenture, credit agreement or other material agreement or instrument to which Primedex or Radiologix or any of their respective subsidiaries or affiliates is a party; and
- all material assets and liabilities (contingent or otherwise, known or unknown) of Primedex and Radiologix were as set forth in the consolidated financial statements provided to Jefferies, as of the dates of such financial statements.

The Jefferies opinion was for the use and benefit of Primedex's board of directors in its consideration of the merger, and did not address the relative merits of the merger as compared to any alternative transactions that might be available to Primedex, nor did it address the underlying business decision by Primedex to engage in the merger or the terms of the merger agreement or the documents referred to therein. Jefferies expressed no opinion as to the price at which shares of Primedex common stock will trade at any future time.

In preparing its opinion, Jefferies performed a variety of financial and comparative analyses. The preparation of a fairness opinion is a complex process involving various determinations as to the most appropriate and relevant quantitative and qualitative methods of financial analysis and the applications of those methods to the particular circumstances and, therefore, is not necessarily susceptible to partial analysis or summary description. Jefferies believes that its analyses must be considered as a whole. Considering any portion of Jefferies' analyses or the factors considered by Jefferies, without considering all analyses and factors, could create a misleading or incomplete view of the process underlying the conclusion expressed in the Jefferies opinion. In addition, Jefferies may have given various analyses more or less weight than other analyses, and may have deemed various assumptions more or less probable than other assumptions, so that the range of valuation resulting from any particular analysis described below should not be taken to be Jefferies' view of Primedex's or Radiologix's actual value. Accordingly, the conclusions reached by Jefferies are based on all analyses and factors taken as a whole and also on the application of Jefferies' own experience and judgment.

In performing its analyses, Jefferies made numerous assumptions with respect to industry performance, general business and economic conditions and other matters, many of which are beyond Jefferies', Primedex's and Radiologix's control. The analyses performed by Jefferies are not necessarily indicative of actual values or actual future results, which may be significantly more or less favorable than those suggested by those analyses. In addition, analyses relating to the value of businesses or assets do not purport to be appraisals or to necessarily reflect the prices at which businesses or assets may actually be sold and are inherently subject to uncertainty. The analyses performed were prepared solely as part of Jefferies' analysis of the fairness, from a financial point of view, to Primedex of the merger consideration and were provided to Primedex's board of directors in connection with the delivery of its opinion.

The following is a summary of the material financial and comparative analyses performed by Jefferies that were presented to the Primedex board of directors on July 6, 2006 in connection with the delivery of its opinion. The financial analyses summarized below include information presented in tabular format. In order to fully understand Jefferies' financial analyses, the tables must be read together with the text of each summary. The tables alone do not constitute a complete description of the financial analyses. Considering the data described below without considering the full narrative description of the financial analyses, including the methodologies and assumptions underlying the analyses, could create a misleading or incomplete view of Jefferies' financial analyses.

Transaction Overview. Based upon the closing price per share of Primedex common stock on July 5, 2006 of \$1.71, Jefferies noted that the aggregate implied value of the consideration to be paid in the merger, including the \$42.95 million in cash, was approximately \$81.65 million, or approximately \$80.4 million excluding estimated amounts payable to Radiologix option holders, which is referred to as

the implied aggregate consideration value. Based upon the implied aggregate consideration value, approximately 22.6 million shares of Radiologix common stock outstanding as of March 31, 2006 (based on the number of shares outstanding as set forth in Radiologix's filing with the SEC on Form 10-Q for the fiscal quarter ended March 31, 2006 plus the number of shares of restricted stock outstanding as provided by Radiologix management), Jefferies noted that the implied value of the consideration to be paid in the merger per share of Radiologix common stock as of that date was approximately \$3.55, which is referred to as the implied per share consideration value. Jefferies noted that the actual value of the merger consideration to be received in the merger per share of Radiologix common stock would depend upon the price per share of Primedex common stock and the number of in-the-money Radiologix options as of the effective time of the merger.

Jefferies compared the implied per share consideration value of \$3.55 to the average daily closing prices for Radiologix common stock and noted the following implied offer premia:

Implied Offer Premia

Time Period Ending July 5, 2006	Radiologix	Premium Implied by	
	Common Stock Price	Implied Per Share Consideration Value Dollars	Percentage
1 day	\$ 2.25	\$ 1.30	57.9 %
1 week	\$ 2.34	\$ 1.21	51.8 %
4 weeks	\$ 2.14	\$ 1.41	66.0 %

Historical Trading Analysis. Jefferies reviewed the share price trading history of the Radiologix common stock for the one-year period ending on July 5, 2006 on a stand-alone basis and also in relation to Primedex, Alliance Imaging Inc. and the Morgan Stanley Healthcare Providers index. During this period, Jefferies noted that the Radiologix common stock traded as low as \$1.40 per share and as high as \$4.55 per share, compared to the closing price of Radiologix common stock on July 5, 2006 of \$2.25 per share and the implied per share consideration value of \$3.55.

Comparable Company Analysis. Using publicly available information and information provided by Radiologix and Primedex management, Jefferies reviewed the trading multiples of Radiologix and the corresponding trading multiples of a group consisting of the following companies:

- Alliance Imaging Inc., and
- Primedex.

In its analysis, Jefferies derived and compared multiples for Radiologix and the selected companies, calculated as follows:

- the enterprise value divided by estimated earnings before interest, taxes, depreciation and amortization, or EBITDA, for calendar year 2007, which is referred to as Enterprise Value/2007E EBITDA.
- the enterprise value divided by estimated EBITDA for calendar year 2006, which is referred to as Enterprise Value/2006E EBITDA, and
- the enterprise value divided by estimated EBITDA for the latest-twelve-month period, or LTM, which is referred to as Enterprise Value/LTM EBITDA.

This analysis indicated the following:

Comparable Public Company Multiples

Benchmark	High	Low	Radiologix*	Primedex**
Enterprise Value/2007E EBITDA	6.2x	5.6x	5.2x	6.2x
Enterprise Value/2006E EBITDA	6.9x	5.7x	3.7x	6.9x
Enterprise Value/LTM EBITDA	7.4x	5.6x	3.8x	7.4x

* Based upon Primedex management projections for Radiologix.

** Based upon Primedex management projections.

Using a reference range of 5.6x to 6.2x Radiologix's estimated 2007 EBITDA, 5.7x to 6.9x Radiologix's estimated 2006 EBITDA and 5.6x to 7.4x Radiologix's LTM EBITDA, Jefferies determined an implied enterprise value for Radiologix. Jefferies then subtracted debt from and added cash to the implied enterprise value to determine an implied equity value, and after accounting for the vesting of in-the-money options and amounts payable to Radiologix optionholders, and the present value of the expected synergies of up to approximately \$44.1 million, calculated as discussed below, this analysis indicated a range of implied Radiologix equity values of approximately \$64.1 million to \$128.3 million using the 2007E EBITDA multiples, approximately \$135.2 million to \$232.7 million using the 2006E EBITDA multiples, and approximately \$127.0 million to \$244.5 million using LTM EBITDA multiples, in each case compared to the implied aggregate consideration value of \$80.4 million.

No company utilized in the comparable company analysis is identical to Radiologix. In evaluating selected companies, Jefferies made judgments and assumptions with regard to industry performance, general business, economic, market and financial conditions and other matters, many of which are beyond Radiologix's and Jefferies' control. Jefferies does not believe that mathematical analysis, such as determining the mean or median, is in itself a meaningful method of using comparable company data.

Synergies Analysis. Jefferies performed an analysis of the present value of the expected synergies projected by the management of Primedex to be realized from the merger. Based upon the expected synergies provided by Primedex management, Jefferies calculated a terminal value of the expected synergies at December 31, 2010 by applying an exit multiple of 6.0x to the expected synergies in that year. The present value of the expected synergies for 2006 through 2010 and the terminal value was then calculated using a discount rate of 13.1%. This analysis resulted in a net present value for the expected synergies of up to approximately \$44.1 million.

Selected Comparable Transaction Analysis. Using publicly available information, Jefferies examined the following fifteen transactions in the diagnostic imaging sector. The transactions considered and the month and year each transaction was announced were as follows:

Buyer	Target	Month and Year Announced
Alliance Imaging	PET Scans of America	October 2005
Evercore Partners (65% interest)	Diagnostic Imaging Group	April 2005
Onex Partners	Center for Diagnostic Imaging	October 2004
InSight Health Services	Comprehensive Medical Imaging (21 fixed sites)	April 2004
InSight Health Services	CDL Medical (22 mobile sites)	June 2003
Trivest Partners	Regional Diagnostics	May 2003
Advent International Corp	American Radiology Services	March 2003
InSight Health Services	Comprehensive Medical Imaging (13 fixed sites)	January 2003
Presgar Medical Imaging	US Diagnostic	September 2002
CapStreet Group, Wachovia Capital Partners	River Oaks Imaging and Diagnostic	September 2002
JPMorgan Partners	MedQuest Associates	August 2002
Halifax Group, J.W. Childs Associates	InSight Health Services	July 2001
Comprehensive Medical Imaging	US Diagnostic (14 imaging centers)	July 2000
InSight Health Services	Wilkes-Barre Imaging Center	May 2000
Kohlberg Kravis Roberts & Co.	Alliance Imaging	September 1999

Using publicly available estimates and other information for each of these transactions, Jefferies reviewed the transaction value as a multiple of the target company's LTM EBITDA immediately preceding announcement of the transaction, which is referred to below as Transaction Value/LTM EBITDA. This analysis indicated the following:

Benchmark	Selected Comparable Transaction Multiples			
	High	Low	Median	Mean
Transaction Value/LTM EBITDA	7.5x	4.2x	5.3x	5.8x

Jefferies used a reference range of 4.2x to 7.5x Radiologix's LTM EBITDA to determine an implied enterprise value for Radiologix. Jefferies then subtracted debt from and added cash to the implied enterprise value to determine an implied equity value, and after accounting for the vesting of in-the-money options and amounts payable to Radiologix optionholders and the present value of the expected synergies calculated as discussed above, this analysis indicated a range of implied Radiologix equity values of approximately \$67.4 million to \$252.3 million, compared to the implied aggregate consideration value of \$80.4 million.

No transaction utilized as a comparison in the comparable transaction analysis is identical to the merger. In evaluating the merger, Jefferies made numerous judgments and assumptions with regard to industry performance, general business, economic, market, and financial conditions and other matters, many of which are beyond Radiologix's and Jefferies' control. Jefferies does not believe that mathematical analysis, such as determining the mean or median, is in itself a meaningful method of using comparable transaction data.

Discounted Cash Flow Analysis. Jefferies performed a discounted cash flow analysis to calculate the estimated present value of the free cash flows of Radiologix through the fiscal year ending

December 31, 2010 using Primedex management's financial forecasts for Radiologix. Jefferies also calculated the terminal value of the enterprise at December 31, 2010 by applying a range of EBITDA exit multiples from 5.5x to 6.5x to Radiologix's 2010 estimated EBITDA. The present value of the cash flows and terminal value was calculated using discount rates ranging from 12.0% to 14.0%. Jefferies then subtracted debt from and added cash to the implied enterprise value to determine an implied equity value, and after accounting for the vesting of in-the-money options and amounts payable to Radiologix optionholders and the present value of the expected synergies calculated as described above, this analysis indicated a range of implied Radiologix equity values of \$34.5 million to \$116.3 million, compared to the implied aggregate consideration value of \$80.4 million.

Premiums Paid Analysis. Using publicly available information, Jefferies analyzed the premia offered in 48 public merger and acquisition transactions in the healthcare industry announced between June 14, 2000 and June 14, 2006 with enterprise values at announcement between \$100 million and \$500 million. For each of these transactions, Jefferies calculated the premium represented by the offer price over the target company's closing share price one day, one week, and four weeks prior to the transaction's announcement, and then applied the mean premium to Radiologix's share price for the same period to calculate a mean implied price per share of Radiologix common stock.

This analysis indicated the following:

Time Period:	Mean
1 Day Prior to Announcement	30.4 %
1 Week Prior to Announcement	35.0 %
4 Weeks Prior to Announcement	39.9 %

Using a reference range of a premium of 30% to 40% over the target company's share price, the price per share of Radiologix common stock on July 5, 2006 and the fully diluted number of shares of Radiologix common stock outstanding as of that date (calculated using the treasury stock method), this analysis indicated a range of implied Radiologix equity values of approximately \$65.6 million to \$70.6 million, compared to the aggregate implied consideration value of \$80.4 million.

Accretion/Dilution Analysis. Jefferies analyzed certain pro forma effects resulting from the merger, including the potential impact of the merger on earnings per share, or EPS, of Primedex common stock following the merger. Jefferies analyzed Primedex's and Radiologix's diluted EPS for 2006 through 2008. Jefferies' analysis included assumptions regarding, among other matters, various tax and accounting considerations, the estimated allocation of the purchase price to goodwill and amortizable intangible assets and the achievement of the expected synergies in the amounts and at the times projected based on discussions with Primedex management.

The following table shows the projected accretion / (dilution) to Primedex's pro forma diluted EPS:

	2006E	2007E	2008E
Accretion/(Dilution) to Primedex diluted EPS	\$ (0.03)	\$ (0.06)	\$ 0.03

The Jefferies opinion was one of many factors taken into consideration by Primedex's board of directors in making its determination to approve the merger and should not be considered determinative of the views of the Primedex board of directors or management with respect to the merger or the merger consideration.

Jefferies and its affiliates may trade or hold securities of Primedex or Radiologix for its own account and for the accounts of its customers and, accordingly, may at any time hold long or short positions in those securities. In addition, Jefferies has in the past provided financing services to Radiologix and may seek in the future to provide investment banking, financial advisory or financial services to Primedex,

Radiologix or other entities that are affiliated with Primedex or Radiologix, for which Jefferies would expect to receive compensation.

Pursuant to an engagement letter between Primedex and Jefferies, dated May 9, 2006, Primedex agreed to pay Jefferies for its services in connection with the merger a fee of \$2,000,000, of which \$500,000 was paid upon delivery of its opinion and the balance of which is payable contingent upon consummation of the merger. Jefferies will also be reimbursed for reasonable expenses incurred, including the fees and disbursements of its counsel. Primedex has also agreed to indemnify Jefferies against liabilities arising out of or in connection with the services rendered or to be rendered by it under its engagement.

Interests of Radiologix Directors and Executive Officers in the Merger

Radiologix's executive officers and members of the Radiologix board of directors, in their capacities as such, may have financial interests in the merger that are in addition to or different from their interests as stockholders of Radiologix generally. Radiologix's board of directors was aware of these interests and considered them, among other matters, in approving the merger agreement and the transactions contemplated thereby. These other interests include the following, among others:

- payments under employment agreements which are triggered in the event of a merger;
- potential appointment to the Primedex board of directors following the merger;
- potentially becoming executive officers, employees or consultants of Primedex after the transaction;
- accelerated vesting and exercisability of Radiologix stock options and accelerated vesting of restricted stock and restricted stock units issued under Radiologix's equity compensation plans;
- with respect to certain Radiologix officers and employees who continue employment with Primedex immediately after the effective date of the merger, to the extent the closing of the merger occurs during the 2006 calendar year, continued benefits under Radiologix plans until December 31, 2006, and to the extent the closing of the merger occurs after the 2006 calendar year, continued benefits under Radiologix plans for six months after the closing or the end of the calendar year in which the closing of the merger occurs, whichever is earlier;
- with respect to the Radiologix officers and directors who do not continue employment with Primedex immediately after the effective date of the merger, payment of up to \$1,000 per month to cover the medical insurance benefits described in such officer's employment agreement until the earlier of (a) two years after the effective date of the merger or (b) the date on which such individual obtains substantially equivalent benefits from another party; and
- Primedex's agreement to indemnify each present and former Radiologix officer and director against liabilities arising out of that person's services as an officer or director, and maintain directors' and officers' liability insurance for a period of six years after closing to cover Radiologix directors and officers, subject to various limitations.

More detailed information about interests of Radiologix Directors and Executive Officers in the merger is available in the section of this joint proxy statement/prospectus titled "The Merger: Employment, Change of Control and Severance Agreements," which begins on page 127.

Primedex Board of Directors After the Merger

The directors of Primedex immediately prior to the merger will continue as directors immediately after the effective date of the merger. Promptly after the effective date of the merger, Primedex shall use its reasonable best efforts to cause to be elected to its board of directors up to three persons designated by Radiologix and reasonably acceptable to Primedex, two of whom shall, no later than January 1, 2007, meet

the independence requirements of the SEC and any applicable exchange on which Primedex's common stock is then traded.

Employment, Change of Control and Severance Agreements

Under the merger agreement, Radiologix may not enter into employment agreements or agree to employment agreement extensions, subject to certain limitations. However, the consummation of the merger or any termination of employment or service in connection therewith or subsequent thereto will result in (i) payments to certain holders of Radiologix's Options as contemplated by the merger agreement, (ii) severance and retention payments as described below, (iii) settlement payments to Sami S. Abbasi, Michael N. Murdock, and Michael L. Silhol, and (iv) deferred portions of 2005 bonuses becoming due to the following individuals in the following amounts:

Sami Abbasi	\$ 175,000
Michael Murdock	\$ 62,500
Stephen Forthuber	\$ 57,500
Michael Silhol	\$ 56,250
Nancy Brandon Murr	\$ 30,000

Employment Agreements

Radiologix has employment agreements with Messrs. Abbasi, Murdock and Silhol, each of whom receives annual base salaries at the rate of \$500,000, \$250,000, and \$225,000, respectively. Each executive is eligible to participate in any bonus or incentive compensation plan that Radiologix may make available to its executive officers. Mr. Abbasi's employment agreement has a four-year term, with automatic successive one-year renewals unless Mr. Abbasi or Radiologix gives notice to the contrary. Mr. Abbasi's employment agreement contains a covenant not to compete with Radiologix for two years following termination of employment. The employment agreements of Messrs. Murdock and Silhol contain covenants not to compete for one year following termination of employment.

Pursuant to his employment agreement, in 2004 Mr. Abbasi was awarded 300,000 restricted shares of Common Stock and options to purchase 500,000 shares of Common Stock. In connection with the commencement of their employment with Radiologix in March 2004 and February 2005, respectively, Messrs. Silhol and Murdock were granted options to acquire 100,000 shares and 200,000 shares of Common Stock, respectively. For additional information on the awards to Messrs. Abbasi, Murdock and Silhol, see Security Ownership of Certain Beneficial Owners and Management, notes 3, 8 and 10.

Mr. Abbasi's employment agreement provides that Radiologix will pay him a lump sum severance payment in an amount equal to two times his then current salary if his employment terminates due to Disability, without Cause, a material default by Radiologix, or an Adverse Change in Duties (as those terms are defined in the employment agreement). Mr. Abbasi will also receive two times his most recent bonus or next targeted bonus, whichever is less. The employment agreements of Messrs. Murdock and Silhol provide that Radiologix will pay the executive a lump sum severance payment in an amount equal to the executive's then current salary if the executive's employment terminates for the same reasons specified in Mr. Abbasi's employment agreement.

Change of Control Agreements

Radiologix's employment agreements with its executive officers contain change of control provisions.

Mr. Abbasi's employment agreement provides that if his employment with Radiologix is terminated in connection with a Change of Control (i) by Radiologix, except for Cause, or (ii) by Mr. Abbasi with Good Reason (as those terms are defined in the employment agreements), then Radiologix will make a lump

sum severance payment to him. The amount of severance to be paid is 2.99 times the sum of his annual base salary plus 2.99 times his most recent annual bonus (or 60% of the executive's then current salary in lieu of the most recent bonus). Radiologix will provide 24 months of benefits, other than medical insurance. Medical benefits will be provided until the earlier of 18 months after the effective date of termination or until Mr. Abbasi obtains substantially equivalent benefits from another party. If the severance payments are subject to excise tax, then Radiologix will pay the executive an additional amount to cover the tax.

The employment agreements of Messrs. Murdock and Silhol generally provide that if their employment with Radiologix is terminated in connection with a Change of Control (i) by Radiologix, except for Cause, or (ii) by them with Good Cause (as those terms are defined in the employment agreements), then Radiologix will make a lump sum severance payment to them in the amount of two times the executives' current annual salary and two times their most recent annual bonus. Radiologix will provide health care and other insurance until the earlier of 24 months from date of termination or until the executives obtain substantially equivalent benefits from another party.

Settlement Payments to Executive Officers

Specifically, under the merger agreement, Sami S. Abbasi, Michael M. Murdock, and Michael L. Silhol will be paid the amounts set forth below in full and final settlement of Radiologix's obligations to them as a result of a Change of Control (as defined in their employment agreements) and (ii) their employment agreements shall automatically terminate and be cancelled effective as of the closing date of the merger except for non-competition covenants and Radiologix's obligation to pay some of the taxes Mr. Abbasi may owe as a result of this payment to him. The amount for each individual set forth below is in addition to the amount payable to him as a 2005 bonus that is disclosed above, the amount to be received by each as a result of the exercise of stock options, and the merger consideration to be received by each with respect to Radiologix common stock. Under the merger agreement Primedex shall, or shall continue to provide each such individual not employed by Primedex after the closing of the merger with up to \$1,000 per month to cover the medical insurance benefits described in their respective employment agreement until the earlier of (A) two years after the closing date of the merger or (B) the date on which the individual obtains substantially equivalent benefits from another party.

Sami S. Abbasi	\$2,392,000
Michael N. Murdock	\$750,000
Michael L. Silhol	\$675,000

Equity-Based Awards

Under the merger agreement, Radiologix may not grant, amend or change the terms of any equity awards of Radiologix stock options or restricted stock, or accelerate or change the period of exercisability or vesting of any Radiologix stock options or restricted stock or authorize cash payments in exchange for any Radiologix stock options or restricted stock, except that Radiologix may grant stock options to purchase up to an aggregate of 100,000 shares of Radiologix common stock in the ordinary course of business to newly hired employees, provided that no one person may be granted Radiologix stock options to purchase more than 20,000 shares of Radiologix common stock.

Radiologix Stock Options

Holders of unvested options exercisable for Radiologix common stock will become vested in their options as a result of the merger. Holders of options for Radiologix common stock, whose exercise price per share is less than the value of the per share merger consideration, will receive for each share subject to such options an amount in cash out of the aggregate merger consideration equal to the difference between

the value of the per share merger consideration and the exercise price per share of their options. Options exercisable for Radiologix common stock with an exercise price per share that is greater than the value of the per share merger consideration shall not be assumed or substituted by Primedex but shall vest upon the effective date of the merger and become fully exercisable to the holder of such option pursuant to the terms of the applicable option agreement. All other options will be cancelled.

Unvested Shares of Radiologix Common Stock

Immediately prior to the effective time of the merger, Radiologix will have cancelled, repurchased, accelerated, vested or otherwise extinguished or awarded all shares of Radiologix common stock that are restricted, not fully vested or subject to any other restriction and there will be no remaining unvested shares of Radiologix common stock at the effective time of the merger.

The following table lists, with respect to the named executive officers, all of Radiologix's executive officers as a group, and all of Radiologix's non-management directors as a group, the number of (i) unvested options to purchase Radiologix common stock, along with the weighted average exercise price of such options, and (ii) restricted shares of Radiologix common stock and restricted stock units, all of which will become vested as a result of either the approval of the merger agreement by Radiologix's stockholders or the consummation of the merger. The information shown on this table is based on the equity awards outstanding as of October 6, 2006.

	Unvested Options to Purchase Common Stock of Radiologix	Weighted Average Price of Unvested Options	Restricted Shares	Restricted Stock Units
Executive Officers, as a group	846,841	\$ 3.15/share	200,000	n/a
Non-Management Directors, as a group	n/a	n/a	n/a	179,505

Retirement Benefits; Profit Sharing Plan; Welfare Benefit Plan

Under the merger agreement, Radiologix shall terminate the Radiologix 401(k) and Profit Sharing Plan, effective no later than the day immediately preceding the effective time of the merger.

Under the merger agreement, Radiologix shall terminate the Radiologix Welfare Benefits Plan no earlier than December 31, 2006. With respect to such Radiologix officers and employees who continue employment after the effective date of the merger, to the extent the closing of the merger occurs during the 2006 calendar year, Primedex will provide continued benefits under Radiologix plans until December 31, 2006, and to the extent the closing of the merger occurs after the 2006 calendar year, Primedex will provide continued benefits under Radiologix plans for six months after the closing or the end of the calendar year in which the closing of the merger occurs, whichever is earlier. With respect to the Radiologix executive officers who do not continue employment with Primedex immediately after the effective date of the merger, Primedex will provide payment of up to \$1,000 per month to cover the medical insurance benefits described in such officer's employment agreement until the earlier of (a) two years after the effective date of the merger or (b) the date on which such individual obtains substantially equivalent benefits from another party.

Financing of the Merger

Primedex has signed a commitment letter with GE Commercial Finance Healthcare Financial Services for a \$405 million senior secured credit facility. The facility will be used to finance the merger, to refinance existing indebtedness, to pay transaction costs and expenses relating to the merger and the credit facility and to provide financing for working capital needs post-merger. Consummation of the financing is a condition to the closing of the merger. The facility will consist of a revolving credit facility of up to \$45

million, a \$225 million term loan and a \$135 million second lien term loan. The revolving credit facility will have a term of five years, the term loan will have a term of six years and the second lien term loan will have a term of seven years. Interest is payable on all loans initially at an Index Rate plus the Applicable Margin, as defined. The Index Rate is initially a floating rate equal to the higher of the rate quoted from time to time by The Wall Street Journal as the base rate on corporate loans posted by at least 75% of the nation's largest 30 banks or the Federal Funds Rate plus 50 basis points. The Applicable Margin on each of the revolving credit facility and the term loan is 2% and on the second lien term loan is 6%. Primedex may, after a certain period, request that the interest rate instead be based on LIBOR plus the Applicable Margin, as defined. It is anticipated that the credit facility will include customary covenants for a facility of this type, including minimum fixed charge coverage ratio, maximum total leverage ratio, maximum senior leverage ratio, limitations on indebtedness, contingent obligations, liens, capital expenditures, lease obligations, mergers and acquisitions, asset sales, dividends and distributions, redemption or repurchase of equity interests, subordinated debt payments and modifications, loans and investments, transactions with affiliates, changes of control, and payment of consulting and management fees. The credit facility will contain such conditions to funding as are customary for senior secured facilities of this type.

Accounting Treatment

The merger will be accounted for as a business combination using the purchase method of accounting. Primedex will be the acquirer for financial accounting purposes.

Appraisal and Dissenters' Rights

Appraisal Rights of Radiologix Stockholders

Delaware General Corporation Law. Holders of record of Radiologix common stock who do not vote in favor of adopting the merger agreement and the transactions contemplated by the merger agreement, including the merger, and who otherwise comply with the applicable provisions of Section 262 of the Delaware General Corporation Law, throughout this joint proxy statement/prospectus as the DGCL, will be entitled to exercise appraisal rights under Section 262 of the DGCL. A person having a beneficial interest in shares of Radiologix common stock held of record in the name of another person, such as a broker, bank or other nominee, must act promptly to cause the record holder to follow the steps summarized below properly and in a timely manner to perfect appraisal rights.

The following discussion is not a complete statement of the law pertaining to appraisal rights under the DGCL and is qualified in its entirety by the full text of Section 262 of the DGCL, which is reprinted in its entirety as Annex F and incorporated into this joint proxy statement/prospectus by reference. All references in Section 262 of the DGCL and in this summary to a shareholder, stockholder or holder are to the record holder of the shares of Radiologix common stock as to which appraisal rights are asserted.

Under Section 262 of the DGCL, holders of shares of Radiologix common stock who follow the procedures set forth in Section 262 of the DGCL will be entitled to have their Radiologix common stock appraised by the Delaware Court of Chancery and to receive payment in cash of the fair value of these shares of Radiologix common stock, exclusive of any element of value arising from the accomplishment or expectation of the merger, together with a fair rate of interest, if any, as determined by that court.

Under Section 262 of the DGCL, when a proposed merger is to be submitted for approval at a meeting of stockholders, as in the case of the approval of the merger agreement and the transactions contemplated by the merger agreement, including the merger, by Radiologix stockholders, Primedex, not less than 20 days prior to the meeting, must notify each of its stockholders who was a stockholder on the record date for this meeting with respect to shares for which appraisal rights are available, that appraisal rights are so available, and must include in this required notice a copy of Section 262 of the DGCL.

This joint proxy statement/prospectus constitutes the required notice to the holders of these shares of Radiologix common stock and the applicable statutory provisions of the DGCL are attached to this joint proxy statement/prospectus as *Annex F*. Any Radiologix stockholder who wishes to exercise their appraisal rights or who wishes to preserve their right to do so should review the following discussion and *Annex F* carefully, because failure to timely and properly comply with the procedures specified in *Annex F* will result in the loss of appraisal rights under the DGCL.

A holder of Radiologix common stock wishing to exercise appraisal rights must not vote in favor of the approval and adoption of the merger agreement and must deliver to Radiologix before the taking of the vote on the merger agreement and the transactions contemplated by the merger agreement, including the merger, at the Radiologix special meeting a written demand for appraisal of their Radiologix common stock. This written demand for appraisal must be separate from any proxy or vote abstaining from the vote on the merger or against the merger. This demand must reasonably inform Radiologix of the identity of the stockholder and of the stockholder's intent thereby to demand appraisal of their shares. A holder of Radiologix common stock wishing to exercise appraisal rights must be the record holder of these shares of Radiologix common stock on the date the written demand for appraisal is made and must continue to hold these shares of Radiologix common stock through the effective date of the merger. Accordingly, a holder of Radiologix common stock who is the record holder of Radiologix common stock on the date the written demand for appraisal is made, but who thereafter transfers these shares of Radiologix common stock prior to consummation of the merger, will lose any right to appraisal in respect of these shares of Radiologix common stock.

A proxy that is signed and does not contain voting instructions will, unless revoked, be voted in favor of the approval and adoption of the merger agreement and the transactions contemplated by the merger agreement, including the merger, and it will constitute a waiver of the stockholder's right of appraisal and will nullify any previously delivered written demand for appraisal. Therefore, a stockholder who votes by proxy and who wishes to exercise appraisal rights must vote against the approval and adoption of the merger agreement and the transactions contemplated by the merger agreement, including the merger, or abstain from voting on the merger agreement.

Only a holder of record of Radiologix common stock on the record date for the Radiologix special meeting is entitled to assert appraisal rights for the shares of Radiologix common stock registered in that holder's name. A demand for appraisal should be executed by or on behalf of the holder of record, fully and correctly, as the holder's name appears on the holder's stock certificates, should specify the holder's mailing address and the number of shares registered in the holder's name, and must state that the person intends to demand appraisal of the holder's shares pursuant to the merger agreement. If the shares of Radiologix common stock are held of record in a fiduciary capacity, such as by a trustee, guardian or custodian, execution of the demand should be made in that capacity, and if the Radiologix common stock is held of record by more than one holder as in a joint tenancy or tenancy in common, the demand should be executed by or on behalf of all joint holders. An authorized agent, including an agent for one or more joint holders, Radiologix may execute a demand for appraisal on behalf of a holder of record. The agent, however, must identify the record holder or holders and expressly disclose the fact that, in executing the demand, the agent is acting as agent for the holder or holders. A record holder such as a broker who holds Radiologix common stock as nominee for several beneficial owners may exercise appraisal rights with respect to the shares of Radiologix common stock held for one or more beneficial owners while not

exercising appraisal rights with respect to the Radiologix common stock held for other beneficial owners. In this case, the written demand should set forth the number of shares of Radiologix common stock as to which appraisal is sought. When no number of shares of Radiologix common stock is expressly mentioned, the demand will be presumed to cover all Radiologix common stock in brokerage accounts or other nominee forms held by such record holder, and those who hold shares in brokerage accounts or other nominee forms and who wish to exercise appraisal rights under Section 262 of the DGCL are urged to consult with their brokers to determine the appropriate procedures for the making of a demand for appraisal by such a nominee.

All written demands for appraisal should be sent or delivered to Radiologix, Inc., 3600 JPMorgan Chase Tower, 2200 Ross Avenue, Dallas, Texas, 75201, Attention: General Counsel.

Within ten days after the effective date of the merger, PR Acquisition Corporation, or its successor in interest, which we refer to as the surviving company, will notify each former Radiologix stockholder who has properly asserted appraisal rights under Section 262 of the DGCL and has not voted in favor of adopting the merger agreement and the transactions contemplated by the merger agreement, including the merger, of the date the merger became effective.

Within 120 days after the effective date of the merger, but not thereafter, the surviving company or any former Radiologix stockholder who has complied with the statutory requirements summarized above may file a petition in the Delaware Court of Chancery demanding a determination of the fair value of the shares of Radiologix common stock that are entitled to appraisal rights. None of Primedex, the surviving company or Radiologix is under any obligation to and none of them has any present intention to file a petition with respect to the appraisal of the fair value of the shares of Radiologix common stock. Accordingly, it is the obligation of Radiologix stockholders wishing to assert appraisal rights to take all necessary action to perfect and maintain their appraisal rights within the time prescribed in Section 262 of the DGCL.

Within 120 days after the effective date of the merger, any former Radiologix stockholder who has complied with the requirements for exercise of appraisal rights will be entitled, upon written request, to receive from the surviving company a statement setting forth the aggregate number of shares of Radiologix common stock not voted in favor of adopting the merger agreement and the transactions contemplated by the merger agreement, including the merger, and with respect to which demands for appraisal have been timely received and the aggregate number of former holders of these shares of Radiologix common stock. These statements must be mailed within ten days after a written request therefore has been received by the surviving company or within 10 days after expiration of the period for delivery of demands for appraisal under Section 262 of the DGCL, whichever is later.

If a petition for an appraisal is filed timely with the Delaware Court of Chancery by a former Radiologix stockholder and a copy thereof is served upon the surviving company, the surviving company will then be obligated within 20 days of service to file with the Delaware Register in Chancery a duly certified list containing the names and addresses of all former Radiologix stockholders who have demanded appraisal of their shares of Radiologix common stock and with whom agreements as to value have not been reached. After notice to such former Radiologix stockholders as required by the Delaware Court of Chancery, the Delaware Court of Chancery may conduct a hearing on such petition to determine those former Radiologix stockholders who have complied with Section 262 of the DGCL and who have become entitled to appraisal rights thereunder. The Delaware Court of Chancery may require the former Radiologix stockholders who demanded appraisal of their shares of Radiologix common stock to submit their stock certificates to the Register in Chancery for notation thereon of the pendency of the appraisal proceeding. If any former stockholder fails to comply with such direction, the Delaware Court of Chancery may dismiss the proceedings as to that former stockholder.

After determining which, if any, former Radiologix stockholders are entitled to appraisal, the Delaware Court of Chancery will appraise their shares of Radiologix common stock, determine their fair value, exclusive of any element of value arising from the accomplishment or expectation of the merger, together with a fair rate of interest, if any, to be paid upon the amount determined to be the fair value. Radiologix stockholders considering seeking appraisal should be aware that the fair value of their shares of Radiologix common stock as determined under Section 262 of the DGCL could be more than, the same as or less than the value of the consideration they would receive pursuant to the merger agreement if they did not seek appraisal of their shares of Radiologix common stock and that investment banking opinions as to fairness from a financial point of view are not necessarily opinions as to fair value under Section 262 of the DGCL. The Delaware Supreme Court has stated that, among other factors, proof of value by any techniques or methods which are generally considered acceptable in the financial community and otherwise admissible in court should be considered in the appraisal proceedings.

In addition, Delaware courts have decided that a stockholder's statutory appraisal remedy may or may not be a dissenter's exclusive remedy, depending on the factual circumstances.

The costs of the appraisal action may be determined by the Delaware Court of Chancery and levied upon the parties as the Delaware Court of Chancery deems equitable. Upon application of a former Radiologix stockholder, the Delaware Court of Chancery may also order that all or a portion of the expenses incurred by any former Radiologix stockholder in connection with an appraisal proceeding, including, without limitation, reasonable attorneys' fees and the fees and expenses of experts used in the appraisal proceeding, be charged pro rata against the value of all of the shares of Radiologix common stock entitled to appraisal.

Any holder of Radiologix common stock who has duly demanded an appraisal in compliance with Section 262 of the DGCL will not, after the consummation of the merger, be entitled to vote the shares of Radiologix common stock subject to this demand for any purpose or be entitled to the payment of dividends or other distributions on those shares of Radiologix common stock (except dividends or other distributions payable to holders of record of Radiologix common stock as of a record date prior to the effective date of the merger).

If any stockholder who properly demands appraisal of their Radiologix common stock under Section 262 of the DGCL fails to perfect, or effectively withdraws or loses, their right to appraisal, as provided in Section 262 of the DGCL, that stockholder's shares of Radiologix common stock will be converted into the right to receive the consideration payable with respect to those shares of Radiologix common stock in accordance with the merger agreement (without interest). A Radiologix stockholder will fail to perfect, or effectively lose or withdraw, their right to appraisal if, among other things, no petition for appraisal is filed within 120 days after the effective date of the merger, or if the stockholder delivers to Radiologix or the surviving company, as the case may be, a written withdrawal of their demand for appraisal. Any attempt to withdraw an appraisal demand in this matter more than 60 days after the effective date of the merger will require the written approval of the surviving company and, once a petition for appraisal is filed, the appraisal proceeding may not be dismissed as to any holder absent court approval.

Failure to follow the steps required by Section 262 of the DGCL for perfecting appraisal rights may result in the loss of these rights, in which event a Radiologix stockholder will be entitled to receive the consideration payable with respect to their shares of Radiologix common stock in accordance with the merger agreement (without interest).

Consequently, any stockholder willing to exercise appraisal rights is urged to consult with legal counsel prior to attempting to exercise such rights.

Appraisal Rights of Primedex Stockholders

California General Corporation Law. If the merger is completed, and Primedex is subject to Section 2115 of the California General Corporation Law when the merger becomes effective, holders of Primedex common stock who do not vote in favor of the merger and merger agreement and who comply with the procedures prescribed in Chapter 13 of the California General Corporation Law (including making written appraisal demand to Primedex prior to the occurrence of the special meeting) may be entitled to a judicial appraisal of the fair market value of their shares which, for purposes of the exercise of appraisal rights under the California General Corporation Law, is determined as of the day before the first announcement of the terms of the merger, excluding any appreciation or depreciation in consequence of the merger, and to require Primedex to purchase the stockholder's shares for cash at such fair market value. To the extent required by California law, a further notice of dissenters' rights will be sent to any stockholder eligible to exercise or exercising such rights within ten days after the special meeting.

The following is a brief summary of the statutory procedures that must be followed by a stockholder of Primedex in order to dissent from the merger and perfect appraisal rights under the California General Corporation Law. This summary is not intended to be a complete statement of the law of dissenters' rights and is qualified in its entirety by reference to Chapter 13 of the California General Corporation Law, the full text of which is attached to this proxy statement as *Annex G* and is incorporated herein by reference. We advise any stockholders of Primedex considering exercising appraisal rights to consult legal counsel.

Under Sections 181 and 1201 of the California General Corporation Law, the merger constitutes a reorganization of Primedex. Chapter 13 of the California General Corporation Law provides appraisal rights for stockholders dissenting from a reorganization under certain circumstances.

Even though a stockholder who wishes to exercise dissenters' rights may be required to take certain actions before the special meeting, if the merger agreement is later terminated and the merger is abandoned, no stockholder of Primedex will have the right to any payment from Primedex by reason of having taken that action. The following discussion is subject to these qualifications.

For a holder of common stock to exercise dissenters' rights as to any shares of Primedex common stock in connection with the merger, the stockholder must not vote in favor of the merger and merger agreement and must make a written demand to have Primedex purchase the shares at their fair market value.

The written demand must:

- be received not later than the date of the special meeting;
- specify the stockholder's name and mailing address and the number and class of Primedex's shares held of record which the stockholder demands Primedex purchase;
- state that the stockholder is demanding purchase of the shares and payment of their fair market value; and,
- state the price which the stockholder claims to be the relevant (see below) fair market value of the shares, which statement will constitute an offer by the stockholder to sell the shares to Primedex at that price.

All written demands should be addressed to Primedex Health Systems, Inc., 1510 Cotner Avenue, Los Angeles, CA 90025, Attention: Corporate Secretary.

Simply failing to vote for, or voting against, the merger and merger agreement will not be sufficient to constitute the demand described above.

In addition, within thirty (30) days after notice of the approval of the merger is mailed to stockholders, the stockholder must also submit to Primedex or a transfer agent of Primedex, for endorsement as dissenting shares, the stock certificates representing Primedex's shares as to which the stockholder is exercising dissenters' rights.

Shares of Primedex's stock held by stockholders who have perfected their dissenters' rights in accordance with Chapter 13 of the California General Corporation Law and have not withdrawn their demands or otherwise lost their rights are referred to in this summary as dissenting shares. Under the California General Corporation Law, a dissenting stockholder may not withdraw his, her or its demand for payment of the fair market value of the stockholder's dissenting shares in cash unless Primedex consents.

Within ten (10) days after the approval of the merger by Primedex's stockholders, Primedex must mail a notice of the approval to each holder of common stock who did not vote in favor of the merger. This notice must state the price determined by Primedex to represent the relevant fair market value of the dissenting shares, which statement will constitute an offer by Primedex to purchase the dissenting shares at the stated amount if the merger closes. Chapter 13 of the California General Corporation Law states that the fair market value, for this purpose, is determined as of the day before the first announcement of the terms of the proposed merger, excluding appreciation or depreciation as a consequence of the proposed merger. The company's notice must also include a brief description of the procedures to be followed by those holders if the holders desire to exercise their dissenters' rights and a copy of Section 1300 through 1304 of Chapter 13 of the California General Corporation Law.

Irrespective of the percentage of Primedex's common stock with respect to which demands for appraisal have been properly filed, Primedex must mail the notice referred to above to any stockholder who has filed a demand with respect to Primedex shares and that are subject to transfer restrictions imposed by Primedex or by any law or regulation. Primedex is not aware of any transfer restrictions on Primedex shares of common stock, except for those restrictions which apply to Primedex common stock held by stockholders who are deemed to be affiliates of Primedex as that term is defined in Rule 144 adopted by the Securities and Exchange Commission under the Securities Act. Any stockholder who believes there is another type of restriction on its shares should consult with its advisor as to the nature of the restriction and its relationship to the availability of dissenters' rights in connection with the merger. If the stockholder and Primedex agree that the shares of Primedex's common stock as to which the stockholder is seeking dissenters' rights are dissenting shares, and also agree upon the price to be paid to purchase the shares, then the dissenting stockholder is entitled to the agreed price with interest thereon at the legal rate on judgments under California General Corporation Law from the date of the merger agreement. Any agreements fixing the fair market value of any dissenting shares as between Primedex and any dissenting stockholder must be filed with the Secretary of Primedex.

However, if Primedex denies that the stockholder's shares qualify as dissenting shares eligible for purchase under Chapter 13 of the California General Corporation Law, or if Primedex and the stockholder fail to agree upon the fair market value of the shares, then the stockholder may, within six months after the date on which Primedex mailed to the stockholder the notice of approval of the merger by the stockholders of Primedex, but not thereafter, file a complaint in the California Superior Court of the proper county requesting the court to determine whether the stockholder's shares qualify as dissenting shares that are eligible to be repurchased pursuant to the exercise of dissenters' rights, the fair market value of such shares, or both, or may intervene in any action pending on such a complaint. If the court is requested to determine the fair market value of the shares, it shall appoint one or more impartial appraisers to determine the fair market value of the shares. Within ten (10) days of their appointment, the appraisers, or a majority of them, will make and file a report with the court. If the court finds the report reasonable, the court may confirm it.

However, if the appraisers cannot determine the fair market value within ten (10) days of their appointment, or within a longer time determined by the court or the report is not confirmed by the court, then the court will determine the fair market value. If the court determines that the stockholder's shares qualify as dissenting shares, then, following determination of their fair market value, Primedex will be obligated to pay the dissenting stockholder the fair market value of the shares, as so determined, together with interest thereon at the legal rate from the date on which judgment is entered. Payment on this judgment will be due upon the endorsement and delivery to Primedex of the certificates for the shares as to which the appraisal rights are being exercised. The costs of the appraisal action, including reasonable compensation to the appraisers appointed by the court, will be allocated among Primedex and dissenting stockholders as the court deems equitable. However, if the appraisal of the fair market value of the shares exceeds the price offered by Primedex, then Primedex shall pay an additional amount equal to the difference. If the fair market value of the shares awarded by the court exceeds 125% of the price offered by Primedex for the shares in the notice of approval of the merger by the stockholders of Primedex, then the court may in its discretion include attorneys' fees, fees of expert witnesses and interest at the legal rate on judgments in the amounts payable by Primedex.

Stockholders of Primedex considering whether to seek appraisal should bear in mind that the fair value of their Primedex common stock determined under Chapter 13 of the California General Corporation Law could be more than, the same as or less than the value of consideration to be paid in the merger as set forth in the merger agreement. Also, Primedex reserves the right to assert in any appraisal proceeding that, for purposes thereof, the fair value of the capital stock of Primedex is less than the value of the consideration to be issued and paid in the merger as set forth in the merger agreement. The process of dissenting requires strict compliance with technical prerequisites. Stockholders wishing to dissent should consult with their own legal counsel in connection with compliance with Chapter 13 of the California General Corporation Law. Any stockholder who fails to comply with the requirements of Chapter 13 of the California General Corporation Law, attached as *Annex G* to this joint proxy statement/prospectus, will forfeit such stockholder's rights to dissent from the merger and exercise appraisal rights and will receive the consideration to be issued and paid in the merger as set forth in the merger agreement.

Delisting and Deregistration of Radiologix Common Stock

If the merger is completed, Radiologix common stock will be delisted from the American Stock Exchange and will be deregistered under the Exchange Act, and Radiologix will no longer file periodic reports with the SEC. The stockholders of Radiologix will become stockholders of Primedex and their rights as stockholders will be governed by applicable New York and California law and by Primedex's certificate of incorporation and by-laws.

Primedex intends to apply to have its shares of common stock listed on the NASDAQ Stock Market as soon as reasonably practicable. Initial listing on the NASDAQ Stock Market requires the satisfaction by Primedex of quantitative listing standards relating to stockholders' equity, market capitalization, number of public stockholders, market value of public float and other criteria. Primedex does not currently qualify for listing under these criteria. Although Primedex will work diligently to be listed on the NASDAQ Stock Market, it can give no assurance that such listing will ever occur.

Federal Securities Laws Consequences; Resale Restrictions; Transfer Restrictions

All shares of Primedex common stock that will be distributed to Radiologix stockholders in the merger will be freely transferable, except for restrictions applicable to affiliates of Radiologix and except that resale restrictions may be imposed by securities laws in non-U.S. jurisdictions insofar as subsequent trades are made within these jurisdictions. In addition, pursuant to the proposals set forth in this proxy statement, Primedex's common stock may be subject to transfer and resale restrictions which are necessary

to preserve Primedex's unrestricted use of its net operating loss carry-forwards. Persons who are deemed to be affiliates of Radiologix may resell shares of Primedex common stock received by them only in transactions permitted by the resale provisions of Rule 145 or as otherwise permitted under the Securities Act of 1933. Persons who may be deemed to be affiliates of Radiologix include executive officers, directors and holders of more than 10% of the outstanding shares of Radiologix. The merger agreement requires Radiologix to use its reasonable best efforts to cause each of its directors and executive officers who Radiologix believes may be deemed to be affiliates of Radiologix to execute a written agreement to the effect that those persons will not sell, assign or transfer any of the shares of Primedex common stock issued to them in the merger unless that sale, assignment or transfer has been registered under the Securities Act of 1933, is in conformity with Rule 145 or is otherwise exempt from the registration requirements under the Securities Act of 1933.

This joint proxy statement/prospectus does not cover any resales of the shares of Primedex common stock to be received by Radiologix stockholders in the merger, and no person is authorized to make any use of this joint proxy statement/prospectus in connection with any resale.

137

MATERIAL UNITED STATES FEDERAL INCOME TAX CONSEQUENCES

The following is a summary of the material U.S. federal income tax consequences of the merger to holders of Radiologix common stock. This summary does not address the tax consequences of any transaction other than the merger. This summary is based upon currently existing provisions of the Internal Revenue Code of 1986, as amended (the Code), U.S. Treasury Regulations promulgated thereunder, and administrative and judicial interpretations thereof, all as in effect on the date hereof and all of which are subject to change, possibly with retroactive effect, and to differing interpretations. There can be no assurance that the U.S. Internal Revenue Service (IRS) will not challenge one or more of the tax results described herein, and Radiologix has not obtained, nor does it intend to obtain, a ruling from the IRS with respect to the U.S. federal income tax consequences described below.

This summary does not discuss all aspects of U.S. federal income taxation that may be important to certain holders of Radiologix common stock in light of their individual investment circumstances or the U.S. federal income tax consequences to holders of Radiologix common stock that are subject to special treatment under U.S. federal income tax laws, including but not limited to banks and other financial institutions, insurance companies, partnership and other pass-through entities, dealers in securities or foreign currency, traders that have elected mark-to-market accounting, tax-exempt organizations, certain former citizens or residents of the United States, persons that hold shares of Radiologix common stock as part of a straddle, hedge, conversion transaction or other integrated investment, or U.S. Holders, as defined below, that have a functional currency other than the U.S. dollar, or stockholders who acquired their shares of Radiologix common stock through the exercise of employee stock options or other compensation arrangements, all of whom may be subject to tax rules that differ significantly from those summarized below. In addition, this summary does not address U.S. federal income tax considerations applicable to holders of options or warrants to purchase Radiologix common stock, or holders of debt instruments convertible into Radiologix common stock. Further, this summary does not discuss any foreign, state, or local tax consequences of the merger.

As used herein, the term U.S. Holder means a beneficial owner of Radiologix common stock that is, for U.S. federal income tax purposes:

- an individual who is a citizen or resident of the United States;
- a corporation (including any entity treated as a corporation for U.S. federal income tax purposes) created or organized under the laws of the United States or any State or political subdivision thereof;
- an estate, the income of which is subject to U.S. federal income taxation regardless of its source; or
- a trust (i) if a court within the United States is able to exercise primary jurisdiction over its administration and one or more U.S. persons have authority to control all of its substantial decisions, or (ii) if, in general, it was in existence on August 20, 1996, was treated as a U.S. person under the Code on the previous day, and made a valid election to continue to be so treated.

The term non-U.S. Holder means a beneficial owner of shares that is not a partnership (or other entity treated as a partnership) for U.S. Federal income tax purposes and is not a U.S. Holder.

If a partnership (including any entity treated as a partnership for U.S. federal income tax purposes) is an owner of Radiologix common stock, the U.S. federal income tax treatment of a partner in the partnership generally will depend upon the status of the partner and the activities of the partnership. Partnerships that are owners of Radiologix common stock, and partners in such partnerships, are urged to consult their own tax advisors regarding the U.S. federal, state, local and foreign tax consequences to them of tendering their shares of Radiologix common stock.

U.S. Holders

Generally

A U.S. holder that receives cash and Primedex common stock in the merger generally will recognize gain or loss equal to the difference, if any, between (i) the sum of the fair market value of the Primedex common stock and the amount of cash received, and (ii) the U.S. holder's tax basis in the Radiologix common stock. Gain or loss will be determined separately for each block of shares (i.e., shares acquired at the same cost in a single transaction) of Radiologix common stock surrendered for the consideration described above pursuant to the merger. Any gain or loss recognized by a U.S. holder generally will be long-term capital gain or loss if the U.S. holder's holding period of the Radiologix common stock is more than one year. Capital gains derived by non-corporate U.S. holders with respect of capital assets held for more than one year are eligible for reduced rates of taxation. Significant limitations apply with respect to the deductibility of capital losses.

Each share of Primedex common stock received by a U.S. holder in the merger will have a tax basis equal to its fair market value on the date received. The U.S. holder's holding period in the Primedex common stock will begin on the date received.

Exercise of Dissenters' Rights

A U.S. Holder that elects to perfect appraisal rights will recognize gain or loss with respect to his or its shares of Radiologix common stock equal to the difference between the amount of cash received and his or its tax basis in the Radiologix common stock. Any gain or loss recognized by the U.S. holder generally will be long-term capital gain or loss if the U.S. holder's holding period in the Radiologix common stock is more than one year.

Information Reporting and Backup Withholding

Information reporting and backup withholding at a rate of 28% may apply with respect to the cash and/or stock consideration paid to a U.S. Holder in the merger or upon the U.S. Holder's exercise of his or its dissenter's rights. In order to avoid backup withholding, unless an exception applies under applicable law and regulations, a U.S. holder must provide the payor with a properly executed IRS Form W-9 or substitute Form W-9 that provides:

- the U.S. Holder's correct taxpayer identification number;
- a certification that the U.S. Holder (i) is exempt from backup withholding, (ii) has not been notified by the IRS that he or it is subject to backup withholding as a result of a failure to report all interest or dividends, or (iii) has been notified by the IRS that he or it is no longer subject to backup withholding; and
- that the U.S. Holder is a U.S. person (including a U.S. resident alien).

A U.S. Holder that does not provide the payor with his or its correct taxpayer identification number may be subject to penalties imposed by the IRS. Any amounts withheld under the backup withholding rules may be allowed as a refund or a credit against the U.S. holder's federal income tax liability, provided that the U.S. holder furnishes certain required information to the IRS.

Non-U.S. Holders

Consequences of Participating in the Merger or Exercising Dissenters' Rights

A non-U.S. Holder that receives cash and Primedex common stock in the merger or elects to exercise his or its dissenters' rights generally will not be subject to U.S. federal income tax on any gain recognized by the non-U.S. Holder unless:

- such gain is effectively connected with the conduct by the non-U.S. Holder of a U.S. trade or business and, if an income tax treaty applies, is attributable to a permanent establishment maintained by the non-U.S. Holder in the United States; or
- the non-U.S. Holder is an individual who is present in the United States for a period or periods aggregating 183 or more days during the taxable year in which the merger occurs and certain other conditions are met.

A non-U.S. Holder described in the first bullet point above will be required to pay U.S. federal income tax on the net gain he or it recognizes as a result of the merger or upon the exercise of his or its dissenters' rights as if such non-U.S. Holder was a U.S. Holder, and if such non-U.S. Holder is a foreign corporation, it may also be required to pay an additional branch profits tax at a rate of 30% (or a lower rate if so specified by an applicable income tax treaty). A non-U.S. Holder described in the second bullet point above will be subject to a 30% (or, if applicable, a lower treaty rate) U.S. federal withholding tax on the gain he or it recognizes as a result of the merger or upon the exercise of his or its dissenters' rights.

Information Reporting and Backup Withholding

Information returns will be filed annually with the IRS and provided to each non-U.S. Holder with respect to the cash and/or stock consideration paid to the non-U.S. Holder in the merger or upon the exercise of his or its dissenters' rights, regardless of whether such payment is subject to withholding tax or is exempt from U.S. withholding tax pursuant to an income tax treaty or for any other reason. In addition, possible backup withholding at a rate of 28% may apply unless the non-U.S. Holder certifies (generally on IRS Form W-8BEN) as to its non-U.S. status under penalties of perjury or otherwise establishes an exemption.

Backup withholding is not an additional tax. A non-U.S. Holder may obtain a refund or a credit against such non-U.S. Holder's U.S. federal income tax liability of any amounts withheld under the backup withholding rules provided the required information is furnished to the IRS in a timely manner.

Non-U.S. Holders should consult their own tax advisors regarding the application of the information reporting and backup withholding rules in their particular situations, the availability of an exemption therefrom, and the procedure for obtaining such an exemption, if available.

The preceding discussion of U.S. federal income tax considerations is for general information only. Each holder should consult its own tax advisor regarding the particular U.S. federal, state, local and foreign tax consequences of the merger, including the consequences of any proposed change in applicable law.

THE MERGER AGREEMENT

The following summary describes the material provisions of the merger agreement. This summary may not contain all of the information about the merger agreement that is important to you. The following summary is qualified in its entirety by reference to the complete text of the merger agreement, which is attached to this joint proxy statement/prospectus as Annex A and is incorporated by reference into this joint proxy statement/prospectus. We encourage you to read it carefully in its entirety for a more complete understanding of the merger agreement.

The merger agreement has been included to provide you with information regarding its terms. It is not intended to provide any other factual information about Primedex. Such information can be found elsewhere in this joint proxy statement/prospectus and in the other public filings Primedex makes with the SEC, which are available without charge at www.sec.gov.

The merger agreement contains representations and warranties Primedex and Radiologix have made to each other. The assertions embodied in those representations and warranties are qualified by information in confidential disclosure schedules that Primedex and Radiologix have exchanged in connection with signing the merger agreement. While we do not believe that these schedules contain information required to be publicly disclosed by Primedex or Radiologix under the applicable securities laws other than information that has already been so disclosed, the disclosure schedules do contain information that modifies, qualifies and creates exceptions to the representations and warranties set forth in the attached merger agreement. Accordingly, you should not rely on the representations and warranties as current characterizations of factual information about Primedex and Radiologix, since they were made as of the date of the merger agreement and are modified in important part by the underlying disclosure schedules. These disclosure schedules contain information that has been included in the general prior public disclosures of Primedex and Radiologix, as well as additional non-public information. Moreover, information concerning the subject matter of the representations and warranties may have changed since the date of the merger agreement, which subsequent information may or may not be fully reflected in the public disclosures of Primedex or Radiologix.

The Merger

The merger agreement provides that, upon the closing, PR Acquisition Corporation, an indirect wholly-owned subsidiary of Primedex which we refer to as Merger Sub, will merge with and into Radiologix with Radiologix surviving as an indirect wholly-owned subsidiary of Primedex. We refer to this transaction as the merger.

Parties to the Merger Agreement

The parties to the merger include Primedex, Merger Sub, Radiologix and RadNet Management, Inc., a wholly-owned subsidiary of Primedex and the sole stockholder of Merger Sub, which we refer to as RadNet.

Completion and Effectiveness of the Merger

The closing of the merger will take place on a date mutually agreed to by Primedex and Radiologix but that will be no later than two business days after the satisfaction or waiver of each of the conditions to closing set forth in the merger agreement, or on such other date as Primedex, Merger Sub, RadNet and Radiologix may agree. The merger will become effective upon the filing of a certificate of merger with the Secretary of State of the State of Delaware.

Conversion of Shares; Procedures for Exchange of Certificates

If the merger is completed, holders of Radiologix common stock (other than Radiologix, Primedex and dissenting Radiologix stockholders who properly exercise their appraisal rights) will be entitled to

receive aggregate consideration of 22,621,922 shares of Primedex and \$42,950,000 in cash (cash and stock together is referred to as the merger consideration). After the merger is completed, Radiologix stockholders will have the right to receive the merger consideration but they will no longer have any rights as a Radiologix stockholder. Based upon the closing price of Primedex common stock on October 6, 2006, the record date, of \$2.69, each Radiologix stockholder would receive \$1.78 in cash for each Radiologix share, plus one share of Primedex common stock for total consideration valued at \$4.47 per share. The merger agreement also provides Primedex the option to elect to reduce the share consideration by up to 3.5 million shares and to increase the cash consideration by \$2 per share, provided that Primedex advises Radiologix of its election prior to the mailing of this Proxy Statement. Primedex has advised Radiologix that it does not intend to exercise this option because Primedex believes it is in the best interests of all stockholders for Primedex to preserve the \$7 million of cash for other purposes. Promptly following the effective time of the merger, U.S. Bank National Association, the exchange agent, will send a letter of transmittal to each former Radiologix stockholder of record. The letter of transmittal will contain instructions for obtaining the merger consideration for shares of Radiologix common stock.

Upon surrender of a stock certificate representing shares of Radiologix common stock, together with a duly completed and validly executed letter of transmittal, and any other documents that may be reasonably required by the exchange agent, the holder of the certificate will be entitled to receive from the exchange agent, acting on behalf of Primedex, the merger consideration for each share represented by the stock certificate, and that stock certificate will be cancelled.

In the event of a transfer of ownership of Radiologix common stock that is not registered in Radiologix's stock transfer books, the merger consideration for shares of Radiologix common stock so transferred may be paid to a person other than the person in whose name the surrendered certificate is registered if the certificate is properly endorsed and is otherwise in proper form for transfer.

No interest will be paid or will accrue on any cash payable in connection with the merger upon the surrender of stock certificates representing shares of Radiologix common stock. The merger consideration paid upon conversion of shares of Radiologix common stock in the merger will be issued in full satisfaction of all rights relating to those shares of Radiologix common stock.

Financing of the Merger

Primedex has signed a commitment letter with GE Commercial Finance Healthcare Financial Services for a \$405 million senior secured credit facility. The facility is expected to be used to finance the merger, to refinance existing indebtedness, to pay transaction costs and expenses relating to the merger and the credit facility and to provide financing for working capital needs post-merger. Consummation of the financing is a condition to the closing of the merger. See *The Merger* Financing of the Merger on page 108.

Fractional Shares

No fractional Primedex common shares will be issued in the merger. Instead, holders who would otherwise be entitled to receive a fractional share of Primedex common stock will receive an amount in cash (without interest) determined by multiplying the fractional share interest by the average closing price for a share of Primedex common stock as reported on the Over-The-Counter Bulletin Board for the ten trading days prior to, but not including, the effective time of the merger.

Radiologix Options and Unvested Shares

Radiologix Stock Options

Holders of unvested options exercisable for Radiologix common stock will become vested in their options as a result of the merger. Holders of options exercisable for Radiologix common stock, whose exercise price per share is less than the value of the per share merger consideration, will receive for each share subject to such options an amount in cash out of the aggregate merger consideration equal to the difference between the value of the per share merger consideration and the exercise price per share of their options. Options exercisable for Radiologix common stock with an exercise price per share that is greater than the value of the per share merger consideration shall not be assumed or substituted by Primedex but shall vest upon the effective date of the merger and become fully exercisable to the holder of such option pursuant to the terms of the applicable option agreement. Any vested option that is not exercised prior to the effective time shall terminate and be void as of the effective time of the merger.

Unvested Shares of Radiologix Common Stock

Immediately prior to the effective time of the merger, Radiologix will have cancelled, repurchased, accelerated, vested or otherwise extinguished or awarded all shares of Radiologix common stock that are restricted, not fully vested or subject to any other restriction and there will be no remaining unvested shares of Radiologix common stock at the effective time of the merger.

Voting Agreement

Contrarian Equity Fund, L.P., a Radiologix stockholder, which owns approximately 16.9% of the outstanding shares of Radiologix common stock, is a party to a voting agreement with Primedex under which it is obligated to vote its shares in favor of adopting the merger agreement and the merger.

Representations and Warranties

The merger agreement contains substantially reciprocal representations and warranties made by Radiologix, on the one hand, and Primedex, on the other, relating to, among other things:

- corporate organization, good standing, qualification and ownership of subsidiaries;
- capital structure;
- corporate authority to execute and deliver the obligations under the merger agreement, and the enforceability of the merger agreement;
- the absence of any conflict with or violation of corporate charter documents, applicable law or contracts as a result of entering into and carrying out the obligations under the merger agreement;
- the absence of a need to obtain any governmental consents, approvals, authorizations or permits or to make any filings with or notifications to any governmental entities in order to complete the merger;
- compliance with SEC rules and regulations;
- accuracy of information provided to the other party;
- the absence of a material adverse effect and other changes since December 31, 2005;
- compliance with applicable laws and contracts relating to employee benefit plans and labor relations;
- disclosure of, and the absence of a default under, material contracts;

- the absence of litigation;
- compliance with environmental laws;
- ownership of intellectual property and the absence of infringement of third party intellectual property rights;
- proper preparation and timely filing of tax returns and timely payment of taxes;
- the existence of adequate insurance coverage;
- receipt of opinion of financial advisors with respect to Radiologix;
- disclosure of broker or financial advisor fees;
- valid title to properties;
- the absence of interested party transactions;
- the absence of affiliates as defined under SEC Rule 145 with respect to Radiologix;
- the absence of ownership of Radiologix's capital stock by Primedex, currently or in the past three years, that would render Primedex an interested stockholder for purposes of Section 203 of the DGCL; and
- effectiveness of a financing commitment letter with respect to Primedex.

All of the representations and warranties expire at the effective time of the merger.

Material Adverse Effect

Several of the representations and warranties contained in the merger agreement are qualified by reference to whether the failure of such representation or warranty to be true is reasonably likely to have a material adverse effect on Radiologix or Primedex, as applicable. The merger agreement provides that a material adverse effect means, when used in connection with either company, any effect, event, occurrence, development, circumstance, change or condition, including without limitation a conflict with, or default or violation of, any law that, individually or in the aggregate with all other effects is, or would:

- materially impede or delay such party's ability to consummate the transactions contemplated by the merger agreement in accordance with its terms and applicable laws; or
- be materially adverse to the capitalization, assets (including intangible assets), liabilities, business, financial condition or results of operations of such party's and its subsidiaries, taken as a whole, except for the purposes of this bullet point, to the extent that such effect results from:
 - changes or conditions affecting economic or capital markets which do not affect such party in a substantially disproportionate manner;
 - changes in political conditions which do not affect such party in a substantially disproportionate manner;
 - changes or conditions affecting the diagnostic imaging services industry which do not affect such party in a substantially disproportionate manner;

- changes in laws, generally accepted accounting principles, or SEC rules and regulations which do not affect such party in a substantially disproportionate manner;
- the announcement of the merger agreement or the transactions contemplated thereby; or

144

- changes in the trading volume or trading prices of such party stock, or any failure to meet analysts' forecasts or projections, but this exclusion will not apply to the underlying cause or causes of such changes or failure.

Conduct of Business Pending the Merger

Radiologix

Under the merger agreement, Radiologix has agreed that prior to the effective time of the merger, subject to certain exceptions, unless Radiologix obtains Primedex's prior written consent or as necessary to comply with legal requirements, Radiologix will and will cause each Radiologix subsidiary to:

- conduct its operations in all material respects only in the ordinary and usual course of business consistent with past practice, and take no action inconsistent with such practice or the merger agreement;
- use reasonable best efforts to keep available the services of current officers, employees and consultants and to preserve present business relationships;
- have in effect and maintain in all material respects insurance substantially of the kinds and in the amounts as are in effect as of the date of the merger agreement; and
- keep substantially in working condition and good order and repair all material assets and other material properties, normal wear and tear excepted.

In addition, Radiologix has also agreed that until the effective time of the merger, subject to exceptions for actions taken in the ordinary course of business, consistent with past practice or below enumerated dollar thresholds, or with Primedex's prior written consent, as necessary to comply with legal requirements, or as specified in the merger agreement, Radiologix will and will cause Radiologix subsidiaries to comply with specific restrictions relating to, among others:

- acquiring any business, corporation, partnership, association or any business organization or division thereof;
- the sale, lease, license or other disposition of any assets;
- amending Radiologix's or Radiologix's subsidiaries' articles of incorporation or amended and restated by-laws or similar organizational documents;
- other than dividends from any wholly-owned subsidiary of Radiologix to its parent, declaring, setting aside or paying any dividend or other distribution with respect to any shares of Radiologix or Radiologix subsidiary capital stock, or purchasing, redeeming or otherwise acquiring any shares of Radiologix or Radiologix subsidiary capital stock, other equity securities or other ownership interests;
- splitting, combining or reclassifying any outstanding shares of Radiologix or Radiologix subsidiary capital stock;
- issuing or agreeing to the issuance of options, warrants or rights to acquire shares of or securities convertible into any equity interests of Radiologix or Radiologix subsidiaries;
- granting, amending or changing the terms of any option or restricted stock unit, except for granting to newly hired employees up to a total of 100,000 options in the ordinary course of business consistent with past practices, provided that no one person may be granted options to purchase more than 20,000 shares of Radiologix common stock;

- taking any action with respect to the grant of any severance or termination pay to, increasing the compensation, bonus, severance or other benefits of, executing any employment or deferred compensation agreement with, or paying any benefit not required by any existing agreement or employee benefit plan to any current or former director, executive officer or employee;
- amending Radiologix's benefit plans or agreements or adopting new plans or agreements, including severance agreements;
- hiring any person as an executive officer or entering into, amending or extending the term of, any employment agreement with any officer or employee, consultant or independent contractor;
- entering into any collective bargaining agreement;
- making any material election, changing in any material respect any accounting method, or taking other actions with respect to tax matters;
- commencing, settling, compromising or resolving any legal proceeding, unless compelled by final non-appealable court order or other binding order of a governmental entity;
- incurring indebtedness or modifying the terms of any existing indebtedness greater than \$100,000, except for letters of credit relating to currently existing insurance programs up to \$1 million;
- assuming or becoming responsible for the obligations of, or making any loans, advances, capital contributions to, or investments in, any individual or entity, other than Radiologix subsidiaries or joint venture partners of the subsidiaries;
- creating any material encumbrance on any material asset, except pursuant to the terms of any existing encumbrance;
- paying or discharging any claims or liabilities other than the payment in the ordinary course of business consistent with past practices of claims or liabilities that were reflected on the Radiologix December 31, 2005 balance sheet or that were incurred after the date of that balance sheet in the ordinary course of business;
- writing off any accounts or notes receivable in excess of \$100,000 in the aggregate except for the write off of patient accounts;
- making any capital expenditures in excess of \$30,000,000 in the aggregate between January 1, 2006 and March 31, 2007; provided that all capital expenditures up to \$30,000,000 between such dates shall be made in the ordinary course of business and in accordance with the capital budget;
- making any loans or advances (other than routine travel advances and sales commission draws to employees consistent with past practice) to, or any investments in or capital contributions to, any person (including any officer, director or employee of Radiologix), or forgiving or discharging any outstanding loans or advances; or otherwise modifying any loan previously granted;
- entering into any agreement that limits Radiologix or its subsidiaries, or that would after the effective time of the merger limit Primedex or its subsidiaries, from engaging or competing in any line of business or any geographic area, or which provides most favored party rights;

- terminating, amending or waiving any provision of a confidentiality or standstill agreement, or upon notice of a material breach, failing to enforce the provisions of such agreement;
- entering into or modifying any agreement the effect of which would be to grant to a third party any actual or potential right or license of any Radiologix intellectual property other than non-exclusive licenses in the ordinary course of business in connection with sales to customers;

146

- amending or terminating any material contract or entering into any other material contract;
- materially changing warranties or indemnification rights of customers in a manner that is adverse to Radiologix or its subsidiaries;
- knowingly taking or agreeing to commit to take any action that would materially impair the ability of Radiologix, Primedex, Merger Sub or Radiologix stockholders to complete the merger or would make any representation or warranty contained in the merger agreement inaccurate in any material respect at the effective date of the merger; or
- committing or agreeing to take any of the actions described in the previous bullet points.

Before the effective time of the merger, Radiologix will exercise complete control and supervision of its operations, consistent with the terms and conditions of the merger agreement.

Radiologix has also agreed to other customary covenants, including providing Primedex and its representatives access at reasonable times to Radiologix's officers, employees, agents, properties, offices and other facilities, as well as to Radiologix's books and records. Radiologix has also agreed to promptly furnish information concerning Radiologix's business, properties, contracts, assets, liabilities, taxes, personnel, internal financial statement and other aspects of Primedex's business. Primedex's access rights are subject to its obligations under its existing confidentiality agreement with Radiologix.

Primedex

Under the merger agreement, Primedex has agreed that prior to the effective time of the merger, subject to exceptions, or as necessary to comply with legal requirements, Primedex will and will cause each Primedex subsidiary to:

- conduct its operations in all material respects in the ordinary and usual course of business consistent with past practice and in accordance with its contractual obligations, and take no action inconsistent with such practice or the merger agreement, including with respect to Primedex's senior credit facility, except to the extent that failure to do so would not have a material adverse effect on Primedex; and
- forbear to amend Primedex's senior credit facility in a manner that is adverse to Primedex without the prior consent of Radiologix (which consent will not be unreasonably withheld).

Limitation on Considering Other Acquisition Proposals

Radiologix has agreed that it will not, and will not permit any of its subsidiaries to, and will use all reasonable efforts to ensure that Radiologix or its subsidiaries' directors, officers, employees, affiliates, accountants, consultants, legal counsel, advisors, investment bankers, brokers, agents and other representatives do not, directly or indirectly:

- solicit, initiate, seek, entertain, encourage, facilitate, support or induce any acquisition proposal or the making of any inquiry or proposal that could reasonably be expected to lead to an acquisition proposal;
- enter into, participate in, maintain or continue any communications or negotiations regarding, or furnish to any person any non-public information in response to or in connection with, any acquisition proposal;
- agree to, accept, approve, endorse or recommend any acquisition proposal;
- enter into any letter of intent or any other contract relating to any acquisition proposal;

- submit any acquisition proposal to the vote of Radiologix stockholders;
- withhold, withdraw or modify, in a manner adverse to Primedex, the approval of the Radiologix board of directors of the merger agreement; or
- take any action or position that is inconsistent with, or withdraw or modify, in a manner adverse to Primedex, the unanimous recommendation of the board that Radiologix stockholders vote in favor of the adoption of the merger agreement.

An acquisition proposal means any agreement, offer, proposal or indication of interest (other than from Primedex) relating to, or involving: the acquisition by any person or group of more than a 10% interest in Radiologix's total outstanding voting securities or more than a 5% interest in the total outstanding voting securities of any material company subsidiary or any tender or exchange offer that would result in any person beneficially owning 10% or more of Radiologix's total outstanding voting securities or more than a 5% interest in the total outstanding voting securities of any material company subsidiary; any merger or other business combination involving Radiologix or its subsidiaries; or any sale, lease, mortgage, exchange, license, acquisition, transfer, pledge or disposition of 10% or more of Radiologix's consolidated assets.

At any time prior to obtaining stockholder approval, subject to restrictions, the Radiologix board of directors may nevertheless in response to an acquisition proposal that the Radiologix board of directors concludes in good faith (after consultation with outside legal and financial advisors) is, or is reasonably likely to become, a superior offer:

- enter into discussions with the person making the acquisition proposal, and
- furnish to the person making the acquisition proposal information with respect to Radiologix and its subsidiaries pursuant to a confidentiality agreement which contains terms that are at least as restrictive as the terms of the confidentiality agreement that Radiologix and Primedex have executed in connection with the merger and provided that Radiologix furnishes Primedex with the same information it has furnished to the person making the acquisition proposal prior to or at the same time as the information is furnished to the person making the acquisition proposal.

However, in each case:

- neither Radiologix, its subsidiaries, nor any of Radiologix's or its subsidiaries' directors, officers, employees, affiliates, accountants, consultants, legal counsel, advisors, investment bankers, brokers, agents and other representatives will have violated the restrictions on considering other acquisition proposals set forth in the merger agreement and summarized in the preceding bullet points;
- the Radiologix board of directors must first conclude in good faith, after consultation with outside legal counsel, that such action is reasonably required for the Radiologix board to comply with its fiduciary obligations to Radiologix stockholders; and
- Radiologix must first notify Primedex in writing of the identity of the person making such acquisition proposal, the material terms and conditions of such acquisition proposal, and Radiologix's intention to take actions in response to such acquisition proposal.

A superior offer means an unsolicited, bona fide written offer made by a third party for the acquisition by any person or group of more than a 50% interest in total outstanding Radiologix voting securities or any tender or exchange offer that would result in any person beneficially owning 50% or more of Radiologix's total outstanding voting securities; any merger or other business combination involving Radiologix or its subsidiaries; or any sale, lease, transfer, pledge or disposition of 50% or more of its consolidated assets, on terms that the Radiologix board of directors has in good faith concluded (after consultation with outside legal counsel and financial advisor) to be more favorable, from a financial point

of view, to Radiologix stockholders than the terms of the merger agreement and is reasonably capable of being consummated.

Radiologix has agreed to advise Primedex within twenty-four hours of the receipt of any acquisition proposal, any inquiry or offer that contemplates an acquisition proposal, any other notice that any person is considering making an acquisition proposal, or any request for non-public information that could reasonably be expected to lead to an acquisition proposal:

- of the material terms and conditions of such acquisition proposal, inquiry or request, and
- the identity of the person making any such acquisition proposal, inquiry or request.

Nothing in the merger agreement prevents the Radiologix board of directors from withholding or modifying its unanimous recommendation to Radiologix stockholders in favor of adoption of the merger agreement, or terminating the merger agreement simultaneously with the payment of a termination fee to Primedex in the amount of \$3 million plus up to \$1 million for incurrence by Primedex of expenses in connection with the transactions contemplated by the merger agreement, if: Radiologix stockholders' approval of the merger has not yet been obtained; Radiologix has not violated any of the restrictions on considering other acquisition proposals set forth in the merger agreement and summarized in the preceding paragraphs; a superior offer is made to Radiologix and is not withdrawn; Radiologix has promptly provided written notice to Primedex of the superior offer and the Radiologix board of directors' intent to change its recommendation or to terminate the merger agreement; Primedex has not, within 5 business days after receipt of the written notice of a superior offer, made an offer to Radiologix that the Radiologix board of directors concludes in its good faith judgment after consultation with a financial advisor of national standing to be at least as favorable to Radiologix stockholders as such superior offer; and the Radiologix board of directors has concluded in good faith, after consultation with legal counsel, that, in light of such superior offer and any offer made by Primedex, it is required to withhold or modify such recommendation, or to terminate the merger agreement and pay to Primedex a termination fee in the amount of \$3 million plus up to \$1 million for incurrence by Primedex of expenses in connection with the transactions contemplated by the merger agreement, to comply with its fiduciary obligations to Radiologix stockholders under applicable legal requirements.

Conditions to the Closing of the Merger

Primedex and Radiologix are not obligated to effect the merger unless the following conditions are satisfied or waived:

- the merger agreement is adopted by Primedex and Radiologix stockholders at the stockholder meetings of the companies;
- the shares of Primedex common stock issuable to Radiologix stockholders pursuant to the merger agreement are authorized for listing on the Over-The-Counter Bulletin Board;
- no governmental entity has obtained, enacted, issued, promulgated or enforced any statute, rule, regulation, executive order, decree, judgment, injunction, arbitration award, finding or other order (whether temporary, preliminary or permanent), in any case that is in effect and prevents or prohibits consummation of the merger;
- any applicable waiting periods, together with any extensions thereof, under the HSR Act and other applicable antitrust laws required to consummate the merger shall have expired or been terminated;
- this joint proxy statement/prospectus has become effective under the Securities Act of 1933, as amended and there are no stop orders or proceedings initiated or threatened to suspend this joint proxy statement/prospectus; and

- there is no pending or threatened action, suit, proceeding, claim, arbitration or investigation in which any governmental entity is a party wherein an unfavorable injunction, judgment, order, decree, charge or ruling would:
- prevent, restrain or otherwise interfere with the consummation of the merger;
- adversely affect the right or powers of Primedex to own, operate or control Radiologix or any portion of the business or assets of Radiologix or Primedex; and
- no such injunction, judgment or ruling is in effect.

Primedex and Merger Sub are not obligated to effect the merger unless the following additional conditions are satisfied or waived:

- the representations and warranties made by Radiologix in the merger agreement related to Radiologix's organization, capitalization, authority to enter into the merger agreement and complete the merger, and its receipt of necessary consents and governmental approvals are true and correct in all material respects as of the date of the merger agreement and as of the effective time of the merger (except that those representations and warranties that address matters only as of a particular date need only be true and correct as of such date);
- Radiologix's remaining representations and warranties in the merger agreement and in any certificate or other writing delivered by Radiologix pursuant to the merger agreement, in each case disregarding all qualifications and exceptions contained therein relating to materiality or material adverse effect, are true and correct as of the date of the merger agreement and as of the effective time of the merger (except that those representations and warranties that address matters only as of a particular date need only be true and correct as of such date), except where the failure of such representations and warranties to be so true and correct has not had and would not have a material adverse effect on Radiologix;
- Radiologix has performed or complied in all material respects with all agreements and covenants required by the merger agreement to be performed or complied with by Radiologix on or prior to the effective time of the merger;
- there has not occurred any material adverse effect with respect to Radiologix;
- Radiologix has obtained the consent or approval of each person or entity whose consent or approval is required under any contract to which Radiologix or any of its subsidiaries is a party, except where the failure to obtain any consent or approval would not have a material adverse effect on Radiologix;
- Radiologix has obtained and delivered to Primedex all consents, waivers and approvals required under all material real property and equipment leases to which Radiologix or any of its subsidiaries is a party, except where the failure to obtain any consent or approval would not have a material adverse effect on Radiologix;
- Radiologix has obtained all permits, authorizations, consents, and approvals required on its part to perform its obligations under and consummate the merger agreement, except where the failure to obtain such permits, authorizations, consents and approval would not have a material adverse effect on Radiologix;
- Radiologix has delivered to Primedex a certificate, signed by Radiologix's chief executive officer and dated as of the closing date, to the effect that the conditions set forth in the merger agreement have been satisfied;

- Primedex has consummated the financing described in the commitment letter from GE Commercial Finance Healthcare Financial Services dated June 27, 2006 with respect to a financing in the amount of \$405 million;
- holders of no more than 10% of outstanding Radiologix common shares entitled to appraisal of their shares have properly demanded appraisal of their shares in accordance with applicable law;
- holders of no more than 10% of outstanding Primedex common shares have exercised or retain the unexpired right to exercise dissenters' rights (or similar rights of dissent) in respect of the merger available under applicable law;
- Primedex has received all permits and approvals necessary under state securities laws to consummate the merger;
- Radiologix has cash (not including restricted cash) on its balance sheet of at least \$32.6 million as of the closing date; and
- Primedex has received an affiliates letter from each of Radiologix's directors and officers identified as an affiliate of Radiologix within the meaning of Rule 145 promulgated under the Securities Act of 1933.

Radiologix is not obligated to effect the merger unless the following additional conditions are satisfied or waived:

- Primedex's and Merger Sub's representations and warranties in the merger agreement related to Primedex's and Merger Sub's organization, capitalization, authority to enter into the merger agreement, necessary consents and governmental approvals are true and correct in all material respects as of the date of the merger agreement and as of the effective time of the merger (except that those representations and warranties that address matters only as of a particular date need only be true and correct as of such date);
- Primedex's and Merger Sub's remaining representations and warranties in the merger agreement and in any certificate or other writing delivered by Primedex or Merger Sub pursuant to the merger agreement, in each case disregarding all qualifications and exceptions contained therein relating to materiality or material adverse effect on Primedex, are true and correct as of the date of the merger agreement and as of the effective time of the merger (except that those representations and warranties that address matters only as of a particular date need only be true and correct as of such date), except where the failure of such representations and warranties to be so true and correct has not had and would not have a material adverse effect on Primedex;
- Primedex has performed or complied with all agreements and covenants required by the merger agreement to be performed or complied with by Primedex on or prior to the effective time of the merger, except where the failure to perform or comply with agreements and covenants required by the merger agreement has not had and would not have a material adverse effect on Primedex;
- there has not occurred any material adverse effect with respect to Primedex; and
- Primedex has delivered to Radiologix a certificate, signed by an authorized officer of Primedex and dated as of the closing date, to the effect that the conditions set forth in the merger agreement have been satisfied.

Termination of the Merger Agreement

Primedex and Radiologix can terminate the merger agreement before the effective date of the merger under certain circumstances, including:

- by mutual written consent of Primedex and Radiologix;
- by either Primedex or Radiologix, if the merger has not been completed before April 30, 2007, provided that such date may be extended by Primedex or Radiologix up to and including May 31, 2007 if all conditions to effect the merger other than one or more of certain regulatory conditions have been or are capable of being satisfied at the time of such extension, and the regulatory conditions have been or are reasonably capable of being satisfied on or prior to May 31, 2007;
- by either Primedex or Radiologix, if any governmental entity has issued any statute, rule, regulation, executive order, decree, judgment, injunction, arbitration award, finding or other order (whether temporary, preliminary or permanent), that is in effect and that prevents or prohibits consummation of the merger;
- by either Primedex or Radiologix, if Radiologix stockholders do not adopt the merger agreement at the special meeting and, in the case of a termination by Radiologix, the failure to obtain stockholder approval is not the result of Radiologix's violation of the merger agreement. If, at the time of such termination, Primedex was entitled to terminate pursuant to the following bullet, termination by Radiologix as a result of Radiologix stockholders' non-adoption of the merger agreement is effective only if Radiologix fulfills any obligations Radiologix may have to pay a termination fee of \$3 million to Primedex and to reimburse Primedex for up to \$1 million for its fees and expenses incurred in connection with the transactions contemplated by the merger agreement;
- by Primedex, if prior to the receipt of Radiologix stockholder approval:
 - Radiologix's board of directors withdraws, withholds, amends or modifies in a manner adverse to Primedex its recommendation to Radiologix's stockholders in favor of adoption of the merger agreement;
 - Radiologix fails to include such recommendation in this proxy statement;
 - Radiologix's board of directors approves or publicly recommends to its stockholders any other acquisition proposal;
 - Radiologix enters into any letter of intent or other contract for any other acquisition proposal;
 - Radiologix breaches any of its covenants relating to its obligation to hold the stockholder meeting, its board of directors' obligation to recommend the adoption of the merger agreement or its obligation not to solicit other acquisition proposals; or
 - Radiologix's board of directors fails to make a statement recommending the rejection of a tender or exchange offer not made by Primedex or any of its affiliates for Radiologix common stock within 10 business days after such tender or exchange offer is first published or given.
- by either Primedex or Radiologix, if Primedex stockholders do not adopt the merger agreement at the special meeting and, in the case of a termination by Primedex, the failure to obtain stockholder approval is not the result of Primedex's violation of the merger agreement;

- by Primedex, if there is a material adverse effect with respect to Radiologix or if any of Radiologix's covenants, agreements, representations or warranties are breached and not cured within 20 business days and, as a result of Radiologix's breach or misrepresentation, the conditions to closing would not be satisfied;

152

- by Radiologix, if there is a material adverse effect with respect to Primedex, RadNet or Merger Sub or if any of the covenants, agreements, representations or warranties of Primedex or Merger Sub is breached and not cured within 20 business days and, as a result, the conditions to closing would not be satisfied; and
- by Radiologix, if prior to the receipt of Radiologix stockholder approval:
- Radiologix has not violated any of the covenants with respect to considering other acquisition proposals, and
- a superior offer is made to Radiologix and is not withdrawn, and
- Radiologix has promptly provided written notice to Primedex advising Primedex that Radiologix has received a superior offer and intends to change the recommendation of its board of directors with respect to the merger or to terminate the merger agreement and the manner and timing in which Radiologix intends to do so, and
- Primedex has not, within five days after receipt of the notice of superior offer, made an offer that Radiologix's board of directors determines in its good faith judgment (after consultation with a financial advisor) to be at least as favorable to Radiologix stockholders as such superior offer, and
- Radiologix's board of directors concludes in good faith, after consultation with its outside legal counsel, that, in light of such superior offer and any offer made by Primedex within five days after receipt of the notice of superior offer, the Radiologix board is required to withdraw or modify its recommendation to Radiologix stockholders to vote in favor of the merger, or to terminate the merger agreement and pay to Primedex a termination fee of \$3 million plus up to \$1 million for fees and expenses incurred by Primedex in connection with the transactions contemplated by the merger agreement, to comply with its fiduciary obligations to Radiologix stockholders under applicable law.

Termination Fees and Expenses

The merger agreement provides that Primedex will pay to Radiologix the sum of the fees and expenses Radiologix incurred in connection with the transactions contemplated by the merger agreement, in an amount up to \$1 million, if the merger agreement is terminated by Radiologix under either of the following circumstances:

- any of Primedex's, RadNet's or Merger Sub's representations or warranties set forth in the merger agreement have become untrue or incorrect, Primedex, RadNet or Merger Sub has not cured the misrepresentation within 20 business days after written notice of the misrepresentation, and the misrepresentation would cause conditions to the closing of the merger not to be satisfied; or
- Primedex, RadNet or Merger Sub has breached any of its covenants or agreements set forth in the merger agreement, has not cured the breach within 20 business days after written notice of the breach and the breach would cause conditions to the closing of the merger not to be satisfied.

The merger agreement provides that Radiologix will pay to Primedex the sum of the fees and expenses Primedex incurred in connection with the transactions contemplated by the merger agreement, in an amount up to \$1 million, if the merger agreement is terminated under the following circumstances:

- by either Primedex or Radiologix, if Radiologix stockholders do not adopt the merger agreement at the special meeting of Radiologix stockholders and an alternative acquisition proposal is publicly announced at any time after the date of the merger agreement and before the vote on the merger agreement at the special meeting;

- by Primedex, if prior to the receipt of Radiologix stockholder approval:
- Radiologix's board of directors withdraws, withholds, amends or modifies in a manner adverse to Primedex its recommendation to Radiologix stockholders in favor of adoption of the merger agreement;
- Radiologix fails to include such recommendation in this proxy statement;
- Radiologix's board of directors approves or recommends to Radiologix stockholders any other acquisition proposal;
- Radiologix enters into any letter of intent or other contract for any other acquisition proposal;
- Radiologix breaches any of its covenants with respect to its obligation to hold the stockholder meeting, its board of director's obligation to recommend to Radiologix stockholders the adoption of the merger agreement, or Radiologix's obligation not to solicit other acquisition proposals; or
- Radiologix's board of directors fails to make a statement recommending the rejection of a tender or exchange offer not made by Primedex or any of its affiliates for Radiologix common stock within 10 business days after such tender or exchange offer is first published or given;
- by Primedex, if:
 - any of Radiologix's representations or warranties set forth in the merger agreement have become untrue or incorrect, Radiologix has not cured the misrepresentation within 20 business days after written notice of the misrepresentation, and the misrepresentation would cause conditions to the closing of the merger not to be satisfied; or
 - Radiologix has breached any of its covenants or agreements set forth in the merger agreement, has not cured the breach within 20 business days after written notice of the breach and the breach would cause conditions to the closing of the merger not to be satisfied;
- by Radiologix, if prior to the receipt of Radiologix stockholder approval:
 - Radiologix has not violated any of the covenants with respect to considering other acquisition proposals, and
 - a superior offer is made to Radiologix and is not withdrawn, and
 - Radiologix has promptly provided written notice to Primedex advising Primedex that Radiologix has received a superior offer and intends to change the recommendation of its board of directors with respect to the merger or to terminate the merger agreement and the manner and timing in which it intends to do so, and
 - Primedex has not, within five days after receipt of the notice of superior offer, made an offer that Radiologix's board of directors determines in its good faith judgment (after consultation with a financial advisor) to be at least as favorable to Radiologix stockholders as such superior offer, and
 - Radiologix's board of directors concludes in good faith, after consultation with its outside legal counsel, that, in light of such superior offer and any offer made by Primedex within five days after receipt of the notice of superior offer, the Radiologix board is required to withdraw or modify its recommendation to Radiologix stockholders to vote in favor of the merger, or to terminate the merger agreement and pay to Primedex a termination fee of \$3 million and reimburse Primedex up to \$1 million of its expenses, to comply with its fiduciary obligations to Radiologix's

stockholders under applicable law.

154

In addition to payment of Primedex's expenses, Radiologix must pay Primedex a termination fee of \$3 million if the merger agreement is terminated:

- by Primedex, if prior to the receipt of Radiologix stockholder approval:
- the Radiologix board of directors withdraws, withholds, amends or modifies in a manner adverse to Primedex its recommendation to Radiologix stockholders in favor of adoption of the merger agreement;
- Radiologix fails to include such recommendation in this proxy statement;
- the Radiologix board of directors approves or recommends to Radiologix stockholders any other acquisition proposal;
- Radiologix enters into any letter of intent or other contract for any other acquisition proposal;
- Radiologix breaches any of its covenants with respect to its obligation to hold the stockholder meeting, its board of director's obligation to recommend to Radiologix stockholders the adoption of the merger agreement, or Radiologix's obligation not to solicit other acquisition proposals; or
- Radiologix's board of directors fails to make a statement recommending the rejection of a tender or exchange offer not made by Primedex or any of its affiliates for Radiologix common stock within 10 business days after such tender or exchange offer is first published or given;
- by Radiologix, if its stockholders do not adopt the merger agreement at the special meeting, and if at such time Primedex was entitled to terminate pursuant to any of the circumstances described in the immediately preceding bullet points;
- by Radiologix or Primedex, if Radiologix stockholders do not adopt the merger as a result of Radiologix's breach of the merger agreement, and an alternative acquisition proposal has been publicly announced at any time after the date of the merger agreement and before the vote on the merger agreement at the special meeting, and Radiologix enters into an alternative acquisition transaction involving at least 50% of its stock or assets within twelve months after the termination of the merger agreement.
- by Radiologix, if prior to the receipt of Radiologix stockholder approval:
- Radiologix has not violated any of the covenants with respect to considering other acquisition proposals, and
- a superior offer is made to Radiologix and is not withdrawn, and
- Radiologix has promptly provided written notice to Primedex advising Primedex that Radiologix has received a superior offer and intends to change the recommendation of its board of directors with respect to the merger or to terminate the merger agreement and the manner and timing in which it intends to do so, and
- Primedex has not, within five days after receipt of the notice of superior offer, made an offer that Radiologix's board of directors determines in its good faith judgment (after consultation with a financial advisor) to be at least as favorable to Radiologix stockholders as such superior offer, and
- Radiologix's board of directors concludes in good faith, after consultation with its outside legal counsel, that, in light of such superior offer and any offer made by Primedex within five days after receipt of the notice of superior

offer, the Radiologix board is required to withdraw or modify its recommendation to Radiologix stockholders to vote in favor of the merger, or to terminate the merger agreement and pay to Primedex a termination fee of \$3 million and

155

reimburse Primedex up to \$1 million of its expenses, to comply with its fiduciary obligations to Radiologix's stockholders under applicable law.

Indemnification and Insurance for Radiologix's Directors and Officers

Primedex will assume, and will cause the surviving corporation of the merger to fulfill, Radiologix's obligations pursuant to any indemnification agreements between Radiologix and its directors and officers and any indemnification and advancement provisions under Radiologix's certificate of incorporation or amended and restated by-laws as in effect on the date of the merger agreement. The certificate of incorporation and by-laws of the surviving corporation will contain provisions with respect to indemnification and advancement that are at least as favorable to the indemnified parties as those contained in Radiologix's certificate of incorporation and amended and restated by-laws as in effect on the date of the merger agreement. Such provisions will not be amended, repealed or otherwise modified for a period of six years from the effective time of the merger in any manner that would adversely affect the rights of the indemnified parties, unless such modification is required by applicable law.

For six years after the effective time of the merger, Primedex will cause to be maintained directors' and officers' liability insurance in respect of acts or omissions occurring prior to the effective time of the merger covering each individual who at the date of the merger agreement was an indemnified party covered by Radiologix's directors' and officers' liability insurance, on terms with respect to coverage and amounts no less favorable than those of such policy in effect on the date of the merger agreement; provided, however, that neither Primedex nor the surviving corporation be required to expend more than the amount per year equal to 200% of the current annual premiums paid by Radiologix for directors' and officers' liability insurance to maintain or procure directors' and officers' liability insurance coverage. If the amount of the annual premiums necessary to maintain or procure directors' and officers' liability insurance coverage exceeds 200% of Radiologix's current annual premiums, Primedex and surviving corporation will procure and maintain for six years after the effective time of the merger as much coverage as reasonably practicable for the amount per year equal to 200% of current annual premiums paid by Radiologix for directors' and officers' liability insurance. Primedex will have the right to cause coverage to be extended under Radiologix's directors' and officers' liability insurance by obtaining a six year tail policy on terms and conditions no less advantageous than Radiologix's existing directors' and officers' liability insurance.

Extension, Waiver and Amendment of the Merger Agreement

Primedex and Radiologix may amend the merger agreement at any time prior to the effective time of the merger. However, after stockholder adoption of the merger agreement has been obtained, no amendment may be made without further stockholder approval that, by law or in accordance with the rules of any relevant stock exchange, requires further approval by the stockholders of either Primedex or Radiologix.

At any time prior to the effective time of the merger, either Primedex or Radiologix may extend the time for the performance of any of the obligations or other acts of the other party, waive any inaccuracies in the representations and warranties of the other party, and waive compliance by the other party with any of the agreements or conditions contained in the merger agreement.

COMPARISON OF RIGHTS OF STOCKHOLDERS

As a result of the merger, holders of Radiologix common stock will become holders of Primedex common stock. See [The Merger Merger Consideration](#) beginning on page 2. The rights of holders of Primedex common stock are governed by applicable New York law, California law, and the provisions of Primedex's certificate of incorporation and bylaws.

The following is a summary of the material differences between the rights of Primedex stockholders and Radiologix stockholders. The rights of stockholders of Radiologix and Primedex are governed by Delaware law, on the one hand, and New York and California law, on the other hand, as well as their respective certificates of incorporation and bylaws, as more specifically set forth in this summary.

This summary is not intended to be a complete discussion of the material differences between the rights of stockholders of Primedex and Radiologix and is qualified in its entirety by reference to the applicable governing corporate instruments (including the certificates of incorporation and bylaws) and applicable law. Radiologix stockholders should carefully read this entire document and the documents referred to in this summary for a more complete understanding of the differences between the rights of holders of Primedex common stock and the rights of holders of Radiologix common stock. Differences in the rights of holders of Primedex capital stock and Radiologix capital stock arise primarily from differences in their respective certificates of incorporation and bylaws and from differences in the applicable law of incorporation of the relevant company. Additionally, Primedex's stockholders may have different rights by virtue of Section 2115 of the California General Corporation Law, which applies certain provisions of its corporate law to corporations incorporated in other states with a significant nexus in California. Under Section 2115, the specified California law is to be applied with respect to the foreign corporation to the exclusion of the law of the jurisdiction in which the foreign company is incorporated whenever there is a conflict. Section 2115 does not apply to a listed corporation, which is defined under California law as a corporation with (1) outstanding securities listed on the New York or American Stock Exchange or (2) a class of securities designated as a national market security on NASDAQ. Upon completion of the merger, holders of Radiologix capital stock will become holders of Primedex capital stock and their rights will be governed by New York law, the certificate of incorporation and bylaws of Primedex, as well as certain provisions of California law if and to the extent Section 2115 applies. The following discussion summarizes material differences between the rights of Primedex stockholders and Radiologix stockholders under the certificates of incorporation and bylaws of Primedex and of Radiologix.

Because this summary does not provide a complete description of these documents, all Radiologix stockholders are urged to carefully read the relevant provisions of Delaware, New York and California law, as well as the certificates of incorporation and bylaws of both Primedex and Radiologix. Copies of the certificates of incorporation and bylaws of Radiologix and Primedex will be sent to Primedex and Radiologix stockholders upon request. See [Where You Can Find More Information](#) for more information beginning on page 263.

Authorized Capital Stock

Primedex

Primedex's certificate of incorporation authorizes it to issue up to 100,000,000 shares of common stock, par value \$0.01 per share, and 10,000,000 shares of preferred stock, par value \$0.01 per share.

Radiologix

Radiologix's certificate of incorporation authorizes it to issue up to 50,000,000 shares of common stock, par value \$0.0001 per share, and 10,000,000 shares of preferred stock, par value \$0.0001 per share.

Voting Rights

Primedex

Under Primedex's certificate of incorporation and bylaws, the holders of common stock shall be entitled to vote at all meetings of the stockholders and shall be entitled to cast one vote for each share of stock held by them respectively and registered in their respective names on the books of Primedex as of the record date fixed by the Primedex board of directors. Series A stockholders are not entitled to vote on any matter, except as may be otherwise required by law.

Although New York law does not require approval of the surviving or acquiring entity or its parent entity in connection with the merger, under California law, applicable to Primedex under Section 2115 of the California General Corporation Law, stockholder approval is required for reorganizations where stockholders of the parent entity immediately prior to the reorganization will own immediately after the reorganization equity securities constituting less than five sixths of the voting power of the surviving or acquiring corporation or its parent entity.

Radiologix

Under Radiologix's certificate of incorporation, the holders of common stock shall be entitled to vote at all meetings of the stockholders and shall be entitled to cast one vote for each share of stock held by them respectively and registered in their respective names on the books of Radiologix at the close of business on the record date fixed by Radiologix's board of directors.

Cumulative Voting

Primedex

Primedex's certificate of incorporation does not provide for cumulative voting; however, Primedex is currently subject to Section 2115 of the California General Corporation Law. California law states that the right to vote cumulatively is mandatory and cannot be taken away by a provision of the certificate of incorporation. As such, under California law, Primedex's stockholders may exercise cumulative voting rights with respect to the election of directors. This means that each holder of common stock will be entitled, for each share held, to the number of votes equal to the number of directors to be elected. Each stockholder may give one candidate, who has been nominated prior to voting, all the votes such stockholder is entitled to cast or may distribute such votes among as many such candidates as such stockholder chooses.

Radiologix

Radiologix's certificate of incorporation does not provide for cumulative voting, and holders of Radiologix's common stock do not have cumulative voting rights in connection with the election of directors.

Stockholders Meetings

Annual and Special Meetings

Primedex. Primedex's bylaws provide that special meetings shall be held within five months after the close of the fiscal year of Primedex, or such other date as the board of directors shall determine in its discretion. Primedex's bylaws provide that special meetings may be called by the board of directors or the president, and shall be called by the president or secretary at the written request of the holders of at least 10% of the shares then outstanding and entitled to vote thereat. All stockholder meetings are to be held at

the principal office of Primedex, or at such other place as shall be designated in the notice or waiver of notice of such meeting.

Radiologix. Radiologix's bylaws provide that annual meetings may be held at such place as shall be designated on an annual basis by the board of directors and stated in the notice of meeting. Radiologix's certificate of incorporation and bylaws provide that special meetings shall be called by: (1) the president; or (2) the secretary, at the request in writing of the president, a majority of the members of the board of directors, or the holders of at least 20% of the shares then outstanding and entitled to vote.

Quorum

Primedex. Primedex's bylaws provide that at all stockholders meetings a quorum shall consist of stockholders, in person or by proxy, holding of record a majority of the total number of the then issued and outstanding shares entitled to vote.

Radiologix. Radiologix's bylaws provide that the holders of a majority of the stock issued and outstanding and entitled to be voted thereat, present in person or by proxy, shall constitute a quorum.

Notice of Stockholder Meetings

Primedex. Primedex's bylaws provide that written notice of every meeting of the stockholders, stating the place, date, and hour of the meeting and, in the case of a special meeting, the purpose or purposes for which the meeting is called and that such notice is being issued by or at the direction of the person or persons calling the meeting, will be given not less than 10 nor more than 50 calendar days before the date of the meeting to each stockholder of record entitled to vote at such meeting. If, at any meeting, action is proposed to be taken that would entitle stockholders to receive payment for their shares pursuant to the New York Business Corporation Law, or NYBCL, the notice of such meeting must include a statement to that purpose and to that effect and shall be accompanied by a copy of Section 623 of the NYBCL or an outline of its material terms.

Radiologix. Radiologix's bylaws provide that written notice of the date, time and place of each annual and special meeting of the stockholders shall be mailed not less than 10 nor more than 60 days previous to the date of such meeting, postage prepaid, to each stockholder of record entitled to vote thereat, at such address as shall appear on Radiologix's books.

Notice of Stockholder Proposals

Primedex. Neither Primedex's bylaws nor the NYBCL expressly provides for notice in connection with stockholder proposals.

Radiologix. Radiologix's bylaws provide that only such business shall be conducted at a meeting of the stockholders as shall be properly brought before such meeting. To be properly brought before an annual meeting, business must be: (1) specified in the notice of the meeting given by or at the direction of the Radiologix board of directors; (2) otherwise properly brought before the meeting by or at the direction of the Radiologix board of directors or (3) otherwise properly brought before the meeting by a Radiologix stockholder. For business to be properly brought before a meeting by a stockholder, timely notice in writing must be given to the secretary. To be timely, a stockholder's notice must be delivered to or mailed and received at the principal place of business not less than 30 days nor more than 60 days before the meeting; provided, however, that in the event that less than 40 days notice or prior public disclosure of the date of the meeting is given to stockholders, notice by the stockholder must be received not later than the close of business on the tenth day following the day on which such notice of the date of the meeting was mailed. No business shall be conducted at a meeting unless properly brought before such meeting in accordance with

the above procedures.

159

Radiologix's bylaws provide that, to be in proper form, stockholder notices must contain for each matter:

- a brief description of the business desired to be brought before the meeting and the reasons for conducting such business at the meeting;
- the name and address as they appear on the corporation's books of the stockholder proposing such business;
- the class and number of shares beneficially owned by the stockholder; and
- any material interest of the stockholder in such business.

Proxy

Primedex. Primedex's bylaws provide that each stockholder entitled to vote or to express consent or dissent without a meeting, may do so by proxy, provided that the instrument authorizing such proxy shall have been executed in writing by the stockholder himself or herself, or by his or her attorney-in-fact duly authorized in writing. No proxy shall be valid after the expiration of eleven months from the date of its execution, unless the persons executing it shall have specified therein the length of time it is to continue in force. Such instrument must be exhibited to the Secretary of Primedex at the meeting and shall be filed with the records of Primedex.

Radiologix. Radiologix's bylaws provide that each stockholder shall at every meeting of the stockholders be entitled to one vote in person or by proxy for each share of the capital stock having voting power held by such stockholder. No proxy shall be valid after three years from its date, unless the proxy provides for a longer period. Each proxy shall be revocable unless it expressly provides that it is irrevocable and unless it is coupled with an interest sufficient in law to support an irrevocable power.

Actions by Written Consent

Under New York law, any action by stockholders to be taken at a meeting of stockholders may be taken without a meeting if written consents stating the action to be taken are signed by the holders of all outstanding shares entitled to vote, or, if the certificate of incorporation so permits, by the holders of outstanding shares having not less than the minimum number of votes required to authorize such action at a meeting at which all shares entitled to vote were present and voted. Under Delaware law, unless the certificate of incorporation provides otherwise, any action by stockholders to be taken at a meeting of stockholders may be taken without a meeting if written consents stating the action to be taken are signed by stockholders having not less than the minimum number of votes necessary to take that action at a meeting at which all shares entitled to vote were present and voted.

Primedex. Primedex's bylaws allow actions to be taken by unanimous written consent of its stockholders.

Radiologix. Radiologix's certificate of incorporation does not specifically allow or prohibit actions to be taken by written consent of the stockholders in lieu of a meeting.

Matters Relating to the Board of Directors

Number

Primedex. Primedex's bylaws provide for at least three but no more than seven directors unless otherwise determined by a vote of a majority of the entire board of directors. The bylaws also provide that the number of directors shall in no event be less than three, unless all of the outstanding shares are owned beneficially and of record by less than three stockholders, in which event the number of directors shall not

be less than the number of stockholders. Primedex's board of directors currently consists of five directors. The members of the board of directors of Primedex are elected by a majority of the votes cast at a meeting of stockholders, by the holders of shares entitled to vote in the election.

Radiologix. Radiologix's bylaws provide that the number of directors shall be fixed from time to time by resolution of the board of directors or by the stockholders at an annual meeting; provided that the number of directors shall be not less than four nor more than nine. Radiologix's board of directors currently consists of seven directors. Radiologix's board members are elected by plurality voting, meaning that the director nominees receiving the greatest number of votes are elected.

Quorum

Primedex. Primedex's bylaws provide that a majority of the entire board of directors shall constitute a quorum.

Radiologix. Radiologix's bylaws provide that a majority of directors then in office shall constitute a quorum.

Classification of Directors

Primedex. Under the NYBCL and Primedex's bylaws, members of the board of directors will be elected by a majority vote at the annual meeting for a term of one year. Primedex's board of directors is not classified by class or otherwise elected for staggered terms.

Radiologix. Under Radiologix's certificate of incorporation, the members of the board of directors are elected by a plurality vote at the annual meeting for a term of one year. Radiologix's board of directors is not classified by class or otherwise elected for staggered terms.

Removal of Directors

Primedex. Primedex's bylaws provide that any director may be removed with or without cause at any time by the stockholders at a special meeting of the stockholders called for that purpose, and may be removed for cause by action of the board. Moreover, under the California General Corporation Law, applicable to Primedex under Section 2115, any director or the entire board of directors may be removed, with or without cause, with the approval of a majority of the outstanding shares entitled to vote; however, no individual director may be removed (unless the entire board is removed) if the number of votes cast against such removal would be sufficient to elect the director under cumulative voting. A corporation's board of directors may not remove a director unless such director has been declared of unsound mind by an order of a court or otherwise convicted of a felony. A vacancy created by a removal of a director may be filled only by the approval of stockholders. California law also provides that the superior court may, upon suit of the stockholders holding at least ten percent of the number of outstanding shares of any class, remove from office any director who engages in fraudulent or dishonest acts or gross abuse of authority or discretion with reference to the corporation and may bar from reelection any director so removed for a period prescribed by the court.

Radiologix. Neither Radiologix's certificate of incorporation, nor its bylaws specifies the permitted reasons or procedure to remove directors. As such, under applicable Delaware law, any director or the entire board of directors may be removed by the holders of a majority of shares then entitled to vote at an election of directors.

Vacancies of the Board

Primedex. Primedex's bylaws provide that any vacancy in the board of directors shall be filled for the unexpired portion of the term by a majority vote of the remaining directors, though less than a quorum, at any regular meeting or special meeting of the board called for that purpose.

Radiologix. Radiologix's bylaws provide that vacancies and newly-created directorships resulting from any increase in the authorized number of directors may be filled by a majority of the directors then in office, though less than a quorum, or by a sole remaining director. The directors so chosen shall serve for the remainder of the term of the vacated directorships being filled and until their successors are duly elected and qualified, unless sooner displaced.

Preemptive Rights

Primedex

Under the NYBCL, with respect to a corporation formed under New York law prior to February 22, 1998, in the case of a proposed issuance by the corporation of, or the proposed granting by the corporation of rights or options to purchase, its equity shares or any shares or other securities convertible into or carrying rights or options to purchase such shares, stockholders of the corporations have preemptive rights to purchase such shares, unless the certificate of incorporation provides otherwise. Primedex's certificate of incorporation expressly eliminates preemptive rights to its shareholders.

Radiologix

Radiologix's certificate of incorporation does not grant any preemptive rights.

Dividends

Primedex

Primedex's bylaws provide that dividends may be declared and paid out of any funds, shares or property available therefor, as often and in such amounts and at such time as the board of directors may determine. However, under California law, no distributions to a corporation's stockholders may be made unless: (i) the amount of the retained earnings of the corporation immediately prior to the distribution equals or exceeds the amount of the proposed distribution; (ii) immediately after the distribution, the sum of the assets of the corporation (excluding certain items) is at least equal to 1¼ times its liabilities; and the current assets of the corporation is at least equal to its current liabilities, or if the average of the earnings of the corporation before taxes on income and before interest expense for the two preceding fiscal years was less than the average of the interest expense of the corporation for those fiscal years, at least equal to 1¼ times its current liabilities. California law generally provides that a corporation may acquire its own shares, with the payment for such shares being subject to the same restrictions as dividend payments.

Radiologix

Radiologix's bylaws provide that dividends may be declared by the board at any duly called regular or special meeting. Under applicable Delaware law, dividends may be paid out of a corporation's surplus or out of its net profits for the fiscal year in which the dividend is declared and/or the previous year.

Limitation of Personal Liability of Directors

Primedex

New York law provides that directors of a corporation who vote for or concur in any of the following corporate actions shall be jointly and severally liable to the corporation for the benefit of its creditors or stockholders, to the extent of any injury suffered by such persons, respectively, as a result of such action: (1) the declaration of any dividend or other distribution to the extent that it is contrary to the provisions of Section 510 of the NYBCL relating to the declaration of dividends; (2) the purchase of the shares of the corporation to the extent that it is contrary to the provisions of Section 513 of the NYBCL relating to the purchase or redemption by a corporation of its own shares; (3) the distribution of assets to stockholders after dissolution of the corporation without paying or adequately providing for all known liabilities of the corporation, excluding any claims not filed by creditors within the time limit set in a notice given to creditors under the provisions of Articles 10 or 11 of the NYBCL relating to corporation dissolution; and (4) the making of any loan contrary to the provisions of Section 714 of the NYBCL relating to loans made to directors.

Primedex's bylaws provide that no director may be liable in any way by reason of the fact that any one or more of the directors of Primedex is or are interested in, or is a director or officer, or are directors or officers of a corporation with which Primedex has entered into a contract or transaction; provided that such facts are disclosed to the board of Primedex. The bylaws also provide that any director, personally and individually, may be a party to or be interested in any contract or transaction of Primedex, and no director shall be liable in any way by reason of such interest; provided further that the fact of such interest be disclosed to the board; and provided that the board shall authorize, approve, or ratify such contract or transaction, notwithstanding the presence of the interested director at the meeting at which such action is taken.

Radiologix

Radiologix's certificate of incorporation provides that no director will be personally liable for monetary damages for any breach of fiduciary duty as a director, except (i) for any breach of the director's duty of loyalty to Radiologix or its stockholders, (ii) for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law, (iii) pursuant to Section 174 of the DGCL relating to unlawful dividend payments, stock purchases or redemptions or (iv) for any transaction from which the director derived an improper personal benefit.

Indemnification of Directors and Officers

Primedex

Primedex's bylaws provide that, subject to the NYBCL, Primedex may indemnify any person made a party to an action by or in the right of Primedex to procure a judgment in its favor by reason of the fact that he, his testator or intestate, is or was a director or officer of Primedex, against the reasonable expenses, including attorneys' fees, actually and necessarily incurred by him in connection with the defense of such action, or in connection with an appeal therein, except in relation to matters as to which such director or officer is adjudged to have breached his duty to Primedex, as such duty is defined in Section 717 of the NYBCL. Subject to the conditions and qualifications set forth in the NYBCL, Primedex may also indemnify any person, made, or threatened to be made, a party to an action or proceeding other than one by or in the right of Primedex to procure a judgment in its favor, whether civil or criminal, including an action by or in the right of any other corporation, domestic or foreign, which he served in any capacity at the request of the corporation by reason of the fact that he, his testator or intestate was a director or officer of the corporation or served it in any capacity against judgments, fines, amounts paid in settlement, and reasonable expenses, including attorneys' fees actually and necessarily incurred as a result of such

action or proceeding, or any appeal therein, if such director or officer acted in good faith for a purpose which he reasonably believed to be in the best interest of Primedex, and in criminal actions or proceedings, in addition had no reasonable cause to believe his conduct was unlawful.

Radiologix

Radiologix's certificate of incorporation provides that the corporation shall, to the broadest and maximum extent permitted by Delaware law, indemnify each person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceedings, whether civil, criminal, administrative or investigative by reason of the fact that he or she is or was a director or officer of Radiologix, or is or was serving at the request of Radiologix as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against expenses, judgments, fines, and amounts paid in settlement actually and reasonably incurred by him or her in connection with such action, suit or proceeding. In addition, Radiologix shall, to the greatest extent permitted by Delaware law, pay to such person any and all expenses incurred in defending or settling any such action, suit or proceeding in advance of the final disposition of such action, suit or proceeding upon receipt of an undertaking by or on behalf of the director or officer to repay such amount if it shall ultimately be determined by a final judgment or other final adjudication that he or she is not entitled to be indemnified by Radiologix under its certificate of incorporation. Radiologix shall not indemnify any such person with respect to any of the following matters: (1) remuneration paid to such person if it shall be determined by a final judgment or other final adjudication that such remuneration was in violation of the law; (2) any accounting of profits made from the purchase or sale of Radiologix's securities within the meaning of Section 16(b) of the Securities Exchange Act of 1934; (3) actions brought about or contributed to by the dishonesty of such person, if a final judgment or other final adjudication adverse to such person establishes that acts of active and deliberate dishonesty were committed or attempted by such person with actual dishonest purpose and intent and were material to the adjudication; (4) actions based on or attributable to such person having gained any personal profit or advantage to which he or she was not entitled, in the event that a final judgment or other final adjudication adverse to such person establishes that such person in fact gained such personal profit or other advantage to which he or she was not entitled; or (5) any matter in respect of which a final decision by a court with competent jurisdiction shall determine that indemnification is unlawful.

Anti-Takeover Matters

Rights Plans

Neither Primedex nor Radiologix has a stockholder rights plan.

Certain Business Combination Restrictions

Section 912 of the NYBCL protects publicly traded New York corporations, such as Primedex, from hostile takeovers and from actions following the takeover, by prohibiting certain kinds of business combinations for a designated period once an acquirer has gained significant holdings in the corporation. A corporation may elect not to be governed by Section 912 of the NYBCL. In addition, Section 513(c) of the NYBCL prevents a corporation which is subject to Section 912 of the NYBCL from purchasing more than 10% of the corporation's stock from a shareholder at a price greater than the market value of the stock unless the purchase is approved by the affirmative vote of the board of directors and a majority of all of the outstanding shares.

Section 203 of the DGCL protects publicly-traded Delaware corporations, such as Radiologix, from hostile takeovers, and from actions following the takeover, by prohibiting some transactions once an

acquirer has gained a significant holding in the corporation. A corporation may elect not to be governed by Section 203 of the DGCL.

Primedex. Neither Primedex's certificate of incorporation nor its bylaws contain anti-takeover provisions, nor do they contain the election not to be governed by Section 912 of the NYBCL. Therefore, Primedex is governed by Section 912 of the NYBCL.

Radiologix. Radiologix's certificate of incorporation specifies that Radiologix elects to be governed by Section 203 of the DGCL. However, Radiologix's board of directors has expressly approved the merger agreement and the transactions contemplated by the merger agreement, including the merger. As such, the restrictions on business combinations set forth in Section 203 of the DGCL do not apply to the merger agreement and the transactions contemplated by the merger agreement, including the merger.

Vote on Certain Fundamental Issues

Primedex. Neither Primedex's certificate of incorporation nor its bylaws includes a provision specifically addressing special voting procedures. As such, Primedex is governed by the voting requirements of Section 912 of the NYBCL.

Radiologix. Radiologix's certificate of incorporation specifies that Radiologix elects to be governed by Section 203 of the DGCL.

Amendments to Constituent Documents

The NYBCL provides that an amendment or change of the certificate of incorporation may be authorized by a vote of the board of directors, followed by a vote of a majority of all outstanding shares entitled to vote thereon at a meeting of stockholders; provided, however, that, whenever the certificate of incorporation requires action by the board of directors, by the holders of any class or series of shares, or by the holders of any other securities having voting power by the vote of a greater number or proportion than is required by the NYBCL, the provision of the certificate of incorporation requiring such greater vote shall not be altered, amended, or repealed except by such greater vote; and provided further that an amendment to the certificate of incorporation for the purpose of reducing the requisite vote by the holders of any class or series of shares or by the holders of any other securities having voting power that is otherwise provided for in the NYBCL that would otherwise require more than a majority of the votes of all outstanding shares entitled to vote thereon shall not be adopted except by the vote of such holders of class or series of shares or by such holders of such other securities having voting power that is at least equal to that which would be required to take the action provided under the NYBCL. The NYBCL also provides that the following changes may be made pursuant to authorization of the board alone: (1) to specify or change the location of the corporation's office; (2) to specify or change the address to which the secretary of state shall mail a copy of any process against the corporation served upon him or her; (3) to make, revoke or change the designation of a registered agent, or to specify or change the address of its registered agent.

Delaware law provides that an amendment to a corporation's certificate of incorporation requires that the board of directors adopt a resolution setting forth the proposed amendment and that a majority of the voting power of the then outstanding capital stock of the corporation approve the amendment.

Primedex

Primedex's certificate of incorporation does not specify a process for amendment of the certificate. Therefore, the provisions of the NYBCL regarding amendment of the certificate govern. Primedex's bylaws provide that they may be altered or repealed and new bylaws made by a majority vote of the stockholders entitled to vote in the election of directors, or by the board of directors, except that the board

shall have no power to change the quorum for meetings of stockholders or the board of directors, or to change any provisions of the bylaws with respect to the removal of directors or the filling of vacancies in the board resulting from the removal by the stockholders.

Radiologix

Radiologix's amended and restated certificate of incorporation provides that Radiologix may amend, alter, change or repeal any provision in the certificate of incorporation in the manner provided by statute. The amended and restated certificate also provides that a majority of the board may adopt, amend or repeal Radiologix's bylaws, except any by-law that expressly provides that it cannot be altered, amended or repealed by the board. Radiologix's bylaws state that if the power to adopt, amend or repeal the bylaws is conferred upon the board in the certificate of incorporation, it shall not divest or limit the power of the stockholders to adopt, amend or repeal the bylaws.

166

INFORMATION ABOUT PRIMEDEX

Business

General

Primedex is a New York corporation. Primedex and its predecessors have been providing diagnostic imaging services in the state of California since October 31, 1985. Imaging services include magnetic resonance imaging, or MRI, computed tomography, or CT, positron emission tomography, or PET, nuclear medicine, mammography, ultrasound, diagnostic radiology, or X-ray, and fluoroscopy.

Primedex operates a group of regional networks comprised of 65 fixed-site, freestanding outpatient diagnostic imaging facilities in California. Primedex has strategically organized its facilities into regional networks in markets that have both high-density and expanding populations, as well as attractive payor diversity.

All of Primedex's facilities employ state-of-the-art equipment and technology in modern, patient-friendly settings. Many of Primedex's facilities within a particular region are interconnected and integrated through advanced information technology systems. Thirty-eight of Primedex's facilities are multi-modality sites, offering various combinations of MRI, CT, PET, nuclear medicine, mammography, ultrasound, X-ray and fluoroscopy. Twenty-three of Primedex's facilities are single-modality sites, offering either X-ray or MRI. Consistent with Primedex's regional network strategy, Primedex locates its single-modality facilities near multi-modality sites to help accommodate overflow in targeted demographic areas.

Primedex provides all of the equipment as well as all non-medical operational, management, financial and administrative services necessary to provide diagnostic imaging services. Primedex gives its facility managers authority to run Primedex's facilities to meet the demands of local market conditions, while Primedex's corporate structure provides economies of scale, corporate training programs, standardized policies and procedures and sharing of best practices across Primedex's networks. Each of Primedex's facility managers is responsible for meeting Primedex's standards of patient service, managing relationships with local physicians and payors and maintaining profitability.

Howard G. Berger, M.D. is Primedex's President and Chief Executive Officer, chair of Primedex's Board of Directors and owns approximately 30% of Primedex's outstanding common stock. Dr. Berger also owns, indirectly, 99% of the equity interests in Beverly Radiology Medical Group III, or BRMG. BRMG provides all of the professional medical services at 46 of Primedex's facilities under a management agreement with Primedex, and contracts with various other independent physicians and physician groups to provide the professional medical services at most of Primedex's other facilities. Primedex obtains professional medical services from BRMG, rather than provide such services directly or through subsidiaries, in order to comply with California's prohibition against the corporate practice of medicine. However, as a result of Primedex's close relationship with Dr. Berger and BRMG, Primedex believes that Primedex is able to better ensure that medical service is provided at Primedex's facilities in a manner consistent with Primedex's needs and expectations and those of Primedex's referring physicians, patients and payors than if Primedex obtained these services from unaffiliated physician groups.

Primedex derives substantially all of its revenue, directly or indirectly, from fees charged for the diagnostic imaging services performed at its facilities. For the year ended October 31, 2005, Primedex performed 958,414 diagnostic imaging procedures and generated net revenue from continuing operations of \$145.6 million.

The following table illustrates Primedex's work performed over the five-year period ended October 31, 2005:

	Year Ended October 31,				
	2001	2002	2003	2004	2005
Total number of MRI, CT and PET systems*	52	60	63	68	68
Total number of procedures performed	690,484	877,574	947,032	946,928	958,414

* All properties. Excludes discontinued operation.

Primedex's executive offices are located at 1510 Cotner Avenue, Los Angeles, CA 90025, telephone number: (310) 478-7808.

Business Strategy

Maximizing Performance At Primedex's Existing Facilities

Primedex intends to enhance its operations and increase scan volume and revenue at its existing facilities by:

- establishing new referring physician and payor relationships;
- increasing patient referrals through targeted marketing efforts to referring physicians;
- adding modalities and increasing imaging capacity through equipment upgrades to existing machinery, additional machinery and relocating machinery to meet the needs of its regional markets;
- leveraging its multi-modality offerings to increase the number of high-end procedures performed; and
- building upon its capitation arrangements to obtain fee-for-service business.

Focusing On Profitable Contracting

Primedex regularly evaluates its contracts with third-party payors and radiology groups, as well as its equipment and real property leases, to determine how Primedex may improve the terms to increase its revenues and reduce its expenses. Because many of its contracts have one-year terms, Primedex can regularly renegotiate these contracts, if necessary. Primedex believes its position as a leading provider of diagnostic imaging services in California, its experience and knowledge of the various geographic markets in California, and the benefits offered by its regional networks enable Primedex to obtain more favorable contract terms than would be available to smaller or less experienced organizations.

Expanding MRI and CT Applications

Primedex intends to continue to use expanding MRI and CT applications as they become commercially available. Most of these applications can be performed by its existing MRI and CT systems with upgrades to software and hardware. By way of example, in January 2005, Primedex placed into service a new piece of equipment which functions in conjunction with the MRI and utilizes focused ultrasound as a completely non-invasive procedure to treat symptomatic uterine fibroids. The equipment costing \$750,000 received FDA approval in late October 2004 and Primedex is the first organization in the Western United States to acquire the equipment. Primedex also intends to introduce applications that will decrease scan and image-reading time to increase its productivity.

Optimizing Operating Efficiencies

Primedex intends to maximize its equipment utilization by adding, upgrading and re-deploying equipment where Primedex experiences excess demand. Primedex will continue to trim excess operating and general and administrative costs where it is feasible to do so, including consolidating, divesting or closing under-performing facilities to reduce operating costs and improve operating income. Primedex also may continue to use, where appropriate, high-trained radiology physician assistants to perform, under appropriate supervision of radiologists, basic services traditionally performed by radiologists. Primedex will continue to upgrade its advanced information technology system to create cost reductions for its facilities in areas such as image storage, support personnel and financial management.

Expanding Primedex's Networks

Primedex intends to expand its networks of facilities through new developments and acquisitions, such as the Merger, using a disciplined approach for evaluating and entering new areas, including consideration of whether Primedex has adequate financial resources to expand. Primedex performs extensive due diligence before developing a new facility or acquiring an existing facility, including surveying local referral sources and radiologists, as well as examining the demographics, reimbursement environment, competitive landscape and intrinsic demand of the geographic market. Primedex generally will only enter new markets where:

- there is sufficient patient demand for outpatient diagnostic imaging services;
- Primedex believes Primedex can gain significant market share;
- Primedex can build key referral relationships or Primedex has already established such relationships; and
- payors are receptive to its entry into the market.

Primedex's Services

Primedex offers the following services: MRI, CT, PET, nuclear medicine, X-ray, ultrasound, mammography and fluoroscopy. Primedex's facilities provide standardized services, regardless of location, to ensure patients, physicians and payors consistency in service and quality. Primedex monitors its level of service, including patient satisfaction, timeliness of services to patients and reports to physicians.

The key features of its services include:

- patient-friendly, non-clinical environments;
- a 24-hour turnaround on routine examinations;
- interpretations within one to two hours, if needed;
- flexible patient scheduling, including same-day appointments;
- extended operating hours, including weekends;
- reports delivered via courier, fax or email;
- availability of second opinions and consultations;
- availability of sub-specialty interpretations at no additional charge;
- standardized fee schedules by region; and
- fees that are more competitive than hospital fees.

Radiology Professionals

In California, a lay person or any entity other than a professional corporation is not allowed to practice medicine, including by employing professional persons or by having any ownership interest or profit participation in or control over any medical professional practice. This doctrine is commonly referred to as the prohibition on the corporate practice of medicine. In order to comply with this prohibition, Primedex contracts directly or through BRMG, with radiologists to provide professional medical services in its facilities, including the supervision and interpretation of diagnostic imaging procedures. The radiology practice maintains full control over the physicians it employs. Pursuant to each management contract, Primedex makes available the imaging facility and all of the furniture and medical equipment at the facility for use by the radiology practice, and the practice is responsible for staffing the facility with qualified professional medical personnel. In addition, Primedex provides management services and administration of the non-medical functions relating to the professional medical practice at the facility, including among other functions, provision of clerical and administrative personnel, bookkeeping and accounting services, billing and collection, provision of medical and office supplies, secretarial, reception and transcription services, maintenance of medical records, and advertising, marketing and promotional activities. As compensation for the services furnished under contracts with radiologists, Primedex receives an agreed percentage of the medical practice billings for, or collections from, services provided at the facility, typically varying between 79% to 84% of net revenue or collections.

At 46 of its facilities, BRMG is its contracted radiology group. At October 31, 2005, BRMG employed approximately 48 full-time and 9 part-time radiologists. At the balance of its facilities Primedex contracts, directly or through BRMG, with other radiology groups to provide the professional medical services. Two imaging facilities previously owned by Burbank Advanced Imaging Center LLC and Rancho Bernardo Advanced Imaging Center LLC were charged a fee, for its services as manager of the limited liability companies, of 10% of the collected revenue of each company after deduction of the professional fees. In addition, as a member owning 75% of the equity interests of those limited liability companies, Primedex was entitled to 75% of income after a deduction of all expenses, including amounts paid for medical services and medical supervision. In the fourth quarter of fiscal 2004, Primedex purchased the interest Primedex did not own in both centers.

Under its management agreement with BRMG, BRMG pays Primedex, as compensation for the use of its facilities and equipment and for its services, a percentage of the amounts collected for the professional services it renders. The percentage is adjusted annually, if necessary, to ensure that the parties receive the fair value for the services they render.

The following are the other principal terms of its management agreement with BRMG:

- The agreement expires on January 1, 2014. However, the agreement automatically renews for consecutive 10-year periods, unless either party delivers a notice of non-renewal to the other party no later than six months prior to the scheduled expiration date. In addition, either party may terminate the agreement if the other party defaults under its obligations, after notice and an opportunity to cure, and Primedex may terminate the agreement if Dr. Berger no longer owns at least 60% of the equity of BRMG.
- At its expense, BRMG employs or contracts with an adequate number of physicians necessary to provide all professional medical services at all of its facilities.
- At its expense, Primedex provides all furniture, furnishings and medical equipment located at the facilities and Primedex manages and administers all non-medical functions at, and provides all nurses and other non-physician personnel required for the operation of, the facilities.

- If BRMG wants to open a new facility, Primedex has the right of first refusal to provide the space and services for the facility under the same terms and conditions set forth in the management agreement.
- If Primedex wants to open a new facility, BRMG must use its best efforts to provide medical personnel under the same terms and conditions set forth in the management agreement. If BRMG cannot provide such personnel, Primedex has the right to contract with other physicians to provide services at the facility.

BRMG must maintain medical malpractice insurance for each of its physicians with coverage limits not less than \$1 million per incident and \$3 million in the aggregate per year. BRMG also has agreed to indemnify Primedex for any losses Primedex suffers that arise out of the acts or omissions of BRMG and its employees, contractors and agents.

Payors

Primedex derives substantially all of its revenue, directly or indirectly, from fees charged for the diagnostic imaging services performed at its facilities. These fees are paid by a diverse mix of payors, as illustrated for the year ended October 31, 2005 by the following table:

Payor Type	Percentage of Net Revenue
Insurance(1)	41 %
Managed Care Capitated Payors	26 %
Medicare/Medi-Cal	18 %
Other(2)	11 %
Workers Compensation/Personal Injury	4 %

(1) Includes Blue Cross/Blue Shield, which represented 15% of its net revenue for the year ended October 31, 2005.

(2) Includes co-payments, direct patient payments and payments through contracts with physician groups and other non-insurance company payors.

With the exception of Blue Cross/Blue Shield and government payors, no single payor accounted for more than 5% of its net revenue for the year ended October 31, 2005.

Primedex has described below the types of reimbursement arrangements Primedex has, directly or indirectly, including through BRMG, with third-party payors.

Insurance

Generally, insurance companies reimburse Primedex, directly or indirectly, including through BRMG, on the basis of agreed upon rates. These rates are on average approximately the same as the rates set forth in the Medicare Fee Schedule for the particular service. The patients are generally not responsible for any amount above the insurance allowable amount.

Managed Care Capitation Agreements

Under these agreements, which are between BRMG and the payor, typically an independent physicians group or other medical group, the payor pays a pre-determined amount per-member per-month in exchange for BRMG providing all necessary covered services to the managed care members included in the agreement. These contracts pass much of the financial risk of providing outpatient diagnostic imaging services, including the risk of over-use, from the payor to BRMG and, as a result of its management agreement with BRMG, to Primedex.

Primedex believes that through its comprehensive utilization management, or UM, program Primedex has become highly skilled at assessing and moderating the risks associated with the capitation agreements, so that these agreements are profitable for Primedex. Primedex's UM program is managed by its UM department, which consists of administrative and nursing staff as well as BRMG medical staff who are actively involved with referring physicians and payor management in both prospective and retrospective review programs. Primedex's UM program includes the following features, all of which are designed to manage its costs while ensuring that patients receive appropriate care:

- **Physician Education** At the inception of a new capitation agreement, Primedex provides the new referring physicians with binders of educational material comprised of proprietary information that Primedex has prepared and third-party information Primedex has compiled, which are designed to address diagnostic strategies for common diseases. Primedex distributes additional material according to the referral practices of the group as determined in the retrospective analysis described below.
- **Prospective Review** Referring physicians are required to submit authorization requests for non-emergency high-intensity services: MRI, CT, special procedures and nuclear medicine studies. The UM medical staff, according to accepted practice guidelines, considers the necessity and appropriateness of each request. Notification is then sent to the imaging facility, referring physician and medical group. Appeals for cases not approved are directed to Primedex. The capitated payor has the final authority to uphold or deny its recommendation.
- **Retrospective Review** Primedex collects and sorts encounter activity by payor, place of service, referring physician, exam type and date of service. The data is then presented in quantitative and analytical form to facilitate understanding of utilization activity and to provide a comparison between fee-for-service and Medicare equivalents. Primedex's Medical Director prepares a quarterly report for each payor and referring physician, which Primedex sends to them. When Primedex finds that a referring physician is over-utilizing services, Primedex work with the physician to modify referral patterns.

Medicare/Medi-Cal

Medicare is the national health insurance program for people age 65 or older and people under age 65 with certain disabilities. Medi-Cal is the California health insurance program for qualifying low income persons. Medicare and Medi-Cal reimburse Primedex, directly or indirectly, including through BRMG, in accordance with the Medicare Fee Schedule, which is a schedule of rates applicable to particular services and annually adjusted upwards or downwards, typically, within a 4-8% range. Medicare patients are not responsible for any amount above the Medicare allowable amount. Medi-Cal patients are not responsible for any unreimbursed portion.

Contracts With Physician Groups and Other Non-Insurance Company Payors

These payors reimburse Primedex, directly or indirectly, on the basis of agreed upon rates. These rates are typically set at 70-80% of the rates set forth in the Medicare Fee Schedule for the particular service. However, Primedex often agrees to a specified rate for MRI and CT procedures that is not tied to the Medicare Fee Schedule. The patients are generally not responsible for the unreimbursed portion.

Facilities

Edgar Filing: RADIOLOGIX INC - Form DEFM14A

Through its wholly-owned subsidiaries, Primedex operates 65 fixed-site, freestanding outpatient diagnostic imaging facilities in California. Primedex leases the premises at which these facilities are located, with the exception of two facilities located in buildings Primedex owns. Primedex leases the land on which both of those buildings are located.

173

Primedex's facilities are located in regional networks that Primedex refers to as regions. Thirty-four of its facilities are multi-modality sites, offering various combinations of MRI, CT, PET, nuclear medicine, ultrasound, X-ray and fluoroscopy services. Twenty-three of its facilities are single-modality sites, offering either X-ray or MRI services. Consistent with its regional network strategy, Primedex locates its single-modality facilities near multi-modality facilities, to help accommodate overflow in targeted demographic areas.

The following table sets forth the number of its facilities for each year during the five-year period ended October 31, 2005:

	Year Ended October 31,				
	2001	2002	2003	2004	2005
Total facilities owned or managed (at beginning of year)	42	46	58	55	56
Facilities added by:					
Acquisition	3	1			
Internal development	4	11	3	4	1
Facilities closed or sold	(3)		(6)	(3)	
Total facilities owned (at year-end)	46	58	55	56	57

Diagnostic Imaging Equipment

The following table indicates, as of December 31, 2005, the quantity of principal diagnostic equipment available at Primedex's facilities, by region:

	MRI	Open MRI	CT	PET/CT	Mammography	Ultra-sound	X-ray	Nuclear Medicine	Total
Beverly Hills	4	1	2	1	3	4	3	1	19
Ventura	2	2	1	2	5	9	15	2	38
San Fernando Valley	3	3	3	1	2	6	7	1	26
Antelope Valley	1	1	1		1	1	2	1	8
Central California	3	3	5		5	10	12	2	40
Northern California	1	2	2				1		6
Orange	2	1	1	1	3	7	4	1	20
Long Beach	1		1		3	4	7	1	17
Northern San Diego		1	1				1		3
Palm Springs	1	1	2		2	7	7	1	21
Inland Empire	5	1	4	1	8	12	12	3	46
Total	23	16	23	6	32	60	71	13	244

The average age of Primedex's MRI and CT units is less than six years, and the average age of its PET units is less than four years. The useful life of the MRI, CT and PET units is typically ten years.

Information Technology

The corporate headquarters and substantially all of Primedex's facilities are interconnected through a state-of-the-art information technology system. This system, which is compliant with the Health Insurance Portability and Accountability Act of 1996, is comprised of a number of integrated applications, provides a single operating platform for billing and collections, electronic medical records, practice management and image management.

This technology has created cost reductions for the facilities in areas such as image storage, support personnel and financial management and has further allowed Primedex to optimize the productivity of all aspects of our business by enabling Primedex to:

- capture all necessary patient demographic, history and billing information at point-of-service;
- automatically generate bills and electronically file claims with third-party payors;
- record and store diagnostic report images in digital format;
- digitally transmit on a real time basis diagnostic images from one location to another, thus enabling networked radiologists to cover larger geographic markets by using the specialized training of other networked radiologists;
- perform claims, rejection and collection analysis; and
- perform sophisticated financial analysis, such as analyzing cost and profitability, volume, charges, current activity and patient case mix, with respect to each of our managed care contracts.

Currently diagnostic reports and images are accessible via the Internet to referring providers. Primedex has worked with some of the larger medical groups with whom it has contracts to provide this form of access.

Employees

At July 31, 2006, Primedex had a total of 1,023 full-time, 65 part-time and 122 per-diem employees. These numbers do not include the 48 full-time and 9 part-time radiologists or the 288 full-time, 40 part-time and 161 per-diem technologists.

Primedex employs a site manager who is responsible for overseeing day-to-day and routine operations at each facility, including staffing, modality and schedule coordination, referring physician and patient relations and purchasing of materials. In turn, Primedex's 8 regional managers and directors are responsible for oversight of the operations of all facilities within their region, including sales, marketing and contracting. The regional managers and directors, along with Primedex's directors of contracting, marketing, facilities, management/purchasing and human resources report to the chief operating officer.

None of Primedex's employees are subject to a collective bargaining agreement.

Marketing

Primedex's marketing team consists of one director of marketing, five territory sales managers and eighteen customer service representatives, one of which is part-time, employs a multi-pronged approach to marketing:

Physician Marketing

Each customer service representative is responsible for marketing activity on behalf of one or more facilities. The representatives act as a liaison between the facility and referring physicians, holding meetings periodically and on an as-needed basis with them and their staff to present educational programs on new applications and uses of our systems and to address particular patient service issues that have arisen. In Primedex's experience, consistent hands-on contact with a referring physician and his or her staff generates goodwill and increases referrals. The representatives also continually seek to establish referral relationships with new physicians and physician groups. In addition to a base salary and a car allowance, each representative receives a quarterly bonus if the facility or facilities on behalf of which he or she markets meets specified net revenue goals for the quarter.

Payor Marketing

Primedex's marketing team regularly meets with managed care organizations and insurance companies to solicit contracts and meet with existing contracting payors to solidify those relationships. The comprehensiveness of the services, the geographic location of the facilities and the reputation of the physicians with whom it contracts all serve as tools for obtaining new or repeat business from payors.

Sports Marketing Program

Primedex has a sports marketing program designed to increase public profile. It provides X-ray equipment and a technician for all of the games of the Los Angeles Lakers, Clippers, Kings, Avengers and Sparks held at the Staples Center in Los Angeles, Anaheim Ducks games held at the Arrowhead Pond in Anaheim, and University of Southern California football games held in Los Angeles. In exchange for this service, Primedex receives an advertisement in each team program throughout the season. In addition, Primedex has a close relationship with the physicians for some of these teams.

Suppliers

Historically, Primedex has acquired almost all of its diagnostic imaging equipment from GE Medical Systems, Inc., and purchases medical supplies from various national vendors. Primedex believes that it has excellent working relationships with all of its major vendors. However, there are several comparable vendors that would be available if one of the current vendors becomes unavailable.

Primedex acquires its equipment primarily through various financing arrangements directly with an affiliate of General Electric Corporation, or GE, involving the use of capital leases with purchase options at minimal prices at the end of the lease term. At October 31, 2005, capital lease obligations, excluding interest, totaled approximately \$62.8 million through 2010, including current installments totaling approximately \$58.6 million. If Primedex opens or acquires additional imaging facilities, it may have to incur material capital lease obligations.

Timely, effective maintenance is essential for achieving high utilization rates of Primedex's imaging equipment. Primedex also has an arrangement with GE Medical Systems under which GE has agreed to be responsible for the maintenance and repair of a majority of Primedex's equipment for a fee that is based upon a percentage of revenue, subject to a minimum payment. Net revenue is reduced by the provision for bad debt, mobile PET revenue and other professional reading service revenue to obtain adjusted net revenue. The fiscal 2005 annual service fee was the higher of 3.50% of our adjusted net revenue, or \$4,970,000. The fiscal 2006 annual service rate will be the higher of 3.62% of our adjusted net revenue, or \$5,393,800. For the fiscal years 2007, 2008 and 2009, the annual service fee will be the higher of 3.62% of our adjusted net revenue, or \$5,430,000. Primedex believes this framework of basing service costs on usage is an effective and unique method for controlling its overall costs on a facility-by-facility basis.

Competition

The market for diagnostic imaging services in California is highly competitive. Primedex competes principally on the basis of its reputation, its ability to provide multiple modalities at many of its facilities, the location of its facilities and the quality of its diagnostic imaging services. Primedex competes locally with groups of radiologists, established hospitals, clinics and other independent organizations that own and operate imaging equipment. Primedex's major national competitors include Alliance Imaging, Inc., HealthSouth Corporation and Insight Health Services. Some of Primedex's competitors may now or in the future have access to greater financial resources than does Primedex and may have access to newer, more advanced equipment. In addition, physician practices may elect to establish their own diagnostic imaging facilities within their group practices and compete with Primedex.

Insurance

Primedex maintains insurance policies with coverage that it believes are appropriate in light of the risks attendant to its business and consistent with industry practice. However, adequate liability insurance may not be available to it in the future at acceptable costs or at all. Primedex maintains general liability insurance and professional liability insurance in commercially reasonable amounts. Additionally, Primedex maintains workers' compensation insurance on all of its employees. Coverage is placed on a statutory basis and responds to California's requirements.

Pursuant to agreements with physician groups with whom Primedex contracts, including BRMG, each group must maintain medical malpractice insurance for the group, having coverage limits of not less than \$1 million per incident and \$3 million in the aggregate per year.

California's medical malpractice cap further reduces Primedex's exposure. California places a \$250,000 limit on non-economic damages for medical malpractice cases. Non-economic damages are defined as compensation for pain, suffering, inconvenience, physical impairment, disfigurement and other non-pecuniary injury. The cap applies whether the case is for injury or death, and it allows only one \$250,000 recovery in a wrongful death case. No cap applies to economic damages.

Primedex maintains a \$5 million key-man life insurance policy on the life of Dr. Berger. Primedex is the beneficiary under the policy.

Regulation

General

The healthcare industry is highly regulated, and Primedex can give no assurance that the regulatory environment in which Primedex operates will not change significantly in the future. Primedex's ability to operate profitably will depend in part upon Primedex, and the contracted radiology practices and their affiliated physicians obtaining and maintaining all necessary licenses and other approvals, and operating in compliance with applicable healthcare regulations. Primedex believes that healthcare regulations will continue to change. Therefore, Primedex monitors developments in healthcare law and modifies its operations from time to time as the business and regulatory environment changes. Although Primedex intends to continue to operate in compliance, Primedex cannot ensure that Primedex will be able to adequately modify its operations so as to address changes in the regulatory environment.

Licensing and Certification Laws

Ownership, construction, operation, expansion and acquisition of diagnostic imaging facilities are subject to various federal and state laws, regulations and approvals concerning licensing of facilities and personnel. In addition, free-standing diagnostic imaging facilities that provide services not performed as part of a physician office must meet Medicare requirements to be certified as an independent diagnostic testing facility to bill the Medicare program. Primedex may not be able to receive the required regulatory approvals for any future acquisitions, expansions or replacements, and the failure to obtain these approvals could limit the market for its services.

Corporate Practice of Medicine

In California, a lay person or any entity other than a professional corporation is not allowed to practice medicine, including by employing professional persons or by having any ownership interest or profit participation in or control over any medical professional practice. The laws of the State of California also prohibit a lay person or a non-professional entity from exercising control over the medical judgments or decisions of physicians and from engaging in certain financial arrangements, such as splitting professional fees with physicians. Primedex structures its relationships with the radiology practices, including the purchase of diagnostic imaging facilities, in a manner that Primedex believes keeps it from

engaging in the practice of medicine or exercising control over the medical judgments or decisions of the radiology practices or their physicians or violating the prohibitions against fee-splitting. However, because challenges to these types of arrangements are not required to be reported, Primedex cannot substantiate its belief. There can be no assurance that its present arrangements with BRMG or the physicians providing medical services and medical supervision at its imaging facilities will not be challenged, and, if challenged, that they will not be found to violate the corporate practice prohibition, thus subjecting Primedex to a potential combination of damages, injunction and civil and criminal penalties or require Primedex to restructure its arrangements in a way that would affect the control or quality of its services or change the amounts Primedex receives under its management agreements, or both.

Medicare and Medicaid Fraud and Abuse

Primedex's revenue is derived through its ownership, operation and management of diagnostic imaging centers and from service fees paid to it by contracted radiology practices. During the year ended October 31, 2005, approximately 18% of its revenue generated at its diagnostic imaging centers was derived from government sponsored healthcare programs (principally Medicare and Medicaid).

Federal law prohibits the knowing and willful offer, payment, solicitation or receipt of any form of remuneration in return for, or to induce, (i) the referral of a person, (ii) the furnishing or arranging for the furnishing of items or services reimbursable under the Medicare, Medicaid or other governmental programs or (iii) the purchase, lease or order or arranging or recommending purchasing, leasing or ordering of any item or service reimbursable under the Medicare, Medicaid or other governmental programs. Enforcement of this anti-kickback law is a high priority for the federal government, which has substantially increased enforcement resources and is scheduled to continue increasing such resources. The applicability of the anti-kickback law to many business transactions in the healthcare industry has not yet been subject to judicial or regulatory interpretation. Noncompliance with the federal anti-kickback legislation can result in exclusion from the Medicare, Medicaid or other governmental programs and civil and criminal penalties.

Primedex receives fees under its service agreements for management and administrative services, which include contract negotiation and marketing services. Primedex does not believe Primedex is in a position to make or influence referrals of patients or services reimbursed under Medicare or other governmental programs to radiology practices or their affiliated physicians or to receive referrals. However, Primedex may be considered to be in a position to arrange for items or services reimbursable under a federal healthcare program. Because the provisions of the federal anti-kickback statute are broadly worded and have been broadly interpreted by federal courts, it is possible that the government could take the position that Primedex's arrangements with the contracted radiology practices implicate the federal anti-kickback statute. Violation of the law can result in monetary fines, civil and criminal penalties, and exclusion from participation in federal or state healthcare programs, any of which could have an adverse effect on its business and results of operations. While Primedex's service agreements with the contracted radiology practices will not meet a safe harbor to the federal anti-kickback statute, failure to meet a safe harbor does not mean that agreements violate the anti-kickback statute. Primedex has sought to structure its agreements to be consistent with fair market value in arm's length transactions for the nature and amount of management and administrative services rendered. For these reasons, Primedex does not believe that service fees payable to it should be viewed as remuneration for referring or influencing referrals of patients or services covered by such programs as prohibited by statute.

Significant prohibitions against physician referrals have been enacted by Congress. These prohibitions are commonly known as the Stark Law. The Stark Law prohibits a physician from referring Medicare patients to an entity providing designated health services, as defined under the Stark Law, including, without limitation, radiology services, in which the physician has an ownership or investment interest or with which the physician has entered into a compensation arrangement. The penalties for violating the

Stark Law include a prohibition on payment by these governmental programs and civil penalties of as much as \$15,000 for each violative referral and \$100,000 for participation in a circumvention scheme. Primedex believes that, although Primedex receives fees under its service agreements for management and administrative services, Primedex is not in a position to make or influence referrals of patients.

On January 4, 2001, the Centers for Medicare and Medicaid Services published final regulations to implement the Stark Law. Under the final regulations, radiology and certain other imaging services and radiation therapy services and supplies are services included in the designated health services subject to the self-referral prohibition. Under the final regulations, such services include the professional and technical components of any diagnostic test or procedure using X-rays, ultrasound or other imaging services, CT, MRI, radiation therapy and diagnostic mammography services (but not screening mammography services). The final regulations, however, exclude from designated health services: (i) X-ray, fluoroscopy or ultrasound procedures that require the insertion of a needle, catheter, tube or probe through the skin or into a body orifice; (ii) radiology procedures that are integral to the performance of, and performed during, nonradiological medical procedures; (iii) nuclear medicine procedures; and (iv) invasive or interventional radiology, because the radiology services in these procedures are merely incidental or secondary to another procedure that the physician has ordered. Beginning January 1, 2007, however, PET and nuclear medicine procedures will be included as designated health services under the Stark Law.

The Stark Law provides that a request by a radiologist for diagnostic radiology services or a request by a radiation oncologist for radiation therapy, if such services are furnished by or under the supervision of such radiologist or radiation oncologist pursuant to a consultation requested by another physician, does not constitute a referral by a referring physician. If such requirements are met, the Stark Law self-referral prohibition would not apply to such services. The effect of the Stark Law on the radiology practices, therefore, will depend on the precise scope of services furnished by each such practice's radiologists and whether such services derive from consultations or are self-generated. Primedex believes that, other than self-referred patients, all of the services covered by the Stark Law provided by the contracted radiology practices derive from requests for consultations by non-affiliated physicians. Therefore, Primedex believes that the Stark Law is not implicated by the financial relationships between its operations and the contracted radiology practices.

In addition, Primedex believes that Primedex has structured its acquisitions of the assets of existing practices, and Primedex intends to structure any future acquisitions, so as not to violate the anti-kickback and Stark Law and regulations. Specifically, Primedex believes the consideration paid to physicians to acquire the tangible and intangible assets associated with their practices is consistent with fair market value in arm's length transactions and is not intended to induce the referral of patients. Should any such practice be deemed to constitute an arrangement designed to induce the referral of Medicare or Medicaid patients, then its acquisitions could be viewed as possibly violating anti-kickback and anti-referral laws and regulations. A determination of liability under any such laws could have an adverse effect on its business, financial condition and results of operations.

The federal government embarked on an initiative to audit all Medicare carriers, which are the companies that adjudicate and pay Medicare claims. These audits are expected to intensify governmental scrutiny of individual providers. An unsatisfactory audit of any of its diagnostic imaging facilities or contracted radiology practices could result in any or all of the following: significant repayment obligations, exclusion from the Medicare, Medicaid or other governmental programs, and civil and criminal penalties.

Federal regulatory and law enforcement authorities have recently increased enforcement activities with respect to Medicare and Medicaid fraud and abuse regulations and other reimbursement laws and rules, including laws and regulations that govern Primedex's activities and the activities of the radiology practices. Primedex's or the radiology practices' activities may be investigated, claims may be made against it or the radiology practices and these increased enforcement activities may directly or indirectly have an adverse effect on Primedex's business, financial condition and results of operations.

California Anti-Kickback and Physician Self-Referral Laws

California has adopted a form of anti-kickback law and a form of Stark Law. The scope of these laws and the interpretations of them are enforced by California courts and by regulatory authorities with broad discretion. Generally, California law covers all referrals by all healthcare providers for all healthcare services. A determination of liability under such laws could result in fines and penalties and restrictions on its ability to operate.

Federal False Claims Act

The Federal False Claims Act provides, in part, that the federal government may bring a lawsuit against any person who it believes has knowingly presented, or caused to be presented, a false or fraudulent request for payment from the federal government, or who has made a false statement or used a false record to get a claim approved. The Federal False Claims Act further provides that a lawsuit thereunder may be initiated in the name of the United States by an individual who is an original source of the allegations. The government has taken the position that claims presented in violation of the federal anti-kickback law or Stark Law may be considered a violation of the Federal False Claims Act. Penalties include civil penalties of not less than \$5,500 and not more than \$11,000 for each false claim, plus three times the amount of damages that the federal government sustained because of the act of that person. Primedex believes that Primedex is in compliance with the rules and regulations that apply to the Federal False Claims Act. However, Primedex could be found to have violated rules and regulations resulting in sanctions under the Federal False Claims Act, and if Primedex is so found in violation, any sanctions imposed could result in fines and penalties and restrictions on and exclusion from participation in federal and California healthcare programs that are integral to its business.

Healthcare Reform Initiatives

Healthcare laws and regulations may change significantly in the future. Primedex continuously monitors these developments and modifies its operations from time to time as the regulatory environment changes. Primedex cannot assure you, however, that Primedex will be able to adapt its operations to address new regulations or that new regulations will not adversely affect its business. In addition, although Primedex believes that it is operating in compliance with applicable federal and state laws, neither its current or anticipated business operations nor the operations of the contracted radiology practices has been the subject of judicial or regulatory interpretation. Primedex cannot assure you that a review of its business by courts or regulatory authorities will not result in a determination that could adversely affect its operations or that the healthcare regulatory environment will not change in a way that restricts its operations.

Health Insurance Portability and Accountability Act of 1996

In an effort to combat healthcare fraud, Congress enacted the Health Insurance Portability and Accountability Act of 1996, or HIPAA. HIPAA, among other things, amends existing crimes and criminal penalties for Medicare fraud and enacts new federal healthcare fraud crimes, including actions affecting non-government payors. Under HIPAA, a healthcare benefit program includes any private plan or contract affecting interstate commerce under which any medical benefit, item or service is provided. A person or entity that knowingly and willfully obtains the money or property of any healthcare benefit program by means of false or fraudulent representations in connection with the delivery of healthcare services is subject to a fine or imprisonment, or potentially both. In addition, HIPAA authorizes the imposition of civil money penalties against entities that employ or enter into contracts with excluded Medicare or Medicaid program participants if such entities provide services to federal health program beneficiaries. A finding of liability under HIPAA could have a material adverse effect on its business, financial condition and results of operations.

Further, HIPAA requires healthcare providers and their business associates to maintain the privacy and security of individually identifiable health information. HIPAA imposes federal standards for electronic transactions with health plans, for the security of electronic health information and for protecting the privacy of individually identifiable health information. Organizations such as ours were obligated to be compliant with the initial HIPAA regulations by April 14, 2003, and with the electronic data interchange mandates by October 16, 2003. The final security regulations were issued in February 2003 with a compliance date of April 2005. Primedex believes that Primedex is in compliance with the current requirements, but Primedex anticipates that Primedex may encounter costs associated with future compliance. A finding of liability under HIPAA's privacy or security provisions may also result in criminal and civil penalties, and could have a material adverse effect on its business, financial condition, and results of operations.

Although its electronic systems are HIPAA compatible, consistent with the HIPAA regulations, Primedex cannot guarantee the enforcement agencies or courts will not make interpretations of the HIPAA standards that are inconsistent with ours, or the interpretations of the contracted radiology practices or their affiliated physicians. A finding of liability under the HIPAA standards may result in criminal and civil penalties. Noncompliance also may result in exclusion from participation in government programs, including Medicare and Medicaid. These actions could have a material adverse effect on its business, financial condition, and results of operations.

Compliance Program

Primedex maintains a program to monitor compliance with federal and state laws and regulations applicable to healthcare entities. Primedex has a compliance officer who is charged with implementing and supervising its compliance program, which includes the adoption of (i) Standards of Conduct for its employees and affiliates and (ii) a process that specifies how employees, affiliates and others may report regulatory or ethical concerns to its compliance officer. Primedex believes that its compliance program meets the relevant standards provided by the Office of Inspector General of the Department of Health and Human Services.

An important part of its compliance program consists of conducting periodic audits of various aspects of its operations and that of the contracted radiology practices. Primedex also conducts mandatory educational programs designed to familiarize its employees with the regulatory requirements and specific elements of its compliance program.

U.S. Food and Drug Administration or FDA

The FDA has issued the requisite premarket approval for all of the MRI and CT systems Primedex uses. Primedex does not believe that any further FDA approval is required in connection with the majority of equipment currently in operation or proposed to be operated. Except under regulations issued by the FDA pursuant to the Mammography Quality Standards Act of 1992, where all mammography facilities are required to be accredited by an approved non-profit organization or state agency. Pursuant to the accreditation process, each facility providing mammography services must comply with certain standards including annual inspection.

Compliance with these standards is required to obtain payment for Medicare services and to avoid various sanctions, including monetary penalties, or suspension of certification. Although the Mammography Accreditation Program of the American College of Radiology currently accredits all of its facilities, which provide mammography services, and Primedex anticipates continuing to meet the requirements for accreditation, the withdrawal of such accreditation could result in the revocation of certification. Congress has extended Medicare benefits to include coverage of screening mammography subject to the prescribed quality standards described above. The regulations apply to diagnostic mammography and image quality examination as well as screening mammography.

Radiologist Licensing

The radiologists providing professional medical services at its facilities are subject to licensing and related regulations by the State of California. As a result, Primedex requires BRMG and the other radiology groups with which Primedex contracts to require those radiologists to have and maintain appropriate licensure. Primedex does not believe that such laws and regulations will either prohibit or require licensure approval of its business operations, although no assurances can be made that such laws and regulations will not be interpreted to extend such prohibitions or requirements to its operations.

Deficit Reduction Act of 2005

On February 8, 2006, the President signed into law the Deficit Reduction Act of 2005, referred to as the DRA. The DRA provides that reimbursement for the technical component for imaging services (excluding diagnostic and screening mammography) in non-hospital based freestanding facilities will be capped at the lesser of reimbursement under the Medicare Part B physician fee schedule or the Hospital Outpatient Prospective Payment System (HOPPS) schedule.

Currently, the technical component of Radiologix's and Primedex's imaging services is reimbursed under the Part B physician fee schedule, which, in most cases, allows for higher reimbursement than under the HOPPS. Under the DRA, Radiologix and Primedex will be reimbursed at the lower of the two schedules, beginning January 1, 2007.

The DRA also codifies the reduction in reimbursement for multiple images on contiguous body parts previously announced by the Centers for Medicare and Medicaid Services (CMS). In November 2005, CMS announced that it will pay 100% of the technical component of the higher priced imaging procedure and 50% of the technical component of each additional imaging procedure for imaging procedures involving contiguous body parts within a family of codes when performed in the same session. Under current methodology, Medicare pays 100% of the technical component of each procedure. CMS had indicated that it would phase in this rate reduction over two years, so that the reduction will be 25% for each additional imaging procedure in 2006 and another 25% in 2007. On August 8, 2006, CMS issued a proposed rule that would eliminate the 25% reduction in 2007.

Primedex and Radiologix believe the implementation of the reimbursement reductions contained in the DRA will have a significant effect on their business, financial condition and results of operations.

Insurance Laws and Regulation

California has adopted laws and regulations affecting risk assumption in the healthcare industry, including those that subject any physician or physician network engaged in risk-based managed care to applicable insurance laws and regulations. These laws and regulations may require physicians and physician networks to meet minimum capital requirements and other safety and soundness requirements. Implementing additional regulations or compliance requirements could result in substantial costs to the contracted radiology practices, limiting their ability to enter into capitated or other risk-sharing managed care arrangements and indirectly affecting its revenue from the contracted practices.

Environmental Matters

Edgar Filing: RADIOLOGIX INC - Form DEFM14A

The facilities Primedex operates or manages generate hazardous and medical waste subject to federal and state requirements regarding handling and disposal. Primedex believes that the facilities that it operates and manages are currently in compliance in all material respects with applicable federal, state and local statutes and ordinances regulating the handling and disposal of such materials. Primedex does not believe that it will be required to expend any material additional amounts in order to remain in compliance with these laws and regulations or that compliance will materially affect its capital expenditures, earnings or competitive position.

181

Properties

Edgar Filing: RADIOLOGIX INC - Form DEFM14A

Information with respect to Primedex's facilities within its regional networks is as follows:

Regional Networks	Number of Facilities	Approximate Square Footage	Lease Expiration (With Options To Extend)
BEVERLY HILLS(3):			
Roxsan	1	6,320	Various through 2012
Wilshire	1	13,778	September 2028
Women's	1	3,830	February 2029
VENTURA(10):			
Camarillo	2	2,035	Various through May 2013
Oxnard	2	5,622	Various month-to-month
Thousand Oaks	3	12,914	Various through November 2019
Ventura	3	12,959	Various through July 2012
SAN FERNANDO VALLEY(8):			
Burbank	2	6,500	Various through August 2010
Northridge	2	9,050	Various through February 2019
Santa Clarita	2	7,293	One through June 2019; other month-to-month
Tarzana	2	6,320	Various through December 2021
ANTELOPE VALLEY(3):			
Antelope Valley	1	2,890	April 2008
Lancaster	2	6,827	Various through October 2006
CENTRAL CALIFORNIA(5):			
Fresno	2	7,231	Various through December 2013
Modesto	1	17,852	December 2014
Sacramento	1	8,083	June 2023
Stockton	1	4,808	December 2006
Vacaville	1	5,927	March 2012
NORTHERN CALIFORNIA(4):			
Emeryville	2	2,086	Various through December 2018
San Francisco	2	8,355	Various through April 2017
Santa Rosa	1	4,235	July 2011
Vallejo	1	2,123	March 2011
ORANGE(5):			
Irvine	1	4,200	September 2011
Tustin	1	2,139	January 2008
LONG BEACH(4):			
Long Beach	4	16,338	Various through July 2010
NORTHERN SAN DIEGO(1):			
Rancho Bernardo	1	9,557	May 2012
PALM SPRINGS(6):			
Palm Desert	4	9,024	Various through May 2021
Palm Springs	2	9,042	Various through June 2013
INLAND EMPIRE(12):			
Corona	1	2,133	November 2011
Chino	1	2,700	June 2021
Rancho Cucamonga	2	11,128	Various through May 2023
Riverside	3	12,534	Various through January 2018
San Gabriel Valley	1	2,871	December 2007
Temecula	5	14,496	Various through January 2021
TOTAL	65		

(1) Includes leased facilities and three facilities operated pursuant to managed care capitation agreements.

182

Primedex's corporate headquarters are located in adjoining premises at 1510 and 1516 Cotner Avenue, Los Angeles, California 90025, in approximately 16,500 square feet occupied under leases, which expire (with options to extend) on June 30, 2017. In addition, Primedex leases 52,941 square feet of warehouse and other space under leases, which expire at various dates between February 2006 and January 2018.

Legal Proceedings

Primedex is involved in the following litigation:

In Re DVI, Inc. Securities Litigation, United States District Court, Eastern District of PA, Docket No. 2:03-CV-05336-LLD

This is a class action securities fraud case under Section 10(b) of the Securities Exchange Act and Rule 10b-5. It was brought by shareholders of DVI, Inc. (DVI), one of Primedex's former major lenders, against DVI officers and directors and a number of third party defendants, including Primedex. The case arises from bankruptcy proceedings instituted by DVI in August 2003. Primedex was named as a defendant in the Third Amended Complaint filed in July 2004.

The putative plaintiff class consists of those persons who purchased or otherwise acquired DVI, Inc. securities between August of 1999 and August of 2003. Plaintiffs allege that in 2000, Primedex acquired from a third party one or more unprofitable imaging centers in order to help DVI conceal the fact that existing DVI loans on the centers were delinquent. Plaintiffs argue that Primedex should have known that DVI was engaging in fraudulent practices to conceal losses, and Primedex's alleged lack of due diligence in investigating DVI's finances in the course of these acquisitions amounted to complicity in deceptive and misleading practices.

Primedex has answered the complaint. The matter is still in its initial stages with discovery just beginning. Primedex intends to vigorously contest the allegations.

Fleet National Bank v. Boyle et. al., U.S. District Court for the Eastern District of Pennsylvania, Docket No. 04-CV-1277

This case is related to *In re DVI Securities Litigation*, but was filed by several of DVI's lenders. It, too, arises from the DVI bankruptcy (referenced in the matter above) and was brought against DVI officers and directors and a number of third party defendants, including Primedex. Primedex was named in the First Amended Complaint filed in this action in September 2004.

The plaintiff alleges violations of the Racketeering Influenced and Corrupt Organizations Act, 18 U.S.C. 1961 et seq., (RICO), and common-law claims, including conspiracy to commit fraud, tortious interference with a contract, conspiracy to commit tortious interference with a contract, conspiracy to commit conversion and aiding and abetting fraud. Plaintiffs allege that in 2000, Primedex acquired from a third party one or more unprofitable imaging centers in order to help DVI conceal the fact that existing DVI loans on the centers were delinquent.

Primedex filed a motion to dismiss the complaint that was granted as to all claims except the RICO claim. Primedex has filed an answer to the complaint. The case is in its initial stages. Primedex intends to vigorously contest the remaining claims.

General

Primedex is engaged from time to time in the defense of lawsuits arising out of the ordinary course and conduct of its business. Primedex believes that the outcome of its current litigation will not have a material adverse impact on its business, financial condition and results of operations. However, Primedex could be subsequently named as a defendant in other lawsuits that could adversely affect Primedex.

Directors and Executive Officers of Primedex

The names, ages and current positions of the directors and executive officers of Primedex are listed below.

Name	Age	Positions and Offices
Howard G. Berger, M.D.	62	President, Chief Executive Officer and Director
Norman R. Hames	50	Vice President, Secretary, Chief Operating Officer and Director
John V. Crues, III, M.D.	56	Vice President and Director
David L. Swartz	63	Director
Lawrence L. Levitt	63	Director
Jeffrey L. Linden	63	Vice President and General Counsel
Mark D. Stolper	34	Chief Financial Officer

The following is a brief description of the business experience of each director and executive officer during the past five years.

Howard G. Berger, M.D. has served as President and Chief Executive Officer of Primedex since 1987. Dr. Berger is also the president of the entities that own BRMG. Dr. Berger has over 25 years of experience in the development and management of healthcare businesses. He began his career in medicine at the University of Illinois Medical School, is Board Certified in Nuclear Medicine and trained in an Internal Medicine residency, as well as in a masters program in medical physics in the University of California system.

Norman R. Hames has served as Primedex's Chief Operating Officer since 1996. Applying his 20 years of experience in the industry, Mr. Hames oversees all aspects of Primedex's facility operations. His management team, comprised of regional directors, managers and sales managers, are responsible for responding to all of the day-to-day concerns of Primedex's facilities, patients, payors and referring physicians. Prior to joining Primedex, Mr. Hames was President and Chief Executive Officer of his own company, Diagnostic Imaging Services, Inc. (which Primedex acquired), which owned and operated 14 multi-modality imaging facilities throughout Southern California. Mr. Hames gained his initial experience in operating imaging centers for American Medical International, or AMI, and was responsible for the development of AMI's single and multi-modality imaging centers.

John V. Crues, III, M.D. is a world-renowned radiologist. Dr. Crues plays a significant role as a musculoskeletal specialist for many of Primedex's patients as well as a resource for physicians providing services at Primedex's facilities. Dr. Crues received his M.D. at Harvard University, completed his internship at the University of Southern California in Internal Medicine, and completed a residency at Cedars-Sinai in Internal Medicine and Radiology. Dr. Crues has authored numerous publications while continuing to actively participate in radiological societies such as the Radiological Society of North America, American College of Radiology, California Radiological Society, International Society for Magnetic Resonance Medicine and the International Skeletal Society.

David L. Swartz is a C.P.A. with thirty-five years of experience providing accounting and advisory services to clients. Since 1993, Mr. Swartz has been the managing partner of Good, Swartz, Brown & Berns. Prior to this, Mr. Swartz served as managing partner and was on the national board of directors of a 50 office international accounting firm. Mr. Swartz is also a former CFO of a publicly held shopping center and development company.

Lawrence L. Levitt is a C.P.A. and has since 1987 been the president and chief financial officer of Canyon Management Company, a company which manages a privately held investment fund. Mr. Levitt is also a director of River Downs Management Company, operator of a thoroughbred racetrack in Ohio.

Jeffrey L. Linden joined Primedex in 2001 as Primedex's Vice President and General Counsel. He is also associated with Cohen & Lord, a professional corporation, outside general counsel to Primedex. Prior to joining Primedex, Mr. Linden had been engaged in the private practice of law. He has lectured before numerous organizations on various topics, including the California State Bar, American Society of Therapeutic Radiation Oncologists, California Radiological Association, and National Radiology Business Managers Association.

Mark D. Stolper joined Primedex in August 2004 as Primedex's Chief Financial Officer. Mr. Stolper had diverse experiences in investment banking, private equity, venture capital investing and operations prior to joining Primedex. Mr. Stolper began his career as a member of the corporate finance group at Dillon, Read and Co., Inc., executing mergers and acquisitions, public and private financings and private equity investments with Saratoga Partners LLP, an affiliated principal investment group of Dillon Read. After Dillon Read, Mr. Stolper joined Archon Capital Partners, backed by the Milken Family and News Corp., which made private equity investments in media and entertainment companies. Mr. Stolper received his operating experience with Eastman Kodak, where he was responsible for business development for Kodak's Entertainment Imaging subsidiary (\$1.5 billion in sales). Mr. Stolper was also co-founder of Broadstream Capital Partners, a Los Angeles-based investment banking firm focused on advising middle market companies engaged in financing merger and acquisition transactions.

None of the directors serves as a director of any other corporation with a class of securities registered pursuant to Section 12 of the Exchange Act or subject to the requirements of Section 15(d) of the Exchange Act. There are no family relationships among any of the officers and directors. There are no arrangements or understandings for any director or officer to serve in such capacity.

Attendance at Board Meetings

The board held six meetings in fiscal 2005, four of which were by unanimous written consent. During fiscal 2005, no director attended fewer than 75%, in the aggregate, of the total number of meetings of the board and board committees on which such director served.

Director Attendance at Special Meetings

As a matter of policy, Primedex expects its directors to make reasonable efforts to attend Primedex's special meetings of stockholders.

Communications with the Board

Interested parties may communicate with the full board, the Audit Committee, directors who are not employees of Primedex, referred to as the non-management directors, or any individual director by communicating through Primedex's Internet website at www.radnetonline.com/contact.html or by mailing such communications to 1510 Cotner Avenue, Los Angeles, CA 90025, Attention: General Counsel. Such communications should indicate to whom they are addressed. Any comments received that relate to accounting, internal accounting controls or auditing matters will be referred to members of the Audit Committee unless the communication is otherwise addressed. Parties may communicate anonymously and/or confidentially if they desire. All communications received will be collected by the Office of the General Counsel of Primedex and forwarded to the appropriate director or directors.

Committees of the Board

Audit Committee

The board has an Audit Committee comprised of two directors Mr. Levitt and Mr. Swartz, who also serves as the Chairperson of the Audit Committee. The Audit Committee reviews the results and scope of the audit and other services provided by Primedex's independent auditors. The board has determined that both Messrs Levitt and Swartz are audit committee financial experts as defined under the rules and regulations of the Securities and Exchange Commission. The board has also determined that both members of the Audit Committee meet the rules and regulation of independence as defined pursuant to the New York Stock Exchange. The Audit Committee met three times in fiscal 2005.

Compensation Committee

The board has a Compensation Committee that determines the salaries and incentive compensation for Primedex's employees and consultants. The Compensation Committee is composed of Mr. Swartz and Dr. Berger. The Compensation Committee did not meet during fiscal 2005.

Nominating and Corporate Governance Committee

The Board has not formed a separate Nominating and Corporate Governance Committee. All members of the Board are currently responsible for the duties relating to nominating and corporate governance matters.

Director Nomination Procedures

Primedex's certificate of incorporation and by-laws provide that members of the board of directors will be elected by a majority of the votes cast at a meeting of stockholders, by holders of stock entitled to vote in the election.

Director Compensation

Independent directors receive compensation of \$25,000 per year and an annual warrant to purchase 50,000 shares of Primedex common stock.

Compensation Committee Interlocks and Insider Participation

During fiscal 2005, all executive compensation was determined by the then members of Primedex's Board of Directors, Howard G. Berger, M.D., Norman R. Hames, John V. Crues, III, M.D. Lawrence L. Levitt and David L. Swartz. In addition, no individual who served as an executive officer of Primedex during fiscal 2005 served, during fiscal 2005 on the board of directors or compensation committee of another entity where an executive officer of the other entity also served on Primedex's Board of Directors except that Dr. Berger and Dr. Crues also serve on the board of BRMG.

Certain Relationships and Related Transactions

Howard G. Berger, M.D. is Primedex's President and Chief Executive, chair of Primedex's Board of Directors, and owns approximately 30% of Primedex's outstanding common stock. Dr. Berger also owns, indirectly, 99% of the equity interests in BRMG. BRMG provides all of the professional medical services at 46 of Primedex's facilities under a management agreement with Primedex, and contracts with various other independent physicians and physician groups to provide all of the professional medical services at most of Primedex's other facilities. Primedex obtains professional medical services from BRMG, rather than providing such services directly or through subsidiaries, in order to comply with California's prohibition against the corporate practice of medicine. However, as a result of this close relationship with Dr. Berger and BRMG, Primedex believes that it is able to better ensure that professional medical services are provided at its facilities in a manner consistent with Primedex's needs and expectations and those of its referring physicians, patients and payors than if Primedex obtained these services from unaffiliated practice groups.

Under Primedex's management agreement with BRMG, which expires on January 1, 2014, BRMG pays Primedex, as compensation for the use of Primedex's facilities and equipment and for Primedex's services, a percentage of the gross amounts collected for the professional services it renders. The percentage, which was 79% at October 31, 2005, is adjusted annually, if necessary, to ensure that the parties receive fair value for the services they render. In operation and historically, the annual revenue of BRMG from all sources closely approximates its expenses, including Dr. Berger's compensation, fees payable to Primedex and amounts payable to third parties. For administrative convenience and in order to avoid inconveniencing and confusing Primedex's payors, a single bill is prepared for both the professional medical services provided by the radiologists and Primedex's non-medical, or technical, services, generating a receivable for BRMG. BRMG maintains a \$15 million revolving credit facility with General Electric Capital Corporation from which it may obtain funds by utilizing its accounts receivable for working capital purposes, if needed. Primedex repays or offsets these advances with periodic payments from BRMG to Primedex under the management agreement. Primedex guarantees BRMG's obligations under this working capital facility.

John V. Crues, III, M.D. agreed to continue his employment and leadership roles with Primedex in consideration of Primedex's agreement in June 2005 to issue to him Primedex's five year warrant to purchase 500,000 shares of Primedex common stock at an exercise price of \$0.36 per share (the price of Primedex common stock on the date of the agreement in the public market in which it trades).

Both Dr. Berger and Dr. Crues receive all or a portion of their salary from BRMG. See Employment Agreements.

At October 31, 2005, we owed Jeffrey L. Linden \$61,151 in connection with Primedex's acquisition of his interest in DIS. The obligation accrues interest at the rate of 6.58% per annum and is due July 1, 2006. In the acquisition transaction, Primedex issued to Mr. Linden warrants to purchase 197,365 shares of common stock at a price of \$0.60 per share expiring June 30, 2004. In connection with an agreement to extend Primedex's obligation to Mr. Linden, Primedex issued to him warrants to purchase 300,000 shares of common stock at a price of \$0.19 per share that he exercised in June 2005. On July 30, 2004, Primedex issued to Mr. Linden a five year warrant to purchase 200,000 shares of Primedex common stock at an exercise price of \$0.30 per share in consideration of Mr. Linden's agreement to subordinate Primedex's obligation to him to Primedex's debt with our revolving line of credit.

Cohen & Lord, a professional corporation, a law firm with which Mr. Linden is associated, received \$365,695 in fees from Primedex during the year ended October 31, 2005. Mr. Linden has specifically waived any interest in Primedex's fees since becoming an officer of Primedex.

On July 30, 2004, Primedex issued to Mark D. Stolper five-year warrants to purchase 650,000 shares of our common stock at \$0.30 per share in consideration of his entry into a three year employment agreement with us under which he became our chief financial officer and his assistance in refinancing our outstanding institutional debt. The warrant exercise price is the price of our common stock on the date of the agreement in the public market in which it trades. In recognition of Mr. Stolper's services to Primedex, on July 11, 2006, Primedex issued to Mr. Stolper a five-year warrant to purchase 200,000 shares of Primedex common stock at \$1.55 per share vesting over a three-year period. This warrant will automatically vest if Primedex common stock reaches \$3.00 per share.

Compliance with Section 16(a) of the Exchange Act

Section 16(a) of the Exchange Act requires Primedex's directors and executive officers, and certain persons who own more than 10% of the common stock outstanding, to file with the SEC initial reports of ownership and reports of changes in ownership of common stock. Executive officers, directors and greater than 10% stockholders are required by SEC rules to furnish Primedex with copies of all Section 16(a) reports they file. See "Beneficial Ownership of Primedex Common Stock" beginning on page 164.

To Primedex's knowledge, based solely on a review of the copies of reports furnished to Primedex and written representations signed by all directors and executive officers that no other reports were required with respect to their beneficial ownership of common stock during fiscal 2005, all reports required by Section 16(a) of the Exchange Act to be filed by the directors and executive officers and all beneficial owners of more than 10% of the common stock outstanding to report transactions in securities were timely filed.

Code of Ethics for Senior Financial Officers

Primedex's Board of Directors has adopted a Code of Ethics for Senior Financial Officers. A copy of the Code of Ethics is available on Primedex's website at www.radnetonline.com.

Executive Compensation

Three-Year Compensation Summary

The following table summarizes the compensation of the President and the four other most highly compensated executive officers of Primedex as of October 31, 2005, referred to as the "Primedex Named Executives," for Primedex's last three fiscal years for services rendered in all capacities to Primedex and its subsidiaries.

SUMMARY COMPENSATION TABLE

Name and Principal Position	Annual Compensation		Long-Term Compensation				
	Year Ended 10/31	Salary (\$)	Other Annual Bonus (\$)	Underlying Securities (1)(7)	Restricted Stock Awards (\$)	LTIP Payouts (\$)	All Other Compensation (\$)
Howard G. Berger, M.D., Chief Executive Officer and President	2005	\$ 200,000 (2)					
	2004	\$ 225,000 (2)					
	2003	\$ 328,846 (2)					
Norman R. Hames, Vice President, Secretary and Chief Operating Officer	2005	\$ 220,000					
	2004	\$ 229,000					
	2003	\$ 225,000					
John V. Crues, III, M.D., Vice President	2005	\$ 440,000 (3)					
	2004	\$ 370,000 (4)		500,000			
	2003	\$ 363,000 (5)					
Jeffrey L. Linden, Vice President and General Counsel	2005	\$ 350,000 (6)					
	2004	\$ 350,000 (6)		200,000			
	2003	\$ 303,015 (6)					
Mark D. Stolper Chief Financial Officer	2005	\$ 223,750					
	2004	\$ 53,780 (8)		700,000			

(1) The dollar value of perquisites and other personal benefits, if any, for each of the Named Executive Officers was less than \$50,000 or 10% of salary and bonus, the reporting thresholds established by the SEC.

(2) Includes \$300,000, \$225,000 and \$200,000 received from BRMG (see Employment Agreements) in 2003, 2004 and 2005, respectively. Dr. Berger voluntarily reduced compensation payable by Primedex in 2003, 2004 and 2005 to assist with Primedex's liquidity.

(3) Received from BRMG.

(4) Includes \$185,000 received from BRMG.

(5) Includes \$200,000 received from BRMG.

(6) Mr. Linden voluntarily reduced compensation payable by Primedex in 2003 to assist with its liquidity. Cohen & Lord, a professional corporation, a law firm with which Mr. Linden is associated, received \$365,695 in fees from Primedex during the year ended October 31, 2005. Mr. Linden has specifically waived any interest in Primedex's fees paid to Cohen & Lord since becoming an officer.

(7) Shares of Primedex's common stock.

(8) Mr. Stolper commenced employment with us on August 1, 2004.

Stock Option Grants and Exercises in Last Fiscal Year

In fiscal 2005, Primedex granted options to John V. Crues, III, M.D. and to no other executive officer. The following table provides information about that option grant and projects potential realizable gains at hypothetical assumed annual compound rates of appreciation. Primedex had outstanding 12,691,937 options and warrants to purchase common stock as of October 31, 2005.

NAME	NUMBER OF TOTAL OPTIONS GRANTED TO EMPLOYEES IN FISCAL YEAR	PERCENT OF TOTAL OPTIONS GRANTED TO EMPLOYEES IN FISCAL YEAR	OPTION GRANT IN 2005 INDIVIDUAL GRANTS	Exercise Price	Expiration Date	POTENTIAL REALIZABLE VALUE AT ASSUMED ANNUAL RATE OF STOCK PRICE APPRECIATION FOR OPTION TERM(1)	
						5%	10%
John V. Crues, III, M.D.	500,000	55.6 %		\$ 0.36	June 07, 2010	\$ 50,000	\$ 96,715

Edgar Filing: RADIOLOGIX INC - Form DEFM14A

(1) These values are solely the mathematical results of hypothetical assumed appreciation of the market value of the underlying shares at an annual rate of 5% and 10% over the full term of the options, less the exercise price. Actual gains, if any, will depend on future stock market performance of the underlying stock, market factors and conditions, and optionee's continued employment through the applicable vesting periods. We make no prediction as to the future value of these options or of the underlying stock, and these values are provided solely as examples required by the SEC rules.

189

AGGREGATED OPTION EXERCISES IN LAST FISCAL YEAR AND FISCAL YEAR END OPTION VALUES

There were no option exercises in the year ended October 31, 2005 by the Named Executives except as follows:

NAME	SHARES ACQUIRED	VALUE REALIZED(1)	NUMBER OF SECURITIES UNDERLYING UNEXERCISED OPTIONS AT FISCAL YEAR END		VALUE OF UNEXERCISED IN-THE-MONEY OPTIONS(2)
	ON EXERCISE		EXERCISABLE	UNEXERCISABLE	EXERCISABLE UNEXERCISABLE
Jeffrey L. Linden	300,000	\$ 63,000	1,275,000		\$ 6,000

(1) The value realized equals the fair market value of the common stock acquired on the date of exercise minus the exercise price.

(2) Based on the closing price of the common stock of \$0.32 per share as of January 13, 2005, less the option exercise price.

STOCK INCENTIVE PLAN

Primedex has one stock incentive plan, the 2000 Long-Term Incentive Plan, or the 2000 Plan and has reserved 2,000,000 shares of common stock for issuance under the 2000 Plan. The material features of the 2000 Plan are as follows:

Administration

The 2000 Plan is presently administered by Primedex’s Board of Directors, but upon locating non-employee directors who have the requisite qualifications will then be administered by a compensation committee appointed by the Board which will consist of two or more non-employee Directors. Subject to the terms of the 2000 Plan, the Board, and the compensation committee, if established, has full authority to administer the 2000 Plan in all respects, including: (i) selecting the individuals who are to receive awards under the 2000 Plan; (ii) determining the specific form of any award; and (iii) setting the specific terms and conditions of each award. Primedex’s senior legal and human resources representatives are also authorized to take ministerial actions as necessary to implement the 2000 Plan and awards issued under the 2000 Plan.

Eligibility

Employees, directors and other individuals who provide services to Primedex, its affiliates and subsidiaries who, in the opinion of the Board, or the compensation committee, if applicable, are in a position to make a significant contribution to Primedex’s success or the success of Primedex’s affiliates and subsidiaries are eligible for awards under the 2000 Plan.

Amount of Awards

The value of shares or other awards to be granted to any recipient under the 2000 Plan are not presently determinable. However, the 2000 Plan restricts the number of shares and the value of awards not based on shares that may be granted to any individual during a calendar year or performance period. In order to facilitate Primedex’s compliance with Section 162(m) of the Internal Revenue Code of 1986, as amended, or the Code, which deals with the deductibility of compensation for any of the chief executive officer and the four other most highly-paid executive officers, the 2000 Plan limits to 500,000 the number of shares for which options, stock appreciation rights or other stock awards may be granted to an individual in a calendar year and limits to \$1,000,000 the value of non-stock-based awards that may be paid to an individual with respect to a performance period. These restrictions were adopted by the Board of Directors as a means of complying with Code Section 162(m) and are not indicative of historical or contemplated awards made or to be made to any individual under the 2000 Plan.

Stock Options

The 2000 Plan authorizes the grant of options to purchase shares of common stock, including options to employees intended to qualify as incentive stock options within the meaning of Section 422 of the Code, as well as non-statutory options. The term of each option will not exceed ten years and each option will be exercisable at a price per share not less than 100% of the fair market value of a share of common stock on the date of the grant.

Generally, optionees will pay the exercise price of an option in cash or by check, although the Board, and the compensation committee, if established, may permit other forms of payment including payment through the delivery of shares of common stock. Options granted under the 2000 Plan are not transferable, except at death or as gifts to Family Members, as defined in the 2000 Plan. At the time of grant or thereafter, the Board, and the compensation committee, if established, may determine the conditions under which stock options vest and remain exercisable.

Unless otherwise determined by the Board, and the compensation committee, if established, unexercised options will terminate if the holder ceases for any reason to be associated with Primedex, its affiliates or subsidiaries. Options generally remain exercisable for a specified period following termination for reasons other than for Cause, as defined in the 2000 Plan, particularly in circumstances of death, Disability and Retirement, as defined in the 2000 Plan. In the event of a Change in Control or Covered Transaction, as defined in the 2000 Plan of Primedex, options become immediately exercisable and/or are converted into options for securities of the surviving party as determined by the Board, and the compensation committee, if established.

Other Awards

The Board, and the compensation committee, if established, may grant stock appreciation rights which pay, in cash or common stock, an amount equal to the difference between the fair market values of the common stock at the time of exercise of the right and at the time of grant of the right. In addition, the Board, and the compensation committee, if established, may grant awards of shares of common stock at a purchase price less than fair market value at the date of issuance, including zero. A recipient's right to retain these shares may be subject to conditions established by the Board, and the compensation committee, if established, if any, such as the performance of services for a specified period or the achievement of individual or company performance targets. The Board, and the compensation committee, if established, may also issue shares of common stock or authorize cash or other payments under the 2000 Plan in recognition of the achievement of performance objectives or in connection with annual bonus arrangements.

Performance Criteria

The Board, and the compensation committee, if established, may condition the exercisability, vesting or full enjoyment of an award on specified Performance Criteria. For purposes of Performance Awards, as defined in the 2000 Plan, that are intended to qualify for the performance-based compensation exception under Code Section 162(m), Performance Criteria means an objectively determinable measure of performance relating to any of the following as specified by the Board, and the compensation committee, if established, determined either on a consolidated basis or, as the context permits, on a divisional, subsidiary, line of business, project or geographical basis or in combinations thereof: (i) sales; revenue; assets; liabilities; costs; expenses; earnings before or after deduction for all or any portion of interest, taxes, depreciation, amortization or other items, whether or not on a continuing operations or aggregate or per share basis; return on equity, investment, capital or assets; one or more operating ratios; borrowing levels, leverage ratios or credit rating; market share; capital expenditures; cash flow; working capital requirements; stock price; stockholder return; sales, contribution or gross margin, of particular products or

services; particular operating or financial ratios; customer acquisition, expansion and retention; or any combination of the foregoing; or (ii) acquisitions and divestitures, in whole or in part; joint ventures and strategic alliances; spin-offs, split-ups and the like; reorganizations; recapitalizations, restructurings, financings of debt or equity and refinancing; transactions that would constitute a change of control; or any combination of the foregoing. Performance Criteria measures and targets determined by the Board, and the compensation committee, if established, need not be based upon an increase, a positive or improved result or avoidance of loss.

Amendments

The Board, and the compensation committee, if established, may amend the 2000 Plan or any outstanding award for any purpose permitted by law, or may at any time terminate the 2000 Plan as to future grants of awards. The Board, and the compensation committee, if established, may not, however, increase the maximum number of shares of common stock issuable under the 2000 Plan or change the description of the individuals eligible to receive awards. In addition, no termination of or amendment to the 2000 Plan may adversely affect the rights of a participant with respect to any award previously granted under the 2000 Plan without the participant's consent, unless the compensation committee expressly reserves the right to do so in writing at the time the award is made. To the extent the Board, and the compensation committee, if established, desires the 2000 Plan to qualify under the Code, certain amendments may require stockholder approval.

Primedex stockholders have adopted the Incentive Stock Option Plan, or the Incentive Plan. The Incentive Plan is designed to qualify as an incentive stock option plan under Section 422A of the Code. Under the Incentive Plan, options to purchase up to 1,600,000 shares of common stock were authorized for grant to key employees, including officers and directors. A committee of three directors appointed by the Board of Directors administers the Incentive Plan and designates the optionees, the number of shares subject to the options, and the terms and conditions of each option.

In May 1992, Primedex's Board of Directors authorized amendments to the Incentive Plan, subject to stockholder approval, increasing the number of shares reserved under the Incentive Plan to 2,000,000 shares of Primedex's common stock and amending the Incentive Plan in accordance with changes adopted in 1986 to the Code. These proposed amendments to the Incentive Plan were adopted by stockholders at the annual meeting of stockholders held on November 17, 1992.

Under the Incentive Plan, as amended, except for options granted to holders of 10% or more of Primedex's outstanding stock, the exercise price of an option must be at least 100% of the fair market value of the common stock on the effective date of grant. Options granted under the Incentive Plan to stockholders possessing more than 10% of Primedex's outstanding stock must be at an exercise price equal to not less than 110% of such fair market value. Primedex is not issuing any additional options under the Incentive Plan because the Incentive Plan terminated in 2002. All options granted must be exercised within 10 years of date of grant. The aggregate fair market value of Primedex's common stock with respect to which options are exercisable for the first time by a grantee under the Incentive Plan during any calendar year may not exceed \$100,000. Options must be exercised by an optionee, if at all, within three months after the termination of such optionee's employment for any reason other than for cause, and within one year after termination of employment due to death or permanent disability, unless by its terms the option expires sooner.

Employment Agreements

BRMG entered into a Management Consulting Agreement with Howard G. Berger, M.D. as of January 1, 1994. The agreement automatically renews annually unless either party delivers notice of non-renewal to the other party no less than 90 days prior to the scheduled termination date. Dr. Berger serves

as the manager of BRMG and the chief executive for BRMG's partnerships, and receives compensation for his services from BRMG equal to \$300,000 per year. Dr. Berger's duties include the direction of day-to-day activities of BRMG, supervision of personnel, and the implementation of policies and plans appropriate to carry out the operational, financial and business objectives of BRMG. Under this agreement, if Primedex terminates his employment for cause, he will be entitled to compensation equal to one year's base salary. If Dr. Berger terminates his agreement without cause, he is entitled to compensation accrued through the effective date of termination, and if his employment is terminated by BRMG without cause, BRMG shall pay to Dr. Berger an amount equal to the sum of (i) his base salary accrued through the effective date of termination; (ii) his base salary for the balance of the term, but not less than his base salary for five years; and (iii) an amount equal to the cost of all benefits he would receive for the balance of the term. Dr. Berger's employment shall not terminate in the event of a merger, consolidation, dissolution or other transaction whereby BRMG would not be the surviving entity of such transaction, and Dr. Berger holds the right to terminate this agreement upon 60 days notice in the event of any such transaction.

John V. Crues, III, M.D. entered into a renewable one-year employment agreement dated as of January 15, 1996 with both Primedex and BRMG which requires him to devote one-half of his time to each entity in exchange for annual combined remuneration currently of \$370,000. Dr. Crues' duties for Primedex include information management systems for radiology practices, imaging facility network development and network marketing and management, utilization management, utilization review, all forms of provider and payor contracts and physician interaction. For BRMG, Dr. Crues' duties include diagnostic imaging, professional physician services, utilization management, utilization review, all forms of provider and payor contracts and physician interaction, some of which require a license to practice medicine.

On April 16, 2001, Primedex entered into a five-year employment agreement with Jeffrey L. Linden for Mr. Linden to serve as vice president and general counsel. The agreement provides for annual compensation of \$350,000, together with the option to purchase 1,000,000 shares of Primedex's common stock at a price of \$0.43 per share (the closing price reported on the Over-The-Counter Bulletin Board on the date the agreement was executed), exercisable throughout his employment, or by June 1, 2006 if Mr. Linden's employment is terminated. The agreement also extended Mr. Linden's ability to exercise 145,000 options previously held by him through May 31, 2006. Under this agreement, if Primedex terminates Mr. Linden's employment for cause, he will be entitled to compensation equal to one year's base salary. If Mr. Linden terminates his agreement without cause, he is entitled to compensation accrued through the effective date of termination, and if his employment is terminated by Primedex without cause, Primedex shall pay Mr. Linden an amount equal to the sum of (i) his base salary accrued through the effective date of termination; (ii) his base salary for the balance of the term, but not less than his base salary for five years; and (iii) an amount equal to the cost of all benefits he would receive for the balance of the term. Mr. Linden's employment shall not terminate in the event of a merger, consolidation, dissolution or other transaction whereby Primedex would not be the surviving entity of such transaction, and Mr. Linden holds the right to terminate his agreement upon 60 days notice in the event of any such transaction. If Mr. Linden's employment is terminated in connection with any such transaction he shall be entitled to the same compensation he would have received if Primedex terminated his employment without cause.

On May 1, 2001, Primedex entered into a three-year employment agreement with Norman R. Hames. Pursuant to the agreement Mr. Hames agreed to continue his employment with Primedex as its vice president and chief operations officer. The agreement provides for Mr. Hames to receive annual compensation of \$225,000. Additionally, in consideration of his entry into the agreement Mr. Hames received the option to purchase 3,000,000 shares of Primedex's common stock at a price of \$0.55 per share (the closing price reported on the Over-The-Counter Bulletin Board on the date the agreement was

executed) exercisable throughout his employment, or by May 1, 2006 if Mr. Hames' employment is terminated. Primedex also agreed to provide a cash bonus to Mr. Hames of \$0.20 for each share that he exercises under the options, up to a maximum of \$600,000. Under this agreement, if Primedex terminates his employment for cause, he will be entitled to compensation equal to one year's base salary. If Mr. Hames terminates his agreement without cause, he is entitled to compensation accrued through the effective date of termination, and if his employment is terminated by Primedex without cause, Primedex shall pay Mr. Hames an amount equal to the sum of (i) his base salary accrued through the effective date of termination; (ii) his base salary for the balance of the term, but not less than his base salary for three years; and (iii) an amount equal to the cost of all benefits he would receive for the balance of the term. Mr. Hames' employment shall not terminate in the event of a merger, consolidation, dissolution or other transaction whereby Primedex would not be the surviving entity of such transaction.

On July 30, 2004, Primedex entered into a three year employment agreement with Mark Stolper for Mr. Stolper to serve as Primedex's chief financial officer. Mr. Stolper received a \$25,000 payment on entry into the agreement and receives annual compensation during the first twelve months of \$215,000 and thereafter of \$250,000 per year. At the end of the first twelve months, Mr. Stolper received a one time payment of \$10,000. In connection with his employment, Mr. Stolper received five-year warrants to purchase 650,000 shares of Primedex common stock at \$0.30 per share (the closing price reported on the Over-The-Counter Bulletin Board on the date the agreement was executed).

Report of the Audit Committee

The primary function of Primedex's Committee is oversight of the Corporation's financial reports, internal accounting and financial controls and the independent audit of the annual consolidated financial statements. Our Committee acts under a charter attached to this proxy statement/prospectus as *Annex H*. We periodically review the adequacy of the charter. Each of our members is independent, and both of our members are audit committee financial experts under Securities and Exchange Commission rules. We held three meetings in fiscal 2005 at which, as discussed in more detail below, we had extensive reports and discussions with the independent auditors, internal auditors and other members of management.

In performing our oversight function, we reviewed and discussed the consolidated financial statements with management and Moss Adams LLP (Moss), the independent auditors. Management and Moss told us that Primedex's consolidated financial statements were fairly stated in accordance with generally accepted accounting principles. We discussed significant accounting policies applied by Primedex in its financial statements, as well as alternative treatments. We discussed with Moss matters covered by the statement on Auditing Standards No. 61 (Communication with Audit Committees). In addition, we reviewed and discussed management's report on internal control over financial reporting.

We also discussed with Moss its independence from Primedex and management, including the matters in Independence Standards Board Standard No. 1 (Independence Discussions with Audit Committees) and the letter and disclosures from Moss to us pursuant to Standard No. 1. We considered the non-audit services provided by Moss to Primedex, and concluded that the auditors' independence has been maintained.

We discussed with Moss the overall scope and plans for their audit. We met with Moss, both with and without management present. Discussions included the results of its examination, its evaluations of Primedex's internal controls and the overall quality of Primedex's financial reporting.

Based on the reviews and discussions referred to above, in reliance on management and Moss, and subject to the limitations of our role described below, we recommended to the Board, and the Board has approved, the inclusion of the audited financial statements in Primedex's Annual Report on Form 10-K for the year ended October 31, 2005, for filing with the Securities and Exchange Commission.

We have also appointed Moss to audit the Corporation's financial statements for 2006, subject to stockholder ratification of that appointment.

In carrying out our responsibilities, we look to management and the independent auditors. Management is responsible for the preparation and fair presentation of Primedex's financial statements and for maintaining effective internal control. Management is also responsible for assessing and maintaining the effectiveness of internal control over the financial reporting process in compliance with Sarbanes-Oxley Section 404 requirements. The independent auditors perform their responsibilities in accordance with the standards of the Public Company Accounting Oversight Board. While our members are or have been professionally engaged in the practice of accounting or auditing, they are not experts under the Securities Act of 1933 in either of those fields or in auditor independence.

Respectfully submitted,
David L. Swartz, Chairperson
Lawrence L. Levitt

Report on Executive Compensation

Primedex's Board of Directors reviews and approves the salaries and equity awards of the executive officers of Primedex as well as all grants of options and warrants to purchase shares of Common Stock and other equity-based compensation awards.

Objectives. The Board of Directors' primary objectives are to retain the best qualified people and to ensure that they are properly motivated to have Primedex prosper over the long term. In furtherance of the foregoing, the Board of Directors, in establishing the components and levels of compensation for its executive officers, seeks (i) to enable Primedex to attract and retain highly qualified executives and (ii) to provide financial incentives in the form of equity compensation in order to align the interests of executive officers more closely with those of the stockholders of Primedex and to motivate such executives to increase stockholder value by improving corporate performance and profitability.

Employment Agreements. Primedex has entered into employment agreements with each of the named executive officers listed in the Summary Compensation Table on page 189, except for Dr. Berger, Primedex's Chief Executive Officer, who has entered into a Management Consultant Agreement with BRMG. The Board has considered the advisability of using employment agreements and has determined that the use of employment agreements is in the best interest of Primedex because it facilitates (consistent with the Board of Directors' overall objectives) Primedex's ability to attract and retain the services of the most highly qualified executive officers. Each such employment agreement separately reflects the terms that the Board of Directors felt were appropriate and/or necessary to retain the services of the particular executive.

Components of Executive Compensation. There are two components of Primedex's executive compensation program:

- Cash compensation.
- Equity compensation.

Cash Compensation. Cash compensation is comprised of base salary. Since, as noted above, each of Primedex's Named Executive Officers was party to employment agreements with Primedex effective during the past fiscal year, their respective cash compensation levels were subject to the provisions of such employment agreements. The Board of Directors subjectively arrived at appropriate base salary compensation levels in the process of negotiating such agreements.

Equity Compensation. Equity compensation is comprised of stock options and stock bonus awards. Stock option and warrant grants reflect the Board of Director's desire to provide a meaningful equity incentive for the executive to have Primedex prosper over the long term. As of July 31, 2006, 11,873,834 options and warrants to purchase shares were outstanding under all equity compensation plans, and of such amount, 5,675,000 options and warrants to purchase shares were held by executive officers of Primedex.

Chief Executive Officer Compensation. Dr. Berger's compensation is determined pursuant to the Management Consultant Agreement described in Executive Compensation Employment Contracts. BRMG paid Dr. Berger's annual salary in 2005. Dr. Berger received no compensation from Primedex in 2005.

Section 162(m). Section 162(m) of the Code generally disallows a deduction to publicly traded companies to the extent of excess compensation over \$1.0 million per year paid to its named executive officers. Qualifying performance-based compensation which is paid in accordance with regulations promulgated under Section 162(m) of the Code is not subject to the deduction limit. Primedex reserves the right to pay compensation to its named executive officers that does not qualify as performance based compensation under Section 162(m) of the Code if compliance with applicable regulations conflicts with Primedex's compensation philosophy or with what is believed to be the best interests of Primedex and its stockholders.

By the Board of Directors,
Howard G. Berger, M.D.
Norman R. Hames
John V. Crues, III, M.D.
David L. Swartz
Lawrence L. Levitt

Stock Performance Graph

The following graph compares the yearly percentage change in cumulative total stockholder return of the Company's Common Stock during the period from 2001 to 2006 with (i) the cumulative total return of the S&P500 index and (ii) the cumulative total return of the S&P500 Healthcare Sector index. The comparison assumes \$100 was invested on January 1, 2001 in the Common Stock and in each of the foregoing indices and the reinvestment of dividends through January 1, 2006. The stock price performance on the following graph is not necessarily indicative of future stock price performance.

This graph shall not be deemed incorporated by reference by any general statement incorporating by reference this joint prospectus/proxy statement into any filing under the Securities Act or under the Exchange Act, except to the extent that Primedex specifically incorporates this information by reference, and shall not otherwise be deemed filed under such Acts.

Dollar Style (\$Millions)

Stock Ownership of Directors and Executive Officers

The following table sets forth certain information regarding the beneficial ownership of Primedex common stock as of August 31, 2006, by (i) each holder known by Primedex to beneficially own more than five percent of the outstanding common stock, (ii) each of Primedex's directors and executive officers, and (iii) all directors and officers as a group. The percentages set forth in the table have been calculated on the basis of treating as outstanding, for purposes of computing the percentage ownership of a particular holder, all shares of Primedex common stock outstanding at such date and all shares of common stock purchasable upon exercise of options and warrants owned by such holder which are exercisable at or within 60 days after such date.

Name of Beneficial Owner	Shares of Common Stock Beneficially Owned(1)	Percent of Class
Howard G. Berger, M.D.*	13,137,400 (2)	21.6 %
John V. Crues, III, M.D.*	1,492,275 (3)	2.5 %
Norman R. Hames*	3,000,000 (4)	4.9 %
David L. Swartz*	150,000 (5)	(5)
Lawrence L. Levitt*	100,000 (6)	(6)
Jeffrey L. Linden*	1,670,000 (7)	2.7 %
Mark D. Stolper*	908,800 (8)	1.2 %
All directors and executive officers as a group (seven persons)	20,458,475 (9)	33.0 %

* The address of all of Primedex's officers and directors is c/o Primedex, 1510 Cotner Avenue, Los Angeles, California 90025.

(1) Subject to applicable community property statutes and except as otherwise noted, each holder named in the table has sole voting and investment power with respect to all shares of common stock shown as beneficially owned.

(2) Includes 122,400 shares issuable upon conversion of Primedex's outstanding convertible debentures convertible at \$2.50 per share. As a result of his stock ownership and his positions as president and a director of Primedex, Howard G. Berger, M.D. may be deemed to be a controlling person of Primedex.

(3) Includes warrants for 1,000,000 shares exercisable between \$0.36 and \$0.46 per share.

(4) Represents warrants exercisable at \$0.56 per share and vesting over a term of years commencing in 2007, unless the public market price of our common stock reaches \$3.00 per share in which case the warrants vest.

(5) Represents warrants exercisable between \$0.40 and \$0.60 per share and is less than 1.0% of the class.

(6) Represents warrants exercisable between \$0.32 per share and \$0.50 and is less than 1.0% of the class.

(7) Includes 775,000 options and warrants exercisable at prices between \$0.30 and \$1.26 per share, of which 500,000 shares vest over a term of years commencing in 2007 unless the market price of our common stock reaches \$3.00 per share in which case the warrants vest.

(8) Includes warrants for 700,000 shares exercisable at prices between \$0.30 and \$0.60 per share and a warrant for 200,000 shares exercisable over a term of years commencing in 2007, unless the market price of our common stock reaches \$3.00 per share in which case the warrant vest.

(9) See the above footnotes. Includes 14,411,075 shares owned of record and 5,847,400 shares issuable upon exercise of presently exercisable options, warrants and convertible debentures.

Securities Authorized for Issuance Under Equity Compensation Plans

The following table shows, as of October 31, 2005, outstanding options, their weighted exercise price, and options remaining available for issuance under Primedex's existing compensation plans.

EQUITY COMPENSATION PLAN INFORMATION

Plan Category	Number of securities to be issued upon exercise of outstanding options, warrants and rights (a)	Weighted-average exercise price of outstanding options, warrants and rights (b)	Number of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in column (a)) (c)
Plans Approved by Stockholders	687,167	\$ 0.51	1,303,334
Plans Not Approved by Stockholders	12,004,770	\$ 0.63	Not Applicable
Total	12,691,937		1,303,334

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS OF PRIMEDEX

The following discussion and analysis of financial condition and results of operations should be read together with Selected Historical Financial Data of Primedex and Primedex's financial statements and accompanying notes appearing elsewhere in this joint proxy statement/prospectus. This discussion contains forward-looking statements, based on current expectations and related to future events and Primedex's future financial performance, that involve risks and uncertainties. Primedex's actual results may differ materially from those anticipated in these forward-looking statements as a result of important factors, including those set forth in the section entitled Risk Factors in Primedex's 10-K filed with the SEC on February 14, 2006, as amended and available on Primedex's website, www.radnetonline.com, and the SEC's website, www.sec.gov.

Overview

Primedex operates a group of regional networks comprised of 65 fixed-site, freestanding outpatient diagnostic imaging facilities in California. Primedex believes its group of regional networks is the largest of its kind in California. Primedex has strategically organized its facilities into regional networks in markets, which have both high-density and expanding populations, as well as attractive payor diversity.

All of its facilities employ state-of-the-art equipment and technology in modern, patient-friendly settings. Many of its facilities within a particular region are interconnected and integrated through its advanced information technology system. Thirty-eight of its facilities are multi-modality sites, offering various combinations of MRI, CT, PET, nuclear medicine, ultrasound, X-ray and fluoroscopy services. Twenty-seven of its facilities are single-modality sites, offering either X-ray or MRI services. Consistent with its regional network strategy, Primedex locates its single-modality sites near multi-modality sites to help accommodate overflow in targeted demographic areas.

Primedex derives substantially all of its revenue, directly or indirectly, from fees charged for the diagnostic imaging services performed at its facilities. For the year ended October 31, 2005, Primedex derived 60% of its net revenue from MRI and CT scans. For the nine months ended July 31, 2006, Primedex derived 58% of its net revenue from MRI and CT scans. Over the past three fiscal years, Primedex has increased net revenue primarily through improvements in net reimbursement, expansions of existing facilities, upgrades in equipment and development of new facilities.

The fees charged for diagnostic imaging services performed at its facilities are paid by a diverse mix of payors, as illustrated for the six months ended July 31, 2006 by the following table:

Payor Type	Percentage of Net Revenue for the Nine Months Ended July 31, 2006		Percentage of Net Revenue for the Year Ended October 31, 2005	
Insurance(1)	41	%	41	%
Managed Care Capitated Payors	27	%	26	%
Medicare/Medi-Cal	18	%	18	%
Other(2)	10	%	11	%
Workers Compensation/Personal Injury	4	%	4	%

(1) Includes Blue Cross/Blue Shield, which represented 15% of its net revenue for the nine months ended July 31, 2006.

(2) Includes co-payments, direct patient payments and payments through contracts with physician groups and other non-insurance company payors.

Primedex's eligibility to provide service in response to a referral often depends on the existence of a contractual arrangement between the radiologists providing the professional medical services or Primedex and the referred patient's insurance carrier or managed care organization. These contracts typically describe the negotiated fees to be paid by each payor for the diagnostic imaging services Primedex provides. With the exception of Blue Cross/Blue Shield and government payors, no single payor accounted for more than 5% of its net revenue for the year ended October 31, 2005 or for the nine months ended July 31, 2006. Under its capitation agreements, Primedex receives from the payor a pre-determined amount per member, per month. If Primedex does not successfully manage the utilization of its services under these agreements, Primedex could incur unanticipated costs not offset by additional revenue, which would reduce its operating margins.

The principal components of its fixed operating expenses, excluding depreciation, include professional fees paid to radiologists, except for those radiologists who are paid based on a percentage of revenue, compensation paid to technologists and other facility employees, and expenses related to equipment rental and purchases, real estate leases and insurance, including errors and omissions, malpractice, general liability, workers compensation and employee medical. The principal components of its variable operating expenses include expenses related to equipment maintenance, medical supplies, marketing, business development and corporate overhead. Because a majority of its expenses are fixed, increased revenue as a result of higher scan volumes per system or improvements in net reimbursement can significantly improve its margins.

BRMG strives to maintain qualified radiologists and technologists while minimizing turnover and salary increases and avoiding the use of outside staffing agencies, which are considerably more expensive and less efficient. In recent years, there has been a shortage of qualified radiologists and technologists in some of the regional markets Primedex serves. As turnover occurs, competition in recruiting radiologists and technologists may make it difficult for its contracted radiology practices to maintain adequate levels of radiologists and technologists without the use of outside staffing agencies. At times, this has resulted in increased costs for Primedex.

For a discussion of other factors that may have an impact on its business and its future results of operations, see **Risks Related to its Business**.

As part of our evaluation of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the fiscal year ended October 31, 2005, we concluded that we had insufficient personnel resources and technical accounting expertise within the accounting function to resolve the following non-routine or complex accounting matters: the recording of non-typical cost-based investments and unusual debt-related transactions and the appropriate analysis of the amortization lives of leasehold improvements in accordance with GAAP. We are committed to establish the necessary environment to ensure the effectiveness of these controls in the future and quality financial reporting. The material weakness in internal controls did not have any impact on our financial statements for the year ended October 31, 2005 or for the nine months ended July 31, 2006.

Adoption of SFAS No. 123(R) and Equity-Based Compensation Expense

During the first quarter of fiscal 2006, we adopted SFAS No. 123(R), *Share-Based Payment*, applying the modified prospective method. This statement requires all equity-based payments to employees, including grants of employee options, to be recognized in the consolidated statement of earnings based on the grant date fair value of the award. Under the modified prospective method, we are required to record equity-based compensation expense for all awards granted after the date of adoption and for the unvested portion of previously granted awards outstanding as of the date of adoption. The fair values of all options were valued using a Black-Scholes model.

In anticipation of the adoption of SFAS No. 123(R), Primedex did not modify the terms of any previously granted awards.

Our operating earnings for the three and nine months ended July 31, 2006 were adversely affected by the impact of equity-based compensation due to the implementation of SFAS No. 123(R). Primedex recorded \$108,000 and \$345,000, respectively, for equity-based compensation during the three and nine months ended July 31, 2006. As of July 31, 2006, total unrecognized share-based compensation expense related to non-vested employee awards was approximately \$2.1 million, which is expected to be recognized over a weighted average period of approximately 7.0 years. The weighted fair value of options granted during the nine months ended July 31, 2006 is \$0.49.

Primedex's Relationship With BRMG

Howard G. Berger, M.D. is its President and Chief Executive, a member of its Board of Directors, and owns approximately 30% of Primedex's outstanding common stock. Dr. Berger also owns, indirectly, 99% of the equity interests in BRMG. BRMG provides all of the professional medical services at 46 of its facilities under a management agreement with Primedex, and contracts with various other independent physicians and physician groups to provide all of the professional medical services at most of its other facilities. Primedex obtains professional medical services from BRMG, rather than providing such services directly or through subsidiaries, in order to comply with California's prohibition against the corporate practice of medicine. However, as a result of its close relationship with Dr. Berger and BRMG, Primedex believes that Primedex is able to better ensure that professional medical services are provided at its facilities in a manner consistent with its needs and expectations and those of its referring physicians, patients and payors than if Primedex obtained these services from unaffiliated practice groups.

Under its management agreement with BRMG, which expires on January 1, 2014, BRMG pays Primedex, as compensation for the use of its facilities and equipment and for its services, a percentage of the gross amounts collected for the professional services it renders. The percentage, which was 79% at October 31, 2005, is adjusted annually, if necessary, to ensure that the parties receive fair value for the services they render. In operation and historically, the annual revenue of BRMG from all sources closely approximates its expenses, including Dr. Berger's compensation, fees payable to Primedex and amounts payable to third parties. For administrative convenience and in order to avoid inconveniencing and confusing its payors, a single bill is prepared for both the professional medical services provided by the radiologists and its non-medical, or technical, services, generating a receivable for BRMG. BRMG finances these receivables under a working capital facility with Bridge Healthcare Finance LLC, or Bridge, and regularly advances to Primedex the funds that it draws under this working capital facility, which Primedex uses for its own working capital purposes. Primedex repays or offsets these advances with periodic payments from BRMG to Primedex under the management agreement. Primedex guarantees BRMG's obligations under this working capital facility. Effective March 9, 2006, the line of credit with Bridge was paid and closed with the issuance of a new \$161 million senior secured credit facility.

As a result of its contractual and operational relationship with BRMG and Dr. Berger, Primedex is required to include BRMG as a consolidated entity in its consolidated financial statements. See Selected Consolidated Financial Data.

Results of Operations

The following table sets forth, for the periods indicated, the percentage that certain items in the statement of operations bears to net revenue.

	Year Ended October 31,			Nine Months Ended July 31,	
	2003	2004	2005	2005	2006
Net revenue	100.0 %	100.0 %	100.0 %	100.0 %	100.0 %
Operating expenses:					
Operating expenses	75.6	77.1	74.9	75.7	74.9
Depreciation and amortization	12.0	12.9	11.7	12.2	10.3
Provision for bad debts	3.6	2.8	3.4	2.6	4.0
Loss on disposal of equipment, net			0.5	0.7	0.1
Total operating expense	91.2	92.8	90.5	91.2	89.3
Income from operations	8.8	7.2	9.5	8.8	10.7
Other expense (income):					
Interest expense	12.8	12.6	12.0	12.1	12.1
Loss/(Gain) on debt extinguishment, net				(0.5)	1.8
Other income	(0.4)	(0.1)	(0.6)	(0.1)	
Other expense	0.2	1.2	0.2		0.7
Total other expense	12.6	13.7	11.6	11.5	14.6
Loss before provision for income taxes, minority interest and discontinued operation	(3.8)	(6.5)	(2.1)	(2.7)	(3.9)
Income tax expense		(3.8)			
Loss before minority interest and discontinued operation	(3.8)	(10.3)	(2.1)	(2.7)	(3.9)
Minority interest in earnings of subsidiaries	0.1	0.3			
Loss from continuing operations	(3.9)	(10.6)	(2.1)	(2.7)	(3.9)
Discontinued operations:					
Income from operations of Westchester Imaging Group	0.2				
Gain on sale of discontinued operations	2.1				
Income from discontinued operation	2.3				
Net loss	(1.6)	(10.6)	(2.1)	(2.7)	(3.9)

Nine Months Ended July 31, 2005 Compared to the Nine Months Ended July 31, 2006

During the last nine months, we continued our efforts to enhance our operations and expand our network, while improving our financial position and cash flows. Our results for the nine months ended July 31, 2006 were affected by the opening and integration of new facilities, the restructuring of our existing line of credit, notes payable and capital lease obligations, increases in capitation reimbursement and our continuing focus on controlling operating expenses. As a result of these factors and the other matters discussed below, we experienced an increase in income from operations of \$3.3 million, but due to increases in interest expense, a legal settlement and costs related to our debt restructuring, we also increased our net loss by \$1.7 million for the nine months ended July 31, 2006 when compared to the same period last year.

We had a working capital deficit of \$557,000 at July 31, 2006 compared to a \$143.4 million deficit at October 31, 2005, and had losses from operations of \$4.6 million and \$2.8 million for the nine months ended July 31, 2006 and 2005, respectively. We also had a stockholders' deficit of \$74.6 million at July 31, 2006 compared to a \$70.6 million deficit at October 31, 2005.

The working capital deficit as of October 31, 2005 included the reclassification of approximately \$109 million in notes and capital lease obligations as current liabilities expected to be refinanced. We were subject to financial covenants under our debt agreements and believed we may have been unable to continue to be in compliance with our existing financial covenants during fiscal 2006. As such, the associated debt was reclassified as a current liability.

Effective March 9, 2006, we completed the issuance of a \$161 million senior secured credit facility that we used to refinance substantially all of our existing indebtedness (except for \$16.1 million of outstanding subordinated debentures and approximately \$5 million of capital lease obligations). We incurred fees and expenses for the transaction of approximately \$5.6 million. Debt issue costs are being amortized on a straight-line basis over 65 months and are included in other assets. In addition, we recorded a net loss on extinguishments of debt of \$2.1 million, which includes \$1.2 million in pre-payment penalty fees that are unpaid as of July 31, 2006 and classified as accrued expenses under current liabilities. The facility provides for a \$15 million five-year revolving credit facility, an \$86 million term loan due in five years and a \$60 million second lien term loan due in six years. The loans are subject to acceleration on December 27, 2007, unless we have made arrangements to discharge or extend our outstanding subordinated debentures by that date. We intend to retire the subordinated debentures prior to their due date of June 30, 2008. Under the terms and conditions of the new Second Lien Term Loan, subject to achieving certain leverage ratios, we have the right to raise up to \$16.1 million in additional funds as part of the Second Lien Term Loan for the purposes of redeeming the subordinated debentures. Additionally, under the current facilities, we have the ability to pursue other funding sources to refinance the subordinated debentures. The new loans are payable interest only monthly except for the \$86 million term loan that requires amortization payments of 1.0% per annum, or \$860,000, paid quarterly.

On July 6, 2006, Primedex entered into an agreement and plan of merger for the acquisition of Radiologix, Inc. by Primedex through the merger of a wholly-owned subsidiary of Primedex with and into Radiologix. Upon successful completion of the merger, Radiologix stockholders will receive a combination of cash and Primedex common stock in exchange for their shares of Radiologix common stock. Pursuant to the merger, Radiologix stockholders will receive aggregate consideration of 22,621,922 shares of Primedex common stock and \$42,950,000 in cash. Based upon the August 17, 2006 closing price of Primedex common stock of \$1.57, each Radiologix stockholder would receive \$1.85 in cash for each Radiologix share, plus one share of Primedex common stock for total consideration valued at \$3.42 per share. The merger agreement also provides Primedex the option to elect to reduce the share consideration by up to 3.5 million shares and to increase the cash consideration by \$2 per share, provided that Primedex advises Radiologix of its election prior to the mailing of the proxy statement. Upon completion of the merger, we estimate that, subject to adjustment as described above, Radiologix's former stockholders will own approximately 34.9% of the then-outstanding shares of Primedex common stock, based on the number of shares of Radiologix and Primedex common stock outstanding on August 17, 2006. Primedex's stockholders will continue to own their existing shares. In connection with the proposals set forth in this joint proxy statement/prospectus, Primedex stock may be subject to transfer restrictions which are necessary to preserve Primedex's unrestricted use of its net operating loss carry forwards.

Primedex has signed a commitment letter with GE Commercial Finance Healthcare Financial Services for a \$405 million senior secured credit facility. The facility is expected to be used to finance the merger, to refinance existing indebtedness, to pay transaction costs and expenses relating to the merger and the credit facility and to provide financing for working capital needs post-merger. Consummation of the financing is a condition to the closing of the merger. The facility will consist of a revolving credit facility

of up to \$45 million, a \$225 million term loan and a \$135 million second lien term loan. The revolving credit facility will have a term of five years, the term loan will have a term of six years and the second lien term loan will have a term of six and one-half years. Interest is payable on all loans initially at an Index Rate plus the Applicable Index Margin, as defined. The Index Rate is initially a floating rate equal to the higher of the rate quoted from time to time by The Wall Street Journal as the base rate on corporate loans posted by at least 75% of the nation's largest 30 banks or the Federal Funds Rate plus 50 basis points. The Applicable Index Margin on each the revolving credit facility and the term loan is 2% and on the second lien term loan is 6%. Primedex may, after a certain period, request that the interest rate instead be based on LIBOR plus the Applicable LIBOR Margin, which is 3.5% for the revolving credit facility and the term loan and 7.5% for the second lien term loan. It is anticipated that the credit facility will include customary covenants for a facility of this type, including minimum fixed charge coverage ratio, maximum total leverage ratio, maximum senior leverage ratio, limitations on indebtedness, contingent obligations, liens, capital expenditures, lease obligations, mergers and acquisitions, asset sales, dividends and distributions, redemption or repurchase of equity interests, subordinated debt payments and modifications, loans and investments, transactions with affiliates, changes of control, and payment of consulting and management fees. The credit facility will contain such conditions to funding as are customary for senior secured facilities of this type.

Net Revenue

Net revenue for the nine months ended July 31, 2006 was \$118.5 million compared to \$105.5 million for the same period in fiscal 2005, an increase of approximately \$13.0 million, or 12.3%.

In addition to new capitation contracts, we have continued to improve our yield from capitation as a result of contractual and negotiated increases in reimbursement coupled with improved collections of co-payments from the individual patients. For the nine months ended July 31, 2006 and 2005, net capitation revenue, including co-payments, was \$32.1 million and \$27.8 million, respectively, an increase of approximately \$4.3 million. In addition, net revenue increased for the nine months ended July 31, 2006 due to increased marketing efforts, new contracts, maturing centers, pull-through or referred business from expanding capitation arrangements, expansion of existing facilities and new satellite locations.

During the nine months ended July 31, 2006, the largest net revenue increases were at the Temecula and Tarzana facilities with combined increases of approximately \$5.5 million when comparing results with the same period last year. Tarzana's continued growth is due to hiring of key physicians in the region, the location of the facilities, the increased utilization of PET, increased marketing efforts and state of the art medical equipment. The Temecula facilities' continued growth is due to a variety of factors including their physical locations, the return of a large capitation agreement, improvements in contracted reimbursement, the opening of additional satellite facilities, the ramp-up of the Murrieta site which opened in December 2004, and increases in patient volume and throughput.

The largest net revenue decrease was at the Beverly Hills facilities with a decrease of approximately \$0.8 million when comparing results with the same period last year. The decrease was due to increased competition in the area.

Operating Expenses

Operating expenses for the nine months ended July 31, 2006 increased approximately \$9.6 million from \$96.2 million during the nine months ended July 31, 2005 to \$105.8 million during the same period this year.

The following table sets forth our operating expenses for the nine months ended July 31, 2005 and 2006 (dollars in thousands):

	Nine Months Ended July 31,	
	2005	2006
Salaries and professional reading fees	\$ 49,122	\$ 55,719
Building and equipment rental	5,837	6,325
General administrative expenses	24,833	26,657
Total operating expenses	79,792	88,701
Depreciation and amortization	12,905	12,175
Provision for bad debt	2,789	4,739
Loss (gain) on disposal of equipment, net	698	210

Salaries and professional reading fees

Salaries and professional reading fees increased \$6.6 million, or 13.4%, for the nine months ended July 31, 2006 when compared to the same period last year. The majority of the increase is due to the \$13.0 million, or 12.3%, increase in net revenue that included the variable labor necessary to service the additional patient volume, the additional locations, and the compensation to physicians with contracted fees based upon a percentage of net revenue. During the third quarter of fiscal 2006, we incurred approximately \$500,000 in additional salaries for several physicians and supporting operational staff that we and BRMG hired in advance of several new acquisitions scheduled to open in the fourth quarter (see Note 6). In addition, during the nine months ended July 31, 2006, we recorded stock-based compensation expense of \$345,000 for the value of the portion of share-based payment awards that is ultimately expected to vest during the period. Stock-based compensation expense included compensation expense for share-based payment awards granted prior to, but not yet vested as of October 31, 2005 based on the grant date fair value estimated in accordance with the pro forma provisions of SFAS 123. No Stock-based compensation expense was recognized in the nine months ended July 31, 2005.

Building and equipment rental

Building and equipment rental expenses increased \$0.5 million for the nine months ended July 31, 2006 when compared to the same period last year. The increase is primarily due to the additional building rental expense for the new centers in Emeryville, Westlake and additional satellite facilities coupled with annual increases in base rentals from previously existing leased facilities.

General and administrative expenses

General and administrative expenses include billing fees, medical supplies, office supplies, repairs and maintenance, insurance, business tax and license, outside services, utilities, marketing, travel and other expenses. Many of these expenses are variable in nature. These expenses increased \$1.8 million during the nine months ended July 31, 2006 when compared to the same period last year. The increase is primarily due to the \$13.0 million increase in net revenue and the related variable general and administrative expenses necessary to service the additional patient volume, and other expenses that are based upon a percentage of net revenue, including equipment maintenance. The equipment maintenance agreement fees increased from 3.50% of net revenue in fiscal 2005 to 3.62% of net revenue in fiscal 2006.

Depreciation and Amortization

Depreciation and amortization decreased by \$0.7 million for the nine months ended July 31, 2006 when compared to the same period last year. At July 31, 2005, net property and equipment was \$71.0 million compared to \$62.8 million at July 31, 2006.

Provision for bad debt

The \$1.9 million increase in the provision for bad debt for the nine months ended July 31, 2006 when compared to the same period last year was primarily a result of increased revenue coupled with a change in timing of writing off older accounts receivable.

Loss on disposal of equipment, net

The \$0.2 million loss on the disposal of equipment for the nine months ended July 31, 2006 was primarily due to the write-off of \$143,000 in leasehold improvements at the Emeryville facility which was closed with the opening of the new facility in the third quarter of fiscal 2006. The \$0.7 million loss on the disposal of equipment for the nine months ended July 31, 2005 was primarily due to the trade-in of an MRI and replacing the equipment with an enhanced machine which improved throughput and volume demands at one of our Tarzana facilities.

Interest expense

Interest expense for the nine months ended July 31, 2006 increased \$1.6 million when compared to the same period last year. The increase was primarily due to the restructuring of our line of credit, notes payable and capital lease obligations in March 2006 and the financing of an additional \$5.6 million in transaction fees coupled with a slightly higher weighted average interest rate during the period. During the nine months ended July 31, 2006, we incurred a mark to market interest expense adjustment of approximately \$0.4 million. As part of the refinancing, we were required to swap at least 50% of the aggregate principal amount of the facilities to a floating rate within 90 days of the close of the agreement on March 9, 2006. On April 11, 2006, effective April 28, 2006, on \$73.0 million (one half of our First and Second Lien Term Loans of \$146.0 million), we entered into an interest rate swap fixing the LIBOR rate of interest at 5.47% for a period of three years. Previously, the interest rate on the \$73.0 million was based upon a spread over LIBOR which floats with market conditions.

Loss (gain) on debt extinguishments, net

In the nine months ended July 31, 2005, we recognized gains from extinguishments of debt for \$0.5 million for the write-off of certain notes payable past statute for \$475,000 and the settlement of other notes payable at a discount of \$40,000. During the nine months ended July 31, 2006, due to the March 2006 debt restructuring, we recognized a net loss on extinguishment of debt of \$2.1 million that is comprised of a gain of \$2.1 million for a discount on notes payable, offset by \$2.1 million in pre-payment penalties and \$2.1 million for the write-off of capitalized debt issue costs.

Other Income

In the nine months ended July 31, 2005, we earned other income of \$0.2 million. During the nine months ended July 31, 2005, we recognized gains from write-off of liabilities previously expensed in fiscal 2004 for approximately \$62,000, deferred rental income of \$67,000, and record copy income of \$44,000. We had no other income during the nine months ended July 31, 2006.

Other Expense

In the nine months ended July 31, 2005 and 2006, we incurred other expense of \$25,000 and \$0.8 million, respectively. During the nine months ended July 31, 2005, we recognized losses on the write-off of other assets of \$25,000. During the nine months ended July 31, 2006, we recorded expenses of \$788,000 that include the \$500,000 settlement with Broadstream and related legal fees.

Equity in Income of Investee

In the nine months ended July 31, 2006, we earned income for our 47.5% investment in a PET center of approximately \$61,000. The investment of \$237,000 was made in February 2006.

Year Ended October 31, 2005 Compared To The Year Ended October 31, 2004

During fiscal 2005, Primedex continued its efforts to enhance its operations and expand its network, while improving its financial position and significantly reducing its net loss. Primedex's results for fiscal 2005 were aided by the opening and integration of new facilities in prior periods, increases in PET volume, and improvements in reimbursement from managed care capitated contracts and other payors. As a result of these factors and the other matters discussed below, Primedex experienced an increase in income from operations of \$4.1 million.

During fiscal 2005, Primedex made more progress in solidifying its financial condition. Effective November 30, 2004, Primedex issued \$4 million in principal amount of notes to Post and Post repurchased the DVI affiliate's line of credit facility with the residual funds utilized by Primedex as working capital. The new note payable has monthly interest only payments at 12% per annum until its maturity in July 2008. In addition, Post acquired \$15.2 million of its notes payable from an affiliate of DVI and the indebtedness was restructured by Post and Primedex. The new note payable has monthly interest only payments at 11% per annum until its maturity in June 2008. The assignment of the note payable to Post will not result in any actual total dollar savings to Primedex over the term of the new obligation, but it will defer cash flow outlays of approximately \$1.3 million per year until maturity. See Financial Condition Liquidity and Capital Resources.

Net Revenue

Net revenue from continuing operations for fiscal 2005 was \$145.6 million compared to \$137.3 million for fiscal 2004, an increase of approximately \$8.3 million, or 6.0%. The largest net revenue increases were at the following facilities:

	Fiscal 05	
	Increase	%
Orange (4 sites)	\$ 2,383,000	17.6 %
Tarzana (2 sites)	\$ 1,775,000	24.2 %
Palm Springs (5 sites)	\$ 1,618,000	21.7 %
Temecula (4 sites)	\$ 1,366,000	21.9 %

Orange's and Palm Springs' net revenue increases were primarily due to increased patient volume, improved contracting and increases in reimbursement from its managed care capitated payors. Temecula's net revenue increase was primarily due to the return of a managed care capitated contract and the opening of an additional facility in Murrieta providing MRI, CT, PET, nuclear medicine and X-ray services in December 2004. Tarzana's net revenue increase was primarily due to increased PET volume with the hiring of a new physician and the upgrade of one of its MRI machines that increased throughput and patient volume.

Managed care capitated payor revenue increased from 25% of net revenue, or approximately \$34 million, to 26% of net revenue, or approximately \$38 million, for the years ended October 31, 2004 and 2005, respectively. Primedex has been successful in retaining existing contracts while obtaining increases in reimbursement from the payors coupled with receiving increases in co-payments from the individual patients upon service. Primedex anticipates maintaining a similar mix of managed care capitated payor business in fiscal 2006.

Operating Expenses

Operating expenses from continuing operations for fiscal 2005 increased approximately \$4.2 million, or 3.3%, from \$127.5 million in fiscal 2004 to \$131.7 million in fiscal 2005. The following table sets forth its operating expenses for fiscal 2004 and 2005 (dollars in thousands):

	Year Ended October 31,	
	2004	2005
Salaries and professional reading fees	\$ 64,932	\$ 66,674
Building and equipment rental	7,804	7,919
General administrative expenses	33,092	34,419
Total operating expenses	105,828	109,012
Depreciation and amortization	17,762	17,101
Provision for bad debt	3,911	4,929
Loss on disposal of equipment, net		696

Salaries and Professional Reading Fees

Salaries and professional reading fees increased \$1.7 million from fiscal 2004 to 2005. The majority of the increase is due to the increase in net revenue from \$137.3 million to \$145.6 million in fiscal 2004 and 2005, respectively. In addition to the hiring of additional employees to staff two new centers in Murrieta and Westlake, California, professional fees increased at certain sites due to contracts where compensation to the professionals is based upon a percentage of net revenue.

Building and Equipment Rental

Building and equipment rental expenses increased \$0.1 million in fiscal year 2005 when compared to the same period last year. The increase is primarily due to cost of living rental increases within existing building lease agreements and the addition of new facilities and the related rental expense.

General and Administrative Expenses

General and administrative expenses include billing fees, medical supplies, office supplies, repairs and maintenance, insurance, business tax and license, outside services, utilities, marketing, travel and other expenses. Many of these expenses are variable in nature. These expenses increased \$1.3 million, or 4.0%, in fiscal 2005 compared to the previous period primarily due to the increase in net revenue. The largest fiscal 2005 increases were expenditures for billing fees and medical supplies that increased \$711,000 and \$635,000, respectively, when compared to the same period last year.

Depreciation and Amortization

Depreciation and amortization decreased by \$0.7 million in fiscal year 2005 when compared to the same period last year. The primary reason for the decrease is the reduction in capital expenditures. During fiscal 2004 and 2005, capital expenditures were \$13.1 million and \$8.8 million, respectively.

Provision For Bad Debt

The \$1 million increase in provision for bad debt was primarily a result of increased net revenue and the increase in bad debts as a percentage of net revenue from 2.8% to 3.4% in fiscal 2004 and 2005, respectively. The bad debt percentage increased due to maturing accounts receivable and the faster write-off of slower-paying receivables to collection agencies to expedite cash receipts and accounts receivable turnover.

Loss On Disposal of Equipment, Net

The \$0.7 million increase in losses on disposal of equipment is primarily due to the trade-in and upgrade of an MRI at its Tarzana Advanced facility that was initiated to improve the existing equipment increasing throughput and patient volume at the site.

Interest Expense

Interest expense for fiscal 2005 increased approximately \$0.2 million, or 1.2%, from the same period in fiscal 2004. Interest expense is primarily from its outstanding notes payable and capital lease obligations, subordinated bond debentures, related party payables and its outstanding line of credit.

Other Income

In fiscal 2004 and 2005, Primedex earned other income of \$0.2 million and \$0.9 million, respectively, principally comprised of sublease income, medical record copying income, deferred rent income, other income related to write-offs of liabilities and business interruption and insurance refunds. During fiscal 2005, Primedex had gains on the settlement of debt of approximately \$0.7 million.

Other Expense

In fiscal 2004 and 2005, Primedex incurred other expense of \$1.7 million and \$0.3 million, respectively, principally comprised of write-offs of miscellaneous receivables and other assets, losses on disposal of equipment, forgiveness of notes, losses on the sale or disposal of assets, and costs related to bond offerings and debt restructures. During fiscal 2004, Primedex incurred approximately \$1.6 million of legal and professional service costs related to its earlier attempts to solidify financing and the related bond offering that was not completed.

Income Tax Expense

In fiscal 2004, Primedex increased the valuation allowance for the net deferred tax asset by \$5.2 million due to its recurring losses from continuing operations over the prior three fiscal years. In fiscal 2005, the valuation allowance was fully reserved.

Minority Interest In Earnings of Subsidiaries

Minority interest in earnings of subsidiaries represents the minority investors' 25% share of the income from the Burbank Advanced Imaging Center LLC and 25% share of the Rancho Bernardo Advanced LLC for the period. Both centers' residual interests were purchased by Primedex in September and July 2004, respectively. Primedex now owns 100% of all its locations and its minority interest liabilities have been eliminated. Minority interest expense was \$351,000 in fiscal 2004.

Year Ended October 31, 2004 Compared To The Year Ended October 31, 2003

During fiscal 2004, Primedex continued its efforts to enhance its operations and expand its network, while improving its financial position and cash flows. Primedex's results for fiscal 2004 were affected by the opening and integration of new facilities and the closure of underperforming operations, the increase in the valuation allowance for net deferred tax assets of \$5.2 million, the expenses involved with a bond offering which did not materialize, the slower than expected improvements in net revenue at Beverly Tower, and its continuing focus on controlling operating expenses. As a result of these factors and the other matters discussed below, Primedex experienced a decrease in income from operations of \$2.6 million and an increase in net loss from continuing operations of \$9.1 million.

Also during fiscal 2004, Primedex made significant progress in solidifying its financial condition. Primedex restructured the majority of its existing notes and capital lease obligations consolidating balances, extending terms and improving future net cash flows for debt service, and Primedex restructured its working capital line with a new lender, Wells Fargo Foothill. Net cash used by financing activities changed from \$20.3 million in fiscal 2003 to \$13.3 million in fiscal 2004, and its working capital deficit improved from \$44.6 million in fiscal 2003 to \$32.2 million in fiscal 2004. At the same time, however, net cash provided by operating activities decreased in fiscal 2004.

Net Revenue

Net revenue from continuing operations for fiscal 2004 was \$137.3 million compared to \$140.3 million for fiscal 2003, a decrease of approximately \$3.0 million, or 2.1%. Of the net revenue decrease, \$1.4 million is attributable to two facilities, La Habra and North County, which were closed in fiscal 2003 and 2004, respectively. The decrease was offset by \$0.4 million in net revenue from one facility, Rancho Bernardo, which opened in December 2002. Primedex's same store facilities, which Primedex defines as facilities open two years or more, net revenue in 2003 and 2004 was \$137.7 million and \$135.8 million, respectively. The same store facilities' net revenue was affected by a \$3.4 million decrease in net revenue at its Beverly Tower facilities over the same period. The decreases in net revenue at its Beverly Tower facilities were attributable to disruptions arising from the dispute described under *Significant Events Termination of Contract with Tower Imaging Medical Group, Inc.* Exclusive of Beverly Tower, its same store facilities had an increase in net revenue of approximately \$1.4 million from fiscal 2003 to fiscal 2004. Primedex presents same store facilities as those open two years or more because Primedex believes that this presentation eliminates the effect of facilities opened only a partial year.

Managed care capitated payor revenue increased from 22% of net revenue, or approximately \$31 million, to 25% of net revenue, or approximately \$34 million, for the years ended October 31, 2003 and 2004, respectively. Primedex has been successful in retaining existing contracts while obtaining increases in reimbursement from the payors coupled with receiving increases in co-payments from the individual patients upon service. Primedex anticipates maintaining a similar mix of managed care capitated payor business in fiscal 2005 due to increases in reimbursement from existing payors, offset by expected decreases in contracts that will not be renewed.

Operating Expenses

Operating expenses from continuing operations for fiscal 2004 decreased approximately \$0.4 million, or 0.3%, from \$127.9 million in fiscal 2003 to \$127.5 million in fiscal 2004. The decrease includes \$1.4 million of net operating expenses related to two facilities, La Habra and North County, which were closed during the last two fiscal years. This was offset by \$0.1 million for Rancho Bernardo which opened in December 2002.

The following table sets forth its operating expenses for fiscal 2003 and 2004 (dollars in thousands):

	Year Ended October 31,	
	2003	2004
Salaries and professional reading fees	\$ 62,454	\$ 64,932
Building and equipment rental	9,375	7,804
General administrative expenses	34,249	33,092
Total operating expenses	106,078	105,828
Depreciation and amortization	16,874	17,762
Provision for bad debt	4,944	3,911

Salaries and Professional Reading Fees

Salaries and professional reading fees increased \$2.5 million from fiscal 2003 to 2004. The amount is net of \$0.4 million relating to two closed facilities, La Habra and North County, and one new facility, Rancho Bernardo, which opened in December 2002. For its same store facilities, salaries increased \$2.2 million and professional reading fees decreased \$0.7 million from fiscal 2003 to fiscal 2004. The \$0.7 million improvement in same store professional reading fees was due to changes in the fee arrangement at its Beverly Tower facilities. In October 2003, the radiologists, who had previously been compensated based on a percentage of net revenue, were eliminated and those physicians rehired by BRMG are now paid a fixed salary. See Significant Events Termination of Contract with Tower Imaging Medical Group, Inc. For fiscal 2003 and 2004, professional reading fees at Beverly Tower were \$3.9 million and \$2.9 million, respectively.

The \$2.2 million increase in salaries is due to the higher costs associated with recruiting and retaining key personnel, the hiring of a chief financial officer, the solidifying of Beverly Tower's non physician staff due to the disruption in October 2003, the hiring of physician assistants, and the costs of additional personnel necessary to open additional satellite locations and the build-out of a new center in Murrieta.

Building and Equipment Rental

Building and equipment rental expenses decreased \$1.6 million in fiscal year 2004 when compared to the same period last year. The decrease is primarily due to the elimination of equipment operating leases including GE operating leases which were converted into \$6 million in capital leases in November 2003, and \$250,000 for Toshiba MR equipment which was converted into a capital lease in April 2004. During fiscal 2003 and 2004, Primedex had equipment rental expenses of \$2.2 million and \$0.3 million, respectively.

General and Administrative Expenses

General and administrative expenses include billing fees, medical supplies, office supplies, repairs and maintenance, insurance, business tax and license, outside services, utilities, marketing, travel and other expenses. Many of these expenses are variable in nature. These expenses decreased \$1.2 million, or 3.4%, in fiscal 2004 compared to the previous period primarily due to the decrease in net revenue. In addition, general and administrative expenses decreased \$0.4 million for two facilities which were closed during the last two fiscal periods, offset by one center which was opened in December 2002.

Depreciation and Amortization

Depreciation and amortization increased by \$0.9 million in fiscal year 2004 when compared to the same period last year. The increase was primarily due to the conversion of \$6.2 million in equipment operating leases into capital leases during fiscal 2004 coupled with a full-year's amortization of the Tower tradename purchased in October 2003 for \$1.5 million and amortized over 10 years.

Provision For Bad Debt

The \$1 million decrease in provision for bad debt was primarily a result of decreased bad debt write-offs, the improvement in billing and collections with the conversion to a single internal system, increased capitation business which has no bad debt, decreased net revenue, and no significant payor dissolutions in fiscal 2004.

Interest Expense

Interest expense for fiscal 2004 decreased approximately \$0.7 million, or 3.7%, from the same period in fiscal 2003. The decrease was primarily due to the consolidation and restructuring of notes payable and capital lease obligations with new terms and interest rates.

Other Income

In fiscal 2003 and 2004, Primedex earned other income of \$0.6 million and \$0.2 million, respectively, principally comprised of sublease income, record copy income, deferred rent income, other income related to write-offs of liabilities and business interruption and insurance refunds. During fiscal 2004, Primedex had no write-offs of liabilities nor business interruption or insurance refunds.

Other Expense

In fiscal 2003 and 2004, Primedex incurred other expense of \$0.3 million and \$1.7 million, respectively, principally comprised of write-offs of miscellaneous receivables and other assets, losses on disposal of equipment, forgiveness of notes, losses on the sale or disposal of assets, and costs related to bond offerings and debt restructures. During fiscal 2004, Primedex incurred approximately \$1.6 million of legal and professional service costs related to its earlier attempts to solidify financing and the related bond offering that was not completed.

Income Tax Expense

In fiscal 2004, Primedex increased the valuation allowance for the net deferred tax asset by \$5.2 million due to its recurring losses from continuing operations over the last three fiscal years.

Minority Interest In Earnings of Subsidiaries

Minority interest in earnings of subsidiaries represents the minority investors' 25% share of the income from the Burbank Advanced Imaging Center LLC and 25% share of the Rancho Bernardo Advanced LLC for the period. The residual interests of both centers were purchased by Primedex in September and July 2004, respectively. Primedex now owns 100% of all its locations and its minority interest liabilities have been eliminated. Minority interest in earnings of subsidiaries increased \$250,000 in fiscal 2004 compared to the same period in the prior period primarily due to the earnings incurred by Rancho Bernardo.

Discontinued Operation

The income from operations of Westchester was \$0.3 million for fiscal 2003. Net revenue was \$2.2 million for fiscal 2003. Effective March 31, 2003, Primedex sold its 50% share of Westchester to its joint venture partner for \$3 million. As part of the transaction, Primedex acquired 100% of the accounts receivable generated through March 31, 2003 for \$1.3 million and reimbursed Westchester \$0.3 million, which represented 50% of the remaining liabilities, resulting in net cash proceeds of approximately \$1.4 million. Primedex recognized a gain on the transaction of approximately \$2.9 million in fiscal 2003.

Summary of Operations By Quarter

The following table presents unaudited quarterly operating results for each of its last eight fiscal quarters. Primedex believes that all necessary adjustments have been included in the amounts stated below to present fairly the quarterly results when read in conjunction with the consolidated financial statements. Results of operations for any particular quarter are not necessarily indicative of results of operations for a full year or predictive of future periods.

STATEMENT OF OPERATIONS DATA
(dollars in thousands)

	2004 Quarter Ended				2005 Quarter Ended			
	Jan 31	Apr 30	Jul 31(1)	Oct 31(2)	Jan 31	Apr 30	Jul 31	Oct 31
Net revenue	\$ 34,047	\$ 35,853	\$ 33,900	\$ 33,477	\$ 34,110	\$ 35,190	\$ 36,178	\$ 40,094
Operating expenses	31,086	32,774	32,820	30,821	32,097	32,059	31,979	35,603
Total other expense	4,265	4,965	5,363	4,173	4,211	3,727	4,236	4,796
Income tax expense				5,235				
Net income (loss)	(1,305)	(1,897)	(4,517)	(6,857)	(2,198)	(596)	(37)	(304)
Basic earnings per share:								
Basic net loss per share	(.03)	(.05)	(.11)	(.16)	(.05)	(.02)		(.01)
Diluted earnings per share:								
Diluted net loss per share	(.03)	(.03)	(.11)	(.16)	(.05)	(.02)		(.01)

(1) Includes costs related to some of its earlier attempts to solidify financing and the related bond offering that was not completed including \$660,000 in professional and legal fees and \$555,000 in interest expense.

(2) Includes \$5.2 million of expense for the increase in the valuation allowance for the net deferred tax asset.

Financial Condition**Liquidity and Capital Resources**

We had a working capital deficit of \$557,000 at July 31, 2006 compared to a \$143.4 million deficit at October 31, 2005, and had losses from operations of \$4.6 million and \$2.8 million for the nine months ended July 31, 2006 and 2005, respectively. We also had a stockholders' deficit of \$74.6 million at July 31, 2006 compared to a \$70.6 million deficit at October 31, 2005.

The working capital deficit as of October 31, 2005 included the reclassification of approximately \$109 million in notes and capital lease obligations as current liabilities expected to be refinanced. We were subject to financial covenants under our debt agreements and believed we may have been unable to continue to be in compliance with our existing financial covenants during fiscal 2006. As such, the associated debt was reclassified as a current liability.

Effective March 9, 2006, we completed the issuance of a \$161 million senior secured credit facility that we used to refinance substantially all of our existing indebtedness (except for \$16.1 million of outstanding subordinated debentures and approximately \$5 million of capital lease obligations). We incurred fees and expenses for the transaction of approximately \$5.6 million. Debt issue costs are being amortized on a straight-line basis over 65 months and are included in other assets. In addition, we recorded a net loss on

extinguishments of debt of \$2.1 million, which includes \$1.2 million in pre-payment penalty fees that are unpaid as of July 31, 2006 and classified as accrued expenses under current liabilities. The facility provides for a \$15 million five-year revolving credit facility, an \$86 million term loan due in five years and a \$60 million second lien term loan due in six years. The loans are subject to acceleration on December 27, 2007, unless we have made arrangements to discharge or extend our outstanding subordinated debentures by that date. We intend to retire the subordinated debentures prior to their due date of June 30, 2008. Under the terms and conditions of the new Second Lien Term Loan, subject to achieving certain leverage ratios, we have the right to raise up to \$16.1 million in additional funds as part of the Second Lien Term Loan for the purposes of redeeming the subordinated debentures. Additionally, under the current facilities, we have the ability to pursue other funding sources to refinance the subordinated debentures. The new loans are payable interest only monthly except for the \$86 million term loan that requires amortization payments of 1.0% per annum, or \$860,000, paid quarterly.

The revolving credit facility and the \$86 million term loan bear interest at a base rate (base rate means corporate loans posted by at least 75% of the nation's 30 largest banks as quoted by the Wall Street Journal) plus 2.5%, or at our election, the LIBOR rate plus 4.0% per annum, payable monthly. The \$60 million second lien term loan bears interest at the base rate plus 7.0%, or at our election, the LIBOR rate plus 8.5% per annum, payable monthly. The \$86 million term loan includes amortization payments of 1.0% per annum, payable in quarterly installments of \$215,000. Upon the close of the refinancing on March 9, 2006, we utilized approximately \$1.5 million of the new \$15 million revolving credit facility.

As part of the refinancing, we were required to swap at least 50% of the aggregate principal amount of the facilities to a floating rate within 90 days of the close of the agreement on March 9, 2006. On April 11, 2006, effective April 28, 2006, on \$73.0 million (one half of our First and Second Lien Term Loans of \$146.0 million), we entered into an interest rate swap fixing the LIBOR rate of interest at 5.47% for a period of three years. Previously, the interest rate on the \$73.0 million was based upon a spread over LIBOR which floats with market conditions. In addition, as a requirement of the deal, 75% of our excess cash flow is to be used to repay principal on the \$86 million term loan once per year within 105 days after our fiscal year end. Excess cash flow is defined as earnings before interest, taxes, depreciation and amortization plus decreases in working capital and extraordinary gains minus: (i) capital expenditures; (ii) interest expense; (iii) scheduled principal payments on existing debt; (iv) income taxes; (v) increases in working capital; (vi) extraordinary losses; (vii) voluntary prepayments of the \$86 million term loan; (viii) and amounts paid for acquisitions.

Under the new facility, we are subject to various financial covenants including a limitation on capital expenditures, maximum days sales outstanding, minimum fixed charge coverage ratio, maximum leverage ratio and maximum senior leverage ratio. Availability under our \$15 million revolving credit facility is governed by the margins calculated under the maximum senior leverage ratio and maximum total leverage ratio covenants. As of July 31, 2006, we had approximately \$8.1 million of availability based upon our borrowing base formula.

During the second quarter of fiscal 2006, Howard G. Berger, M.D., our president, director and largest shareholder had outstanding advances to us of \$2,605,000. Our obligation to Dr. Berger was repaid as part of our March 9, 2006 refinancing.

On July 6, 2006, Primedex entered into an agreement and plan of merger for the acquisition of Radiologix, Inc. by Primedex through the merger of a wholly-owned subsidiary of Primedex with and into Radiologix. Upon successful completion of the merger, Radiologix stockholders will receive a combination of cash and Primedex common stock in exchange for their shares of Radiologix common stock. Pursuant to the merger, Radiologix stockholders will receive aggregate consideration of 22,621,922 shares of Primedex common stock and \$42,950,000 in cash. Based upon the August 17, 2006 closing price of Primedex common stock of \$1.57, each Radiologix stockholder would receive \$1.85 in cash for each Radiologix

share, plus one share of Primedex common stock for total consideration valued at \$3.42 per share. The merger agreement also provides Primedex the option to elect to reduce the share consideration by up to 3.5 million shares and to increase the cash consideration by \$2 per share, provided that Primedex advises Radiologix of its election prior to the mailing of the proxy statement. Upon completion of the merger, we estimate that, subject to adjustment as described above, Radiologix's former stockholders will own approximately 34.9% of the then-outstanding shares of Primedex common stock, based on the number of shares of Radiologix and Primedex common stock outstanding on August 17, 2006. Primedex's stockholders will continue to own their existing shares. In connection with the proposals set forth in this joint proxy statement/prospectus, Primedex stock may be subject to transfer restrictions which are necessary to preserve Primedex's unrestricted use of its net operating loss carry-forwards.

Primedex has signed a commitment letter with GE Commercial Finance Healthcare Financial Services for a \$405 million senior secured credit facility. The facility will be used to finance the merger, to refinance existing indebtedness, to pay transaction costs and expenses relating to the merger and the credit facility and to provide financing for working capital needs post-merger. Consummation of the financing is a condition to the closing of the merger. The facility will consist of a revolving credit facility of up to \$45 million, a \$225 million term loan and a \$135 million second lien term loan. The revolving credit facility will have a term of five years, the term loan will have a term of six years and the second lien term loan will have a term of six and one-half years. Interest is payable on all loans initially at an Index Rate plus the Applicable Index Margin, as defined. The Index Rate is initially a floating rate equal to the higher of the rate quoted from time to time by The Wall Street Journal as the "base rate on corporate loans posted by at least 75% of the nation's largest 30 banks" or the Federal Funds Rate plus 50 basis points. The Applicable Index Margin on each the revolving credit facility and the term loan is 2% and on the second lien term loan is 6%. Primedex may, after a certain period, request that the interest rate instead be based on LIBOR plus the Applicable LIBOR Margin, which is 3.5% for the revolving credit facility and the term loan and 7.5% for the second lien term loan. It is anticipated that the credit facility will include customary covenants for a facility of this type, including minimum fixed charge coverage ratio, maximum total leverage ratio, maximum senior leverage ratio, limitations on indebtedness, contingent obligations, liens, capital expenditures, lease obligations, mergers and acquisitions, asset sales, dividends and distributions, redemption or repurchase of equity interests, subordinated debt payments and modifications, loans and investments, transactions with affiliates, changes of control, and payment of consulting and management fees. The credit facility will contain such conditions to funding as are customary for senior secured facilities of this type.

We operate in a capital intensive, high fixed-cost industry that requires significant amounts of capital to fund operations. In addition to operations, we require significant amounts of capital for the initial start-up and development expense of new diagnostic imaging facilities, the acquisition of additional facilities and new diagnostic imaging equipment, and to service our existing debt and contractual obligations. Because our cash flows from operations have been insufficient to fund all of these capital requirements, we have depended on the availability of financing under credit arrangements with third parties. Historically, our principal sources of liquidity have been funds available for borrowing under our existing lines of credit, now with General Electric Capital Corporation. We finance the acquisition of equipment mainly through capital and operating leases. As of July 31, 2006 and October 31, 2005, our line of credit liabilities were \$6.9 million and \$13.3 million, respectively.

The interim disclosures regarding liquidity and capital resources should be read in conjunction with the consolidated financial statements and related notes thereto contained in our Annual Report of Form 10-K for the year ended October 31, 2005.

Our business strategy with regard to operations will focus on the following:

- Maximizing performance at our existing facilities;

- Focusing on profitable contracting;
- Expanding MRI and CT applications
- Optimizing operating efficiencies; and
- Expanding our networks.

Our ability to generate sufficient cash flow from operations to make payments on our debt and other contractual obligations will depend on our future financial performance. A range of economic, competitive, regulatory, legislative and business factors, many of which are outside of our control, will affect our financial performance. Taking these factors into account, including our historical experience and our discussions with our lenders to date, although no assurance can be given, we believe that through implementing our strategic plans and continuing to restructure our financial obligations, we will obtain sufficient cash to satisfy our obligations as they become due in the next twelve months.

Sources and Uses of Cash

During the nine months ended July 31, 2005, cash increased \$1,000. There was no change in cash during the nine months ended July 31, 2006.

Cash provided by operating activities for the nine months ended July 31, 2006 was \$4.6 million compared to \$6.8 million for the same period in 2005, a decrease of \$2.2 million. The primary reasons for the decrease in cash provided by operating activities was due to increases in other current and noncurrent assets, including deposits on medical equipment, and reductions in accounts payable and accrued expenses during the nine months ended July 31, 2006.

Cash used by investing activities for the nine months ended July 31, 2006 was \$6.3 million compared to \$2.8 million for the same period in 2005. For the nine months ended July 31, 2006 and 2005, we purchased property and equipment for approximately \$6.0 million and \$2.8 million, respectively. During the nine months ended July 31, 2005, we received proceeds from the sale of equipment of \$65,000. During the nine months ended July 31, 2006, we invested \$0.2 million in a PET center.

Cash provided by financing activities for the nine months ended July 31, 2006 was \$1.6 million. Cash used for financing activities for the nine months ended July 31, 2005 was \$4.1 million. For fiscal 2006 and 2005, we made principal payments on capital leases and notes payable of \$6.1 million and \$9.6 million, respectively, increased our cash disbursements in transit by \$2.3 million and \$1.3 million, respectively, and received proceeds from borrowings on lines of credit and notes payable of approximately \$5.6 million and \$5.3 million, respectively. In addition, as part of the March 2006 debt restructuring, we repaid existing debt of \$141.2 million and debt issue costs of \$5.6 million with proceeds from borrowings on notes payable of \$146.5 million and cash. During the nine months ended July 31, 2006, we received proceeds from the issuance of common stock of \$182,000 and from the sale of equipment of \$15,000. During the nine months ended July 31, 2005, we made payments on lines of credit of \$2.4 million and received proceeds from borrowings from related parties of \$1.4 million.

Contractual Commitments

Our future obligations for notes payable, equipment under capital leases, lines of credit, subordinated debentures, equipment and building operating leases and purchase and other contractual obligations for the next five years and thereafter as of July 31, 2006 include (dollars in thousands):

For the twelve months ended July 31,

	2007	2008	2009	2010	2011	Thereafter	Total
Notes payable	\$ 873	\$ 145,100	\$ 14	\$ 14	14	34	\$ 146,049
Capital leases*	2,256	1,613	1,543	699	145		6,256
Line of credit		6,868					6,868
Subordinated debentures		16,147					16,147
Operating leases(1)	8,415	7,813	7,572	7,431	7,352	60,763	99,346
Purchase obligations(2)	625						625
Total(3)	\$ 12,169	\$ 177,541	\$ 9,129	\$ 8,144	\$ 7,511	\$ 60,797	\$ 275,291

* Includes interest.

(1) Includes all existing options to extend lease terms.

(2) Includes a three-year obligation to purchase imaging film from Fuji. Primedex must purchase an aggregate of \$7.5 million of film at a rate of approximately \$2.5 million per year over the term of the agreement.

(3) Does not include Primedex's obligation under its maintenance agreement with GE Medical Systems described below.

In addition, we have an arrangement with GE Medical Systems under which it has agreed to be responsible for the maintenance and repair of the majority of our equipment for a fee that is based upon a percentage of our revenue, subject to a minimum payment. Net revenue is reduced by the provision for bad debt, mobile PET revenue and other professional reading service revenue to obtain adjusted net revenue. The fiscal 2005 annual service fee was the higher of 3.50% of our adjusted net revenue, or \$4,970,000. The fiscal 2006 annual service rate is the higher of 3.62% of our adjusted net revenue, or \$5,393,800. For the fiscal years 2007, 2008 and 2009, the annual service fee will be the higher of 3.62% of our adjusted net revenue, or \$5,430,000. We believe this framework of basing service costs on usage is an effective and unique method for controlling our overall costs on a facility-by-facility basis.

Critical Accounting Estimates

Primedex's discussion and analysis of financial condition and results of operations are based on its consolidated financial statements that were prepared in accordance with generally accepted accounting principles, or GAAP. Management makes estimates and assumptions when preparing financial statements. These estimates and assumptions affect various matters, including:

- Primedex's reported amounts of assets and liabilities in its consolidated balance sheets at the dates of the financial statements;
- Primedex's disclosure of contingent assets and liabilities at the dates of the financial statements; and
- Primedex's reported amounts of net revenue and expenses in its consolidated statements of operations during the reporting periods.

These estimates involve judgments with respect to numerous factors that are difficult to predict and are beyond management's control. As a result, actual amounts could materially differ from these estimates.

The Securities and Exchange Commission, or SEC, defines critical accounting estimates as those that are both most important to the portrayal of a company's financial condition and results of operations and require management's most difficult, subjective or complex judgment, often as a result of the need to make estimates about the effect of matters that are inherently uncertain and may change in subsequent periods. In Note 2 to its consolidated financial statements, Primedex discusses its significant accounting policies, including those that do not require management to make difficult, subjective or complex judgments or estimates. The most significant areas involving management's judgments and estimates are described below.

Revenue Recognition

Revenue is recognized when diagnostic imaging services are rendered. Revenue is recorded net of contractual adjustments and other arrangements for providing services at less than established patient billing rates. Primedex estimates contractual allowances based on the patient mix at each diagnostic imaging facility, the impact of managed care contract pricing and historical collection information. Primedex operates 61 facilities, each of which has multiple managed care contracts and a different patient mix. Primedex reviews the estimated contractual allowance rates for each diagnostic imaging facility on a monthly basis. Primedex adjusts the contractual allowance rates, as changes to the factors discussed above become known. Depending on the changes Primedex makes in the contractual allowance rates, net revenue may increase or decrease.

Accounts Receivable

Substantially all of Primedex's accounts receivable are due under fee-for-service contracts from third party payors, such as insurance companies and government-sponsored healthcare programs, or directly from patients. Services are generally provided pursuant to one-year contracts with healthcare providers. Receivables generally are collected within industry norms for third-party payors. Primedex continuously monitors collections from its clients and maintain an allowance for bad debts based upon any specific payor collection issues that Primedex has identified and its historical experience. For fiscal 2003, 2004 and 2005 its provision for bad debts as a percentage of net revenue was 3.5%, 2.8% and 3.4% respectively.

Deferred Tax Assets

Primedex evaluates the realizability of the net deferred tax assets and assess the valuation allowance periodically. If future taxable income or other factors are not consistent with its expectations, an adjustment to its allowance for net deferred tax assets may be required. Even though Primedex expects to utilize its net operating loss carry forwards in the future, the last three fiscal year losses and available evidence cause the valuation of its net deferred tax assets to be uncertain in the near term. As of October 31, 2005, Primedex has fully allowed for its net deferred tax assets.

Valuation of Goodwill and Long-Lived Assets

Primedex's net goodwill at October 31, 2005 was \$23.1 million. Goodwill is recorded as a result of its acquisition of operating facilities. The operating facilities are grouped by region into reporting units. Primedex evaluates goodwill, at a minimum, on an annual basis and whenever events and changes in circumstances suggest that the carrying amount may not be recoverable in accordance with Statement of Financial Accounting Standards, or SFAS, No. 142, *Goodwill and Other Intangible Assets*. Impairment of goodwill is tested at the reporting unit level by comparing the reporting unit's carrying amount, including goodwill, to the fair value of the reporting unit. The fair values of the reporting units are estimated using a combination of the income or discounted cash flows approach and the market approach, which uses comparable market data. If the carrying amount of the reporting unit exceeds its fair value, goodwill is considered impaired and a second step is performed to measure the amount of impairment loss, if any.

Primedex's long-lived assets at October 31, 2005 consist of net property and equipment of \$68.1 million and other net intangible assets of \$1.2 million. Primedex evaluates long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable in accordance with SFAS No. 144, *Accounting for the Impairment or Disposal of Long-Lived Assets*. An asset is considered impaired if its carrying amount exceeds the future net cash flow the asset is expected to generate. If such asset is considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds its fair market value. Primedex assesses the recoverability of its long-lived and intangible assets by determining whether the unamortized balances can be recovered through undiscounted future net cash flows of the related assets. For each of the three years in the period ended October 31, 2005, Primedex recorded no impairment of goodwill or property and equipment. However, if its estimates or the related assumptions change in the future, Primedex may be required to record impairment charges to reduce the carrying amount of these assets.

Recent Events

On April 4, 2006, Primedex settled a claim with Broadstream for \$500,000. This claim arose in connection with a financing agreement Primedex entered into with a third party. James Goldfarb, a partner of Broadstream Capital Partners, LLC, or Broadstream, and once a member of Primedex's board of directors, arranged a meeting between it and a third party to discuss the third party financing the purchase of a portion of Primedex's debt owed to DVI Financial Services, which had filed for bankruptcy. Goldfarb alleged that, on behalf of Broadstream, he entered into an oral agreement with Primedex under which Primedex owed Broadstream a finder's fee for setting up this meeting. Broadstream filed suit against Primedex, and Howard G. Berger, M.D., Primedex's president, for damages. Pursuant to the settlement, Primedex agreed to pay to Broadstream \$500,000 payable over a one and one-half year period.

Primedex is engaged from time to time in the defense of lawsuits arising out of the ordinary course and conduct of its business. Primedex believes that the outcome of its current litigation will not have a material adverse impact on its business, financial condition and results of operations. However, Primedex could be subsequently named as a defendant in other lawsuits that could adversely affect Primedex.

On July 6, 2006, Primedex entered into an agreement and plan of merger for the acquisition of Radiologix, Inc. by Primedex through the merger of a wholly-owned subsidiary of Primedex with and into Radiologix. Upon successful completion of the merger, Radiologix stockholders will receive a combination of cash and Primedex common stock in exchange for their shares of Radiologix common stock. Pursuant to the merger, Radiologix stockholders will receive aggregate consideration of 22,621,922 shares of Primedex common stock and \$42,950,000 in cash. Based upon the August 17, 2006 closing price of Primedex common stock of \$1.57, each Radiologix stockholder would receive \$1.85 in cash for each Radiologix share, plus one share of Primedex common stock for total consideration valued at \$.42 per share. The merger agreement also provides Primedex the option to elect to reduce the share consideration by up to 3.5 million shares and to increase the cash consideration by \$2 per share, provided that Primedex advises Radiologix of its election prior to the mailing of this proxy statement. Upon completion of the merger, we estimate that, subject to adjustment as described above, Radiologix's former stockholders will own approximately 34.9% of the then-outstanding shares of Primedex common stock, based on the number of shares of Radiologix and Primedex common stock outstanding on August 17, 2006. Primedex's stockholders will continue to own their existing shares. In connection with the proposals set forth in this joint proxy statement/prospectus, Primedex stock may be subject to transfer restrictions which are necessary to preserve Primedex's unrestricted use of its net operating loss carry-forwards.

Primedex has signed a commitment letter with GE Commercial Finance Healthcare Financial Services for a \$405 million senior secured credit facility. The facility is expected to be used to finance the merger, to refinance existing indebtedness, to pay transaction costs and expenses relating to the merger.

and the credit facility and to provide financing for working capital needs post-merger. Consummation of the financing is a condition to the closing of the merger. The facility will consist of a revolving credit facility of up to \$45 million, a \$225 million term loan and a \$135 million second lien term loan. The revolving credit facility will have a term of five years, the term loan will have a term of six years and the second lien term loan will have a term of seven years. Interest is payable on all loans initially at an Index Rate plus the Applicable Margin, as defined. The Index Rate is initially a floating rate equal to the higher of the rate quoted from time to time by The Wall Street Journal as the base rate on corporate loans posted by at least 75% of the nation's largest 30 banks or the Federal Funds Rate plus 50 basis points. The Applicable Margin on each of the revolving credit facility and the term loan is 2% and on the second lien term loan is 6%. Primedex may, after a certain period, request that the interest rate instead be based on LIBOR plus the Applicable Margin, as defined. It is anticipated that the credit facility will include customary covenants for a facility of this type, including minimum fixed charge coverage ratio, maximum total leverage ratio, maximum senior leverage ratio, limitations on indebtedness, contingent obligations, liens, capital expenditures, lease obligations, mergers and acquisitions, asset sales, dividends and distributions, redemption or repurchase of equity interests, subordinated debt payments and modifications, loans and investments, transactions with affiliates, changes of control, and payment of consulting and management fees. The credit facility will contain such conditions to funding as are customary for senior secured facilities of this type. See *The Merger Financing of the Merger*.

On August 25, 2006, Primedex acquired the assets and business of Corona Imaging Center, in Corona, California, from an external third party for \$1,500,000 financed through a third party lender over five years at 8.5%. In addition, Primedex financed certain medical equipment for approximately \$243,000 as part of the transaction. The center provides MRI, CT, ultrasound, and x-ray services. The center is 2,133 square feet with a monthly rental of approximately \$3,839 per month with an initial lease term through November 2011. No goodwill is expected to be recorded in the transaction.

On September 1, 2006, effective September 5, 2006, Primedex acquired the net assets and business of San Francisco Advanced Imaging Center, in San Francisco, California, from an external third party for \$1,650,000 paid from working capital. The center provides MRI, CT and x-ray services. The center is 7,115 square feet with a monthly rental of approximately \$29,000 with an initial lease term through April 2017. No goodwill is expected to be recorded in the transaction.

As of September 11, 2006, Primedex is in the process of acquiring the assets and business of two additional facilities in Fresno, California and Irvine, California for an estimated \$1,500,000 in cash and \$500,000 in assumed liabilities, respectively. Both centers will offer MRI, CT, ultrasound and x-ray services and no goodwill is expected to be recorded in either transaction.

Recent Accounting Pronouncements

Share-Based Payment

In December 2004, the FASB issued SFAS No. 123 (Revised 2004), *Share-Based Payment*, which was amended effective April 2005. The new rule requires that the compensation cost relating to share-based payment transactions be recognized in financial statements based on the fair value of the equity or liability instruments issued. Primedex will be required to apply Statement 123R as of the first annual reporting period starting after June 15, 2005, which is its first quarter beginning November 1, 2005. Primedex routinely uses share-based payment arrangements as compensation for its employees. During fiscal 2003, 2004 and 2005, had this rule been in effect, Primedex would have recorded the non-cash expense of \$82,000, \$379,000 and \$341,000, respectively.

Determining Amortization Period For Leasehold Improvements

In June 2005, the EITF issued EITF Issue No. 05-06, *Determining the Amortization Period for Leasehold Improvements Purchased after Lease Inception or Acquired in a Business Combination* (EITF 05-06). EITF 05-06 provides that the amortization period for leasehold improvements acquired in a business combination or purchased after the inception of a lease be the shorter of (a) the useful life of the assets or (b) a term that includes required lease periods and renewals that are reasonably assured upon the acquisition or the purchase. The provisions of EITF 05-06 are effective on a prospective basis for leasehold improvements purchased or acquired beginning July 1, 2005. The adoption of EITF 05-06 during the three months ended October 31, 2005 did not have a material affect on the Company's consolidated financial statements.

Exchanges Of Nonmonetary Assets

In December 2004, the FASB issued FASB Statement No. 153, *Exchanges of Nonmonetary Assets - An Amendment of APB Opinion No. 29*. The amendments made by Statement 153 are based on the principle that exchanges of nonmonetary assets should be measured based on the fair value of the assets exchanged. Further, the amendments eliminate the narrow exception for nonmonetary exchanges of similar productive assets and replace it with a broader exception for exchanges of nonmonetary assets that do not have commercial substance. The provisions in Statement 153 are effective for nonmonetary asset exchanges occurring in fiscal periods beginning after June 15, 2005. Adoption of this standard is not expected to have a material impact on the consolidated financial statements.

Disclosures About Segments of An Enterprise and Related Information

In September 2004, the Emerging Issues Task Force (EITF) reached a consensus on EITF Issue No. 04-10, *Applying Paragraph 19 of FAS 131 in Determining Whether to Aggregate Operating Segments That Do Not Meet the Quantitative Thresholds*. The consensus states that operating segments that do not meet the quantitative thresholds can be aggregated only if aggregation is consistent with the objective and basic principles of SFAS No. 131, *Disclosures about Segments of an Enterprise and Related Information*, the segments have similar economic characteristics, and the segments share a majority of the aggregation criteria (a)-(e) listed in paragraph 17 of SFAS 131. The consensus was ratified by the FASB at their October 13, 2004 meeting. The effective date of the consensus in this issue has been postponed indefinitely at the November 17-18 EITF meeting. The Company does not anticipate a material impact on the financial statements from the adoption of this consensus.

Determining Whether To Report Discontinued Operations

In November 2004, the Emerging Issues Task Force (EITF) reached a consensus on EITF Issue No. 03-13, *Applying the Conditions in Paragraph 42 of FASB Statement No. 144, Accounting for the Impairment or Disposal of Long-Lived Assets, in Determining Whether to Report Discontinued Operations*. The consensus provides guidance in determining: (a) which cash flows should be taken into consideration when assessing whether the cash flows of the disposal component have been or will be eliminated from the ongoing operations of the entity, (b) the types of involvement ongoing between the disposal component and the entity disposing of the component that constitute continuing involvement in the operations of the disposal component, and (c) the appropriate (re)assessment period for purposes of assessing whether the criteria in Paragraph 42 have been met. The consensus was ratified by the FASB at their November 30, 2004 meeting and should be applied to a component of an enterprise that is either disposed of or classified as held for sale in fiscal periods beginning after December 15, 2004. The Company does not anticipate a material impact on the financial statements from the adoption of this consensus.

Quantitative and Qualitative Disclosures About Market Risk

Primedex sells its services exclusively in the United States and receives payment for its services exclusively in United States dollars. As a result, Primedex's financial results are unlikely to be affected by factors such as changes in foreign currency exchange rates or weak economic conditions in foreign markets.

The majority of Primedex's interest expense is not sensitive to changes in the general level of interest in the United States because the majority of Primedex's indebtedness has interest rates that were fixed when Primedex entered into the note payable or capital lease obligation. None of Primedex's long-term liabilities have variable interest rates. Primedex's credit facility, classified as a current liability on its financial statements, is interest expense sensitive to changes in the general level of interest because it is based upon the current prime rate plus a factor.

223

INFORMATION ABOUT RADIOLOGIX

Overview

Radiologix is a leading national provider of diagnostic imaging services through its ownership and operation of freestanding, outpatient diagnostic imaging centers. Radiologix utilizes sophisticated technology and technical expertise to perform a broad range of imaging procedures, such as MRI, CT, PET, nuclear medicine, ultrasound, mammography, DEXA, X-ray and fluoroscopy. As of August 18, 2006, Radiologix owned, operated or maintained an ownership interest in imaging equipment at 69 locations, with imaging centers located in 7 states, including primary operations in the Mid-Atlantic; the Bay Area, California; the Treasure Coast area, Florida; Northeast, Kansas; and the Finger Lakes (Rochester) and Hudson Valley areas of New York state. Radiologix offers multi-modality imaging services at 56 of its diagnostic imaging centers, which provide patients and referring physicians access to advanced diagnostic imaging services in one convenient location.

Radiologix also provides administrative, management and information services to certain radiology practices that provide professional services in connection with Radiologix's diagnostic imaging centers and to hospitals and radiology practices with which Radiologix operates joint ventures. The services Radiologix provides leverage its existing infrastructure, and Radiologix believes the services improve the profitability, efficiency and effectiveness of the radiology practice or joint venture.

For the year ended December 31, 2005, Radiologix performed over 1.5 million diagnostic imaging procedures and generated service fee revenue of \$251.4 million. In addition, Radiologix generated net cash flows from operating activities of \$29.6 million for the year ended December 31, 2005.

Competitive Strengths/Business Strategy

Radiologix's focus is on the following five goals:

- Provide exceptional service
- Increase market share
- Enhance Radiologix's partnership with physicians
- Reduce denial rates
- Build the best teams with the best people

Provide exceptional service

Radiologix provides a broad range of diagnostic imaging services within its primary operations. Radiologix's 56 multi-modality centers enable Radiologix to offer one-stop shopping to payors, referring physicians and patients. In Radiologix's experience, referring physicians and payors prefer to enter into relationships with diagnostic imaging providers that offer a broad spectrum of services at convenient locations, benefiting referring physicians and patients who require more than one type of diagnostic imaging procedure. From January 1, 2003 to December 31, 2005, Radiologix spent approximately \$70.4 million on diagnostic imaging equipment and leasehold improvements to enhance Radiologix's diagnostic imaging centers and increase the number of modalities offered per center. Radiologix continues to focus on enhancing Radiologix's operations and increase procedure volume and revenue at its existing centers by:

- expanding referring physician, hospital and payor relationships;
- increasing patient referrals through targeted marketing efforts; and
- leveraging Radiologix's multi-modality offerings to increase the number of high-end procedures performed.

Increase market share

Radiologix has a concentrated presence in its primary operations, which enables Radiologix to offer patients, referring physicians and payors a higher degree of responsiveness and convenience than independent operators or hospitals and consequently drive organic growth. Radiologix provides flexible scheduling, convenient locations and expanded hours of operation, as well as the expeditious delivery of radiology reports to referring physicians. Radiologix's primary operations, which include 66 imaging centers, generated 97% of Radiologix's service fee revenue for the year ended December 31, 2005. Radiologix believes that payors contract with Radiologix because of its strong market presence, the high quality of its services and its ability to provide a single point of contact and centralized administration. In addition, its leading position enables Radiologix to increase its procedure volume, optimize equipment utilization, benefit from economies of scale in purchasing and negotiation of payor contracts and leverage Radiologix's administrative and information technology infrastructure in its primary operations.

Enhance Radiologix's partnership with physicians

In Radiologix's primary operations, Radiologix contracts with leading radiology practices to provide professional radiology services in connection with its diagnostic imaging centers. Radiologix believes that its affiliation with these leading radiology practices enhances its reputation with referring physicians and their patients. Radiologix also provides administrative, management and information services to certain radiology practices. In light of an ongoing shortage of radiologists, Radiologix believes that its contractual relationships with large, established radiology practices are important to maintaining its high quality service.

Reduce denial rates

Radiologix's revenue base comprises a diverse mix of payors, including managed care organizations, Medicare, Medicaid, private and other payors. For the year ended December 31, 2005, revenue generated at its diagnostic imaging centers consisted of 62% from managed care payors, 29% from Medicare and Medicaid, and 9% from private and other payors. In addition, Radiologix has experienced relatively stable pricing in most markets and across most modalities. In addition, Radiologix has further mitigated its exposure to unfavorable reimbursement trends by creating a list of the top five reasons that payors deny submitted claims and have developed best practices to address these reasons. As a result of these efforts, Radiologix reduced its denial rate from 10.9% in 2004 to 6.9% in 2005. This denial reduction effort will continue in 2006.

Build the best teams with the best people

Radiologix has a highly experienced management team lead by one of its founders, CEO Sami Abbasi. Radiologix's senior management team has an average of approximately 20 years of healthcare services experience. Radiologix believes management has positioned Radiologix to (1) achieve disciplined volume and service fee revenue growth in its primary operations and (2) explore accretive acquisition and development opportunities.

To facilitate the achievement of the above goals, Radiologix has committed to spend approximately \$7 million through the fourth quarter of 2006 to complete the implementation of a comprehensive Radiology Information System/Picture Archival Communications System (RIS/PACS) common platform among all its facilities. Radiologix refers to this initiative as its *Radiologix Enhanced Workflow And Record Distribution or REWARD* Program. Radiologix expects this program to significantly enhance operational efficiencies by: (1) standardizing processes and protocols across Radiologix, (2) automating, accelerating and simplifying workflow, (3) improving the capture of front-end data including billing and patient scheduling information, (4) providing more timely digitized images and records to referring physicians, and (5) reducing film and storage costs.

Diagnostic Imaging Centers

Radiologix operates through two segments: Radiologix's primary operations and its Questar subsidiary operations.

Radiologix's primary operations consist of owning and operating diagnostic imaging centers and providing administrative, management and information services to the contracted radiology practice groups under long-term agreements that provide professional interpretation and supervision services in connection with Radiologix's diagnostic imaging centers and to hospitals and radiology practices with which Radiologix operates joint ventures.

Radiologix's Questar subsidiary operations consist of short-term agreements with radiology practice groups. These operations have different characteristics from Radiologix's primary operations, including location, market concentration, contracting leverage, capital requirements, the single modality nature of most of the centers and the structure of the management service agreements with physicians.

Additional information related to the number and locations of Radiologix's diagnostic-imaging centers within its two operating segments is set forth below:

		Diagnostic Imaging Centers		
		Owned Centers	Joint Venture Centers	Other
Primary Operations				
Mid-Atlantic	Baltimore, MD/Washington Metro Area	20	11	
Finger Lakes	Rochester, NY	5		
Hudson Valley	Rockland County, NY	5		2
Bay Area	San Francisco/Oakland/San Jose, CA	16		
Northeast Kansas	Topeka and Northeast KS	1	1	
Treasure Coast	St. Lucie County, FL	3		
Primary operations		50	12	2
Questar operations	Multiple locations(1)	5		
Total		55	12	2

(1) Includes diagnostic imaging centers in California, Colorado and Minnesota that are not integrated into Radiologix's primary market operations.

As of June 30, 2006, Radiologix operated 496 diagnostic imaging units in 69 centers. These include 58 fixed MRI units, 51 CT units, 1 PET, 7 PET/CT units, 30 nuclear medicine cameras, 112 ultrasound units, 65 general mammography units, 1 digital mammography unit, 5 breast biopsy units, 32 DEXA units, 92 x-ray units and 42 fluoroscopy units. The average age of Radiologix's MRI units is 4.1 years, CT units 3.2 years and its PET units 1.6 years.

To increase the convenience of Radiologix's diagnostic imaging centers to patients, Radiologix implements market-wide scheduling systems where practical. In these instances, each diagnostic imaging center in a market area can access the patient appointment calendar of other centers in the market area. Each center also can schedule patient appointments at other centers within the network. This system permits each of Radiologix's centers within a market area to efficiently allocate time available at its diagnostic imaging centers within that market area and to meet a patient's appointment time, date or location preferences.

Radiologix focuses on providing quality patient care and service to ensure patient and referring physician satisfaction. Radiologix's development of comprehensive radiology networks permits it to invest in technologically advanced imaging equipment, including MRI, open MRI, spiral CT and PET. Radiologix's consolidation of diagnostic imaging centers into coordinated networks improves response time, increases overall patient accessibility, permits Radiologix to standardize certain customer relations

procedures and permits Radiologix to develop best practices for Radiologix's diagnostic imaging centers. Radiologix seeks the input and participation of the contracted radiology practices to which Radiologix provides administrative, management and information services to develop best practices and to improve productivity and the quality of services. By focusing on further improving and, where appropriate, standardizing the operations of Radiologix's diagnostic imaging centers, Radiologix believes that it can increase patient and referring physician satisfaction, which should lead to increased referrals and increased utilization of Radiologix's diagnostic imaging centers.

Payment for diagnostic imaging services comes primarily from managed care payors, governmental payors (including Medicare and Medicaid), private and other payors. Radiologix's centers are principally dependent on its ability to attract referrals from primary care physicians, specialists and other healthcare providers. The referral often depends on the existence of a contractual arrangement with the referred patient's health benefit plan. The following table illustrates Radiologix's approximate payor mix, based on revenue generated at Radiologix's diagnostic imaging centers, for the years ended December 31, 2005, 2004 and 2003:

Payor	2005	2004	2003
Managed Care	62 %	62 %	63 %
Medicare and Medicaid	29 %	29 %	28 %
Private and Other	9 %	9 %	9 %

For the years ended December 31, 2005, 2004 and 2003, approximately 6%, 6% and 6%, respectively, of Radiologix's diagnostic imaging center revenue was generated from capitated arrangements.

Contracted Radiology Practices

Radiologix contracts with radiology practices to provide professional services, including supervision and interpretation of diagnostic imaging procedures performed in Radiologix's diagnostic imaging centers. Radiologix does not engage in the practice of medicine nor does it employ physicians. The radiology practices maintain full control over the provision of professional radiological services. The contracted radiology practices generally have outstanding physician and practice credentials and reputations; strong competitive market positions; a broad sub-specialty mix of physicians; a history of growth and potential for continued growth; and a willingness to embrace Radiologix's strategy for the delivery of diagnostic imaging services.

Radiologix has two models by which it contracts with radiology practices: a comprehensive services model and a technical services model. Under Radiologix's comprehensive services model, Radiologix enters into a long-term agreement with a radiology practice group (typically 40 years). Under this arrangement, in addition to obtaining technical fees for the use of Radiologix's diagnostic imaging equipment and the provision of technical services, Radiologix provides management services and receives a fee based on the practice group's professional revenue, including revenue derived outside of Radiologix's diagnostic imaging centers. Under Radiologix's technical services model, which relates primarily to Radiologix's Questar subsidiary operations, Radiologix enters into a shorter-term agreement with a radiology practice group (typically 10 to 15 years) and pays them a fee based on cash collections from reimbursements for imaging procedures. In both the comprehensive services and technical services models, Radiologix owns the diagnostic imaging assets and, therefore, receives 100% of the technical reimbursements associated with imaging procedures. Additionally, in most instances, both the comprehensive services and the technical services models contemplate an incentive technical bonus for the radiology group if the net technical income exceeds specified thresholds.

The agreements with the radiology practices under Radiologix's comprehensive services model contain provisions whereby both parties have agreed to certain restrictions on accepting or pursuing radiology opportunities within a five to fifteen-mile radius of any of Radiologix's owned, operated or

managed diagnostic imaging centers at which the radiology practice provides professional radiology services or any hospital at which the radiology practice provides on-site professional radiology services. Each of these agreements also restricts the applicable radiology practice from competing with Radiologix and its other contracted radiology practices within a specified geographic area during the term of the agreement. In addition, the agreements require the radiology practices to enter into and enforce agreements with their physician shareholders at each radiology practice (subject to certain exceptions) that include covenants not to compete with Radiologix for a period of two years after termination of employment or ownership, as applicable.

Under Radiologix's comprehensive services model, Radiologix has the right to terminate each agreement if the radiology practice or a physician of the contracted radiology practice engages in conduct, or is formally accused of conduct, for which the physician employee's license to practice medicine reasonably would be expected to be subject to revocation or suspension or is otherwise disciplined by any licensing, regulatory or professional entity or institution, the result of any of which (in the absence of termination of this physician or other action to monitor or cure this act or conduct) adversely affects or would reasonably be expected to adversely affect the radiology practice.

Under Radiologix's comprehensive services model, upon termination of an agreement with a radiology practice, depending upon the termination event, Radiologix may have the right to require the radiology practice to purchase and assume, or the radiology practice may have the right to require Radiologix to sell, assign and transfer to it, the assets and related liabilities and obligations associated with the professional and technical radiology services provided by the radiology practice immediately prior to the termination. The purchase price for the assets, liabilities and obligations would be the lesser of their fair market value or the return of the consideration received in the acquisition. However, the purchase price may not be less than the net book value of the assets being purchased.

The agreements with most of the radiology practices under Radiologix's technical services model contain non-compete provisions that are generally less restrictive than those provisions under Radiologix's comprehensive services model. The geographic scope of and types of services covered by the non-compete provisions vary from practice to practice. Under Radiologix's technical services model, Radiologix generally has the right to terminate the agreement if a contracted radiology practice loses the licenses required to perform the service obligations under the agreement, violates non-compete provisions relating to the modalities offered or if income thresholds are not met.

Radiologix's contractual relationships with two radiology groups ended in June 2004 (M&S Imaging Associates, P.A. in San Antonio) and January 2005 (WB&A Imaging, P.C. in the Mid-Atlantic).

Sales and Marketing

Radiologix selectively invests in marketing and sales resources and activities in an effort to attract new patients, expand business relationships, grow revenue at Radiologix's existing centers and maintain present business alliances and contractual agreements. Marketing activities include organizing and presenting educational programs on new applications and uses of technology to referring physicians, developing and conducting customer service programs and proactively calling managed care organizations and third-party insurance companies to generate additional contracts.

Government Regulation and Supervision

General

Edgar Filing: RADIOLOGIX INC - Form DEFM14A

The healthcare industry is highly regulated, and Radiologix can give no assurance that the regulatory environment in which Radiologix operates will not change significantly in the future. Radiologix's ability to operate profitably will depend in part upon Radiologix, the contracted radiology practices and their affiliated physicians obtaining and maintaining all necessary licenses, certificates of need and other

228

approvals and operating in compliance with applicable healthcare regulations. Radiologix believes that healthcare regulations will continue to change. Therefore, Radiologix monitors developments in healthcare law and modifies its operations from time to time as the business and regulatory environment changes. Although Radiologix intends to continue to operate in compliance, Radiologix cannot ensure that it will be able to adequately modify its operations to address changes in the regulatory environment. MedPAC recently recommended proposals that seek more effective use of imaging services while controlling costs. Private payors have also begun adopting policies to control imaging costs. Although Radiologix believes it is well-positioned for these changes there is no guarantee that it will ultimately benefit from them.

Licensing and Certification Law

Ownership, construction, operation, expansion and acquisition of diagnostic imaging centers are subject to various federal and state laws, regulations and approvals concerning licensing of centers, personnel, certificates of need and other required certificates for certain types of healthcare centers and major medical equipment. Free-standing diagnostic imaging centers that provide services not performed as part of a physician office must meet Medicare requirements to be certified as an independent diagnostic testing facility to bill the Medicare program. Radiologix may not be able to receive the required regulatory approvals for any future acquisitions, expansions or replacements, and the failure to obtain these approvals could limit the market for Radiologix's services.

Fee-Splitting; Corporate Practice of Medicine

The laws of many states, including many of the states in which the contracted radiology practices are located, prohibit Radiologix from exercising control over the medical judgments or decisions of physicians and from engaging in certain financial arrangements, such as splitting professional fees with physicians. These laws and their interpretations vary from state to state and are enforced by state courts and regulatory authorities, each with broad discretion. A component of Radiologix's business has been to enter into service agreements with radiology practices. Radiologix provides management, administrative, technical and other non-medical services to the radiology practices in exchange for a service fee. Radiologix structures its relationships with the radiology practices, including the purchase of diagnostic imaging centers, in a manner that Radiologix believes keeps Radiologix from engaging in the practice of medicine or exercising control over the medical judgments or decisions of the radiology practices or their physicians or violating the prohibitions against fee-splitting. State regulatory authorities or other parties may assert that Radiologix is engaged in the corporate practice of medicine or that the payment of service fees to Radiologix by the radiology practices constitutes fee splitting. If such a claim were successfully asserted, Radiologix could be subject to civil and criminal penalties and could be required to restructure or terminate the applicable contractual arrangements. This result or Radiologix's inability to successfully restructure its relationships to comply with these statutes could jeopardize Radiologix's business strategy.

Medicare and Medicaid Reimbursement Program

Radiologix's revenue is derived through its ownership, operation and management of diagnostic imaging centers and from service fees paid to Radiologix by contracted radiology practices. During the year ended December 31, 2005, approximately 29% of Radiologix's revenue generated at its diagnostic imaging centers was derived from government sponsored healthcare programs (principally, Medicare and Medicaid).

In 2005, Congress legislated an increase (fee schedule update) of approximately 1.5% in the overall reimbursement rates for physician and outpatient services, including diagnostic imaging services. Combined with increased valuation of some radiology procedure relative value units, overall reimbursement for Radiologix's services increased slightly beyond the 1.5% rate for 2005.

On February 8, 2006, the President signed into law the Deficit Reduction Act of 2005, or DRA. The DRA provides that reimbursement for the technical component for imaging services (excluding diagnostic and screening mammography) in non-hospital based freestanding facilities will be capped at the lesser of reimbursement under the Medicare Part B physician fee schedule or the Hospital Outpatient Prospective Payment System (HOPPS) schedule.

As part of the DRA, Congress legislated that no change be made in 2006 in the overall reimbursement rate for physician and outpatient services including diagnostic imaging services. However, Radiologix's overall Medicare reimbursement will increase slightly over 2005 due to increased valuation of some radiology procedure relative value units, among other factors.

Currently, the technical component of Radiologix's imaging services is reimbursed under the Part B physician fee schedule, which generally allows for higher reimbursement than under the HOPPS. Under the DRA, Radiologix will be reimbursed at the lower of the two schedules, beginning January 1, 2007.

The DRA also codifies the reduction in reimbursement for multiple images on contiguous body parts previously announced by the Centers for Medicare and Medicaid Services (CMS). In November 2005, CMS announced that it will pay 100% of the technical component of the higher priced imaging procedure and 50% for the technical component of each additional imaging procedure for imaging procedures involving contiguous body parts within a family of codes when performed in the same session. Under current methodology, Medicare pays 100% of the technical component of each procedure. CMS had indicated that it would phase in this rate reduction over two years, so that the reduction will be 25% for each additional imaging procedure in 2006 and another 25% in 2007. On August 8, 2006, CMS issued a proposed rule that would eliminate the 25% reduction in 2007.

Radiologix believes the implementation of the reimbursement reductions contained in the DRA will have a significant effect on Radiologix's business, financial condition and results of operations.

Medicare and Medicaid Fraud and Abuse

Federal law prohibits the knowing and willful offer, payment, solicitation or receipt of any form of remuneration in return for, or to induce, (i) the referral of a person, (ii) the furnishing or arranging for the furnishing of items or services reimbursable under the Medicare, Medicaid or other governmental programs or (iii) the purchase, lease or order or arranging or recommending purchasing, leasing or ordering of any item or service reimbursable under the Medicare, Medicaid or other governmental programs. Enforcement of this anti-kickback law is a high priority for the federal government, which has substantially increased enforcement resources and is likely to continue increasing such resources. The applicability of the anti-kickback law to many business transactions in the healthcare industry has not yet been subject to judicial or regulatory interpretation. Noncompliance with the federal anti-kickback legislation can result in exclusion from the Medicare, Medicaid or other governmental programs and civil and criminal penalties.

Radiologix receives fees under its service agreements for management and administrative services, which include contract negotiation and marketing services. Radiologix may be considered to be in a position to make or influence referrals of patients or services reimbursed under Medicare, Medicaid or other governmental programs to radiology practices or their affiliated physicians or to receive referrals. Because the provisions of the federal anti-kickback statute are broadly worded and have been broadly interpreted by federal courts, the government could take the position that Radiologix's marketing programs or arrangements with the referring physicians implicate the federal anti-kickback statute. Violation of the law can result in monetary fines, civil and criminal penalties, and exclusion from participation in federal or state healthcare programs, any of which could have an adverse effect on Radiologix's business and results of operations. While Radiologix's service agreements with the contracted radiology practices will not meet a safe harbor to the federal anti-kickback statute, failure to meet a

safe harbor does not mean that agreements violate the anti-kickback statute. Radiologix has sought to structure its agreements to be consistent with fair market value in arms length transactions for the nature and amount of management and administrative services rendered. For these reasons, Radiologix does not believe that service fees payable to Radiologix should be viewed as remuneration for referring or influencing referrals of patients or services covered by such programs as prohibited by statute.

The Stark Law prohibits a physician from referring Medicare or Medicaid patients to an entity providing designated health services, including, without limitation, radiology services, in which the physician has an ownership or investment interest or with which the physician has entered into a compensation arrangement. The penalties for violating the Stark Law include a prohibition on payment by these governmental programs and civil penalties of as much as \$15,000 for each violative referral and \$100,000 for participation in a circumvention scheme.

Under CMS regulations, radiology and certain other imaging services and radiation therapy services and supplies are included in the designated health services and supplies subject to the self-referral prohibition. Included are the professional and technical components of any diagnostic test or procedure using X-rays, ultrasound or other imaging services, CT, MRI, radiation therapy and diagnostic mammography services (but not screening mammography services). The regulations, however, exclude from designated health services: (i) X-ray, fluoroscopy or ultrasonic procedures that require the insertion of a needle, catheter, tube or probe through the skin or into a body orifice; (ii) radiology procedures that are integral to the performance of, and performed during, non-radiological medical procedures; (iii) nuclear medicine procedures; and (iv) invasive or interventional radiology, because the radiology services in these procedures are merely incidental or secondary to another procedure that the physician has ordered. Beginning January 1, 2007, however, PET and nuclear medicine procedures will be included as designated health services under the Stark Law.

The Stark Law provides that a request by a radiologist for diagnostic radiology services or a request by a radiation oncologist for radiation therapy, if such services are furnished by or under the supervision of the radiologist or radiation oncologist pursuant to a consultation requested by another physician, does not constitute a referral by a referring physician. If these requirements were met, the Stark Law self-referral prohibition would not apply to such services. The effect of the Stark Law on the radiology practices, therefore, depends on the precise scope of services furnished by each such practice's radiologists and whether such services derive from consultations or are self-generated. Radiologix believes that (other than self-referred patients) all of the services covered by the Stark Law provided by the contracted radiology practices derive from requests for consultations by non-affiliated physicians and therefore are exempt from the Stark Law.

In addition, Radiologix believes that it has structured its acquisitions of the assets of existing practices, and Radiologix intends to structure any future acquisitions, to comply with the anti-kickback and Stark Law and regulations. Specifically, Radiologix believes the consideration paid by Radiologix to physicians to acquire the tangible and intangible assets associated with their practices is consistent with fair market value in arms length transactions and is not intended to induce the referral of patients. Should any such practice be deemed to constitute an arrangement designed to induce the referral of Medicare or Medicaid patients, then Radiologix's acquisitions could be viewed as possibly violating anti-kickback and self-referral laws and regulations. A determination of liability under any such laws could have an adverse effect on Radiologix's business, financial condition and results of operations.

All Medicare carriers routinely perform audits of Medicare claims. These carriers are contracted by CMS to adjudicate and pay Medicare claims. Although there were none, an unsatisfactory audit of any of Radiologix's diagnostic imaging centers or contracted radiology practices could result in significant repayment obligations, exclusion from the Medicare, Medicaid, or other governmental programs and/or civil and criminal penalties.

Federal regulatory and law enforcement authorities have increased enforcement activities with respect to Medicare and Medicaid fraud and abuse regulations and other reimbursement laws and rules, including laws and regulations that govern Radiologix's activities and the activities of the contracted radiology practices. Radiologix's activities, or those of the contracted radiology practices, may be investigated, claims may be made against Radiologix or the contracted radiology practices and these increased enforcement activities may directly or indirectly have an adverse effect on Radiologix's business, financial condition and results of operations.

State Anti-kickback and Physician Self-referral Laws

All of the states in which Radiologix's diagnostic imaging centers are located have adopted a form of anti-kickback law and almost all of those states have also adopted a form of Stark Law. The scope of these laws and the interpretations of them vary from state to state and are enforced by state courts and regulatory authorities, each with broad discretion. Generally, state laws cover all referrals by all healthcare providers for all healthcare services. A determination of liability under these laws could result in fines and penalties and restrictions on Radiologix's ability to operate in these jurisdictions.

Federal False Claims Act

The Federal False Claims Act provides, in part, that the federal government may bring a lawsuit against any person whom it believes has knowingly presented, or caused to be presented, a false or fraudulent request for payment from the federal government, or who has made a false statement or used a false record to get a claim approved. The Federal False Claims Act further provides that a lawsuit thereunder may be initiated in the name of the United States by an individual who is an original source of the allegations. The government has taken the position that claims presented in violation of the federal anti-kickback law or Stark Law may be considered a violation of the Federal False Claims Act. Penalties include civil penalties of not less than \$5,500 and not more than \$11,000 for each false claim, plus three times the amount of damages that the federal government sustained because of the act of that person. Radiologix believes that Radiologix is in compliance with the rules and regulations that apply to the Federal False Claims Act. However, Radiologix could be found to have violated certain rules and regulations resulting in sanctions under the Federal False Claims Act, and if Radiologix is so found in violation, any sanctions imposed could result in fines and penalties and restrictions on and exclusion from participation in federal and state healthcare programs that are integral to Radiologix's business.

Healthcare Laws and Regulations

Healthcare laws and regulations may change significantly in the future. Radiologix continuously monitors these developments and modifies its operations from time to time as the regulatory environment changes. Radiologix cannot assure you, however, that it will be able to adapt its operations to address new regulations or that new regulations will not adversely affect its business. In addition, although Radiologix believes that it is operating in compliance with applicable federal and state laws, neither its current or anticipated business operations nor the operations of the contracted radiology practices has been the subject of judicial or regulatory interpretation. Radiologix cannot assure you that a review of its business by courts or regulatory authorities will not result in a determination that could adversely affect its operations or that the healthcare regulatory environment will not change in a way that restricts its operations.

Health Insurance Portability and Accountability Act of 1996

In an effort to combat healthcare fraud, Congress enacted the Health Insurance Portability and Accountability Act of 1996 (HIPAA). Under HIPAA, a healthcare benefit program includes any private plan or contract affecting interstate commerce under which any medical benefit, item or service is provided. A person or entity that knowingly and willfully obtains the money or property of any healthcare

benefit program by means of false or fraudulent representations in connection with the delivery of healthcare services is subject to a fine and/or imprisonment. In addition, HIPAA authorizes the imposition of civil money penalties against entities that employ or enter into contracts with excluded Medicare or Medicaid program participants if such entities provide services to federal health program beneficiaries. A finding of liability under HIPAA could have a material adverse effect on Radiologix's business, financial condition and results of operations.

Further, the Administrative Simplification provisions of HIPAA required the promulgation of regulations establishing national standards for, among other things, certain electronic healthcare transactions, the use and disclosure of certain individually identifiable patient health information, and the security of the electronic systems maintaining this information. These are commonly known as the HIPAA transaction and code set standards, privacy standards, and security standards, respectively.

The administrative provisions of HIPAA direct the federal government to adopt national electronic standards for automated transfer of certain healthcare data between healthcare payors, plans and providers. HIPAA is designed to enable the entire healthcare industry to communicate electronic data using a single set of standards, thus eliminating all nonstandard formats currently in use. Radiologix's contracted radiology practices and diagnostic imaging centers are covered entities under HIPAA, and as such, must be in compliance with the privacy standards and the HIPAA electronic data interchange mandates.

Although Radiologix's electronic systems are HIPAA compatible and consistent with the HIPAA regulations, Radiologix cannot guarantee that enforcement agencies or courts will not make interpretations of the HIPAA standards that are inconsistent with ours, or the interpretations of the contracted radiology practices or their affiliated physicians. A finding of liability under the HIPAA standards may result in criminal and civil penalties. Noncompliance also may result in exclusion from participation in government programs, including Medicare and Medicaid. These actions could have a material adverse effect on Radiologix's business, financial condition, and results of operations.

Many states recently have adopted statutes and regulations that are similar to the HIPAA privacy standards. In some cases these restrictions are difficult to harmonize with the federal regulations.

Compliance Program

Radiologix implemented a program to monitor compliance with federal and state laws and regulations applicable to healthcare entities. Radiologix has appointed a compliance officer who is charged with implementing and supervising Radiologix's compliance program, which includes the adoption of (i) Standards of Conduct for Radiologix's employees and affiliates and (ii) an Ethics Process that specifies how employees, affiliates and others may report regulatory or ethical concerns to Radiologix's compliance officer. Radiologix believes that Radiologix's compliance program meets the relevant standards provided by the Office of Inspector General of the Department of Health and Human Services. An important part of Radiologix's compliance program consists of conducting periodic reviews of various aspects of Radiologix's operations and that of the contracted radiology practices. Radiologix also conducts mandatory educational programs designed to familiarize Radiologix's employees with the regulatory requirements and specific elements of its compliance program.

Insurance Laws and Regulation

Certain states have enacted statutes or adopted regulations affecting risk assumption in the healthcare industry, including statutes and regulations that subject any physician or physician network engaged in risk-based managed care contracting to applicable insurance laws and regulations. These laws and regulations may require physicians and physician networks to meet minimum capital requirements and other safety and soundness requirements. Implementing additional regulations or compliance

requirements could result in substantial costs to Radiologix and the contracted radiology practices and limit Radiologix's ability to enter into capitated or other risk-sharing managed care arrangements.

Competition

The market for diagnostic imaging services is competitive. Radiologix competes principally on the basis of its reputation, its ability to offer multiple modalities, its conveniently located centers and its ability to provide cost-effective, high-quality diagnostic imaging services. Radiologix competes locally with groups of radiologists and non-radiologist physician practices, established hospitals, clinics and certain other independent organizations that own and operate imaging equipment. Radiologix's major national competitors include Alliance Imaging, Inc., InSight Health Services Corp., Medical Resources, Inc., and MedQuest, Inc. Some of Radiologix's local or national competitors that provide diagnostic-imaging services may now or in the future have access to greater financial resources than Radiologix does and may have access to newer more advanced equipment.

Each of the contracted radiology practices under Radiologix's comprehensive services model has entered into agreements with its physician shareholders and full-time employed radiologists that generally prohibit those shareholders and radiologists from competing for a period of two years within defined geographic regions after they cease to be owners or employees, as applicable. In most states, a covenant not to compete will be enforced only:

- to the extent it is necessary to protect a legitimate business interest of the party seeking enforcement;
- if it does not unreasonably restrain the party against whom enforcement is sought; and
- if it is not contrary to public interest.

Enforceability of a non-compete covenant is determined by a court based on all of the facts and circumstances of the specific case at the time enforcement is sought. For this reason, it is not possible to predict whether, or to what extent, a court will enforce the contracted radiology practices' covenants. The inability of the contracted radiology practices or Radiologix to enforce radiologists' non-compete covenants could result in increased competition from individuals who are knowledgeable about Radiologix's business strategies and operations.

Radiologix may not be able to compete effectively for the acquisition of diagnostic imaging centers, joint venture opportunities or other outsourcing relationships. Radiologix's competitors may have better-established operating histories and greater resources than Radiologix does. Competitors may make it more difficult to complete acquisitions or joint ventures on terms beneficial to Radiologix.

Corporate Liability and Insurance

Radiologix may be subject to professional liability claims including, without limitation, for improper use or malfunction of its diagnostic imaging equipment. Radiologix maintains insurance policies with coverages that Radiologix believes are appropriate in light of the risks attendant to its business and consistent with industry practice. Radiologix also requires the contracted radiology practices to maintain sufficient professional liability insurance consistent with industry practice. However, adequate liability insurance may not be available to Radiologix and the contracted radiology practices in the future at acceptable costs or at all.

Providing medical services entails the risk of professional malpractice and other similar claims. The physicians employed by the contracted radiology practices are from time to time subject to malpractice claims. Radiologix structures its relationships with the practices under its agreements with them in a manner that Radiologix believes does not constitute the practice of medicine by Radiologix or subject

Radiologix to professional malpractice claims for acts or omissions of physicians in the contracted radiology practices. Nevertheless, claims, suits or complaints relating to services provided by the contracted radiology practices may be asserted against Radiologix in the future, including malpractice.

Any claim made against Radiologix not fully covered by insurance could be costly to defend and result in a substantial damage award against Radiologix and divert the attention of Radiologix's management from its operations, which could have an adverse effect on its financial performance. In addition, claims might adversely affect Radiologix's business or reputation.

The contracted radiology practices maintain professional liability insurance coverage primarily on a claims-made basis. This insurance provides coverage for claims asserted when the policy is in effect, regardless of when the events that caused the claim occurred. The contracted radiology practices are required by the terms of the service agreements to maintain medical malpractice liability insurance consistent with minimum limits mandated in their hospital contracts or by applicable state law.

Radiologix maintains general liability and umbrella coverage in commercially reasonable amounts. Additionally, Radiologix maintains workers compensation insurance on all employees. Coverage is placed on a statutory basis and responds to each state's specific requirements.

Radiologix has assumed and succeeded to substantially all of the obligations of some of the operations that Radiologix has acquired. Therefore, claims may be asserted against Radiologix for events that occurred prior to Radiologix's acquiring these operations. The sellers of the operations that Radiologix has acquired have agreed to indemnify Radiologix for certain claims. However, Radiologix may not be able to collect payment under these indemnity agreements, which could adversely affect its business.

Employees

As of August 18, 2006, Radiologix had 2,213 employees, 77 of whom were assigned to Radiologix's corporate headquarters with the remainder assigned to its regional offices and diagnostic imaging centers. Radiologix believes that its relationship with its employees is good.

Properties

Radiologix's corporate headquarters are located at 3600 JPMorgan Chase Tower, 2200 Ross Avenue, Dallas, Texas 75201-2776, in approximately 26,000 square feet occupied under a lease, which expires on September 30, 2011.

Radiologix also has a regional office of approximately 39,000 square feet occupied under a lease in Baltimore, Maryland which expires on September 30, 2012.

Legal Proceedings

Radiologix is not currently subject to any material litigation nor, to Radiologix's knowledge, is any material litigation threatened against Radiologix. All of Radiologix's current litigation is (i) expected to be covered by liability insurance or (ii) not expected to materially adversely affect its business. Some risk exists, however, that Radiologix could subsequently be named as a defendant in additional lawsuits or that pending litigation could materially adversely affect Radiologix.

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS OF RADIOLOGIX

The following discussion and analysis of financial condition and results of operations should be read together with Selected Historical Financial Data of Radiologix and Radiologix's financial statements and accompanying notes appearing elsewhere in this joint proxy statement/prospectus. This discussion contains forward-looking statements, based on current expectations and related to future events and Radiologix's future financial performance, that involve risks and uncertainties. Radiologix's actual results may differ materially from those anticipated in these forward-looking statements as a result of many important factors, including those set forth in the section entitled Risk Factors in Radiologix's Form 10-K, filed with the SEC on March 31, 2006, as amended, and available on Radiologix's website, www.radiologix.com, and the SEC's website, www.sec.gov.

Restatement of Financial Statements

In reviewing the PresGar equipment lease contract acquired on October 31, 2004, Radiologix determined that its original accounting treatment of capitalizing the \$13.9 million lease termination costs was incorrect and in fact should have been expensed. Accordingly, Radiologix restated its financial statements for the year ended December 31, 2004 to increase operating expense and decrease intangible assets, net. Radiologix has also restated its financial statements for the three and six months ended June 30, 2005 to decrease depreciation and amortization expense by \$193,000 and \$387,000, respectively, and decrease intangible assets, net of accumulated amortization, of \$13.4 million.

Radiologix did not record a tax benefit for the \$13.9 million lease termination costs because Radiologix determined that a valuation allowance was necessary due to the fact that Radiologix has had losses for the previous three years and the realization of additional deferred tax assets is questionable. Income tax expense was decreased by \$364,000 and \$605,000 for the three and six months ended June 30, 2005, respectively, due to the utilization of book net operating losses.

Radiologix has also reclassified certain previously reported amounts for all periods presented, including (1) distributions from joint ventures and distributions to minority interests in consolidated subsidiaries have been reclassified from net cash used in investing activities to net cash from operating activities in the consolidated statement of cash flows, (2) certain balances in the Consolidating Balance Sheets and the Consolidating Statements of Operations in Note 13, Supplemental Guarantor Information, have been revised; these revisions primarily consist of separate reporting of investments in subsidiaries and intercompany receivables/payables in the Consolidating Balance Sheets and separate reporting of equity in income of wholly owned subsidiaries in the Consolidating Statements of Operations, and (3) adjusted cash paid for interest in the Consolidated Statement of Cash Flows to remove a non-cash component.

Overview

Radiologix's results may be impacted by variability due to changes in modality mix and the volume of procedures performed, physician referral and vacation patterns, the impact of hospital and physician-affiliated imaging centers that compete in Radiologix's primary and Questar operations, the timing and negotiation of managed care and service contracts, the availability of technologists and other personnel resources, and trends in receivable collectibility. Radiologix is impacted by seasonality in that referring physicians and technologists often schedule vacations in the summer months which typically results in a decline in Radiologix's volumes and service fee revenue while increasing costs of services as Radiologix contracts for the services of temporary technologists at higher rates.

Radiologix is a leading national provider of diagnostic imaging services through its ownership and operation of free-standing, outpatient diagnostic imaging centers. Radiologix utilizes sophisticated technology and technical expertise to perform a broad range of imaging procedures, such as magnetic

resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), PET/CT, nuclear medicine, ultrasound, mammography, bone densitometry (DEXA), general radiography (X-ray) and fluoroscopy. For the three and six months ended June 30, 2006, Radiologix derived 86% and 86%, respectively, of its service fee revenue from the ownership, management and operation of its imaging center network, and 14% and 14% of its service fee revenue from administrative, management and information services provided to contracted radiology practices. As of June 30, 2006, Radiologix owned, operated or maintained, through its two operating segments, an ownership interest in imaging equipment at 69 locations, with imaging centers located in 7 states, including (1) primary operations in the Mid-Atlantic; the Bay Area, California; Treasure Coast, Florida; Northeast, Kansas; and the Finger Lakes (Rochester) and Hudson Valley markets in New York state; and (2) Questar operations with imaging centers located in California, Colorado and Minnesota.

Service fee revenue from Radiologix's primary operations is comprised primarily of billed charges for both the technical and professional components for services performed, reduced by estimated contractual adjustments and by amounts retained by contracted radiology practice groups for their professional services, pursuant to its management services agreements. Under these management services agreements, Radiologix provides contracted radiology practices with the facilities and equipment used in its medical practice, assumes responsibility for the management of the operations, and employs substantially all of the non-physician personnel utilized by the contracted radiology practices. In connection with operations related to Radiologix's Questar subsidiary, service fee revenue is comprised primarily of billed charges for technical services performed at Radiologix's Questar imaging centers reduced by estimated contractual adjustments. Revenue is recognized once services are performed by contracted radiology practices, the imaging centers, or both. The provision for doubtful accounts related to established charges is reflected as an operating expense rather than a reduction of revenue. Radiologix's patient accounting system currently does not record contractual adjustments at the time of billing. Instead, adjustments for contractual adjustments and doubtful accounts are estimated based on historical collection experience using a retrospective collection analysis. As these factors change, changes in estimates are made in the appropriate period.

Radiologix's charge masters at its imaging centers are generally set at approximately two times the current Medicare fee schedule because Radiologix is generally paid the lower of (1) billed charges, (2) a negotiated flat rate or (3) a multiple of the current Medicare fee schedule. Additionally, because the majority of Radiologix's managed care payor contracts have fixed rates, Radiologix generally does not raise charge master pricing (gross charges). It is Radiologix's policy that proposed price (gross charge) increases to any subsidiary charge master must be approved in writing by the Vice President of Radiologix's Patient Services Group.

The table below reflects Radiologix's consolidated accounts receivable aging report at June 30, 2006, which is used to review accounts receivable aging patterns (in thousands):

Payor	0-30 Days	31-60 Days	61-90 Days	91-180 Days	>180 Days	Total
<i>Medicare</i>	\$ 9,114	\$ 3,254	\$ 1,107	\$ 1,576	\$ 2,128	\$ 17,179
<i>Medicaid</i>	1,264	944	545	1,027	1,590	5,370
<i>Blue Cross</i>	6,376	1,882	764	1,175	1,373	11,570
<i>Commercial Insurance</i>	1,059	1,027	400	356	237	3,079
<i>Managed Care</i>	10,100	5,546	1,828	2,582	2,319	22,375
<i>Capitated</i>	39	20	22	25	12	118
<i>Self Pay</i>	1,440	2,800	2,684	5,109	2,040	14,073
<i>Workers Compensation</i>	796	959	719	752	952	4,178
<i>Other</i>	(23)	714	388	737	634	2,450
<i>Total by payor</i>	\$ 30,165	\$ 17,146	\$ 8,457	\$ 13,339	\$ 11,285	\$ 80,392
<i>Other subsidiary(1)</i>	1,427	516	315	421	399	3,078
<i>Gross accounts receivable per aging</i>	\$ 31,592	\$ 17,662	\$ 8,772	\$ 13,760	\$ 11,684	\$ 83,470
<i>Accrued gross charges(2)</i>						13,964
<i>Allowance for contractual adjustments(3)</i>						(48,124)
<i>Allowance for doubtful accounts(3)</i>						(7,912)
<i>Other</i>						(161)
<i>Accounts receivable, net of allowances</i>						\$ 41,237

(1) Aging by payor is not available.

(2) Procedures have been completed but charges have not been entered into the billing system.

(3) Allowances are not allocated to individual aging periods.

Radiologix's service fee revenue is dependent upon the operating results of the contracted radiology practice groups and diagnostic imaging centers. Where state law allows, service fees due under the management services agreements for the contracted radiology practice groups are derived from two distinct revenue streams: (1) a negotiated percentage of the professional revenues, reduced by certain expenses (non-physician salaries and benefits, rent, depreciation, insurance, interest and other physician costs), as defined in the management services agreements; and (2) 100% of the adjusted technical revenues, as defined in the management service agreements, up to a designated ceiling at which point certain of the management services agreements provide for a technical bonus to the contracted radiology practice groups for a percentage amount in excess of this ceiling. In states where the law requires a flat fee structure, Radiologix has negotiated a base service fee, which approximates the estimated fair market value of the services provided under the management services agreements and which is renegotiated each year to equal the fair market value of the services provided under the management services agreements.

Radiologix's diagnostic imaging centers are also principally dependent on its ability to attract referrals from primary care physicians, specialists and other healthcare providers. The referral often depends on the existence of a contractual arrangement with the referred patient's health benefit plan. Radiologix has contracts with health benefit plans representing many of the patients in the markets Radiologix serves.

Results of Operations

Radiologix's primary operations consist of owning and operating diagnostic imaging centers and providing administrative, management, information, and other services to certain contracted radiology practice groups. These contracted radiology practice groups provide professional interpretation and supervision services to Radiologix's diagnostic imaging centers and to hospitals and joint ventures in which Radiologix participates. Radiologix's services are designed to leverage its existing infrastructure and improve radiology practice groups or joint venture profitability, efficiency and effectiveness. Radiologix also operates primarily single modality imaging centers through Radiologix's Questar subsidiary. Because of different characteristics from Radiologix's primary operations, including location, market concentration, contracting leverage, and capital requirements, the single modality nature of most of the centers and the structure of the management service agreements with physicians related to Radiologix's Questar operations, senior management makes resource allocation decisions separately for Questar and Radiologix's primary operations.

Six Months Ended June 30, 2006 Compared to Six Months Ended June 30, 2005

The following tables outline Radiologix's service fee revenue, volumes and operating expenses (excluding stock compensation expense of \$747,000 and \$213,000), for the six months ended June 30, 2006 and 2005, respectively, below (in thousands):

	2006	2005	Percent Increase (Decrease)	Percent of Service Fee Revenue		Basis Point Change
				2006	2005	
Service fee revenue	\$ 130,246	\$ 127,062	2.5 %			
Field salaries and benefits	\$ 45,696	\$ 44,271	3.2 %	35.1 %	34.8 %	30
Field supplies	7,333	7,655	(4.2)	5.6	6.0	(40)
Facility rent	7,346	6,873	6.9	5.7	5.4	30
Other field expenses	20,873	21,650	(3.6)	16.0	17.1	(110)
Cost of services	\$ 81,248	\$ 80,449	1.0 %	62.4 %	63.3 %	(90)
Equipment lease	7,642	6,037	26.6	5.9	4.7	120
Provision for doubtful accounts	10,887	9,126	19.3	8.4	7.2	120
Depreciation and amortization	12,024	11,502	4.5	9.2	9.1	10
Corporate, general and administrative	8,417	9,120	(7.7)	6.4	7.2	(80)
Interest expense, net	8,803	9,241	(4.7)	6.8	7.3	(50)
Total operating expense	\$ 129,021	\$ 125,475	2.8 %	99.1 %	98.8 %	30

A summary of Radiologix's volumes and service fee revenue follows (in thousands):

	For the Six Months Ended June 30,	
	2006	2005
High end volumes(1)	178,859	187,887
Other volumes	595,844	586,797
Professional component	\$ 18,304	\$ 16,737
Technical component	111,942	110,325
Service fee revenue	\$ 130,246	\$ 127,062

(1) Defined as MRI, PET, CT and PET/CT procedures.

Capitation revenue of \$6.8 million and \$7.7 million in the six months ended June 30, 2006 and 2005, respectively, is included in service fee revenue above. For the six months ended June 30, 2006 and 2005, approximately 5% and 6%, respectively, of Radiologix's diagnostic imaging center service fee revenue was generated from capitated arrangements. Of this 5% and 6%, two-thirds relates to contracts with two physician groups and the remainder relates to a contract with one managed care payor.

Comparable results excluding certain Management Services Agreement operations (San Antonio and the terminated Mid-Atlantic agreement, the terminated MSA operations) are presented below:

	2006	2005	Percent Increase (Decrease)	Percent of Service Fee Revenue		Basis Point Change
				2006	2005	
Service fee revenue	\$ 130,246	\$ 126,093	3.3 %			
Field salaries and benefits	\$ 45,696	\$ 44,078	3.7 %	35.1 %	35.0 %	10
Field supplies	7,331	7,618	(3.8)	5.6	6.1	(50)
Facility rent	7,346	6,847	7.3	5.7	5.4	30
Other field expenses	20,860	21,468	(2.8)	16.0	17.0	(100)
Cost of services	\$ 81,233	\$ 80,011	1.5 %	62.4 %	63.5 %	(110)
Equipment lease	7,634	6,019	26.8	5.9	4.8	110
Provision for doubtful accounts	10,917	8,883	22.9	8.4	7.0	140
Depreciation and amortization	12,024	11,501	4.6	9.2	9.1	10
Corporate, general and administrative	8,417	9,120	(7.7)	6.4	7.2	(80)
Interest expense, net	8,803	9,241	(4.7)	6.8	7.3	(50)
Total operating expense	\$ 129,028	\$ 124,775	3.4 %	99.1 %	98.9 %	20

For the six months ended June 30, 2006 compared to the six months ended June 30, 2005, service fee revenue increased \$3.2 million or 2.5%. This increase is primarily attributable to an increase in PET/CT volume and improved collection results experienced thus far in 2006. Service fee revenue, excluding the terminated MSA operations, increased \$4.2 million or 3.3%.

Field salaries and benefits as a percentage of service fee revenue from continuing operations for the six months ended June 30, 2006 was 35.1% compared to 34.8% for the six months ended June 30, 2005. This percentage increased primarily from (1) merit increases, (2) higher technologist costs, and (3) overtime costs for employee training in connection with Radiologix's REWARD program described below. Field salaries and benefits as a percentage of service fee revenue from continuing operations for the six months ended June 30, 2006 and 2005, excluding the terminated MSA operations, were 35.1% and 35.0%, respectively. Management continually evaluates Radiologix's service offerings, patient flows and technology offerings to identify more efficient and less costly methods of providing high quality patient care and continually evaluates its back office and support operations for new opportunities to gain economies of scale. Radiologix believes its Radiologix Enhanced Workflow And Record Distribution or REWARD (a comprehensive Radiology Information System/Picture Archival Communications System) Program will help Radiologix achieve greater efficiencies and lower its operating costs. Radiologix expects REWARD to enhance operational efficiencies by: (1) standardizing processes and protocols across Radiologix, (2) automating, accelerating and simplifying workflow, (3) improving the capture of front-end data including billing and patient scheduling information, (4) providing more timely digitized images and records to referring physicians and (5) reducing film and storage costs once fully implemented.

Field supplies, excluding the terminated MSA operations, as a percentage of service fee revenue were 5.6% for the six months ended June 30, 2006 compared to 6.1% for the six months ended June 30, 2005.

This percentage decrease was due primarily to lower film costs resulting from the ongoing implementation of Radiologix's REWARD program.

Facility rent, excluding the terminated MSA operations, as a percentage of service fee revenue was 5.7% for the six months ended June 30, 2006 compared to 5.4% for the six months ended June 30, 2005. This percentage increased primarily from a new imaging center that began operations in the later part of 2005.

Other field expenses, excluding the terminated MSA operations, as a percentage of service fee revenue were 16.0% for the six months ended June 30, 2006 compared to 17% for the six months ended June 30, 2005. The decrease is primarily due to (1) the recording of larger gains on sales of equipment in 2006 as compared to 2005 and (2) lower physician purchased service costs due primarily to paying certain physicians for incremental coverage on reading contracts during the first six months of 2005 that were not paid in 2006 due to the closure of two centers related to this activity in December 2005 and January 2006, offset by increased service contract costs resulting from new coverage on equipment coming off warranty.

Equipment lease expenses, excluding the terminated MSA operations, as a percentage of service fee revenue were 5.9% in the six months ended June 30, 2006 compared to 4.8% for the six months ended June 30, 2005. This increase was primarily due to acquiring new imaging equipment through leasing arrangements.

Provision for doubtful accounts, excluding the terminated MSA operations, increased by \$2.0 million in the six months ended June 30, 2006 compared to the six months ended June 30, 2005 primarily due to increased write-offs in Radiologix's hospital business.

Depreciation and amortization increased in the six months ended June 30, 2006 compared to the six months ended June 30, 2005 primarily due to the impact of new imaging centers and new equipment placed in service, lease buyouts, and the acquisition of diagnostic equipment.

Corporate, general and administrative expenses decreased by \$703,000 in the six months ended June 30, 2006 compared to the six months ended June 30, 2005 primarily due to costs recorded in 2005 for consulting services related to compliance with the Sarbanes-Oxley Act of 2002, as well as business development studies.

Interest expense (net of interest income), including amortization of deferred financing costs decreased by \$438,000 for the six months ended June 30, 2006 compared to the six months ended June 30, 2005 primarily due to an increase in interest income on additional invested funds, as well as higher interest rates on invested funds.

Income tax expense for the six months ended June 30, 2006 and 2005 was \$170,000 and \$169,000, respectively. In each period, this expense reflects state taxes only as Radiologix's federal effective tax rate was zero due to the utilization of federal net operating loss carryforwards.

Year Ended December 31, 2005 Compared to Year Ended December 31, 2004

For the year ended December 31, 2005, Radiologix's operations reflected decreases of 2.8% in technical service volumes compared to the year ended December 31, 2004. Service fee revenue increased 0.1% over the year ended December 31, 2004.

Imaging Centers Questar

A summary of Radiologix's Questar operations is as follows (in thousands):

	As of and For the Year Ended December 31,		
	2005	2004	2003
Centers in continuing operations at year end	5	6	17
Centers in discontinued operations at year end		2	5
Service fee revenues continuing operations	\$ 7,679	\$ 9,227	\$ 8,575
Service fee revenues discontinued operations	\$ 270	\$ 10,553	\$ 18,196
Impairment of goodwill continuing operations	\$ 2,241	\$ 6,809	\$
Impairment of goodwill discontinued operations	\$	\$ 10,206	\$ 8,400
Impairment of long-lived assets discontinued operations	\$	\$ 617	\$
Gain (loss) on dispositions of centers, net	\$	\$ (1,483)	\$ 11
Pre-tax income (loss) continuing	\$ (1,257)	\$ (5,636)	\$ 363
Pre-tax loss discontinued	\$ (1,252)	\$ (11,431)	\$ (10,437)

In December 2005, Radiologix recorded a \$2.2 million pre-tax impairment charge to continuing operations to write-off goodwill related to Radiologix's remaining Questar centers in California, Colorado and Minnesota. Increased competition in these markets has eroded the profitability of these centers. The increased competition throughout 2005 coupled with management's decision to not invest in new equipment has reduced the future expectations for these centers, thus lowering their value.

In November 2005, Radiologix closed the Questar center in Arizona. This center continued to experience poor performance despite efforts to turn it around.

In December 2004, Radiologix recorded a \$1.1 million pre-tax charge to continuing operations related to the impairment of goodwill at Radiologix's Questar center in Arizona. This center was one of six Questar sites that Radiologix chose to keep in continuing operations at December 31, 2004.

In November 2004, Radiologix sold its 80% joint venture interest in Radiologix's Questar Tampa operations, including accounts receivable, to its venture partner for \$275,000 in cash, resulting in a loss of \$591,000, including the write-off of goodwill for \$354,000.

In June 2004, Radiologix sold a Questar center for \$3.1 million in cash, resulting in a gain of \$682,000, net of a write-off of goodwill for \$500,000.

In the first quarter of 2004, Radiologix recorded a \$5.5 million charge related to Questar in connection with its annual assessment of goodwill based on its internal analysis, which included a valuation performed by an independent valuation firm. In June 2004, after performing an extensive reassessment of Radiologix's Questar imaging center portfolio, management concluded that certain centers were not strategic to Radiologix's future plans and would be unable to meet and sustain its profitability requirements going forward. That reassessment considered: location, contracting leverage, expected capital requirements, the single modality nature of most of these sites, current operating trends, and the sale of Radiologix's most profitable Questar center on June 21, 2004. Radiologix's decision to dispose of this group of imaging centers created an event that required Radiologix to reassess the carrying value of the assets related to these centers, including goodwill at Radiologix's Questar segment. This reassessment considered the impact on the value of the ongoing, deteriorating operating trends in these centers, as well as the implications of disposing of individual centers versus operating those centers as part of an ongoing operating enterprise. To assist Radiologix in that reassessment, it engaged an independent valuation firm to estimate the fair value of Radiologix's combined Questar sites. As a result of Radiologix's reassessment

and the independent valuation, Radiologix recorded a \$10.4 million pre-tax charge to continuing operations related to the impairment of Questar goodwill in June 2004. Radiologix also recorded a \$617,000 pre-tax charge to impair long-lived assets of certain Questar centers in June 2004.

Radiologix assesses the viability of its imaging centers throughout the year. In the event Radiologix decides to dispose of one or more imaging centers, additional charges may result depending on cash flow and market conditions at the time of its assessment.

Management Services Agreements

In addition to continually assessing the financial viability of Radiologix's imaging centers, management also evaluates the businesses surrounding Radiologix's relationships with radiologists and radiology practice groups that have reading privileges at its facilities. These businesses may include Radiologix imaging centers and/or professional reading agreements involving another entity's inpatient or outpatient imaging centers.

In most cases, individual radiologists and radiology practice groups serve in Radiologix's facilities pursuant to management services agreements entered into when Radiologix acquired the practice group's assets. The value of these arrangements is recorded as intangible assets when acquired. Although the agreements may extend for longer periods, the value of the intangible assets is amortized over no more than 25 years based on SEC guidance.

Mid-Atlantic Management Services Agreement

During the third quarter of 2004, management determined that the ability of one of the radiology groups to perform in accordance with a management services agreement administered by one of Radiologix's Mid-Atlantic subsidiaries had diminished significantly. With several owned imaging centers covered by the management services agreement operating at financial losses, deteriorating financial conditions at hospitals involving professional reading arrangements, and the resignation from the practice of two physician leaders, management concluded that the value of intangible assets related to this management services agreement had become significantly impaired.

As a result, Radiologix and the radiology group terminated the management services agreement on January 31, 2005. Radiologix decided to dispose of three unprofitable imaging centers and to transfer the professional reading responsibility for certain other centers to another radiology group that operates under a management services agreement with Radiologix in the Mid-Atlantic market.

Based on Radiologix's assessment and the actions that Radiologix has undertaken, Radiologix recorded 2004 third quarter impairment charges of: \$6.5 million to write off the unamortized portion of intangible assets related to this group's management services agreement, and \$800,000 to write off long-lived assets related to the centers planned for disposition, all of which were disposed of at December 31, 2005.

Service fee revenue and pre-tax income (loss) for the two centers disposed of in 2005, and the professional reading arrangements that Radiologix no longer is a party to, as reflected in continuing operations (including impairment charges) are as follows (in thousands):

	For the Year Ended	
	December 31,	
	2005	2004
Service fee revenue	\$ 968	\$ 5,910
Pre-tax income (loss)	\$ 417	\$ (5,871)

- San Antonio, Texas Management Services Agreement

Radiologix completed the sale of its operations in San Antonio, Texas in the second quarter of 2004. The purchase price was \$10.5 million, resulting in a pre-tax gain on sale of approximately \$4.7 million. Net cash received was \$9.7 million after purchase price adjustments. The sale included (1) assets Radiologix owned and leased in its operation of M&S Imaging Partners, Inc., (2) a diagnostic imaging center, and (3) certain partnership interests, but did not include accounts receivable aggregating approximately \$4.7 million, which Radiologix retained.

- Other Management Services Agreements

In addition to the management services agreement Radiologix terminated effective January 31, 2005 (see Note 6 of Item 8), Radiologix amended (1) a management services agreement which resulted in a 15% reduction in Radiologix's management fee effective January 1, 2004 and (2) a separate management services agreement which resulted in the establishment of a technical bonus to the contracted radiology group and 3% reduction in Radiologix's management fee effective October 1, 2004.

Radiologix's management fees for certain other management services agreements declined by 1% in 2005 and will decline by an additional 1% in 2006. The estimated annual impact to Radiologix's service fee revenue for these 1% decreases is approximately \$500,000.

In connection with the amendment of a management services agreement with a contracted radiology group in July 2002, Radiologix recorded deferred revenue of \$3.3 million in consideration for the amended agreement, which amount is amortized over 20 years. In December 2002, Radiologix amended the management services agreement of another contracted radiology practice and recorded deferred revenue of \$4.8 million in consideration for the amended agreement, which is amortized over 19 years.

Other Charges

A summary of other charges in continuing operations (in addition to the impairment amounts discussed above) is as follows (in thousands):

	For the Year Ended	
	December 31,	
	2005	2004
	(As restated)	
Other impairment(1)	\$ (370)	\$ 538
Contract termination costs(2)	\$	\$ 515
Severance and related costs(3)	\$ 670	\$ 405
Litigation and regulatory matters(4)	\$	\$ 295
Lease termination expense(5)	\$	\$ 13,948

(1) Radiologix incurred impairment charges and other costs aggregating \$263,000 in the third quarter of 2004 associated with damages from hurricanes impacting Radiologix's Southeastern operations. Radiologix received insurance proceeds of \$370,000 relating to these damages in the second quarter of 2005. In the fourth quarter of 2004, Radiologix recorded additional impairment charges of \$275,000 for software related to Radiologix's Radiology Information System (RIS) in Radiologix's Northeast operations where software has been replaced in connection with the implementation of Radiologix's Radiologix Enhanced Workflow And Record Distribution (REWARD) Program.

(2) In the third quarter of 2004, Radiologix recorded \$315,000 for lease termination costs related to diagnostic equipment no longer in use; and \$200,000 to write-off software costs associated with canceling a software contract.

(3) During the years ended December 31, 2005 and 2004, Radiologix recognized \$670,000 and \$405,000 in charges, respectively, in connection with severance and other related costs for changes in Radiologix's senior management team.

(4) In the third quarter of 2004, Radiologix recorded \$295,000 for a litigation settlement.

(5) In 2004, Radiologix incurred costs of \$13.9 million in connection with the termination of an operating lease assumed in the PresGar transaction.

Operating Expenses

The following table outlines Radiologix's operating expenses, excluding (1) \$557,000 and \$78,000 of restricted stock expense in 2005 and 2004, respectively, (2) the \$4.7 million gain on sale of Radiologix's San Antonio operations in 2004, (3) the aggregate \$2.2 million and \$14.6 million in charges for impairment of goodwill, intangible and long-lived assets for 2005 and 2004, respectively, and items (1) through (5) in the above table, for the years ended December 31, 2005 and 2004 below (in thousands):

	2005	2004 (As restated)	Percent Increase (Decrease)		Percent of Service Fee Revenue 2005	2004	Basis Point Change
Service fee revenue	\$ 251,440	\$ 251,291	0.1 %				
Cost of services	\$ 161,268	\$ 158,159	2.0 %	64.1 %	62.9 %	120	
Equipment leases	13,035	17,660	(26.2)	5.2	7.0	(180)	
Provision for doubtful accounts	19,033	22,337	(14.8)	7.6	8.9	(130)	
Depreciation and amortization	23,430	22,999	1.9	9.3	9.2	10	
Corporate, general and administrative	16,315	18,346	(11.1)	6.5	7.3	(80)	
Interest expense, net	18,295	18,596	(1.6)	7.3	7.4	(10)	
Total operating expenses, excluding gain, severance, impairment and other charges	\$ 251,376	\$ 258,097	(2.6)%	100.0 %	102.7 %	(270)	

Comparable results excluding certain Management Services Agreement operations (San Antonio and the terminated Mid-Atlantic agreement) are presented below:

	2005	2004 (As restated)	Percent Increase (Decrease)		Percent of Service Fee Revenue		Basis Point Change
					2005	2004	
Service fee revenue	\$ 250,472	\$ 239,393	4.6 %				
Cost of services	\$ 160,661	\$ 152,074	5.7 %	64.1 %	63.5 %	60	
Equipment leases	12,999	17,546	(25.9)	5.2	7.3	(210)	
Provision for doubtful accounts	18,797	19,714	(4.7)	7.5	8.2	(70)	
Depreciation and amortization	23,430	22,311	5.0	9.4	9.3	10	
Corporate, general and administrative	16,315	18,346	(11.1)	6.5	7.7	(120)	
Interest expense, net	18,294	18,420	(0.7)	7.3	7.7	(40)	
Total operating expenses, excluding gain, severance, impairment and other charges	\$ 250,496	\$ 248,411	0.8 %	100.0 %	103.7 %	(370)	

Cost of services consists of (1) field salaries and benefits, (2) field supplies, (3) field rent (lease) and (4) other field expenses.

Field salaries and benefits as a percentage of service fee revenue from continuing operations for the year ended December 31, 2005 and 2004 were unchanged at 34.4%. Field salaries and benefits as a percentage of service fee revenue from continuing operations for the year ended December 31, 2005 and 2004, excluding the San Antonio and the terminated Mid-Atlantic operations, were 34.5% and 34.9%, respectively. Management continues to evaluate Radiologix's service offerings, patient flows and technology offerings to identify more efficient and less costly methods of providing high quality patient care and continues to evaluate its back office and support operations for new opportunities to gain economies of scale. Radiologix believes its REWARD Program, once fully implemented, will help Radiologix achieve greater efficiencies and lower Radiologix's operating costs. In connection with field salaries and benefits, market studies performed in Radiologix's primary operating locations indicate that certain employee positions could be above or below market salary rates. Radiologix addresses performance and merit increases on an annual basis in March through Radiologix's Focal Point Review process.

Field supplies, excluding the terminated MSA operations, as a percentage of service fee revenue were 6.1% for the year ended December 31, 2005 compared to 6.0% for the year ended December 31, 2004. Field supply costs generally increase as Radiologix performs more high-end diagnostic procedures. High-end procedures typically utilize more supplies such as contrast and radio-pharmaceuticals.

Facility rent, excluding the terminated MSA operations, as a percentage of service fee revenue increased to 5.7% for the year ended December 31, 2005 compared to 5.6% for the year ended December 31, 2004, primarily due to facility rent for a new imaging center that began operations in April 2005 and higher facility rent in Radiologix's Bay Area, California operations, offset by the reversal of a \$229,000 lease accrual (of which \$62,000 was recorded in the 2005 first quarter) no longer required as a result of settling a facility lease obligation with the trustee of a bankrupt landlord.

Other field expenses, excluding the terminated MSA operations, as a percentage of service fee revenue increased to 17.8% for the year ended December 31, 2005 compared to 17.0% for the year ended December 31, 2004 primarily due to (1) increased service contract costs resulting from new coverage on (a) equipment coming off warranty and (b) equipment acquired in connection with the acquisition of an

equipment lease contract effective October 31, 2004, (2) system conversion, upgrade and outsourcing costs for Radiologix's patient accounting systems, (3) higher marketing costs in Radiologix's primary operations, (4) higher physician purchased service costs primarily due to paying certain physicians for incremental coverage on reading contracts, (5) higher workers' compensation costs, (6) higher diagnostic equipment repair costs, (7) higher telephone and communication cost related to Radiologix's operations and installation of REWARD and (8) a \$176,000 write-off of leasehold improvement costs related to an imaging center closed in the 2005 second quarter. These increased costs were offset by (1) a \$370,000 gain from insurance proceeds received in settlement for equipment damaged by a hurricane, (2) gains on sales of diagnostic equipment, (3) lower malpractice insurance costs and (4) lower off-site storage costs.

Equipment lease expenses, excluding the terminated MSA operations, as a percentage of service fee revenue decreased to 5.2% for the year ended December 31, 2005 compared to 7.3% for the year ended December 31, 2004 primarily due to the impact of lease buyouts and the acquisition of an equipment lease contract effective October 31, 2004, which eliminates equipment lease expense that was previously recorded based on volume.

Provision for doubtful accounts decreased by \$3.3 million in the year ended December 31, 2005 compared to the year ended December 31, 2004 primarily due to improved denial rates in 2005 and lower professional revenue charges in 2005, which historically have higher provision for doubtful accounts.

Depreciation and amortization increased to \$23.4 million in the year ended December 31, 2005 compared to \$23.0 million in the year ended December 31, 2004 primarily due to (1) the impact of new imaging centers and new equipment placed in service in 2004 and 2005 and (2) lease buyouts, offset by (1) no longer operating the terminated San Antonio operations that were sold in the second quarter of 2004, (2) no longer operating the terminated Mid-Atlantic operations effective January 31, 2005, (3) the effect of lower asset bases as a result of asset impairments in 2004 and (4) assets that became fully depreciated in 2004 and 2005.

Corporate, general and administrative expenses decreased to \$16.3 million in the year ended December 31, 2005 compared to \$18.3 million in the year ended December 31, 2004 primarily due to (1) lower executive recruiting and relocation costs, (2) reduced legal costs as a result of establishing an in-house legal department which resulted in reducing Radiologix's contracted legal costs, (3) lower costs related to Sarbanes-Oxley Section 404 compliance as a result of concluding Radiologix's initial stage of establishing, documenting, and implementing Radiologix's company wide internal control processes, (4) lower 2005 health benefits costs, and (5) the lack of chief operating officer salary and benefit costs in the 2005 first and second quarters as this position remained open from December 2004 through July 2005.

Interest expense (net of interest income), including amortization of deferred financing costs, decreased to \$18.3 million in the year ended December 31, 2005 compared to \$18.6 million in the year ended December 31, 2004 primarily due to Radiologix's \$1.7 million retirement of debt in the second quarter of 2004 and earning interest income on additional invested funds.

Equity in earnings increased in 2005 compared to 2004 primarily due to improved profitability at Radiologix's joint ventures.

Due to losses for the last three years, the realization of deferred tax assets is uncertain. Therefore, valuation allowances for net deferred tax assets were recorded in 2004 and 2005. The tax provision of \$662,000 for the year ended December 31, 2005 is for state income taxes and federal alternative minimum tax. No federal or state tax benefits were recorded for the full year 2005.

Year Ended December 31, 2004 Compared to Year Ended December 31, 2003

For the year ended December 31, 2004, Radiologix's operations reflected increases of 4.0% in technical service volumes compared to the year ended December 31, 2003. In the fourth quarter of 2004, Radiologix received additional service fee revenue of approximately \$500,000 as a result of renegotiating a capitated contract in its Bay Area market and approximately \$400,000 from a new management contract in its Mid-Atlantic market. These amounts were offset by a \$350,000 decrease in service fee revenue due to the renegotiation of a management services agreement which resulted in a decrease in Radiologix's management fee percentage and an increase in the technical bonus component to the contracted radiology group. Overall, the above activities resulted in an increase in service fee revenue of 3.8% over the year ended December 31, 2003 and reflect the impact of Radiologix's improved organic growth including the addition of new imaging centers and imaging equipment placed into operations since December 31, 2003.

The impact of hurricanes on Radiologix's Southeastern operations resulted in an estimated \$480,000 loss of revenue in September 2004 compared to an estimated \$394,000 loss of revenue due to the impact of Hurricane Isabel on Radiologix's Mid-Atlantic operations in September 2003.

Imaging Centers Questar

A summary of Radiologix's Questar operations is as follows (in thousands):

	For the Year Ended December 31,	
	2004	2003
Centers in continuing operations at year end	6	17
Centers in discontinued operations at year end	2	5
Service fee revenues continuing operations	\$ 9,227	\$ 8,575
Service fee revenues discontinued operations	\$10,553	\$18,196
Impairment of goodwill continuing operations	\$ 6,809	\$
Impairment of goodwill discontinued operations	\$10,206	\$ 8,400
Impairment of long-lived assets discontinued operations	\$ 617	\$
Gain (loss) on dispositions of centers, net	\$ (1,483)	\$ 11
Pre-tax income (loss) continuing	\$ (5,636)	\$ 363
Pre-tax loss discontinued	\$(11,431)	\$(10,437)

In November 2004, Radiologix sold its 80% joint venture interest in Radiologix's Questar Tampa operations, including accounts receivable, to its venture partner for \$275,000 in cash, resulting in a loss of \$591,000, including the write-off of goodwill for \$354,000.

In June 2004, Radiologix sold a Questar center for \$3.1 million in cash, resulting in a gain of \$682,000, net of a write-off of goodwill for \$500,000.

In fiscal 2003, Radiologix recorded an \$8.4 million pre-tax charge to discontinued operations related to the impairment of goodwill of Questar. In the first quarter of 2004, Radiologix recorded a \$5.5 million charge related to Questar in connection with Radiologix's annual assessment of goodwill based on Radiologix's internal analysis, which included a valuation performed by an independent valuation firm. In June 2004, after performing an extensive reassessment of Radiologix's Questar imaging center portfolio, management concluded that certain centers were not strategic to Radiologix's future plans and would be unable to meet and sustain Radiologix's profitability requirements going forward. That reassessment considered: location, contracting leverage, expected capital requirements, the single modality nature of most of these sites, current operating trends, and the sale of Radiologix's most profitable Questar center on June 21, 2004. Radiologix's decision to dispose of this group of imaging centers created an event that required Radiologix to reassess the carrying value of the assets related to these centers, including goodwill

at Radiologix's Questar segment. This reassessment considered the impact on the value of the ongoing, deteriorating operating trends in these centers, as well as the implications of disposing of individual centers versus operating those centers as part of an ongoing operating enterprise. To assist Radiologix in that reassessment, Radiologix engaged an independent valuation firm to estimate the fair value of Radiologix's combined Questar sites. As a result of Radiologix's reassessment and the independent valuation, Radiologix recorded a \$10.4 million pre-tax charge to continuing operations related to the impairment of Questar goodwill in June 2004. Radiologix also recorded a \$617,000 pre-tax charge to impair long-lived assets of certain Questar centers in June 2004.

In December 2004, Radiologix recorded a \$1.1 million pre-tax charge to continuing operations related to the impairment of goodwill at Radiologix's Questar center in Arizona. This center is one of six Questar sites that Radiologix chose to keep in continuing operations at December 31, 2004. Radiologix did not anticipate this impairment previously as the center is in a strategic new location and was projected to improve in volumes, profitability and net cash flows in the fourth quarter of 2004 and throughout 2005. However, it appears that because of disruption caused by the move to this new location, confusion in the community due to a change in the center's name, and increased local competition, Radiologix has had difficulty in achieving the volumes, profitability and net cash flow levels that it expected in the fourth quarter of 2004 and budgeted for in 2005. Accordingly, although Radiologix intends to keep this center open in an attempt to engineer a turnaround in its operations, Radiologix's revised volume, profitability and cash flow estimates did not support the recoverability of this center's goodwill at December 31, 2004.

Radiologix assesses the viability of its imaging centers throughout the year. In the event Radiologix decides to dispose of one or more imaging centers, additional charges may result depending on cash flow and market conditions at the time of Radiologix's assessment.

Management Services Agreements

• Mid-Atlantic Management Services Agreement

During the third quarter of 2004, management determined that the ability of one of the radiology groups to perform in accordance with a management services agreement administered by one of Radiologix's Mid-Atlantic subsidiaries had diminished significantly. With several owned imaging centers covered by the management services agreement operating at financial losses, deteriorating financial conditions at hospitals involving professional reading arrangements, and the resignation from the practice of two physician leaders, management concluded that the value of Radiologix's intangible asset had become significantly impaired.

As a result, Radiologix and the radiology group agreed to terminate the management services agreement. Radiologix has decided to dispose of three unprofitable imaging centers and to transfer the professional reading responsibility for certain other centers to another radiology group that operates under a management services agreement with Radiologix in the Mid-Atlantic market. As of December 31, 2004, Radiologix will no longer be a party to most of the professional reading arrangements at certain hospitals and accordingly, Radiologix will receive minimal service fee revenue from these arrangements in 2005. Radiologix received \$6.3 million in service fee revenue from these professional reading arrangements in 2004.

Based on Radiologix's assessment and the actions that Radiologix has undertaken, Radiologix recorded 2004 third quarter impairment charges of: \$6.5 million to write off the unamortized portion of intangible assets related to this group's management services agreement, and \$800,000 to write off long-lived assets related to the centers planned for disposition, one of which was disposed of in December 2004.

Service fee revenue and pre-tax income (loss) for the remaining two centers disposed of in 2005, and the professional reading arrangements that Radiologix will no longer be a party to, as reflected in continuing operations (including impairment charges), are as follows (in thousands):

	For the Year Ended December 31,	
	2004	2003
Service fee revenue	\$5,910	\$5,890
Pre-tax income (loss)	\$(5,871)	\$2,312

• San Antonio, Texas Management Services Agreement

Radiologix completed the sale of Radiologix's operations in San Antonio, Texas in the second quarter of 2004. The purchase price was \$10.5 million, resulting in a pre-tax gain on sale of approximately \$4.7 million. Net cash received was \$9.7 million after purchase price adjustments. The sale included (1) assets Radiologix owned and leased in its operation of M&S Imaging Partners, Inc., (2) a diagnostic imaging center, and (3) certain partnership interests, but did not include accounts receivable aggregating approximately \$4.7 million, which Radiologix retained.

• Other Management Services Agreements

In addition to the management services agreement Radiologix terminated effective January 31, 2005 (see Note 6 of Item 8), Radiologix amended (1) a management services agreement which resulted in a 15% reduction in its management fee effective January 1, 2004 and (2) a separate management services agreement which resulted in the establishment of a technical bonus to the contracted radiology group and 3% reduction in its management fee effective October 1, 2004.

Radiologix's management fees for certain other management services agreements declined by 1% in 2004 and will decline by an additional 1% in 2005. The estimated annual impact to Radiologix's service fee revenue for these 1% decreases is approximately \$650,000.

In connection with the amendment of a management services agreement with a contracted radiology group in July 2002, Radiologix recorded deferred revenue of \$3.3 million in consideration for the amended agreement, which amount is amortized over 20 years. In December 2002, Radiologix amended the management services agreement of another contracted radiology practice and recorded deferred revenue of \$4.8 million in consideration for the amended agreement, which is amortized over 19 years.

Other Charges

A summary of other charges in continuing operations (in addition to the impairment amounts discussed above) is as follows (in thousands):

	For the Year Ended December 31,	
	2004 (As restated)	2003
Other impairment(1)	\$ 538	\$ 523
Contract termination costs(2)	\$ 515	\$
Severance and related costs(3)	\$ 405	\$1,568
Litigation and regulatory matters(4)	\$ 295	\$1,621
Amendment of credit facility(5)	\$	\$ 363
Lease termination expense(6)	\$ 13,948	\$

(1) Radiologix incurred impairment charges and other costs aggregating \$263,000 in the third quarter of 2004 associated with damages from hurricanes impacting Radiologix's Southeastern operations. In the

fourth quarter of 2004, Radiologix recorded additional impairment charges of \$275,000 for software related to Radiologix's RIS system in Radiologix's Northeast operations where software has been replaced in connection with the implementation of Radiologix's REWARD Program. In fiscal 2003, Radiologix incurred impairment charges of \$523,000 to write-off a patient scheduling software system that Radiologix replaced.

(2) In the third quarter of 2004, Radiologix recorded \$315,000 for lease termination costs related to diagnostic equipment no longer in use; and \$200,000 to write-off software costs associated with canceling a software contract.

(3) During the years ended December 31, 2004 and 2003, Radiologix recognized \$405,000 and \$1.6 million in charges, respectively, in connection with severance and other related costs for changes in Radiologix's senior management team.

(4) In the third quarter of 2004, Radiologix recorded \$295,000 for a litigation settlement. For the year ended December 31, 2003, Radiologix recorded a \$775,000 charge for regulatory matters and related legal and consulting costs in connection with self-reporting a matter to the U.S. Department of Health and Human Services' Office of the Inspector General (OIG), \$546,000 in costs to meet HIPAA compliance requirements, and a \$300,000 litigation settlement related to Radiologix's Mid-Atlantic operations.

(5) In 2003, Radiologix incurred costs of \$363,000 in connection with amending a credit facility.

(6) In 2004, Radiologix incurred costs of \$13.9 million in connection with the termination of an operating lease assumed in the PresGar transaction.

Operating Expenses

The following table outlines Radiologix's operating expenses, excluding (1) \$78,000 and \$27,000 of restricted stock expense in 2004 and 2003, respectively, (2) the \$4.7 million gain on sale of its San Antonio operations in 2004, (3) the aggregate \$14.6 million in charges for impairment of goodwill, intangible and long-lived assets and items (1) through (6) in the above table, for the years ended December 31, 2004 and 2003 below (in thousands):

	2004 (As restated)	2003	Percent Increase (Decrease)	Percent of Service Fee Revenue		Basis Point Change
				2004	2003	
Service fee revenue	\$ 251,291	\$ 242,038	3.8 %			
Cost of services	\$ 158,159	\$ 148,259	6.7 %	62.9 %	61.3 %	160
Equipment leases	17,660	17,230	2.5	7.0	7.1	(10)
Provision for doubtful accounts	22,337	20,228	10.4	8.9	8.4	50
Depreciation and amortization	22,999	23,926	(3.9)	9.2	9.9	(70)
Corporate, general and administrative	18,346	14,099	30.1	7.3	5.8	150
Interest expense, net	18,596	19,281	(3.6)	7.4	8.0	(60)
Total operating expenses, excluding gain, severance, impairment and other charges	\$ 258,097	\$ 243,023	6.2 %	102.7 %	100.5 %	220

Comparable results excluding certain Management Services Agreement operations (San Antonio and the terminated Mid-Atlantic agreement) are presented below:

2004	2003	Percent Increase (Decrease)	Percent of Service Fee Revenue	Basis Point
------	------	-----------------------------	--------------------------------	-------------